<SEC-DOCUMENT>0001842952-22-000096.txt : 20221109
<SEC-HEADER>0001842952-22-000096.hdr.sgml : 20221109
<ACCEPTANCE-DATETIME>20221109160652
ACCESSION NUMBER:		0001842952-22-000096
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221109
DATE AS OF CHANGE:		20221109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Context Therapeutics Inc.
		CENTRAL INDEX KEY:			0001842952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				863738787
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40654
		FILM NUMBER:		221372558

	BUSINESS ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		267-225-7416

	MAIL ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Context Therapeutics LLC
		DATE OF NAME CHANGE:	20210128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cntx-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6,d:6128ef27165d4066a955a859b4b0ee27--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:cntx="http://www.contexttherapeutics.com/20220930" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cntx-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN18zLTEtMS0xLTQ5NzEy_af830281-1932-429b-b13f-61feb33b050f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN180LTEtMS0xLTQ5NzEy_a9f4c4e8-382f-4241-94db-1efb7379573e">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN181LTEtMS0xLTQ5NzEy_694c2193-a4a7-4fac-bd5b-bdd6dcee51e0">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN182LTEtMS0xLTQ5NzEy_ff061ddd-1513-4fe9-ae9f-8c88fcea2010">0001842952</ix:nonNumeric><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN183LTEtMS0xLTQ5NzEy_5c08594f-49d5-4ea3-b99d-f148fc6139c5">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6bfb3d422efb4a2184822401861fbbb9_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfOTk5_9bce99fb-680f-4b4e-95c7-aea7eb7069f0">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ia4a410a7e6134fa78385a8cc70a725e0_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjUxNQ_9f1ec537-f564-4137-94fe-554fb0d09f1f">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cntx-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id897838cf09a4fb98dd25ffc123540c1_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i061af97dccdb4fda98333d1bb3013560_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02120c98aecd422bb636957763abc278_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91d778453bdd415ca0474d3b80c97e81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab19c1394c44429ac9cf701c02bacd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8044192b7fa3405f8f099c5b69712352_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7d6b0e50bc4558a6bf3ad8ad190e64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbda5f1db214fb88786236031b5e24c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d87d55ccb734efb9c7ed1999f656107_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0f5d0c94a24a37bbe2603f3a941447_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dff8bbfea2e482896c4ab248a7dda24_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9523681451b740f0a62eab036c049fcf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e70673670b454697bd3e735f7ead67_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab094eb4f1c449799a6a0a40dfaefe12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5be68e8b1d499185e82be5b03a485f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1985a71fd2e840d0a0b035d856815619_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i053e2d5b4fdd45cba9f89d705600f026_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c334b6a33324fb8ab9e49483ece3d16_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i469bd896d0404212882a523d504522da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d5ed2cb14343529f70dad75a4e6f8d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e677df66a94349ade55221ca159924_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6441b83d394e10b602af00c07a1e9a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf64ab93cf964595a69c22ef2bf1bbc3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4251d780d94171abc72a54e3f1d40b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72999784f84f4f78976de510cce92938_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb364b5e1db7443e829eab3187e71baf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd008432ea34dd495de31355c35c5b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab1984306aeb45b086de0b8f791fa525_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4538f14815a4c249d92da084a9a25ed_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ac2f42af1e46f28082b9e44edd8bd1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bf85e416f34002b19f3f5ac5bdba47_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39eb46827db041658824ba64d452487b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba3cd3b4cb54008bf47ddd2a959ae16_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88cf0f3abb49481aa205ca8023e30fbc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia720be76271949ebb4bd4ecc9a63607a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9faae0f7b5144a19efc12326f0f220e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5595b49782e4a2696ca3a2a49ad6925_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd60ff9a89c748609e3e159d17b22413_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id904dd6c948942fa95d470d8f7fc4c71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017447a0256f4196a4817dfa28f8e101_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d3dccad9594e50872f23a00f725fff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ab355349f74b32990f6a5b1420ee6e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9a2c2fcc664d35b2b5d1dd7995760c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1810fec077b40c0930be13c655ee345_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e87e049d31a4a989377c27f50ee7a17_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ebe5df39614a3fa046b9dec55140fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539fb2bc4bb345aabb6f8dfdd9ba6f6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799f37f97f4a4744b4bc59d2d24293d4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9c37e644824b0d84879f473b9cf77e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54220fa169e4707885970ecdc945467_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica83b1571ad4481baeba3aef75b2db8c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5486e6d972204740a82b09a1b927049f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8d9514a6a745a0a488a3f6c4207777_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8b2d08e4604b7e9b651b2457ac44d6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b116b88064480fb840617b61eabdf0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896495c2f35f47858d0e21309439c662_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeaf8efe24bd416fa817b05f01fdc15f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db5b6f078814f8e95ab6d13d23d25e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38bed32e2197428db5b6ab17d60a789b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065c7e802d2941d1a5f4e25656709a56_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455a6e88e29d4ef2a78a2a38f261295b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i046810a1fd7d400da5a699c022e8d9f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5737c76ba5424054a9aeed887403599b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fdea296ead7488282261bdc319ef5d1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5dbc3701bbc4b54a21909b1998fe19c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0008c07757234399a7495a0798d22f5b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2471273c7ae344129757969381e9512f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e9a07f9c2946a8b52c28630a825031_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cntx:ContextTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i18dfaee2fd0749dea6d251e8a01ce718_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07512b61ceef49069b0fde3492828089_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic464fb81556f45ecbf3818ed885dba50_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:PlacementAgentsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb18b5ff7dd4565b0689e48dd33cb0f_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic30db45c99284874bb93ab62a6ede5bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97c72893b0b45f9ac13a510ac0ce919_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be4c088e38d48fca44ed64b3a9cc35b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7c76c52c0843d4b179f34fcc164f44_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661fcc5b4602480e8cc52211d82446d0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855cb448971a4619b544a94285a0cc96_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad85129c8a58499f94bd8e3d2af6078f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8472e008fd846c1af7dbda2c91dddc6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5403ef21acee45fbab5d4ad32b444c79_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91b81907a7d94fc1a709a3a7f59a42f2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4603fb59699f4e428a7f38a3b3c0ae44_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18940842a4d4141bb83557faaaa3f5d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea3bc90fc5e45babe9d16439371f804_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9cfc17885754c02bf2915c69856a33b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdfc0ddf63e14d7082cb9c967c847020_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6eea0a991414c36a0929d31f1d3d7f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5916c4827b84fc8b33f7160c0b78aab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e8a39dfcb84e878ff3f8aa02b39b95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc04475ba4c443bb02c7f09ee9c52a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52408a7bafe3490ea2b90900d2fd960a_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27893806b30342149eb85b8143f8df92_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e645342cf74ea6b3b63d9596768247_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ad34f7e1fb4d8694c59f20b25c8ba6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae18aea4a6d4d3c9f8d5c3d37e7307e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ba8f04e8d44ad486f7a21607ab601a_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie29255ae26c54473ad60f4e96b040b6a_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d517722f68464aa57cb746d8b6b0fc_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37765677fef04878bfd307079cffd395_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a68f56ad3d4f398d8120b6f54fc354_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea511a0f86dd4c4daa7a2411ba8f627d_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb7a61f34a4b428e9a376347e43312f6_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab205c27896840a48993517f0d658e53_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88481b1f040d4ae9ab9358ec2a521621_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ff4879231b4c58a0d8f431b824853d_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6909f0d3984eef85455ec758334932_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7142d15699314123900d44fdfb1d6fa7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0d08a54b2d45fcbab6217ef7c19f5c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6b6924916f49cebf4a3197558fd9aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b557d2dee24d6d85852c77416f09b7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b03a95d6ac1446db1df7032d377d274_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893010e7c4d84530bb4e535807bafd81_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfb3d422efb4a2184822401861fbbb9_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d27a8b650fb459ea73fa6afb06d6686_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390779b4e1374f78a3d2ff4696312717_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3552069f01754175946fbde459157a66_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac7d80114ef46d39ae9a53271640ba1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f47e32ce8e4ceab933f1129b620c5e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73ab2ac402a4838afab49d9909a77b3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i452d4086812e4e2eb52bd1a594c530b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if870d3ee8de04697b45e9489a10d6c63_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia42107d884244b2ab5d0ba0cf3931add_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id527e215cc174d55a56cc5895cb43547_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a3137493924173b60421527f2075d0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffa84374b394851b73ca24a8916a301_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd804bfec7bc4f1d89cace194a5d9f99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a410a7e6134fa78385a8cc70a725e0_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa6a3da81d5470497285d540411a506_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib894c6511aad4955ac97436b31cd674f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89136a0062a546e4bba3db98f38f30c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629d249a546f43ebb5ec4d9fc839c160_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8fbecc9e72463d930d63daeec62a21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8773e0c5834143cbb0d43e34a17e2a92_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6ef50417cb4013b7ac39e1693b2f04_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcabaf70069543ae99e3fe4be7d87d00_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d331e039ce4907b44d8c6829eb96ab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf836415560143e7aa246d7036b09772_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6128ef27165d4066a955a859b4b0ee27_1"></div><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">FORM <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTYw_4de4dd48-715f-4804-9d34-3628a59ba706">10-Q</ix:nonNumeric></span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">       (Mark one)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6ODQ0YjEyODk2MjhkNGU2NTkzM2E0ZjY1NWNjZjYxMWMvdGFibGVyYW5nZTo4NDRiMTI4OTYyOGQ0ZTY1OTMzYTRmNjU1Y2NmNjExY18wLTEtMS0xLTQ5NzEy_577051d8-18ff-4e1a-9a56-1495161c1546">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">For the quarterly period ended <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTM_2563fbd2-5def-43e9-bd53-484773d47885">September 30, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NzZlZjQ0ZGM0YzgzNDUyN2IzMTI2YjdlZmVjMmI4MzgvdGFibGVyYW5nZTo3NmVmNDRkYzRjODM0NTI3YjMxMjZiN2VmZWMyYjgzOF8wLTEtMS0xLTQ5NzEy_d572da6b-2f6c-460b-bff1-96ac5911e204">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the transition period from ___________ to ______________.</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:80%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Commission file number:  <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU0_c4429d95-bfca-4f70-9055-127aa07cfe81">001-40654</ix:nonNumeric></span></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ5_20db404a-91ce-475f-a40a-afe65bfc1a0e">CONTEXT THERAPEUTICS INC.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">___________________________________</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:80%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NGZhNWUzYzc4YjFmNDI5ZWI2NjVlNTI3M2ZlMjgwMjcvdGFibGVyYW5nZTo0ZmE1ZTNjNzhiMWY0MjllYjY2NWU1MjczZmUyODAyN18wLTAtMS0xLTQ5NzEy_a7ce617b-8e54-4d2c-acf1-ef5ffa85aa14">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NGZhNWUzYzc4YjFmNDI5ZWI2NjVlNTI3M2ZlMjgwMjcvdGFibGVyYW5nZTo0ZmE1ZTNjNzhiMWY0MjllYjY2NWU1MjczZmUyODAyN18wLTEtMS0xLTQ5NzEy_4695dd05-5e7f-4461-b4ff-c09d8fc6b334">86-3738787</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">(State of other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUz_c7a51b91-268f-46d1-aac5-bab51f86b9d4">2001 Market Street,</ix:nonNumeric> <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTYx_8005dd00-b537-421c-a2ce-d0499a27ee13">Suite 3915, Unit #15</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU3_96821f27-b9cd-476e-a444-6982c1e61b6a">Philadelphia,</ix:nonNumeric> <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUx_b11ef277-d7f5-4f19-a6e6-893f46c60a24">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF81MTE_48b9f4b7-ad38-41e7-b3c3-2cc22eea6555">19103</ix:nonNumeric> </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF81Nzg_7b25c4db-01d7-4a28-85d6-c54f34d589d8">267</ix:nonNumeric>) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ3_81426f8c-b5da-4f53-beb0-e3ccc2aa7512">225-7416</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:8.52pt;padding-right:8.52pt;text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:39.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTAtMS0xLTQ5NzEy_1751a0f8-bb29-4fb2-acfd-2f918ac7e7ff">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTEtMS0xLTQ5NzEy_03915ff1-bf96-43f0-b54b-ca2ba0cf0d86">CNTX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTItMS0xLTQ5NzEy_f9596a07-d76c-4f08-b27e-a79e677643c8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ4_a20de20c-5b12-4043-85db-0f99c2b93297">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#160; No&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">o</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUy_6ad24768-d099-46b9-9079-150b3930a48b">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">o</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18xLTAtMS0xLTQ5NzEy_6694b805-9a91-4a1d-8e4a-463c6b6d5c60">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18xLTQtMS0xLTQ5NzEy_852e4e3e-c33b-44ea-8e1c-d4ba9e6617e3">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18yLTQtMS0xLTQ5NzEy_a7eaa096-4cb6-438f-8532-4d364a60c15e">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU4_347cd3f4-d248-41ae-9d68-19cb429ad862">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU5_4598a963-1061-42be-96ad-73ab06f1b850">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#253;</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">The number of shares of common stock outstanding at November 4, 2022 was <ix:nonFraction unitRef="shares" contextRef="id897838cf09a4fb98dd25ffc123540c1_I20221104" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTM2_a777224a-c6c0-4fdf-9440-cce338e43ca6">15,966,053</ix:nonFraction> shares.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%"> INDEX TO FORM 10-Q </span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_10">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_10">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_16">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_16">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_19">Item 1.&#160;&#160;&#160;&#160;&#160;Financial Statements (unaudited)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_22">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_25">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_28">Condensed Consolidated Statement of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Deficit</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_31">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_37">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_37">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_70">Item 2.&#160;&#160;&#160;&#160;&#160;Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_70">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_100">Item 3.&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_100">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_103">Item 4.&#160;&#160;&#160;&#160;&#160;Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_103">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_106">PART II &#8211; OTHER INFORMATION&#160;</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_106">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_109">Item 1.&#160;&#160;&#160;&#160;&#160;Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_109">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_112">Item 1A.&#160;&#160;Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_112">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_115">Item 2.&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_115">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_118">Item 3.&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_118">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_121">Item 4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_121">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_124">Item 5.&#160;&#160;&#160;&#160;&#160;Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_124">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_127">Item 6.&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_127">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_130">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_130">35</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">         </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_________________________</span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context otherwise requires, all references in this Form 10-Q to "Context," "Company," "we," "us," and "our" refer to Context Therapeutics Inc. and its subsidiaries.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_________________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:202%;text-decoration:underline">Trademark Notice</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Context Therapeutics&#174; is a trademark of ours in the United States. All other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This Quarterly Report (including, for purposes of this Note Regarding Forward-Looking Statements, any information or documents incorporated herein by reference) includes express and implied forward-looking statements. All statements other than statements of historical facts are forward-looking statements.  These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.85pt">the timing of preliminary results for our ongoing Company-sponsored trial and investigator-sponsored trials;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the timing, progress and results of preclinical studies and clinical trials for onapristone extended release (&#8220;ONA-XR&#8221;), anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsAb&#8221;), and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the timing, scope and likelihood of U.S. and foreign regulatory filings and approvals, including timing of Investigational New Drug applications and final U.S. Food and Drug Administration approval of ONA-XR, CLDN6 BsAb and any other future product candidates; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to develop and advance ONA-XR, CLDN6 BsAb, and any other future product candidates, and successfully complete, clinical studies; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our manufacturing, commercialization, and marketing capabilities, implementations thereof, and strategy; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus, sales strategy, and our ability to grow a sales team; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the impact of the COVID-19 pandemic and other economic uncertainties on our business and operations, including clinical trials, manufacturing suppliers, collaborators, use of contract research organizations and employees; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the need to hire additional personnel and our ability to attract and retain such personnel; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our expectations regarding the approval and use of our product candidates in combination with other drugs; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;our dependence on collaborations with third parties for certain research, development and commercialization activities;</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our competitive position and the success of competing therapies that are or may become available; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to obtain and maintain regulatory approval of our product candidates; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our plans relating to the further development of our product candidates, including additional indications we may pursue; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;existing regulations and regulatory developments in the United States, Europe and other jurisdictions; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ONA-XR, CLDN6 BsAb, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to obtain, and negotiate favorable terms of, collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the pricing and reimbursement of ONA-XR, CLDN6 BsAb and other product candidates we may develop, if approved; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the rate and degree of market acceptance and clinical utility of ONA-XR, CLDN6 BsAb and other product candidates we may develop; </span></div><div style="margin-bottom:0.05pt;margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </span></div><div style="margin-bottom:0.05pt;margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our current plans and ability to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources and the availability and terms of such future sources of capital;</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our financial performance; </span></div><div style="margin-bottom:0.05pt;margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the impact of laws and regulations; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our anticipated use of our existing cash and cash equivalents; and </span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221;;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as other statements relating to our future operations, financial performance and financial condition, prospects, strategies, objectives or other future events. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.  As a result, you should not place undue reliance on forward-looking statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the forward-looking statements contained in this Form 10-Q represent our views only as of the date of this Form 10-Q (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the reports that we file with the U.S. Securities and Exchange Commission ("SEC").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-Q. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></div><div><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_13"></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Market, Industry and Other Data</span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Form 10-Q contains estimates, projections, market research and other data generated by independent third parties, by third parties on our behalf and by us concerning markets for ONA-XR and CLDN6 BsAb. Information that is based on estimates, projections, market research or similar methodologies is inherently subject to uncertainties and actual results, events or circumstances may differ materially from results, events and circumstances reflected in this information. As a result, you are cautioned not to give undue weight to such information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Form 10-Q also contains certain data and information, which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications include projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part I - Financial Information</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Financial Statements</span></div><div><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Balance Sheets </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Note 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNC0xLTEtMS00OTcxMg_713a9893-9586-4f9b-bfbe-9136002ff5e0">39,427,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNC0zLTEtMS00OTcxMg_64315d63-9a80-4efa-a05e-11a8f5b3d86e">49,635,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNS0xLTEtMS00OTcxMg_46409073-af8a-4adf-a65c-3664281eed45">2,512,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNS0zLTEtMS00OTcxMg_c35e04e2-9fbc-48c6-84ab-8340d8a87326">1,620,164</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNi0xLTEtMS00OTcxMg_29b0b6e2-1456-4888-8a6e-f3ec9c6d6eba">41,939,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNi0zLTEtMS00OTcxMg_bc795ec6-4f1b-43ca-a11e-f07719088d85">51,255,361</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNy0xLTEtMS00OTcxMg_6b4c2220-fcb2-470a-894c-6e2e4cb9e14d">73,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNy0zLTEtMS00OTcxMg_2714bbe7-ba7e-4bf9-bcae-ff31c378935d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOC0xLTEtMS00OTcxMg_e767fd3c-fc7b-4a43-83c1-c67f07357974">30,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOC0zLTEtMS00OTcxMg_0905f010-9cba-4745-b41f-01271e8e8f85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOS0xLTEtMS00OTcxMg_29fb71a6-551f-40c9-9402-d5364b084351">39,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOS0zLTEtMS00OTcxMg_dc6233f4-5053-4ef9-8bf0-36fd70942870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTAtMS0xLTEtNDk3MTI_700edbf1-fb6d-4b6b-8bc1-155e7e8f8ece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTAtMy0xLTEtNDk3MTI_28d86d01-2c58-4cfb-b517-fd5c6231fae7">50,389</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTEtMS0xLTEtNDk3MTI_03ed4867-0ca2-469d-a519-7d3062d2d688">42,083,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTEtMy0xLTEtNDk3MTI_754e4397-cee3-4f64-b0d7-5d4af951e4eb">51,305,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTQtMS0xLTEtNDk3MTI_fa57f685-f1c2-4736-99fd-244ad6985315">1,494,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTQtMy0xLTEtNDk3MTI_8d7a1898-7c5a-48f5-95f7-b4b54c965c0b">1,826,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTUtMS0xLTEtNDk3MTI_3c3eac73-bfc7-47f7-b164-cc8f8da5b7d2">2,438,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTUtMy0xLTEtNDk3MTI_5d5e2dac-5cf0-47cb-bdda-099f29227799">1,207,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTYtMS0xLTEtNDk3MTI_21f96253-752f-4d6b-9704-bd52b51a5f84">78,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTYtMy0xLTEtNDk3MTI_fa47fdd5-298b-4e94-a0ae-dee6ea1163ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTctMS0xLTEtNDk3MTI_5ea7117b-f383-4d98-85bf-4dd2473a3379">4,011,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTctMy0xLTEtNDk3MTI_d8323ee6-5466-41b6-ab40-c542c2e9aca9">3,033,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTktMS0xLTEtNDk3MTI_826ebea7-3b1c-4a6f-b67c-eca76565bea7">4,011,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTktMy0xLTEtNDk3MTI_4cba41af-1add-40bf-a99d-62b74d920005">3,033,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjAtMS0xLTEtNDk3MTI_950a32ee-686b-4a6f-a5db-3a2ee82cad97"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjAtMy0xLTEtNDk3MTI_f8a4690a-da19-4e24-ae79-058a85bd1ec6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:19.5pt;text-indent:-13.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8yMQ_a737279c-1313-4ccf-840a-4b9957d0cc6b"><ix:nonFraction unitRef="usdPerShare" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8yMQ_d325b640-f562-4350-8899-0cad2a27b4ca">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8zNQ_b4754ddc-ecba-4267-9ff7-dd3aee026cad"><ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8zNQ_c4825cd1-7415-4f9e-b50f-5c280b0a0ae4">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_5802f078-0785-431c-ba80-946facd12cd4"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_7de1e803-5185-4da9-b9e5-00fb643eb0cf"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_9ca7d8ac-2895-42d2-9e61-43238d8afd9d"><ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_cd529052-e105-48ce-bee4-668df48a979c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMS0xLTEtNDk3MTI_ec56b248-55b1-415a-ae01-fb2a5e5b9051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMy0xLTEtNDk3MTI_9ebdfdcd-e688-40b3-9f04-d08508993c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:19.5pt;text-indent:-13.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8xOA_258f6e0a-3732-428b-b630-089456267097"><ix:nonFraction unitRef="usdPerShare" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8xOA_f58133ab-e3d5-46e6-99b5-3f5e4543007f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8zMg_4661b880-a904-4966-9dc6-c808b9a24d3d"><ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8zMg_9026d6a8-f2a2-4be3-b358-c6bc1b0e1dae">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_4e1cdd3c-1d10-4dc4-a964-81e75967eb56"><ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_6bdfc8af-e75a-470c-89a7-b0f715fd1839"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_9b432b29-2f45-48cb-b402-7ab709474eee"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_ee1678b4-28c3-415b-8e93-af1ab45fd526">15,966,053</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMS0xLTEtNDk3MTI_6b7146f5-ce9b-42f2-8b68-633181d723db">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMy0xLTEtNDk3MTI_7e477ba8-c521-43c6-a577-6503eb796275">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjQtMS0xLTEtNDk3MTI_71932b6e-8c1e-47c2-9f1d-be846450cb93">78,589,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjQtMy0xLTEtNDk3MTI_98a972e8-0cfc-4af7-84fa-4e6ceb0d8c15">77,510,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjUtMS0xLTEtNDk3MTI_136f98ff-446e-4d7c-9900-3e0121bd26ea">40,533,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjUtMy0xLTEtNDk3MTI_83c4aae7-fe1b-4134-89b6-68bcdfcc1bb7">29,254,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjYtMS0xLTEtNDk3MTI_696f0b53-0c2d-4f88-bd6b-ca3f95a73564">38,071,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjYtMy0xLTEtNDk3MTI_deba6bf5-c07e-495a-82ed-fe4183ac8766">48,272,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjctMS0xLTEtNDk3MTI_9699d476-0d86-48e5-9c02-c096c17c88da">42,083,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjctMy0xLTEtNDk3MTI_9fadf479-d4cd-4c4c-8c34-d1ed523f5edc">51,305,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:46.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy0xLTEtMS00OTcxMg_923581f2-05c8-4a8b-8e8d-03b0e6476093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy0zLTEtMS00OTcxMg_461e75da-f558-4806-ad8e-47c1a2cd0a20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy01LTEtMS00OTcxMg_068d0f5b-6168-44ac-8d54-7bbc5d2771b3">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy03LTEtMS00OTcxMg_ca647cb7-4d25-4bb0-947c-db938192c579">3,087,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC0xLTEtMS00OTcxMg_1fa241ab-0901-4b91-853a-88d0d26e2c24">2,077,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC0zLTEtMS00OTcxMg_49e02b83-9c59-4e18-86c8-41b12204e4cf">739,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC01LTEtMS00OTcxMg_773f1b3c-fa2e-4c88-9c58-63f2ac8ba166">4,946,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC03LTEtMS00OTcxMg_c5a36242-223b-4c20-a34f-3f55b6540ba3">2,511,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS0xLTEtMS00OTcxMg_ac70a21c-6535-4f25-b804-7019f302c73b">1,970,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS0zLTEtMS00OTcxMg_38806a74-4da8-4e33-a966-8cf10de4e863">828,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS01LTEtMS00OTcxMg_57a3cd17-c053-4649-bb1d-2a0d3e985ad2">6,052,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS03LTEtMS00OTcxMg_0cfe3518-05ce-4b0c-80fb-ffe21b7d62f4">1,834,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi0xLTEtMS00OTcxMg_4b0e3c2f-8a81-4f12-b4b1-e921fa45c2af">4,048,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi0zLTEtMS00OTcxMg_6f441a10-734b-4f2e-aa9c-705b3123cc91">1,568,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi01LTEtMS00OTcxMg_028e5797-1a0d-4ee1-b22f-e6f310866a84">11,498,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi03LTEtMS00OTcxMg_f23cb09b-bb4a-43ff-b21c-c4d317198a36">7,433,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy0xLTEtMS00OTcxMg_a196acd3-0545-4a4b-b323-a9268de6dcd5">192,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy0zLTEtMS00OTcxMg_01827078-a9b4-4055-befc-756d3aa034bf">1,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy01LTEtMS00OTcxMg_7b6d6295-4395-44ec-b924-60f7cb9655c2">219,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy03LTEtMS00OTcxMg_f0ed5bcb-dc55-4834-a145-e804203675e1">64,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of convertible promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC0xLTEtMS00OTcxMg_46a2813e-c848-487d-9341-5ca6e2e86be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC0zLTEtMS00OTcxMg_a02ef09c-58bb-4ae2-8052-7ee15e84ca74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC01LTEtMS00OTcxMg_a8182f6d-cbb1-4db1-9356-c51db94f0c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC03LTEtMS00OTcxMg_5f1557c2-c21d-409a-b665-ae862ebf03eb">9,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS0xLTEtMS00OTcxMg_b322d735-ca0d-4538-a90a-0f31240d54df">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS0zLTEtMS00OTcxMg_c67fecf2-4f6c-4ce4-aeea-45be602c2eff">126,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS01LTEtMS00OTcxMg_8ecd4cb8-7b5d-4ccf-84a6-d2e0fe9e59b7">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS03LTEtMS00OTcxMg_1291771a-df82-4d03-881f-a0dd0cfb4713">124,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtMS0xLTEtNDk3MTI_989bbae3-09af-455b-a2e3-b140ab0b494d">3,854,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtMy0xLTEtNDk3MTI_878e1968-4f4a-410e-b5fd-75b120200a7a">1,442,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtNS0xLTEtNDk3MTI_972bf84c-4ba2-4438-8ef6-b93c905fc64c">11,279,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtNy0xLTEtNDk3MTI_496aaa9d-2ca9-43b2-8d87-aaf75dd89e5c">7,365,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMS0xLTEtNDk3MTI_0964f98c-37f0-43ad-9c92-bb3134f0d57c"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMS0xLTEtNDk3MTI_883c2eb6-758c-4238-9dbb-12917f175739">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMy0xLTEtNDk3MTI_e1323283-cc8b-441a-98a5-29aa8492c789"><ix:nonFraction unitRef="usdPerShare" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMy0xLTEtNDk3MTI_ebea069b-aae3-4776-903d-0b5c00eb6108">4.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNS0xLTEtNDk3MTI_6231ed5c-c4f4-4e63-a692-d80175410285"><ix:nonFraction unitRef="usdPerShare" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNS0xLTEtNDk3MTI_b810ca34-3826-4683-b7f8-de5acc461c78">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNy0xLTEtNDk3MTI_985ef353-01fb-435f-8740-6c87d4976238"><ix:nonFraction unitRef="usdPerShare" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNy0xLTEtNDk3MTI_dd6da342-4977-4d95-9c3f-68218bf2c5cf">20.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMS0xLTEtNDk3MTI_7563f6eb-88f5-47b1-9168-2fcdb0077783"><ix:nonFraction unitRef="shares" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMS0xLTEtNDk3MTI_b52672e6-0de4-4936-9b7b-8b4fcc3f49ad">15,966,053</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMy0xLTEtNDk3MTI_4001669d-eb20-49c4-85a2-c18a764c2dab"><ix:nonFraction unitRef="shares" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMy0xLTEtNDk3MTI_6dd492a1-da8a-444a-9d6e-2bfc577a5b6d">361,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNS0xLTEtNDk3MTI_c1c8c4a3-fc9c-4791-b105-6add37c2fe6c"><ix:nonFraction unitRef="shares" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNS0xLTEtNDk3MTI_cbeb1744-0cbe-4135-8f18-82524f0c62ca">15,966,053</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNy0xLTEtNDk3MTI_920257d8-1056-4fba-a87b-e113a12aa6f9"><ix:nonFraction unitRef="shares" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNy0xLTEtNDk3MTI_a27dd9db-132f-4a93-8f38-3028d6b66ae4">355,087</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statement of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Deficit </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Series A<br/>Preferred Stock&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Series Seed<br/>Preferred Stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Redeemable<br/>Common Stock </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Common&#160;Stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional<br/>Paid-in<br/>Capital </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated<br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total<br/>Stockholders&#8217;<br/>Deficit </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i91d778453bdd415ca0474d3b80c97e81_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xLTEtMS00OTcxMg_0f789e0f-c8bb-4ddc-876c-7d7d83478475">210,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i91d778453bdd415ca0474d3b80c97e81_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0zLTEtMS00OTcxMg_666fa77b-6758-4ff9-9c73-55b3e0fcf220">1,400,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i7ab19c1394c44429ac9cf701c02bacd3_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi01LTEtMS00OTcxMg_20471bd9-1c38-4a08-817a-8e7a54b648bd">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i7ab19c1394c44429ac9cf701c02bacd3_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi03LTEtMS00OTcxMg_bb0ae81e-3aa1-4610-b469-fb31670fc033">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi05LTEtMS00OTcxMg_4e57054b-218d-4dcd-a8d1-47e1ba9f50c8">16,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xMS0xLTEtNDk3MTI_53c38111-b0d7-4189-9748-2ce205842c33">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xNC0xLTEtNDk3MTI_d7e39e4a-f5dc-4fbd-ab7d-4d7b743027a3">331,789</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xNi0xLTEtNDk3MTI_b81bbbfe-df1a-49fd-9130-1c96004a355a">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i8044192b7fa3405f8f099c5b69712352_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xOC0xLTEtNDk3MTI_44f7f4bb-3e40-4121-9125-b7df493ecd72">1,876,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i9c7d6b0e50bc4558a6bf3ad8ad190e64_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0yMC0xLTEtNDk3MTI_4f6c03fb-1cc3-4bd5-b591-d519fae0c31c">18,797,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i2dbda5f1db214fb88786236031b5e24c_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0yMi0xLTEtNDk3MTI_768da387-eb8b-44be-8838-cdc40332585b">16,921,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Sale of Series A preferred stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0wLTEtMS00OTcxMi90ZXh0cmVnaW9uOjNkNzM0NTZkZGRlNTQ3NzM5YjM4ZmJjYmIxYmFmNWU0XzYz_971e83c3-7e83-4f17-9b75-f9ef97610915">213,073</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0xLTEtMS00OTcxMg_2fafb12b-29a6-4987-87e1-d1bef8df0396">453,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0zLTEtMS00OTcxMg_a9750c5a-7c39-4071-8b4b-09e3e984abd2">3,034,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0xLTEtMS00OTcxMg_0eeef742-2221-481e-bba8-ab22b88caa32">844,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0zLTEtMS00OTcxMg_622c1dcb-2041-4fa9-812e-4190deabf23b">5,728,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0xOC0xLTEtNDk3MTI_63058e8a-a871-4607-ad4d-a32b60579ce9">137,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0yMi0xLTEtNDk3MTI_92f7594c-8f97-4417-92f2-58e11a1230b7">137,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued in conjunction with the Series A preferred stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0zLTEtMS00OTcxMg_f43c0de5-1a5a-4391-a5c2-9503b4209743">158,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i8d87d55ccb734efb9c7ed1999f656107_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0xOC0xLTEtNDk3MTI_5b45433b-ef28-43cd-9333-327f8e189494">158,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i0d0f5d0c94a24a37bbe2603f3a941447_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0yMi0xLTEtNDk3MTI_8c061b53-aaba-4a63-8b90-2d7b36f55fa2">158,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued as placement agent fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0zLTEtMS00OTcxMg_6a6c6484-99dd-4c15-9236-a6d1ec5e0984">13,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331" decimals="0" name="cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0xOC0xLTEtNDk3MTI_173263e6-8447-45f2-be17-0e8a1713ad5a">13,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331" decimals="0" name="cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0yMi0xLTEtNDk3MTI_f9d1361d-9839-47e6-afcf-3208172118b5">13,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xNC0xLTEtNDk3MTI_3a42ab54-83b1-43fa-9db4-48697cd6b57a">4,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xNi0xLTEtNDk3MTI_15c35ae9-6257-4852-b613-50833a71d77f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xOC0xLTEtNDk3MTI_a2dd7d04-8505-4fb1-ad9e-d9c6c7851ce9">25,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0yMi0xLTEtNDk3MTI_6e1f5348-839f-44cb-86a8-8072866eb642">25,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i0dff8bbfea2e482896c4ab248a7dda24_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOS0yMC0xLTEtNDk3MTI_8efe0d05-65af-484a-b278-11ff58b4e12a">892,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOS0yMi0xLTEtNDk3MTI_440b8e89-2c21-4c10-87e1-33d27e725746">892,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9523681451b740f0a62eab036c049fcf_I20210331" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMS0xLTEtNDk3MTI_f7b00b6a-4556-4b5f-a2a4-364e92241074">1,508,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9523681451b740f0a62eab036c049fcf_I20210331" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMy0xLTEtNDk3MTI_fdb2ca2d-b785-4811-aa82-ec6b1b9a49f3">9,992,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i23e70673670b454697bd3e735f7ead67_I20210331" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtNS0xLTEtNDk3MTI_a431267a-2593-44e8-aaea-9ca3bbed0200">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i23e70673670b454697bd3e735f7ead67_I20210331" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtNy0xLTEtNDk3MTI_1c564e60-c502-4367-908e-445eeb365f8b">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="iab094eb4f1c449799a6a0a40dfaefe12_I20210331" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtOS0xLTEtNDk3MTI_d7bddee7-0408-4d77-9315-7617bdaf1c7e">16,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iab094eb4f1c449799a6a0a40dfaefe12_I20210331" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTEtMS0xLTQ5NzEy_56ddcda2-07f2-48c0-a7f7-3a9b0ffa969b">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i5e5be68e8b1d499185e82be5b03a485f_I20210331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTQtMS0xLTQ5NzEy_4b304cb6-17e3-4a59-985c-4e9ff36343f8">336,007</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i5e5be68e8b1d499185e82be5b03a485f_I20210331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTYtMS0xLTQ5NzEy_0652b57f-78ec-4f65-bce8-23e9d4ffcc9d">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i1985a71fd2e840d0a0b035d856815619_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTgtMS0xLTQ5NzEy_20d1f16b-7ff3-43f2-811e-fb48facf7d1f">2,211,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i053e2d5b4fdd45cba9f89d705600f026_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMjAtMS0xLTQ5NzEy_c0c07ed9-f12e-4f3a-80af-98f79fabbdef">19,689,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3c334b6a33324fb8ab9e49483ece3d16_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMjItMS0xLTQ5NzEy_9df26a76-3559-478d-95e0-8ef210eeade0">17,478,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Sale of Series A preferred stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjphMDdjY2E4NzNkNzk0ZTdiOTQ1Y2UyNjM5YjJjMjBhNl82Mw_f5ddb8a2-f4c3-4f7a-ac98-f89e7d2e5f86">96,948</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMS0xLTEtNDk3MTI_2a84cafb-5588-4f1d-b90e-1e4ef2384e0a">285,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMy0xLTEtNDk3MTI_3a30db1a-def5-49ce-b4b2-1a5b99670cb5">1,948,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTItMS0xLTEtNDk3MTI_bb6a46fd-5b59-4921-a9fd-d0c460c69d10">418,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTItMy0xLTEtNDk3MTI_fe63646b-326f-4243-ba6c-7022178fd8ac">2,837,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued in conjunction with the Series A preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMy0xLTEtNDk3MTI_7a956b0a-72cd-4f5b-900f-716f83c3e548">106,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i469bd896d0404212882a523d504522da_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMTgtMS0xLTQ5NzEy_95923447-be29-4d32-bafb-0e9e56c76baf">106,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id2d5ed2cb14343529f70dad75a4e6f8d_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMjItMS0xLTQ5NzEy_dd8e9371-087e-497b-aeac-cc9908511a23">106,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued as placement agent fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMy0xLTEtNDk3MTI_9f39ecdd-34ea-43b9-b93b-e85aa91f37c9">30,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630" decimals="0" name="cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMTgtMS0xLTQ5NzEy_b5108b5e-b079-4442-ae0d-92261c6f0a0a">30,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630" decimals="0" name="cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMjItMS0xLTQ5NzEy_7c6ce12b-217f-47fb-bc0e-6a2d37192f22">30,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTQtMS0xLTQ5NzEy_d1540675-6b95-43ce-8258-0198ff6d42a8">6,262</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTYtMS0xLTQ5NzEy_20f5e916-9b09-4fe0-85d7-c3827385f3e4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTgtMS0xLTQ5NzEy_d96e0464-b154-4113-8ca3-d1bc57f6c944">119,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMjItMS0xLTQ5NzEy_3041b77c-8fb9-4c7c-b8f1-565e30f7a1b1">119,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Change in fair value of redeemable common stock to redemption value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifd6441b83d394e10b602af00c07a1e9a_D20210401-20210630" decimals="0" name="cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMTEtMS0xLTQ5NzEy_7c2a5107-bb9a-4f9c-8987-9f01b3c1e7ac">53,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMTgtMS0xLTQ5NzEy_aff3f488-f3f3-400d-99e7-0dbed9e2cf8c">53,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMjItMS0xLTQ5NzEy_e0fb2cb4-898f-4e78-bfc6-eba372ba1ce3">53,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="icf64ab93cf964595a69c22ef2bf1bbc3_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTctMjAtMS0xLTQ5NzEy_385daf5f-2a77-41d4-86d6-7e5c41eca846">5,030,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTctMjItMS0xLTQ5NzEy_86696421-7946-4f21-83fa-b1fe09d1f0b0">5,030,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i8e4251d780d94171abc72a54e3f1d40b_I20210630" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMS0xLTEtNDk3MTI_bbddfc2a-599d-4134-aff5-8682f5e45ef7">2,212,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i8e4251d780d94171abc72a54e3f1d40b_I20210630" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMy0xLTEtNDk3MTI_ef7255cb-7e43-4b25-b1c6-468be0655b5c">14,641,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i72999784f84f4f78976de510cce92938_I20210630" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtNS0xLTEtNDk3MTI_7796f20d-84dc-43c6-90f9-9ad7e60b55a2">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i72999784f84f4f78976de510cce92938_I20210630" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtNy0xLTEtNDk3MTI_dccc3ce9-ecf2-4877-9df4-51c8858bacce">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ifb364b5e1db7443e829eab3187e71baf_I20210630" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtOS0xLTEtNDk3MTI_2ea6d635-ff0e-44a4-a358-fb7e36b5dc58">16,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifb364b5e1db7443e829eab3187e71baf_I20210630" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTEtMS0xLTQ5NzEy_e2b4980b-a002-47ce-8494-3a45990d5a78">82,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTQtMS0xLTQ5NzEy_d0cdd8f7-f797-4498-87f1-0fee9f71b1cc">342,269</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTYtMS0xLTQ5NzEy_c1a4fcf5-5da6-4404-a0ac-6df75a0be807">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibfd008432ea34dd495de31355c35c5b8_I20210630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTgtMS0xLTQ5NzEy_fecdb11d-6ae3-45c4-84d2-30ce3f2c06f0">2,414,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="iab1984306aeb45b086de0b8f791fa525_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMjAtMS0xLTQ5NzEy_5d2ab032-ac64-4175-bf15-9738e5bba5fd">24,719,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="if4538f14815a4c249d92da084a9a25ed_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMjItMS0xLTQ5NzEy_1595e473-536e-40fb-82eb-257f7d7668f6">22,304,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i41ac2f42af1e46f28082b9e44edd8bd1_D20210701-20210930" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTktMTgtMS0xLTUxNDIw_f5a83868-107c-48f3-8334-34617d8eafa3">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i79bf85e416f34002b19f3f5ac5bdba47_D20210701-20210930" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTktMjItMS0xLTUxNDIw_0f1c99e7-9d30-411e-8601-d6f2fe8b6b1a">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTQtMS0xLTUxNDIw_2c3e1a39-512c-48cb-92bb-a6ad2329789b">6,262</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTYtMS0xLTUxNDIw_227801aa-55b3-437d-9e00-523932d2df66">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i39eb46827db041658824ba64d452487b_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTgtMS0xLTUxNDIw_a8a69c8e-1bc0-43da-a3a1-abeef4344421">161,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMjItMS0xLTUxNDIw_b5c2bfbb-20ca-4841-80f6-ec88cf9d8af0">161,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3ba3cd3b4cb54008bf47ddd2a959ae16_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjEtMjAtMS0xLTUxNDIw_b3819e34-c804-4d03-b3c5-ff52117273e1">1,442,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjEtMjItMS0xLTUxNDIw_683a522c-0b14-42d5-8c30-5aa8b19f0da9">1,442,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMS0xLTEtNTE0MzI_bb543168-7754-41dd-94c6-859a4cb2a16d">2,212,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMy0xLTEtNTE0MzI_822ec977-7ddc-47de-bbd7-1b64a5c681e9">14,641,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i88cf0f3abb49481aa205ca8023e30fbc_I20210930" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItNS0xLTEtNTE0MzI_3207b941-6e96-421f-9845-80358c7cfd79">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i88cf0f3abb49481aa205ca8023e30fbc_I20210930" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItNy0xLTEtNTE0MzI_56bfb606-d495-442f-a12b-ecf5ba9e36da">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItOS0xLTEtNTE0MzI_c7f49169-668d-4461-8b35-1b235559dae1">16,666</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTEtMS0xLTUxNDMy_c5e5b5d0-b144-4fb0-a2ab-a9ec3a05907b">82,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ia720be76271949ebb4bd4ecc9a63607a_I20210930" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTQtMS0xLTUxNDMy_c2495526-2c7c-43f4-a955-bb15020224c2">348,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia720be76271949ebb4bd4ecc9a63607a_I20210930" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTYtMS0xLTUxNDMy_3f6a5014-b27f-4b7f-8b54-36f3425bca0c">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ic9faae0f7b5144a19efc12326f0f220e_I20210930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTgtMS0xLTUxNDMy_fb689a47-26d1-47c8-ac64-2c61759935f9">2,948,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ib5595b49782e4a2696ca3a2a49ad6925_I20210930" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMjAtMS0xLTUxNDMy_9766a434-0136-4ef7-a08c-23932b3eedee">26,162,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ifd60ff9a89c748609e3e159d17b22413_I20210930" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMjItMS0xLTUxNDMy_b0761558-c4b8-42a1-b20a-d2840b795fd8">23,213,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-right:-7.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;padding-right:-7.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.238%"><tr><td style="width:1.0%"></td><td style="width:61.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.519%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Common&#160;Stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional<br/>Paid-in<br/>Capital </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated<br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi0xLTEtMS00OTcxMg_08a598b1-0cfb-42fb-a92f-0d76d3487b0d">15,966,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi0zLTEtMS00OTcxMg_f4c753de-1249-4b6e-95df-c70ac3440ff6">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id904dd6c948942fa95d470d8f7fc4c71_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi01LTEtMS00OTcxMg_1a35adc5-2f07-4d39-9431-cf6d2a2be66a">77,510,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i017447a0256f4196a4817dfa28f8e101_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi03LTEtMS00OTcxMg_0af2d8a2-6f18-45ba-8201-f062c46a6c6e">29,254,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi05LTEtMS00OTcxMg_268424dd-05b4-4596-a393-91c59da154ff">48,272,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i90d3dccad9594e50872f23a00f725fff_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMy01LTEtMS00OTcxMg_163d4d37-4a9e-447f-8ae0-ec38aea7f660">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i57ab355349f74b32990f6a5b1420ee6e_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMy05LTEtMS00OTcxMg_1e6ccb28-ea65-43f6-b2d8-c9578c9f636c">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="idf9a2c2fcc664d35b2b5d1dd7995760c_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNC01LTEtMS00OTcxMg_13718dd4-1337-4a3f-b162-93d49267699d">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNC05LTEtMS00OTcxMg_a6e573b1-0621-41b2-88f4-f6214ac0b123">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ic1810fec077b40c0930be13c655ee345_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNS03LTEtMS00OTcxMg_cc451caf-2f21-49bd-a9cd-3d7c0ea8fb4c">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNS05LTEtMS00OTcxMg_255e8768-19db-462a-b163-cee21b8bbbe6">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i3e87e049d31a4a989377c27f50ee7a17_I20220331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi0xLTEtMS00OTcxMg_5edfc7bd-47ab-4483-83e8-f4374319095f">15,966,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3e87e049d31a4a989377c27f50ee7a17_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi0zLTEtMS00OTcxMg_0c1b12de-0aab-4309-909f-7b823c674194">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02ebe5df39614a3fa046b9dec55140fb_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi01LTEtMS00OTcxMg_cb02dd28-89e4-4ba5-a07c-7c5ee9ff4fc7">78,071,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i539fb2bc4bb345aabb6f8dfdd9ba6f6b_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi03LTEtMS00OTcxMg_a362b7c8-b393-4630-bc17-4f9e1ec2f509">32,692,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i799f37f97f4a4744b4bc59d2d24293d4_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi05LTEtMS00OTcxMg_e0abc88f-fdef-4bb4-a23d-39951c4a8c54">45,394,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6e9c37e644824b0d84879f473b9cf77e_D20220401-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNy01LTEtMS00OTcxMg_b2a2df64-d581-4f3c-85df-05c05fdc9460">241,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ib54220fa169e4707885970ecdc945467_D20220401-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNy05LTEtMS00OTcxMg_00089e2e-f65b-45ed-8000-5ade45c87303">241,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ica83b1571ad4481baeba3aef75b2db8c_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOC03LTEtMS00OTcxMg_2410d64a-d462-4c59-931d-07546130f2bd">3,986,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ib54220fa169e4707885970ecdc945467_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOC05LTEtMS00OTcxMg_19521edf-ed3c-46e1-b9c9-e6106637d0b2">3,986,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i5486e6d972204740a82b09a1b927049f_I20220630" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS0xLTEtMS00OTcxMg_8dbae2e5-0c94-4248-be48-62b06b25c238">15,966,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i5486e6d972204740a82b09a1b927049f_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS0zLTEtMS00OTcxMg_fdade631-560a-406c-bc5f-536c1e60c513">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i2d8d9514a6a745a0a488a3f6c4207777_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS01LTEtMS00OTcxMg_04c2a359-6f56-42c8-99c8-80c4c6bb49b9">78,312,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i2f8b2d08e4604b7e9b651b2457ac44d6_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS03LTEtMS00OTcxMg_60d02801-8af4-4b75-a0ba-3edc579a6976">36,679,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i06b116b88064480fb840617b61eabdf0_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS05LTEtMS00OTcxMg_3f522d6b-cde6-4a6d-98f3-bd37104ffd5e">41,649,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i896495c2f35f47858d0e21309439c662_D20220701-20220930" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTAtNS0xLTEtNTE3MDI_b48b409a-2252-48d0-a5be-d33e0e7809d3">276,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTAtOS0xLTEtNTE0NDM_4fb5c9fc-42dd-4143-b105-8a41490ac261">276,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf8efe24bd416fa817b05f01fdc15f_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTEtNy0xLTEtNTE3MTA_9b9888ab-26e7-41bf-900b-ad315f0f7423">3,854,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTEtOS0xLTEtNTE0NDM_35034a90-5c00-415c-a1c7-778d3a811b6d">3,854,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItMS0xLTEtNTE0NDM_dd3a479d-f3f0-4a74-84b6-3747196e908a">15,966,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItMy0xLTEtNTE0NDM_6b283ff9-8f8d-40a9-a523-d29beda38164">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3db5b6f078814f8e95ab6d13d23d25e9_I20220930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItNS0xLTEtNTE0NDM_9450a778-06db-4d20-8f4d-981104c6325e">78,589,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i38bed32e2197428db5b6ab17d60a789b_I20220930" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItNy0xLTEtNTE0NDM_eda08cd1-7da6-4c35-9a2c-b806280ab088">40,533,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItOS0xLTEtNTE0NDM_ba759316-db99-4996-b08d-97f47413fb24">38,071,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-right:-7.1pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNC0xLTEtMS00OTcxMg_e3408d18-17e8-40d8-9dde-d10434f57764">11,279,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNC0zLTEtMS00OTcxMg_9c696207-1556-469b-9c96-ece1ce6ea239">7,365,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Acquired in-process research and development charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNi0xLTEtMS00OTcxMg_bffadea7-683a-496c-a887-1faaf07935d8">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNi0zLTEtMS00OTcxMg_6f893e65-3b34-4166-95bf-3aee8ca8ffcf">3,087,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fair value of warrants for services provided</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNy0xLTEtMS00OTcxMg_18031e02-4b58-4e5b-b17d-4e59c40c743a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNy0zLTEtMS00OTcxMg_aac513e9-b98f-43ed-99bc-286a796ac968">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOC0xLTEtMS00OTcxMg_ed14e1d7-e9a6-4bf1-a188-2179322e8786">732,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOC0zLTEtMS00OTcxMg_8d66f193-705d-41df-9332-8ec46e9c5d73">306,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOS0xLTEtMS00OTcxMg_66208a6b-af6d-44f1-b348-2e04c479f2e1">6,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOS0zLTEtMS00OTcxMg_ba10660d-4164-4af3-af09-6713cababe92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTAtMS0xLTEtNDk3MTI_1b7ad7ee-7be4-4f70-ad6b-3fc6ea1210bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTAtMy0xLTEtNDk3MTI_95cb89b2-eed3-4548-b740-43d06f579102">64,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of convertible promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTEtMS0xLTEtNDk3MTI_e8c4639d-766a-4a9f-88e3-096e42d5eba2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTEtMy0xLTEtNDk3MTI_3f4a4cd0-d286-4158-8acb-f794a99809c6">9,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reduction in the carrying amount of operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTItMS0xLTEtNDk3MTI_edc122dc-5bea-41c5-8d9e-c4c16706b468">56,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTItMy0xLTEtNDk3MTI_5fdaca14-f432-4ade-af7f-46f2488ed42a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gain on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTMtMS0xLTEtNTI0NDE_e17bd808-a389-4741-93d5-f50e590f5a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTMtMy0xLTEtNTI0MjA_ceed27b1-5769-4ce7-94c5-4d9ba707b5ed">125,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTQtMS0xLTEtNDk3MTI_da641b17-c67c-4027-ba84-7728d0cf8b01">891,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTQtMy0xLTEtNDk3MTI_f9ad80bd-9bba-4d48-9208-9e22e45ec9e0">9,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTUtMS0xLTEtNDk3MTI_0849e2a3-f9ab-4e68-88dc-20c0cf595c16">39,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTUtMy0xLTEtNDk3MTI_219d4234-770d-4ddc-a799-7298fe219aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTYtMS0xLTEtNDk3MTI_707f8506-3f90-4fe2-b8d4-a860e6a26847">229,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTYtMy0xLTEtNDk3MTI_01e8d992-8a69-48c6-97bc-06334eaa3036">179,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTctMS0xLTEtNDk3MTI_c9552a4c-851a-4dc5-a46d-dce94d1e61f6">1,576,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTctMy0xLTEtNDk3MTI_6828d76b-eed4-48f6-85dd-768decb37a7a">20,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTgtMS0xLTEtNDk3MTI_7e9f52b9-71ca-4e40-aac2-d6a83436b036">52,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTgtMy0xLTEtNDk3MTI_9bb09535-b2a0-4e4e-b43e-39f2c7f7e423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTktMS0xLTEtNDk3MTI_e43b1ad5-b81d-493b-a219-d3d0850922ba">9,619,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTktMy0xLTEtNDk3MTI_1a681f86-c68e-4f60-a9e6-606acda09b82">3,837,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjEtMS0xLTEtNDk3MTI_1ecc5157-c0b8-4a6d-82fe-9cd1f47a4e04">500,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjEtMy0xLTEtNDk3MTI_3d2b5918-c141-4396-8db8-8043ebfbe3e5">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjItMS0xLTEtNDk3MTI_624c38f7-cd56-4b4c-a3aa-22f168ce7c09">36,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjItMy0xLTEtNDk3MTI_e2199a36-a286-485c-8a66-cc9ac1f4a1cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjMtMS0xLTEtNDk3MTI_2a5de524-f2f0-4268-9592-506bb32d09f1">536,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjMtMy0xLTEtNDk3MTI_9b5b1f0d-758c-40df-a841-dbc71677e053">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Payments for offering costs related to the private placement sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i065c7e802d2941d1a5f4e25656709a56_D20220101-20220930" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjUtMS0xLTEtNDk3MTI_47de4ecd-0006-4227-bdb1-9b40aee5bb38">102,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i455a6e88e29d4ef2a78a2a38f261295b_D20210101-20210930" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjUtMy0xLTEtNDk3MTI_b394f57d-2873-45a3-9647-99a8eab39afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Proceeds from the sale of Series A preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjYtMS0xLTEtNDk3MTI_3d3902cd-318b-48ad-89c1-a1b037c8f7df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjYtMy0xLTEtNDk3MTI_33938b8c-2279-4b37-a4d3-0020509433f7">4,982,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Payment of offering costs related to initial public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i046810a1fd7d400da5a699c022e8d9f9_D20220101-20220930" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMS0xLTEtNTI0MzA_ed1df21a-1936-4cf1-974a-1153b9e48de1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i5737c76ba5424054a9aeed887403599b_D20210101-20210930" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMy0xLTEtNTI0MzA_22450d30-34af-4a57-895d-4fec86cf253e">816,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjctMS0xLTEtNDk3MTI_030442a9-a36b-4d20-8310-1d9b7f6c0563">102,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjctMy0xLTEtNDk3MTI_d44821e1-f570-489a-b47e-deaca171fab7">4,165,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjgtMS0xLTEtNDk3MTI_3cab3356-15a1-47dc-af71-4172aeb9dfb7">10,258,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjgtMy0xLTEtNDk3MTI_8d4a64a6-5926-46a7-befe-36a81c4cb37f">78,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMS0xLTEtNDk3MTI_fb07250f-e034-47e5-b350-1521031e2d4e">49,685,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i2dbda5f1db214fb88786236031b5e24c_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMy0xLTEtNDk3MTI_e0ffc535-751d-4211-a342-4b3f17d7b8f5">341,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzAtMS0xLTEtNDk3MTI_25e500a4-5553-4ea2-94ff-b285f9ec7e33">39,427,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifd60ff9a89c748609e3e159d17b22413_I20210930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzAtMy0xLTEtNDk3MTI_1850254d-0bd9-45aa-aee7-df3ab0a1db65">419,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzMtMS0xLTEtNDk3MTI_10e9da6d-f24a-445b-9eb4-3948709c4564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzMtMy0xLTEtNDk3MTI_a67e0dfa-4cbc-4962-a7b0-1fe68fff6de1">5,866,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issuance of warrants in conjunction with Series A preferred stock</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i2fdea296ead7488282261bdc319ef5d1_D20220101-20220930" decimals="0" name="cntx:WarrantsIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzQtMS0xLTEtNDk3MTI_800933e3-7d0c-4412-999b-311828d2eccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia5dbc3701bbc4b54a21909b1998fe19c_D20210101-20210930" decimals="0" name="cntx:WarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzQtMy0xLTEtNDk3MTI_a68be806-0162-4fcd-aa9d-5eb64624b983">309,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series A preferred stock issued for acquired in-process research and development</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzUtMS0xLTEtNDk3MTI_b459f268-2ef3-4a49-a33e-82b4014e398b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzUtMy0xLTEtNDk3MTI_851a585e-210d-4acf-8f07-82c1981bea94">2,837,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Deferred offering costs in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="cntx:DeferredOfferingCostIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzYtMS0xLTEtNDk3MTI_173ebaf2-5ad4-4f4c-8891-eeb54b87f9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="cntx:DeferredOfferingCostIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzYtMy0xLTEtNDk3MTI_6590a676-0f33-4531-9e20-46f77664b60f">1,004,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issuance of warrants for services provided</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i0008c07757234399a7495a0798d22f5b_D20220101-20220930" decimals="0" name="cntx:WarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzgtMS0xLTEtNDk3MTI_9059fc85-b086-4735-8255-946ed0862864">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i2471273c7ae344129757969381e9512f_D20210101-20210930" decimals="0" name="cntx:WarrantsIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzgtMy0xLTEtNDk3MTI_d2521830-9520-41cc-9ed5-275d9adc9fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Right-of-use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzktMS0xLTEtNDk3MTI_3d6dbd92-81f4-4e61-947f-6b9ca521ecae">130,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzktMy0xLTEtNDk3MTI_eb0bda00-7bef-475c-930f-7564fdea0d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of redeemable common stock to redemption value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNDAtMS0xLTEtNDk3MTI_ae3165cd-c1ab-4d4e-bb5d-59200325a00e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNDAtMy0xLTEtNDk3MTI_e80e957a-5a8b-4375-9d1c-e0e794432f9f">53,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONTEXT THERAPEUTICS INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(1) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180MC9mcmFnOmYxZDUxOTIwZDM5OTRkYTdhOGQwMjIwNmI4N2YwOTMwL3RleHRyZWdpb246ZjFkNTE5MjBkMzk5NGRhN2E4ZDAyMjA2Yjg3ZjA5MzBfMTIzMw_f4950940-1f72-4316-a59f-a61e4d2ada44" continuedAt="ica85d1c102414654b330b0cd1aab4029" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ica85d1c102414654b330b0cd1aab4029">Context Therapeutics Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of <ix:nonFraction unitRef="number" contextRef="ie6e9a07f9c2946a8b52c28630a825031_I20210430" decimals="0" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180MC9mcmFnOmYxZDUxOTIwZDM5OTRkYTdhOGQwMjIwNmI4N2YwOTMwL3RleHRyZWdpb246ZjFkNTE5MjBkMzk5NGRhN2E4ZDAyMjA2Yjg3ZjA5MzBfNDc5_de1f19da-bad0-4869-a0d1-b46d51417977">100</ix:nonFraction>% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction the condensed consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</ix:continuation></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(2) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="cntx:RisksAndLiquidityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfNDcxMQ_544f48fd-1cbe-4085-bb79-1f0b2f773cfb" continuedAt="id1592c388c6b4689a0469eab9bb30c73" escape="true">Risks and Liquidity </ix:nonNumeric></span></div><ix:continuation id="id1592c388c6b4689a0469eab9bb30c73" continuedAt="i9cdcb593dc15439f83efdd1fa8454311"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTUy_70da8732-818b-487e-8436-374f3905bfbd">40.5</ix:nonFraction>&#160;million as of September&#160;30, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company believes its cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMzkz_091f83d8-0d71-4917-a13a-b54270aab61d">39.4</ix:nonFraction> million as of September&#160;30, 2022 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first half of 2021, the Company raised $<ix:nonFraction unitRef="usd" contextRef="i18dfaee2fd0749dea6d251e8a01ce718_D20210101-20210930" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfODcw_bdd1ac88-cf6b-4bed-8af7-443caf775434">5.0</ix:nonFraction>&#160;million in net proceeds related to the sale of its Series A convertible preferred stock (&#8220;Series A Stock&#8221;) and warrants for common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company closed an initial public offering (&#8220;IPO&#8221;), in which it issued and sold <ix:nonFraction unitRef="shares" contextRef="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTEwNA_cfbeac0b-34f4-449b-b4f9-802770a0ae18">5,750,000</ix:nonFraction> shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i07512b61ceef49069b0fde3492828089_I20211031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTE0NA_b23f72c6-f711-4ef4-9ad9-2e2aac655aa5">5.00</ix:nonFraction> per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTI0NA_8c655182-fc3d-4a39-aa0c-e2caa8f845ef">250,000</ix:nonFraction> shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTM2NA_708be903-7a4c-4151-8d75-38bc747c9bac">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTM5MQ_fb8d1ec3-33a5-40a2-aaea-505797504399">five years</ix:nonNumeric> from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTU2NQ_f5d73510-36f5-4c52-863d-5066a3bfead2">4,853,533</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ifdb18b5ff7dd4565b0689e48dd33cb0f_I20211031" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTU5NQ_0a504933-2a11-482a-9bfe-b8a4ac07b1a2">480,415</ix:nonFraction> warrants converted into <ix:nonFraction unitRef="shares" contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031" decimals="0" name="cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTYyMg_ae7f2ac2-d1ea-436b-bf6a-f8639d6fc5dc">9,816</ix:nonFraction> shares of common stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTcwMA_ffefbcfc-a0df-4bba-9051-d42f52148645">24.4</ix:nonFraction>&#160;million as a result of the offering. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTc2OQ_5b3aa155-4a78-4458-8543-b7555d488e54">5,000,000</ix:nonFraction> shares of its common stock together with warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTgzNA_7a64603f-2ba5-47c4-8897-96f363cc51e9">5,000,000</ix:nonFraction> shares of common stock in a private placement and received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTkyNg_c6508bf4-f1c0-4137-a2fe-204aff43f03b">28.9</ix:nonFraction>&#160;million. Each share of common stock and accompanying warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjAzMw_a3aead29-182f-4e10-a6ae-c5c28e62c71d">6.25</ix:nonFraction>. The warrants have a term of <ix:nonNumeric contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjA2NQ_fa199a4a-1880-4902-9e6a-eb7e7a11cd48">5.5</ix:nonNumeric> years and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjA5Mw_f13b0577-6ec5-44a6-a98d-aee7afe0fa4d">6.25</ix:nonFraction> per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjIwNw_a8d3c593-42d0-49d2-a93b-ccb5c4610f37">250,000</ix:nonFraction> shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjMyNw_f13b0577-6ec5-44a6-a98d-aee7afe0fa4d">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjM1NA_fa199a4a-1880-4902-9e6a-eb7e7a11cd48">5.5</ix:nonNumeric> years from the date of issuance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i9cdcb593dc15439f83efdd1fa8454311">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</ix:continuation> </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODI_38f3acb5-27fa-4dfd-92ec-8466dcfa67b1" continuedAt="i996087f7744649ac96e84f7a844ed5e9" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i996087f7744649ac96e84f7a844ed5e9" continuedAt="if4602b78476e42c49c9fa5e0fb4ce4b6"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzc_818d866c-5481-4447-b682-64534b389f6d" continuedAt="ia17bc46aabdc4b84babe27974b4b5aef" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia17bc46aabdc4b84babe27974b4b5aef">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and its results of operations for the three and nine months ended September&#160;30, 2022 and 2021 and cash flows for the nine months ended September&#160;30, 2022 and 2021. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. The consolidated financial information as of December&#160;31, 2021 included herein has been derived from the annual audited consolidated financial statements.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzg_b8063a10-602e-46ea-8bf8-fc6271b40487" escape="true">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODY_7b5272ad-def0-49af-a310-3a9fc1b5ba7d" continuedAt="i658e8710335b403e9bd654785b40c091" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i658e8710335b403e9bd654785b40c091">Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of convertible debt and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODM_692affe1-55d1-457b-8f40-b41e31358751" continuedAt="iffd385b9b61a4023a44f5c156d023ef3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="if4602b78476e42c49c9fa5e0fb4ce4b6" continuedAt="i49812099593343dbbdb656f5516382d8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iffd385b9b61a4023a44f5c156d023ef3">limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODQ_5e1c0feb-3a50-4cce-9349-1ced343d26fe" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTI_82470bd7-1758-4a39-af94-763133f27900" continuedAt="i10f5ae6831324f79854d1c311a296181" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i10f5ae6831324f79854d1c311a296181">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintained approximately $<ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfNDQyNw_c3d628ee-20c7-4e60-a197-5b31469ca303">50,000</ix:nonFraction> as collateral for the Company&#8217;s credit card program at December 31, 2021, which is reported as restricted cash on its condensed consolidated balance sheets.  There were <ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfNDU5OQ_ba36c5bb-727f-4db3-b7bf-353c174be7e5">no</ix:nonFraction> amounts restricted as of September 30, 2022, as the collateral was released to the Company in the first quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODA_2161a1db-72ed-46bb-aa9f-5152cb912d8f" continuedAt="i62a9b58fc34242fea8b3129c9a374611" escape="true">Deferred Offering Costs </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i62a9b58fc34242fea8b3129c9a374611">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.</ix:continuation> </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTM_064df7b9-4ec0-46cd-9b04-2bc163ca0c31" continuedAt="i7029ade4b5c045b489632a315dd8be4e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i7029ade4b5c045b489632a315dd8be4e">Property and equipment consist of office equipment, furniture, and leasehold improvements and is recorded at cost. Property and equipment is depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzk_2fecab80-c649-4b2c-9c20-fe8bfab1fdfa" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="cntx:PatentCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODc_688016e2-1e47-409e-a003-68ed86b9b069" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODg_d00f1eab-d9a0-4f04-ba1c-3e0c7fcb17b7" continuedAt="ic0bf758cb4b54e7a812235913252d777" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="i49812099593343dbbdb656f5516382d8" continuedAt="idad970ce4d4f4eafae1a85fb0670218e"><ix:continuation id="ic0bf758cb4b54e7a812235913252d777"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted share-based awards based on the grant date fair value of the awards.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODU_ac60e336-36a4-45a0-a0a3-fb33dbedf924" continuedAt="i63207a57f93c41a0936c5009695eb060" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i63207a57f93c41a0936c5009695eb060">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODE_e6980917-0e8a-4e7e-b547-3c57755989ce" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"></td><td style="width:55.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.889%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series Seed convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ic97c72893b0b45f9ac13a510ac0ce919_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfMy0xLTEtMS00OTcxMg_4a647e4d-486b-4ec4-8593-91fa1eee2160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i7be4c088e38d48fca44ed64b3a9cc35b_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfMy0zLTEtMS00OTcxMg_a32ca88a-0910-4113-a2b3-d5de5ee6eccc">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="iba7c76c52c0843d4b179f34fcc164f44_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNC0xLTEtMS00OTcxMg_28ce0e75-f324-4f51-996a-245759127c80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i661fcc5b4602480e8cc52211d82446d0_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNC0zLTEtMS00OTcxMg_f9f43430-2961-4988-8a20-32fec68f1782">2,212,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i855cb448971a4619b544a94285a0cc96_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNS0xLTEtMS00OTcxMg_37767340-b35b-40c7-9d65-0fe6010101ce">1,341,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="iad85129c8a58499f94bd8e3d2af6078f_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNS0zLTEtMS00OTcxMg_70091dd4-1492-4b5f-b75e-90c066e54dd0">436,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ie8472e008fd846c1af7dbda2c91dddc6_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNi0xLTEtMS00OTcxMg_4b60c486-6514-41a6-b24b-cf5489746ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i5403ef21acee45fbab5d4ad32b444c79_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNi0zLTEtMS00OTcxMg_6eff1c2c-daeb-4d5d-be49-2fdbb9a4da98">33,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i91b81907a7d94fc1a709a3a7f59a42f2_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNy0xLTEtMS00OTcxMg_dd451a88-1dc8-4ce9-a0f1-93c3af4b8559">5,860,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i4603fb59699f4e428a7f38a3b3c0ae44_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNy0zLTEtMS00OTcxMg_c12812e6-a0a3-4162-a451-476715f89c49">480,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfOC0xLTEtMS00OTcxMg_b038f080-9f46-4a2a-a08c-90aae9de83e4">7,201,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfOC0zLTEtMS00OTcxMg_696d7225-26e2-4788-a5ec-64c092509b4c">5,787,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts in the above table reflect common stock equivalents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Emerging Growth Company Status </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="idad970ce4d4f4eafae1a85fb0670218e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTA_8b2fb37b-0c3f-4156-88f8-6e4ca6a790c1" continuedAt="ib6039cc62114420b8d1ebd18e34e6364" escape="true">Recently Issued Accounting Pronouncements </ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ib6039cc62114420b8d1ebd18e34e6364"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its condensed consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</span></ix:continuation></div></ix:continuation><div id="i6128ef27165d4066a955a859b4b0ee27_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(4) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RleHRyZWdpb246MGZmMmFjZjUyZGM4NGQ5MzhjZTY5ZDFhMTBkNGQxMmVfODQ0_8b7a66b8-d630-41e5-ae84-e2eb90a26319" continuedAt="i0d8c13ee7868466089ff3aa7648ca8ae" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i0d8c13ee7868466089ff3aa7648ca8ae"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;3 &#8211; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RleHRyZWdpb246MGZmMmFjZjUyZGM4NGQ5MzhjZTY5ZDFhMTBkNGQxMmVfODQ1_142eb705-f730-4fa2-b15f-7b93386ce911" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if18940842a4d4141bb83557faaaa3f5d_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy0xLTEtMS00OTcxMg_d5696b5c-c5df-4734-8a26-e49abdf6775d">1,921,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9ea3bc90fc5e45babe9d16439371f804_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy0zLTEtMS00OTcxMg_035945d3-b50e-4bbc-8dbb-26bc45ba32fc">1,921,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ib9cfc17885754c02bf2915c69856a33b_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy01LTEtMS00OTcxMg_fa35085a-e473-4b2f-9158-ea7d730f7237">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibdfc0ddf63e14d7082cb9c967c847020_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy03LTEtMS00OTcxMg_b3eb07b6-e5ee-47bc-ab5e-7fc096e7b734">&#8212;</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if6eea0a991414c36a0929d31f1d3d7f8_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy0xLTEtMS00OTcxMg_bd261844-ead0-4b22-8e51-82b1a6e17377">49,051,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id5916c4827b84fc8b33f7160c0b78aab_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy0zLTEtMS00OTcxMg_ce3507a1-61f5-44b5-9d10-b2ab38e29cf0">49,051,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i72e8a39dfcb84e878ff3f8aa02b39b95_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy01LTEtMS00OTcxMg_fb77eb85-5f75-47e1-b370-64ede4858aa5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iefc04475ba4c443bb02c7f09ee9c52a0_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy03LTEtMS00OTcxMg_0fdcb875-4344-43f7-be64-0909abecd8ff">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:51.29pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:79.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(5) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RleHRyZWdpb246NzBmZTJkMTk5Y2FjNDI1NGFjZjRiYzNiOWM2ZTQxZWNfMTMz_b612913c-b7b2-4c62-8010-8f3db8b72155" continuedAt="i34a6f5c781d04083ba1b335a704da53e" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i34a6f5c781d04083ba1b335a704da53e"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RleHRyZWdpb246NzBmZTJkMTk5Y2FjNDI1NGFjZjRiYzNiOWM2ZTQxZWNfMTM0_06ca63a8-0bf6-46f4-8a81-d356f9103276" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:49.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMS0xLTEtMS00OTcxMg_55e875b7-c58d-48a9-9d29-ad4ee6dfd16a">564,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMS0zLTEtMS00OTcxMg_3d380ed7-6d8a-4167-ab9c-0bf632efa05f">436,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="cntx:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMi0xLTEtMS00OTcxMg_6a260099-96a0-4824-9ade-9fce578c4da2">1,801,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="cntx:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMi0zLTEtMS00OTcxMg_13aa7105-62b9-463d-88aa-0b5eae5aa2d9">339,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMy0xLTEtMS00OTcxMg_5940f8f6-af98-4158-92bc-8554e1e6f273">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMy0zLTEtMS00OTcxMg_c23be5f7-ee75-44cc-9070-aa3720d3eb44">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNC0xLTEtMS00OTcxMg_6681b63b-44bb-4d79-9f0e-440ccf864833">60,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNC0zLTEtMS00OTcxMg_df906393-13f3-417c-87f6-3b83b15c7ddc">85,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNS0xLTEtMS00OTcxMg_6c76960b-67fc-4bd6-9c0a-bb6a953aaf5a">2,438,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNS0zLTEtMS00OTcxMg_a1fdcb19-44de-4724-abce-774b75ada169">1,207,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(6) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjQxMQ_8e396ba4-4753-4b65-87c4-f5f557692e96" continuedAt="id45cba6165db4bfdab57f002a04a6dc7" escape="true">Convertible Promissory Notes and Other Debt</ix:nonNumeric></span></div><ix:continuation id="id45cba6165db4bfdab57f002a04a6dc7" continuedAt="if77fcf6175dc4cf6a1a18fadbda5d482"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Convertible Notes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company previously issued certain convertible promissory notes to various investors which were converted into Senior Convertible Notes (the &#8220;Senior Convertible Notes&#8221;, and collectively, the &#8220;Convertible Promissory Notes&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfNDYz_600a0e62-67e3-43ac-afb9-371548288f69">844,824</ix:nonFraction> shares of Series A Stock in February 2021, of which <ix:nonFraction unitRef="shares" contextRef="i52408a7bafe3490ea2b90900d2fd960a_D20210201-20210228" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfNTE4_d12d8f73-f954-430d-a790-dd105b51ee66">430,467</ix:nonFraction> shares were issued to the Company's Chief Executive Officer and an immediate family member (the "Related Party"). Due to certain embedded features within the Senior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Senior Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i27893806b30342149eb85b8143f8df92_I20210228" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfOTAx_7827297c-2162-47e1-844d-2d284a9ac4c1">5.7</ix:nonFraction> million and was reclassified to Series A Stock. The Company recorded a non-cash credit of $<ix:nonFraction unitRef="usd" contextRef="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930" decimals="-3" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTAwOA_549fafe3-ef08-4689-a6aa-e4363425658e">9,000</ix:nonFraction> in the condensed consolidated statement of operations for the nine months ended September 30, 2021 related to the decrease in fair value of the Senior Convertible Notes. For the nine months ended September&#160;30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTIzNg_4b9e78bf-8502-46b6-9d5f-c629aa17337c"><ix:nonFraction unitRef="usd" contextRef="i65e645342cf74ea6b3b63d9596768247_D20210701-20210930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTIzNg_e476a3b5-5b1a-48b6-85b5-a81405ecbf21">46,000</ix:nonFraction></ix:nonFraction> of interest expense in connection with the Senior Convertible Notes, including $<ix:nonFraction unitRef="usd" contextRef="i88ad34f7e1fb4d8694c59f20b25c8ba6_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTMxOA_a9eec32f-6a9f-4b4a-afa9-240895eb0e52"><ix:nonFraction unitRef="usd" contextRef="iaae18aea4a6d4d3c9f8d5c3d37e7307e_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTMxOA_eee04279-d869-4dc2-96d7-90cf013369a8">23,000</ix:nonFraction></ix:nonFraction> payable to the Related Party, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paycheck Protection Program </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="if77fcf6175dc4cf6a1a18fadbda5d482">In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender for a loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTU1Nw_fbb06226-9a3d-4837-90ab-00747be70d12">0.1</ix:nonFraction> million (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act implemented by the U.S. Small Business Administration.  In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that the Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#8217;s loan forgiveness covered period. The Loan was set to mature in <ix:nonNumeric contextRef="ib0ba8f04e8d44ad486f7a21607ab601a_D20200501-20200531" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjE5Mw_fc852a86-609f-4527-85d3-3cf7de09784b">two years</ix:nonNumeric> and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjIyNw_6e61bf66-adc4-4a4e-9af6-9c391436cc17">1.0</ix:nonFraction>% per year, with all payments deferred through September&#160;5, 2021. The outstanding principal balance of the Loan of $<ix:nonFraction unitRef="usd" contextRef="ie29255ae26c54473ad60f4e96b040b6a_I20210731" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjE5OTAyMzI1OTQ3Nw_225e91ba-81d4-4572-a2f4-a6a8a8781b59">0.1</ix:nonFraction>&#160;million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the condensed consolidated statements of operations during the three and nine months ended September 30, 2021.</ix:continuation> </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(7) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjY1MQ_ce258876-cf87-4559-97e4-9f0dca6603bd" continuedAt="i62410f0159ec4592999670b3a53edc25" escape="true">Convertible Preferred Stock, Redeemable Common Stock and Common Stock</ix:nonNumeric></span></div><ix:continuation id="i62410f0159ec4592999670b3a53edc25" continuedAt="ic1b9b9fec8e345b0a25890a7094a736f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series A convertible preferred stock and Series Seed convertible preferred stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February, March and April 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEz_a4e2b89c-0bdb-473e-8f43-e5658fd84127">738,445</ix:nonFraction> shares of Series A Stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="i02d517722f68464aa57cb746d8b6b0fc_I20210430" decimals="3" name="cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjQ1_d1c62cba-c655-467a-a0cf-6d2c72c34b22">7.168</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjc4_b180eebf-0bda-4cc1-b9c5-430407010e17">5.0</ix:nonFraction> million. The Company also issued <ix:nonFraction unitRef="shares" contextRef="i37765677fef04878bfd307079cffd395_I20210430" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMzA2_6ab39b7c-fb9d-40c2-a42f-9d78899f9da3">184,597</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i37765677fef04878bfd307079cffd395_I20210430" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMzY3_277687f8-8c87-4f3c-8110-7ddbaa6c0541">7.168</ix:nonFraction> to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued <ix:nonFraction unitRef="shares" contextRef="i94a68f56ad3d4f398d8120b6f54fc354_I20210430" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNDcz_20b23783-1ff3-4187-845c-31ad2b0af0f3">24,134</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i94a68f56ad3d4f398d8120b6f54fc354_I20210430" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNTM0_3571e5c8-d785-4e3b-90ad-9b4198d9316d">7.168</ix:nonFraction> to placement agents as a part of the Series A Stock financing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, the Company converted $<ix:nonFraction unitRef="usd" contextRef="iea511a0f86dd4c4daa7a2411ba8f627d_D20210201-20210228" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNjQx_bc0d5118-f882-4bea-b744-69d31cdd0434">6.1</ix:nonFraction> million of principal and interest related to Senior Convertible Notes into <ix:nonFraction unitRef="shares" contextRef="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNzEx_7864292a-a4db-4f7f-a42d-e01da68bb593">844,824</ix:nonFraction> shares of Series A Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb7a61f34a4b428e9a376347e43312f6_I20210228" decimals="3" name="cntx:DebtConversionConvertedInstrumentPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNzUz_5b5cb989-745d-4cca-b11f-8025b67d3d49">7.168</ix:nonFraction> per share. In addition, warrants with a fair value of $<ix:nonFraction unitRef="usd" contextRef="iab205c27896840a48993517f0d658e53_D20210201-20210228" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfODEw_ba472495-9690-4799-a86b-0984fc93625d">0.1</ix:nonFraction> million associated with the Senior Convertible Notes were reclassified into additional paid-in capital. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="ic1b9b9fec8e345b0a25890a7094a736f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company completed its IPO in which the Company sold <ix:nonFraction unitRef="shares" contextRef="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfOTgz_976c63e7-96c1-46b9-a090-d35e1a320eba">5,750,000</ix:nonFraction> shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i07512b61ceef49069b0fde3492828089_I20211031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTAyMw_278d0883-b748-4834-af2d-789efeb6214d">5.00</ix:nonFraction> per share. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i88481b1f040d4ae9ab9358ec2a521621_D20210930-20210930" decimals="0" name="cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTE4MQ_199b732d-f27f-46a3-b875-eb8d724ac172">4,853,533</ix:nonFraction> shares of common stock and all of the outstanding warrants converted into <ix:nonFraction unitRef="shares" contextRef="i13ff4879231b4c58a0d8f431b824853d_D20210930-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTI1OA_c09e844c-7ed7-4fef-852c-3c4932886fdd">9,816</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTMyMg_63b49a01-0b8a-4879-9cc6-2f94fb72454c">24.4</ix:nonFraction>&#160;million as a result of the offering. The Company issued <ix:nonFraction unitRef="shares" contextRef="iaf6909f0d3984eef85455ec758334932_I20211031" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTM3Mw_6b2a8a57-06cb-4692-8870-43e01cdccdcc">250,000</ix:nonFraction> warrants to a placement agent as part of the offering with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf6909f0d3984eef85455ec758334932_I20211031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTQ1Ng_df71647d-ab1e-436f-ae02-45f11315cd2b">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="iaf6909f0d3984eef85455ec758334932_I20211031" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTQ4Mw_c43dba84-d884-4921-b73a-2d20e856c902">5.0</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTUyMw_bfedc1d2-583b-4939-bb84-d809da073d4f">5,000,000</ix:nonFraction> shares of common stock together with warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTU4NA_4a2be141-3d65-45cd-993a-680db700a348">5,000,000</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTYzOQ_4f80710d-de4f-4ef9-bd9a-5edfb0f3ef9d">28.9</ix:nonFraction>&#160;million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTc2OQ_458f1bcd-3bf5-442d-885b-63595290460a">6.25</ix:nonFraction>. The warrants have a term of <ix:nonNumeric contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTgwMQ_6247d32f-e693-4812-834d-4a03647bf3b0">5.5</ix:nonNumeric> years and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTgyOQ_78067a26-31aa-4a66-ac71-323e6dae02c7">6.25</ix:nonFraction> per share. The Company also issued <ix:nonFraction unitRef="shares" contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTg2Nw_2ee73fdf-3871-4cf2-9cdf-672a67341a32">250,000</ix:nonFraction> warrants to a placement agent as part of the offering with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTk1MA_79487c76-28e4-4fe7-8d81-eec784ca5ea7">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTk3Nw_66861e63-7de6-4864-aed7-5369a94cd11b">5.5</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrants for Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjA0Mw_fea7605a-b895-4aec-b981-b4f1295f2985">360,000</ix:nonFraction> warrants to purchase common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEwNg_d59e4877-30df-4c09-8130-fe2d5161b374">10.00</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEzMw_7bcc91bb-0aa6-4867-940c-7bb346f067a8">5.76</ix:nonNumeric> years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $<ix:nonFraction unitRef="usd" contextRef="i0f0d08a54b2d45fcbab6217ef7c19f5c_D20210101-20211231" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjI1Mg_07512ce2-ed4e-45c6-b657-e9730bda2c37">0.3</ix:nonFraction>&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.</span></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjY1Mg_265cda74-a96d-421e-a6bf-170f9bbb8ed1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At September&#160;30, 2022, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:42.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i2b6b6924916f49cebf4a3197558fd9aa_I20220930" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMS0xLTEtMS00OTcxMg_317079a2-f0c6-4e40-832f-fc9c85db0599">250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b6b6924916f49cebf4a3197558fd9aa_I20220930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMS0zLTEtMS00OTcxMg_d63a83ad-b9ec-4d99-a9d2-0cb6d9dfbf67">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMi0xLTEtMS00OTcxMg_f28e7611-c39f-4861-95fa-a64a834eaa96">5,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMi0zLTEtMS00OTcxMg_e51b0b5c-3b62-4e48-9dd9-b67826fa4e15">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i44b557d2dee24d6d85852c77416f09b7_I20220930" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMy0xLTEtMS00OTcxMg_c70b1f0f-6d44-41b0-846e-2a1db2f62b9b">360,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44b557d2dee24d6d85852c77416f09b7_I20220930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMy0zLTEtMS00OTcxMg_e209b833-6686-4d3d-8ba0-3eef540b2ceb">10.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfNC0xLTEtMS00OTcxMg_72738b3b-9743-4668-8b7c-53b462d472d0">5,860,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6128ef27165d4066a955a859b4b0ee27_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(8) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1OQ_b3eadc36-7537-460d-a43f-2d72765a27d8" continuedAt="i23e322e109e64981bdddacaabb50b181" escape="true">Share-based Compensation</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:continuation id="i23e322e109e64981bdddacaabb50b181" continuedAt="i34977573a2d343d4a704e2c7a967d21c"> </ix:continuation></span></div><ix:continuation id="i34977573a2d343d4a704e2c7a967d21c" continuedAt="i72dcd76fd0114e54ab904e103d8b9880"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i2b03a95d6ac1446db1df7032d377d274_I20210430" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMzQ5_dc6944e2-d2ba-44cc-8ed6-fc1ca101e801">1,266,092</ix:nonFraction> shares of common stock (the &#8220;Share Limit&#8221;).  The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (<ix:nonFraction unitRef="number" contextRef="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430" decimals="2" name="cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfNjQx_e607ec05-b727-4f84-bc4c-50f4d5a52952">4</ix:nonFraction>%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of September&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i893010e7c4d84530bb4e535807bafd81_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfODk3_c7c41c3f-5d11-4bd4-88d1-50bd7722dce0">546,535</ix:nonFraction> shares remained available for future grants. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based awards generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfOTk5_9bce99fb-680f-4b4e-95c7-aea7eb7069f0">one</span> to <ix:nonNumeric contextRef="i9d27a8b650fb459ea73fa6afb06d6686_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMTAwNQ_e0ec93b2-d1ae-4ac9-83d1-36f565312960">four years</ix:nonNumeric>, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is <ix:nonNumeric contextRef="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMTE0NQ_23c9018c-5c9e-4742-8ac8-ba196e97f24e">ten years</ix:nonNumeric>. The expiration dates of the outstanding share-based awards range from January 2028 to August 2032. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk2MA_c2f33bc1-0866-4bf8-a3c4-7411bb80d84f" continuedAt="i002638223bbd4621a4411d0aa80de652" escape="true">Share-based compensation expense related to the issuance of stock options was as follows for the three and nine months ended September 30, 2022 and 2021: </ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="i72dcd76fd0114e54ab904e103d8b9880"><div><ix:continuation id="i002638223bbd4621a4411d0aa80de652"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:32.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i390779b4e1374f78a3d2ff4696312717_D20220701-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi0xLTEtMS00OTcxMg_cfcda6f3-b44f-4a33-9248-77d7830820ea">14,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3552069f01754175946fbde459157a66_D20210701-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi0zLTEtMS00OTcxMg_82f6bc85-9111-4754-b871-71a7772f573b">17,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iaac7d80114ef46d39ae9a53271640ba1_D20220101-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi01LTEtMS00OTcxMg_869146d2-3e70-48a8-bad4-ac40a28f194a">74,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia3f47e32ce8e4ceab933f1129b620c5e_D20210101-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi03LTEtMS00OTcxMg_62e06fe6-93d9-4320-bb4e-cb58b20e3af2">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ib73ab2ac402a4838afab49d9909a77b3_D20220701-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy0xLTEtMS00OTcxMg_d7231dcd-ffd3-4f72-aaf2-9eca366e5a7d">262,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i452d4086812e4e2eb52bd1a594c530b4_D20210701-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy0zLTEtMS00OTcxMg_8f08e0a9-51b3-4a69-a158-812a731ecdcb">133,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="if870d3ee8de04697b45e9489a10d6c63_D20220101-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy01LTEtMS00OTcxMg_a6867df2-3d7c-40e1-b2a5-c87ce633ebd6">658,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia42107d884244b2ab5d0ba0cf3931add_D20210101-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy03LTEtMS00OTcxMg_fbc7fcb0-8c5f-43d5-992b-935e6408ff2b">224,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC0xLTEtMS00OTcxMg_83d005cf-9079-408e-8d5b-96a4665c135d">276,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC0zLTEtMS00OTcxMg_cdea628b-4347-419e-bee9-7854cc1ddc88">151,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC01LTEtMS00OTcxMg_0ac237f8-aee3-4457-a5f1-b114c6c031f2">732,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC03LTEtMS00OTcxMg_0eafc801-fceb-480c-8f63-cab45331a9c6">280,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk2MQ_a1e7809f-c6b0-4ac4-860a-1ab229ccbd2d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the nine months ended September&#160;30, 2022 and 2021, respectively, were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:66.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMS0yLTEtMS00OTcxMg_89b01d21-f6e3-4c46-8f7b-55214418bb84">87.02</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMS00LTEtMS00OTcxMg_66d413c1-b44d-4aae-a352-12bb63e75d4b">97.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMi0yLTEtMS00OTcxMg_bb9859bc-6246-4306-aaa4-61387d9f15a0">2.17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMi00LTEtMS00OTcxMg_e1f16fa7-8b1d-4f17-9375-b7622dda6098">1.03</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMy0yLTEtMS00OTcxMg_74eb2b6b-84c2-4a34-ab18-ad65e114b18d">5.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMy00LTEtMS00OTcxMg_79456cdf-d98d-4ae5-8c04-41f4d8399e6a">5.77</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfNC0yLTEtMS00OTcxMg_9e6068d3-1b8e-4bec-90e9-9660a316a833">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfNC00LTEtMS00OTcxMg_e81b262d-578b-4bf5-8427-94bfd08249a6">&#8212;</ix:nonFraction>&#160;&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1Nw_457a6a51-1fa0-4d86-9054-d0b0402552ee" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS0xLTEtMS00OTcxMg_6834ea30-4805-4ba0-b1a2-db130b7b333c">506,691</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS0zLTEtMS00OTcxMg_300895a4-3f76-436a-9551-3d9f14ad1548">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ibffa84374b394851b73ca24a8916a301_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS01LTEtMS00OTcxMg_ec9c629d-c3b6-4fd9-b066-33d951e2d725">9.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMi0xLTEtMS00OTcxMg_35bd2636-d5c3-4f0e-8d11-66a53958f1df">890,058</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMi0zLTEtMS00OTcxMg_34b4e7fa-b439-44f9-8191-9b82a7da58f2">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="shares" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0xLTEtMS01MjU1MQ_feb6799e-db73-4e1d-9e0e-f86fc38e3ee7">55,245</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.57pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0zLTEtMS01MjU1MQ_175046f0-8ab2-4795-992b-111b1d98201e">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0xLTEtMS00OTcxMg_1b382d0c-723a-4bc7-9f60-546400a97e7b">1,341,504</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0zLTEtMS00OTcxMg_a5eb4775-1fbe-4a7a-a9b4-d9304f247697">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy01LTEtMS00OTcxMg_28808637-2671-4c4b-b0f8-61e99b6f80d9">9.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC0xLTEtMS00OTcxMg_a00817ac-eb9b-4a10-b205-b16b1efdac8f">275,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC0zLTEtMS00OTcxMg_94521a11-0ded-40a6-80aa-02654a7a1182">5.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC01LTEtMS00OTcxMg_cf81991a-2e8a-48b0-9ebb-8e12b35965f0">8.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS0xLTEtMS00OTcxMg_14f3e102-d69a-427b-a1ed-fbe2c25c8af0">1,341,504</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS0zLTEtMS00OTcxMg_03279383-f026-4219-9b09-46cc7779e019">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS01LTEtMS00OTcxMg_427a57a2-9b73-4ed5-9469-cad95f12fd4e">9.1</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average fair value of share-based awards granted during the nine months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjE4Mw_5f04b18b-ead0-41a9-8b1d-f08d8ab00f2d">1.38</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjE5MA_cd961160-ccd8-4b2b-80ea-498b16ed3632">3.76</ix:nonFraction>, respectively. As of September&#160;30, 2022, the unrecognized compensation cost related to outstanding share-based awards was $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjI5OQ_6a5f57ce-68b9-474e-8ed6-6697e86ea0af">1.9</ix:nonFraction>&#160;million and is expected to be recognized as expense over a weighted-average period of approximately <ix:nonNumeric contextRef="ibd804bfec7bc4f1d89cace194a5d9f99_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjM5NA_9d7db2f6-29a2-4ed7-8897-91ddb8bde884">2.25</ix:nonNumeric> years. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company issues RSUs to employees and consultants that generally vest monthly over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjUxNQ_9f1ec537-f564-4137-94fe-554fb0d09f1f">one</span> to <ix:nonNumeric contextRef="i3aa6a3da81d5470497285d540411a506_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1OA_89063d21-b052-4121-9f04-9493aa5ccb31">three-year</ix:nonNumeric> periods. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded share-based compensation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="ib894c6511aad4955ac97436b31cd674f_D20210701-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjc5Mg_7807661f-2d27-41e4-9d78-da1bdc7f7a31">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i89136a0062a546e4bba3db98f38f30c7_D20210101-20210930" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjc5OQ_1eb28e49-1de4-421f-99cf-97c9d24f8079">25,000</ix:nonFraction> in research and development expense for the three and nine months ended September&#160;30, 2021, respectively, related to RSUs. There were <ix:nonFraction unitRef="shares" contextRef="i629d249a546f43ebb5ec4d9fc839c160_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjkwOA_050971a8-7a78-4b1a-84e6-827b3a64128f"><ix:nonFraction unitRef="shares" contextRef="icb8fbecc9e72463d930d63daeec62a21_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjkwOA_39c2ca3b-2ff8-4b77-9bb4-9ee2f5fcd937">no</ix:nonFraction></ix:nonFraction> RSUs outstanding as of September&#160;30, 2022 or December 31, 2021.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(9) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTk0Mw_2e3324c0-8b2f-49c3-9320-cba67be9e8df" continuedAt="i80fb260ae9bb40a8be890a68286e8a87" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i80fb260ae9bb40a8be890a68286e8a87" continuedAt="ib8ae6829d6b940c5b35ad44cd8761b87"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2022, the operating lease right-of-use asset and the operating lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzgy_6a3df771-1d89-4966-8719-bdf0fcf872ce">74,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzg5_9c2299c2-6924-44b2-bdf8-1c7f46afc1df">78,000</ix:nonFraction>, respectively. The weighted average discount rate used to account for the Company&#8217;s operating leases under Topic 842 is the Company&#8217;s estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTY2_6173a73b-ad9b-4276-adc6-406166578020">5.0</ix:nonFraction>%. The remaining term of the Company&#8217;s noncancellable operating lease is <ix:nonNumeric contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNjQw_d4c4b7a2-8551-4fd3-9c81-bcbf85f50523">0.83</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rent expense related to the Company&#8217;s operating lease was approximately $<ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNzE3_1735e1c7-c3cb-41d3-af6a-b1f053047f84">23,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNzI0_87fc8064-07c3-4cee-84e0-3a5b9e459568">60,000</ix:nonFraction> for the three and nine months ended September&#160;30, 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future minimum lease payments under the sublease are $<ix:nonFraction unitRef="usd" contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930" decimals="0" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfOTc0_e7ee869c-e930-4046-bd2c-5e182d937ba6">80,000</ix:nonFraction> at September 30, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employee Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to <ix:nonFraction unitRef="number" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTE0OQ_b5b4c1d9-2e93-4864-bdbd-4f044c51b635">100</ix:nonFraction>% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to <ix:nonFraction unitRef="number" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTMwMw_1d76d59a-b5a7-4196-9ecb-109dda9fc6b8">3</ix:nonFraction>% of employees&#8217; compensation. The Company generally assumes all administrative costs of the plan. For the three and nine months ended September&#160;30, 2022, the Company provided contributions of approximately $<ix:nonFraction unitRef="usd" contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930" decimals="0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTQ5Mw_2575fc03-2441-426a-baea-996a8bbc7d7b">12,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" decimals="0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTUwMA_879e074a-cef1-40aa-9cee-dd0511056cdc">54,000</ix:nonFraction>, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company entered into a process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#8220;ONA-XR&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#8220;Tyligand License Agreement&#8221; and, together with the Tyligand Process Development Agreement, the &#8220;Tyligand Agreements&#8221;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company retains rights in the rest of the world to commercialize ONA-XR. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Tyligand Process Development Agreement, the Company paid Tyligand $<ix:nonFraction unitRef="usd" contextRef="i8773e0c5834143cbb0d43e34a17e2a92_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjUxMA_f0ee5811-2f53-40d0-9d31-66e47ffe640b">0.8</ix:nonFraction> million and issued <ix:nonFraction unitRef="shares" contextRef="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjUyNA_57c8524e-3ca3-42e5-86d8-3080d2e04d59">111,576</ix:nonFraction> warrants to purchase shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjU5NQ_45646acf-2844-46ec-a016-c41e30899685">7.17</ix:nonFraction> per share upon successful completion of the manufacturing development plan in 2021.  The warrants were cancelled in connection with the Company&#8217;s IPO. In addition, $<ix:nonFraction unitRef="usd" contextRef="ibc6ef50417cb4013b7ac39e1693b2f04_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjc2Mg_9629f533-4c47-4ddc-856b-c507f4fc414d">2.0</ix:nonFraction> million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#8220;GMP&#8221;)-grade compound and $<ix:nonFraction unitRef="usd" contextRef="ibcabaf70069543ae99e3fe4be7d87d00_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjkxNA_2f94c38b-d552-4118-b80c-eec3ba4f9d0f">3.0</ix:nonFraction> million upon the Company&#8217;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand <ix:nonFraction unitRef="number" contextRef="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzE5NA_2dcc9340-433c-42f2-bb25-9e396af583ec">1</ix:nonFraction>% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) <ix:nonNumeric contextRef="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331" name="cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzc4Mw_ca011791-f8fd-44f6-8850-e2bb317ebb8b">15</ix:nonNumeric> years after the date of the first commercial sale of product in the Territory. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><ix:continuation id="ib8ae6829d6b940c5b35ad44cd8761b87"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration and Licensing Agreement with Integral Molecular </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsAb&#8221;) for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDYwMw_fcc96258-a475-461b-8854-411d7b2aad92">0.3</ix:nonFraction> million, granted <ix:nonFraction unitRef="shares" contextRef="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDYxOA_1f72eeb3-adb1-4ce5-b69d-4b9396b8ac84">418,559</ix:nonFraction> shares of Series A Stock with a fair market value of approximately $<ix:nonFraction unitRef="usd" contextRef="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430" decimals="-5" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDY4OA_cdb676ad-7d2f-497f-bea1-4bcbe0be3356">2.8</ix:nonFraction> million, and expensed these costs to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ic7d331e039ce4907b44d8c6829eb96ab_I20220930" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDk0Nw_5f195a21-ee4c-4f33-a446-a02c378d3794">55</ix:nonFraction>&#160;million, sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430" decimals="-6" name="cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDk5MQ_e3f77fdd-bbeb-461e-bf0e-2ae1f99eb6de">130.0</ix:nonFraction> million, and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTAyNQ_f90c4dc4-8e34-4d96-929f-ec84e7bc542c">12</ix:nonFraction>% of net sales of certain products developed under this agreement. In the second quarter of 2022, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="ibf836415560143e7aa246d7036b09772_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTE0NQ_233cbe05-df1a-45fd-9583-da47a97c974b">0.5</ix:nonFraction>&#160;million in acquired in-process research and development related to a development milestone achieved under the agreement with Integral.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require upfront payments and long-term commitments of cash.</span></div></ix:continuation><div id="i6128ef27165d4066a955a859b4b0ee27_514"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(10) <ix:nonNumeric contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181MTQvZnJhZzozMDZlZjNhNjEyNWU0Yzg0YTY5Yzg2MmNhZDUzZDlhMi90ZXh0cmVnaW9uOjMwNmVmM2E2MTI1ZTRjODRhNjljODYyY2FkNTNkOWEyXzIxOTkwMjMyNTY5NzA_f75ed3c3-6a8e-4160-a512-4eb79cbb895f" continuedAt="i8bce1e0eb350478291e454f7a3391ccb" escape="true">Subsequent Event</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8bce1e0eb350478291e454f7a3391ccb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 7, 2022, the Company entered into a Development and Manufacturing Services Agreement (the &#8220;Lonza Development Agreement&#8221;), with Lonza Sales AG (&#8220;Lonza Sales&#8221;) and Lonza AG (collectively, &#8220;Lonza&#8221;). Under the terms of the Lonza Development Agreement, Lonza will provide services relating to the development and manufacture of the Company&#8217;s anti-claudin 6 bispecific monoclonal antibody product (the &#8220;Product&#8221;) in accordance with the project plan attached to the Lonza Development Agreement and any other work as may be agreed to between the Company and Lonza. The Lonza Development Agreement will terminate upon the completion of the agreed upon services, unless earlier terminated by the Company or Lonza for uncured material breaches, insolvency of the other party, or if a party determines that it is not possible to complete the services for material scientific or material technical reasons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, on November 7, 2022, the Company entered into a License Agreement (the &#8220;Lonza License Agreement&#8221;) with Lonza Sales. Under the terms of the Lonza License Agreement, to the extent incorporated into the Product, Lonza granted the Company a non-exclusive license to use certain proprietary Lonza intellectual property and systems for the Company to develop, manufacture and commercially exploit the Product.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our financial condition and results of operations together with our unaudited  condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and other financial information included in this report and our audited consolidated financial statements and related notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission ("SEC"), on March 23, 2022. In addition to historical information, the following discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_73"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, including breast, ovarian, and endometrial (uterine) cancer. Our most advanced product candidate, onapristone extended-release (&#8220;ONA-XR&#8221;), builds upon a foundation of successful drug development by our management team and advisors in the field of hormone-dependent cancers. ONA-XR is a potent and selective antagonist of the progesterone receptor, which has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, across female hormone-dependent cancers. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our first program, ONA-XR, is being advanced across various investigator-sponsored trials and a Company-sponsored trial:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">An ongoing Phase 2 investigator-sponsored trial is being conducted in collaboration with Jefferson Health to evaluate ONA-XR in combination with anastrozole to treat women with progesterone receptor positive ("PR+") endometrial adenocarcinoma who have failed front line therapy with a platinum/taxane-based chemotherapy regimen. As of September 30, 2022, we note the following:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The trial has enrolled 12 of 25 planned patients.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The preliminary 4-month progression free survival ("PFS") rate was 77.7%, based on nine evaluable patients. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Three patients received treatment for greater than 12 months.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Overall, seven patients remain in the trial. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">There have been no treatment-related serious adverse events reported.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial is ongoing and updated trial results are expected in mid-2023. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">An ongoing Phase 2 investigator-sponsored basket trial is being conducted in collaboration with Memorial Sloan Kettering Cancer Center to evaluate ONA-XR in combination with anastrozole to treat women with PR+ recurrent gynecologic cancers. As of September 30, 2022, we note the following:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Cohort 1, which treats patients with PR+ recurrent granulosa cell tumors with ONA-XR as a single agent, completed accrual to stage 1 and has shown a 12-month PFS rate of 20.1% and a Clinical Benefit Rate (stable disease) of 35.7%. Two patients continued on active treatment for greater than 18 months. One patient remains on trial.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Cohort 4, which treats patients with PR+ recurrent granulosa cell tumors with ONA-XR in combination with anastrozole, enrolled 14 patients in stage 1 and will expand to stage 2 when greater than or equal to one response is observed. Seven patients remain on trial.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">There have been no treatment-related serious adverse events reported.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial is ongoing and updated trial results are expected in mid-2023.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">An ongoing Phase 2 investigator-sponsored trial is being conducted in collaboration with Wisconsin Oncology Network to evaluate ONA-XR in combination with fulvestrant in second line or third line advanced or metastatic estrogen receptor positive ("ER+"),PR+,HER2-  breast cancer (the &#8220;SMILE&#8221; trial). This trial is intended to evaluate potential ONA-XR plus fulvestrant drug synergy after treatment failure of CDK4/6 and/or PIK3&#945; inhibitors, with initial clinical data expected in December 2022. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The SMILE trial will also evaluate radiolabeled progesterone (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">F-FFNP&#8221;) distribution in PR target tissues and quantify available PR binding sites via positron emission tomography (PET)/computed tomography (CT) imaging in breast tumors when co-treated with ONA-XR. Data is expected in 2023. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On August 1, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (the &#8220;Menarini Agreement&#8221;) with Berlin-Chemie AG - Menarini Group - (&#8220;Menarini&#8221;). Pursuant to the Menarini Agreement, we will conduct a Phase 1b/2 study of elacestrant in combination with ONA-XR in patients with advanced or metastatic ER+,PR+,HER2- breast cancer (the &#8220;ELONA&#8221; trial). Menarini will provide, at no cost to us, elacestrant, its nonsteroidal combined selective estrogen receptor modulator and selective estrogen receptor degrader therapy, for use in combination with our investigational drug, ONA-XR, in the ELONA trial. Under the Menarini Agreement, we will sponsor, fund and conduct the ELONA trial, and Menarini has agreed to manufacture and supply elacestrant at Menarini's cost and for no charge to us for use in the ELONA trial and to provide cell-free nucleic acid analysis of the anonymized blood samples of all ELONA trial patients. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">In November 2022, we initiated the ELONA trial, with Phase 1b data expected in the fourth quarter of 2023.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">The observations from the ongoing clinical trials noted above are based on information available as of September 30, 2022. These trials are still actively enrolling patients and these preliminary clinical findings may materially fluctuate on a month-to-month basis as the trials progress and may not be representative of results after all patients complete the respective trial and all data is collected and analyzed. Further, this data is subject to continuing audit and verification procedures that will not be complete until the conclusion of the respective trial and therefore the interim data is subject to change.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our second program, CLDN6xCD3 bispecific antibody, is being advanced toward an Investigational New Drug Application ("IND") submission. CLDN6xCD3 BsAb is an anti-CD3 x anti-Claudin 6 (&#8220;CLDN6&#8221;) antigen bispecific monoclonal antibody (&#8220;BsAb&#8221;) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple cancers, including ovarian and endometrial tumors, and absent from or expressed at very low levels in normal adult tissues. We reached the first development milestone under our collaboration and license agreement with Integral Molecular ("Integral") in the second quarter of 2022. We expect to select a candidate to support Investigational New Drug ("IND")-enabling studies for CLDN6xCD3 BsAb in December 2022 and an IND submission is planned in the first quarter of 2024. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated in April 2015 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We operate as one business segment and have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. We have funded our operations primarily through the issuance of convertible debt, convertible preferred stock and sale of common stock. Our net loss was $11.3&#160;million for the nine months ended September&#160;30, 2022. As of September&#160;30, 2022, we had an accumulated deficit of $40.5&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, we closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which we issued and sold 5,750,000 shares at a public offering price of $5.00 per share. We received gross proceeds of approximately $28.8 million as a result of the offering. In December 2021, we sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement for gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into the first quarter of 2024. Currently, our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures as well as general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, in connection with the closing of our IPO, we have incurred and continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our ongoing and planned clinical trials and our expenses on other research and development activities. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue to incur net operating losses for at least the next several&#160;years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">continue our ongoing and planned research and development of our most advanced product candidate ONA-XR; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">continue nonclinical studies and initiate clinical trials for our CLDN6 BsAb product and for any additional product candidates that we may pursue; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">acquire or in-license other product candidates and technologies, including related upfront, milestone and royalty payments; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">attract, hire and retain additional executive officers, clinical, scientific, quality control, and manufacturing management and administrative personnel; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expand our operations in the United States and to other geographies; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings and/or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_76"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The COVID-19 Pandemic and its Impacts on Our Business </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic instability and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact our ongoing or planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations (&#8220;CROs&#8221;), and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact our ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material adverse effect on our business and financial condition. At the current time, we are unable to quantify the potential effects of this pandemic on our future consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Components of Our Results of Operations </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses have consisted primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">personnel expenses, including salaries, benefits and share-based compensation expense for our employees and consultants engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">costs of funding research performed by third parties, including pursuant to agreements with CROs that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and clinical studies; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses incurred under agreements with contract manufacturing organizations ("CMOs"), including manufacturing scale-up expenses, milestone-based payments, and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">fees paid to consultants who assist with research and development activities; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">allocated expenses for facility costs, including rent, utilities and maintenance. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We track outsourced development costs and other external research and development costs to specific product candidates on a program-by-program basis, fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including share-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates. </span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses have consisted primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and business development functions. General and administrative expense also includes corporate facility costs not otherwise included in research and development expense, including rent, utilities and insurance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. Additionally, we will continue to incur  significant costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of our current or future product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income consists of interest earned on our cash and cash equivalents.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Expense </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest expense has consisted primarily of interest related to our convertible promissory notes that converted to Series A stock in 2021.  All of the previously outstanding convertible promissory notes of the Company were converted as of February 2021. </span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_82"></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Three Months Ended September 30, 2022 and 2021 </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth our results of operations for the three months ended September&#160;30, 2022 and 2021: </span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,077,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">739,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,337,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,970,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">828,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,142,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(4,048,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1,568,062)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,480,025)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">192,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">193,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(15345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">126,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(124,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,854,310)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1,442,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,411,518)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased by approximately $1.3 million for the three months ended September&#160;30, 2022 as compared to the same period in 2021. The following table summarizes our research and development expenses for the three months ended September&#160;30, 2022 as compared to the same period in 2021: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">ONA-XR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,422,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">331,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,090,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">CLDN6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">299,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">207,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">92,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Personnel-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">331,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">199,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">132,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">24,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">23,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,077,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">739,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,337,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in ONA-XR expense of $1.1 million was primarily due to an increase of $0.6 million in contract manufacturing costs and an increase of $0.4 million in clinical trial costs, mostly as a result of preparing to initiate our Phase 1b/2 ELONA trial. Personnel-related costs, which include salaries, benefits and stock compensation expense, increased by approximately $0.1 million, primarily due to higher headcount over the prior year period.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased by approximately $1.1 million for the three months ended September&#160;30, 2022 as compared to the same period in 2021. The increase was primarily due to an increase of $0.4 million in compensation and share-based compensation as a result of an increase in our general and administrative headcount and changes to compensation arrangements, higher insurance costs of $0.4 million and $0.3 million of other costs associated with operating as a public company.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income (Expense), net </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net, increased by approximately $0.2 million for the three months ended September&#160;30, 2022 as compared to the same period in 2021 primarily due to higher interest income earned as a result of higher cash and cash equivalent balances and higher interest rates.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Income</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income of $0.1 million for the three months ended September 30, 2021 was primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Nine Months Ended September 30, 2022 and 2021 </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth our results of operations for the nine months ended September&#160;30, 2022 and 2021: </span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,087,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,587,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,946,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,511,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,434,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">6,052,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,834,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,217,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,498,860)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(7,433,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(4,064,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">219,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(64,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">283,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Change in fair value of convertible promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(9,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">124,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(123,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(11,279,158)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(7,365,005)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,914,153)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired in-process research and development expense of $0.5 million for the nine months ended September&#160;30, 2022 reflects the expense recognized related to a development milestone achieved in the second quarter of 2022 under the collaboration and licensing agreement with Integral for the development of CLDN6 BsAb.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired in-process research and development expense of $3.1 million for the nine months ended September 30, 2021 reflects the fair value of the initial consideration paid/issued under the collaboration and licensing agreement with Integral for the development of CLDN6 BsAb. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased by approximately $2.4 million for the nine months ended September&#160;30, 2022 as compared to the same period in 2021. The following table summarizes our research and development expenses for the nine months ended September&#160;30, 2022 as compared to the same period in 2021: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">ONA-XR expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,283,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,423,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,860,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">CLDN6 expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">452,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">523,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(70,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Personnel-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,101,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">545,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">555,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">108,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">19,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">89,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,946,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,511,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,434,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in ONA-XR expenses of $1.9 million was primarily due to an increase of $1.1 million in contract manufacturing costs and an increase of $0.5 million in clinical trial costs, mostly as a result of preparing to initiate our Phase </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1b/2 ELONA trial. Personnel-related costs, which include salaries, benefits and stock compensation expense, increased by approximately $0.6 million, primarily due to higher headcount over the prior year period.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased by approximately $4.2 million for the nine months ended September&#160;30, 2022 as compared to the same period in 2021. The increase was mainly due to an increase of $1.8 million in compensation and share-based compensation as a result of an increase in our general and administrative headcount and changes to compensation arrangements. Additionally, expenses increased due to higher insurance costs of $1.3 million and $0.9 million of other costs associated with operating as a public company.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income (Expense), net </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net, increased by approximately $0.3 million for the nine months ended September&#160;30, 2022 as compared to the same period in 2021 primarily due to higher interest income earned as a result of higher cash and cash equivalent balances and higher interest rates. In addition, interest expense was lower for the nine months ended September&#160;30, 2022 due to the conversion of all convertible promissory notes during 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Change in Fair Value of Convertible Promissory Notes </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The change in fair value of convertible promissory notes was $9,317 for the nine months ended September&#160;30, 2021. This change was attributable to a decrease in the fair value of our common stock. </span></div><div style="margin-bottom:0.05pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Income</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income of $0.1 million for the nine months ended September 30, 2021 was primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_85"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div style="margin-bottom:0.05pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Overview </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">           Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception through September&#160;30, 2022, we have funded our operations through the sale of convertible debt, convertible preferred stock and common stock. As of September&#160;30, 2022, we had $39.4 million in cash and cash equivalents and had an accumulated deficit of $40.5&#160;million. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, we closed an IPO on the Nasdaq Stock Market, in which we issued and sold 5,750,000 shares at a public offering price of $5.00 per share. We received gross proceeds of approximately $28.8 million as a result of the offering. In December 2021, we sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement for gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into the first quarter of 2024. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and various general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of manufacturing our product candidates for clinical trials and in preparation for regulatory approval and commercialization; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the extent to which we enter into additional collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses needed to attract and retain skilled personnel; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">costs associated with being a public company; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs required to scale up our clinical, regulatory and manufacturing capabilities; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive regulatory approval; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive regulatory approval. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need additional funds to meet our operational needs and capital requirements for clinical trials, other research and development expenditures, and general and administrative expenses. We currently have no credit facility or committed sources of capital. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows a summary of our cash flows for the periods indicated: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:66.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(9,619,561)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,837,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(536,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(250,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(102,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,165,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(10,258,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">78,115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Nine Months Ended September&#160;30, 2022 and 2021</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Activities </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2022, we used $9.6 million of cash in operating activities. Cash used in operating activities reflected our net loss of $11.3 million partially offset by in-process research and development charges of $0.5 million, non-cash share-based compensation of $0.7 million, and a change in our operating assets and liabilities of $0.4 million. The primary uses of cash were to fund our operations related to the development of our product candidates. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2021, we used $3.8 million of cash in operating activities. Cash used in operating activities reflected our net loss of $7.4 million, a gain of $0.1 million from the extinguishment of debt and an increase in our operating assets and liabilities of $0.2 million. This was offset by non-cash in-process research and development charges of $3.1 million, the non-cash fair value measurement of warrants for services of $0.4 million and non-cash interest expense and share-based compensation of $0.4 million. The primary uses of cash were to fund our operations related to the development of our product candidates.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2022, cash used in investing activities was primarily attributable to the payment of a development milestone of $0.5&#160;million under the collaboration and licensing agreement with Integral for the development of CLDN6 BsAb for gynecologic cancer therapy. In addition, we used $37,000 of cash to purchase property and equipment.</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September 30, 2021, cash used in investing activities was attributable to the initial upfront license fee of $0.3 million related to our acquired in-process research and development.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2022, cash used in financing activities was $0.1 million, consisting of the payment of offering costs related to our December 2021 private placement.</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2021, financing activities provided $4.2 million, primarily consisting of net proceeds of $5.0 million from the sale of Series A preferred stock and warrants for common stock, partially offset by the payment of $0.8 million of offering costs related to our IPO.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_88"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended September&#160;30, 2022, there were no material changes to our critical accounting policies and estimates from those described in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_94"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note&#160;3 to our unaudited condensed consolidated financial statements found elsewhere in this Quarterly Report for a description of recent accounting pronouncements applicable to our condensed consolidated financial statements. </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_97"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Emerging Growth Company and Smaller Reporting Company Status </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on other exemptions and reduced reporting requirements under the JOBS Act, including without limitation, exemption from the requirements to provide an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act. We will remain an emerging growth company until the earlier to occur of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of our IPO (December 31, 2026), (ii)&#160;in which we have total annual gross revenues of at least $1.235&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means that we have been required to file annual and quarterly reports under the Securities Exchange Act of 1934, as amended (the "Exchange Act") for a period of at least 12 months and have filed at least one annual report pursuant to the Exchange Act and either (a)&#160;the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company until either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_103"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the evaluation of our disclosure controls and procedures as of September&#160;30, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable assurance level.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PART II &#8211; Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are not presently a party to any material legal proceedings.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 23, 2022. Other than as set forth below, there have been no material changes to the risk factors described in that report. The occurrence of any of the events or developments described in our Risk Factors could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The passage of the Inflation Reduction Act of 2022 may negatively impact our ability to sell our product candidates, if approved, profitably.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was passed, which among other things, allows for The Centers for Medicare &amp; Medicaid Services to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses at $2,000. The effect of the IRA on our business and the healthcare industry in general is not yet known.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i6128ef27165d4066a955a859b4b0ee27_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;Defaults upon Senior Securities</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i6128ef27165d4066a955a859b4b0ee27_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i6128ef27165d4066a955a859b4b0ee27_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Because we are filing this Quarterly Report on Form 10-Q within four business days after the triggering event, we are making the following disclosure under this Item 5 instead of filing a Current Report on Form 8-K under Item 1.01, Entry into a Material Definitive Agreement:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Development and Manufacturing Services Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 7, 2022, Context Therapeutics Inc. (the &#8220;Company&#8221;) entered into a Development and Manufacturing Services Agreement (the &#8220;Lonza Development Agreement&#8221;), with Lonza Sales AG (&#8220;Lonza Sales&#8221;) and Lonza AG (collectively, &#8220;Lonza&#8221;). Under the terms of the Lonza Development Agreement, Lonza will provide services relating to the development and manufacture of the Company&#8217;s anti-claudin 6 bispecific monoclonal antibody product (the &#8220;Product&#8221;) in accordance with the project plan attached to the Lonza Development Agreement and any other work as may be agreed to between the Company and Lonza. The Lonza Development Agreement will terminate upon the completion of the agreed upon </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">services, unless earlier terminated by the Company or Lonza for uncured material breaches, insolvency of the other party, or if a party determines that it is not possible to complete the services for material scientific or material technical reasons.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company can terminate certain services under the Lonza Development Agreement, but in addition to payment for certain non-cancellable commitments, the Company would be required to pay a cancellation fee, such fee to be determined depending on the timing of such notice prior to the commencement of the related services. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The License Development Agreement requires the Company to obtain a license from Lonza prior to receipt of the Product or in vivo clinical studies or any other commercial use or sale of the Product, which the Company entered into concurrently with the License Development Agreement, as further described below. Additionally, should the Company desire to either manufacture the Product itself or have it manufactured by a third party, the Company would be required to obtain Lonza&#8217;s consent (not to be unreasonably withheld, conditioned or delayed) and would need to enter into a separate technology transfer agreement with Lonza for a non-exclusive license to the extent necessary to manufacture, have manufactured and supply the Product at a licensing fee up to &#163;750,000.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Lonza Development Agreement also contains customary representations, warranties, indemnification and other obligations of the Company and Lonza. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">License Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 7, 2022, the Company entered into a License Agreement (the &#8220;Lonza License Agreement&#8221;) with Lonza Sales. Under the terms of the Lonza License Agreement, to the extent incorporated into the Product, Lonza granted the Company a non-exclusive license to use certain proprietary Lonza intellectual property and systems for the Company to develop, manufacture and commercially exploit the Product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company shall pay certain royalties and annual payments in respect of the manufacturing and sale of Product, which amounts shall be determined by the party manufacturing the Product and ranges from a potential annual payment of up to less than $500,000 and a royalty on net sales from 0% up to a low single digit percentage. The royalty payments and annual payments would be reduced in certain circumstances, including should the valid claims for any such patent rights not exist in the country in which such Product is being sold, and the royalty payments would expire upon the later of the expiration of the licensed patents in the country in which such Product is being sold, the expiration of the licensed patents in the country in which such Product is being manufactured, and ten years from the first commercial sales of the Product in such country of sale.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Lonza License Agreement continues until terminated, and the Company or Lonza may terminate the Lonza License Agreement for uncured material breaches or insolvency of the other party.  The Company can unilaterally terminate the Lonza License Agreement with prior written notice to Lonza, and Lonza can also unilaterally terminate the Lonza License Agreement upon certain actions by the Company.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Lonza License Agreement also contains customary representations, warranties, indemnification and other obligations of the Company and Lonza. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The foregoing description of the Lonza Development Agreement and Lonza License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lonza Development Agreement and Lonza License Agreement, which will be filed as exhibits to a subsequent filing with the Securities and Exchange Commission (the &#8220;Commission&#8221;), as permitted by the rules of the Commission. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">33</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;<br/>Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521305465/d251040dex31.htm">Amended &amp; Restated Certificate of Incorporation of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521305465/d251040dex32.htm">Amended and Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295222000071/amendment2tosahmoud-oncost.htm">Clinical Trial Collaboration and Supply Agreement, dated August 1, 2022, by and between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on August 11, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="tyligand-cntxamendno3proce.htm">Amendment No. 3  to Process Development Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="tyligand-cntxamendno3proce.htm">&amp;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="tyligand-cntxamendno3proce.htm"> Amendment No. 1 to License, Development, Manufacturing &amp; Marketing Agreement, dated November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="tyligand-cntxamendno3proce.htm">7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="tyligand-cntxamendno3proce.htm"> 2022, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.3*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lonzacontextdmsa.htm">Development and Manufacturing Services Agreement, dated November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lonzacontextdmsa.htm">7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lonzacontextdmsa.htm"> 2022, between Lonza Sales AG, Lonza AG and Context Therapeutics Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.4*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="context-lonzalicenseagreem.htm">License Agreement, dated November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="context-lonzalicenseagreem.htm">7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="context-lonzalicenseagreem.htm"> 2022, between Lonza Sales AG and Context Therapeutics Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx-20220930x10qexhibit311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx-20220930x10qexhibit312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32.1*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx-20220930x10qexhibit321.htm">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">101*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following financial statements from Context Therapeutics Inc.&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statement of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Deficit; (iv) Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 hereto)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*      Filed herewith </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">#       Certain confidential information contained in this agreement has been omitted because it is both not material and is the type that the registrant treats as private or confidential</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+    This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">34</span></div></div></div><div id="i6128ef27165d4066a955a859b4b0ee27_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6128ef27165d4066a955a859b4b0ee27_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: November 9, 2022</span></div><div style="margin-bottom:5pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CONTEXT THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;/s/ Martin Lehr</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Martin Lehr</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ Jennifer Minai-Azary</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jennifer Minai-Azary</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="text-indent:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>tyligand-cntxamendno3proce.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9a3bd8dd9b924987bcded1c8296da8d1_1"></div><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.548%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4.05pt;padding-left:70.62pt;padding-right:70.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT &#38; AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING &#38; MARKETING AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Development Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">and AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING &#38; MARKETING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">License Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively with the Development Amendment, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is effective as of this 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of November 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at Floor 1 (West Lobby and Auxiliary Room), 4 and 5, Tower 12 (No.1), No. 3728, Jinke Road, Shanghai Pilot Free Trade Zone of PRC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Tyligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Context Therapeutics LLC, a Delaware limited liability company having its registered office at 2001 Market Street, Suite 3915, Unit#15, Philadelphia, PA 19103 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Context</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Tyligand and Context are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:8.05pt;padding-left:70.52pt;padding-right:70.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Tyligand and Context entered into that certain Process Development Agreement, effective as of the 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">th </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">day of March 2020, as amended by Amendment No. 1 effective as of the 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> day of April 2021, and as amended by Amendment No. 2 effective as of the 3rd day of June 2021 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Development Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), which outlines the rights and obligations of Tyligand and Context with respect to the conduct of certain services to be performed by Tyligand&#59;</font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">due to the Successful Completion (as defined in the Development Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of Tyligand&#8217;s process development efforts,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parties also entered into that certain License, Development, Manufacturing &#38; Marketing Agreement on the 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of August 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), for Tyligand&#8217;s development and commercialization of the Compound (as defined in the License Agreement) in the Territory (as defined in the License Agreement)&#59;</font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties intend to enter into the Development Amendment to recognize and agree that the provisions in Sections 3.1 (Milestones), 3.2 (Royalty), 3.6 (Method of Payments) and 3.7 (Conflict) in ARTICLE III, CONSIDERATION of the Development Agreement shall survive the Term (as defined in Section 10.1 of the Development Agreement)&#59;</font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="padding-left:10pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties intend to enter into the License Amendment to (i) amend and restate Section 1.52 in ARTICLE 1 DEFINITIONS of the License Agreement, (ii) amend and restate Section 4.2.1 (Grant Back) in ARTICLE 4 IMPROVEMENT of the License Agreement, and (iii) recognize and agree that the provisions in Section 4.2.1 (Grant Back) in ARTICLE 4 IMPROVEMENT and Section 9.1 (Term) in ARTICLE 9 TERM AND TERMINATION of the License Agreement shall survive the expiration of the License Agreement subject to terms and conditions thereof&#59;</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in order to avoid any confusion,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, wish to enter into this Amendment and agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All capitalized terms used herein shall have the meaning ascribed to&#160;&#160;&#160;&#160;each of them as defined herein and, if not defined herein, shall have the meaning ascribed to each &#160;&#160;&#160;&#160;of them in the Development Agreement or License Agreement, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Development Amendment</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Section 10.7 of the Development Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Amendment Effective Date, Section 10.7 of the Development Agreement is hereby amended and restated as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;10.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to terms and conditions of this Agreement, the termination or expiration of this Agreement shall not affect the survival and continuing validity and enforceability of provisions herein expressed to survive and operate following such expiration or termination, including Sections 3.1, 3.2, 3.6 and 3.7, and Article VI through Article XI.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.170%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.548%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">License Amendment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Section 1.52 of the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Amendment Effective Date, Section 1.52 of the License Agreement is hereby amended and restated as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:2pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Tyligand Know-How&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means all Know-How that relate solely and directly to the Compound or the Product which becomes Controlled by Tyligand or its Affiliates, sublicensees or contractors.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Section 4.2.1 of the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Amendment Effective Date, Section 4.2.1 of the License Agreement is hereby amended and restated as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;4.2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Back</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to terms and conditions of this Agreement, Tyligand hereby grants Context an exclusive, fully-paid up, royalty-free license (which shall become perpetual and irrevocable upon the expiration of this Agreement or the earlier termination of this Agreement by Context pursuant to Section 9.2.1, 9.2.2, or 9.2.3 or by Tyligand pursuant to Section 9.2.4), with the right to grant sublicenses, to any Improvement and Tyligand Know-How resulting from the activities undertaken by Tyligand or its Affiliates or sublicensees related to the Compound, related to the Product, or pursuant to this Agreement, whether patentable or non-patentable, for Context and its Affiliates and sublicensees to (i) make, have made, use, research, develop, commercialize, sell, offer to sell, import and export the Compound or any improvements thereto outside the Territory, and (ii) make, have made, use, research, develop, import and export the Compound, Product or any improvements thereto inside or outside the Territory for use, research, development, sale and commercialization outside the Territory.&#8221;  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Section 9.4 of the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Amendment Effective Date, the following sentence shall be added at the end of Section 9.4&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tyligand further acknowledges and agrees that subject to terms and conditions of this Agreement, Sections 4.2.1 and 9.1 of this Agreement shall survive any termination or expiration of this Agreement.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">General Terms</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party acknowledges that this Amendment, together with the Development Agreement and License Agreement, as applicable, constitutes the entire agreement of the Parties with respect to the subject matter hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Full Force and Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly amended hereby, all of the other terms and conditions of the Development Agreement and License Agreement, as applicable, shall remain unchanged and in full force and effect in accordance with their original terms.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party hereby represents and warrants that is has full power and authority to enter into this Amendment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:1.25pt;padding-right:1.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature page follows&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.170%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.548%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have each caused a duly authorized representative to execute this Amendment as of the Amendment Effective Date.</font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.610%"><tr><td style="width:1.0%"></td><td style="width:42.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:111%">CONTEXT&#58;</font></div><div><font><br></font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Context Therapeutics LLC</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10pt;padding-right:-2.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%;text-decoration:underline">&#47;s&#47; Martin Lehr&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%"> Name&#58; Martin Lehr</font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">Title&#58; Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:111%">TYLIGAND&#58;</font></div><div><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tyligand Bioscience (Shanghai) Limited</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:53.45pt;padding-right:15.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%;text-decoration:underline">&#47;s&#47; Tony Zhang&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:233%"> Name&#58; Tony Y. Zhang</font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">Title&#58; Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.170%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>lonzacontextdmsa.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iabb26425555444e0b3c0119569319c3a_1"></div><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development and Manufacturing Services Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">between</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lonza Sales AG</font></div><div style="margin-bottom:42pt;text-align:center"><font><br></font></div><div style="margin-bottom:42pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:42pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lonza AG</font></div><div style="margin-bottom:42pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Context Therapeutics Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><div id="iabb26425555444e0b3c0119569319c3a_4"></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made the      7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of November 2022 (&#8220;Effective Date&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;LONZA SALES AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;LONZA AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:35.45pt;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;CONTEXT THERAPEUTICS INC., of 2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103 (&#8220;Customer&#8221;).</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Lonza AG and Lonza Sales AG together or individually referred to as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lonza</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as applicable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of a certain product&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Lonza and its Affiliates have among other things expertise in the evaluation, development and manufacture of biologic products&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement&#59; and </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Definitions and Interpretation</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Affiliate&#8221;&#160;&#160;&#160;&#160;means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party.  &#8220;Control&#8221; means the ownership of more than fifty percent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Agreement&#8221;&#160;&#160;&#160;&#160;means this agreement incorporating all Appendices and Project Plans, as amended from time to time by written agreement of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Applicable Laws&#8221;&#160;&#160;&#160;&#160;means all relevant U.S. and European Union federal, state and local laws, statutes, rules, and regulations, which are applicable to a Party&#8217;s activities hereunder, including the applicable regulations and guidelines of any Regulatory Authority together with amendments thereto.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Approval&#8221;&#160;&#160;&#160;&#160;means the first marketing approval by the FDA or EMA of Product from the Facility for commercial supply.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Background Intellectual Property&#8221; &#160;&#160;&#160;&#160;means any Intellectual Property either&#58; (i) owned or controlled by a Party or any of its Affiliates prior to the Effective Date&#59; or (ii) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">developed or acquired by a Party or any of its Affiliates independently from the performance of the Services hereunder during the Term of this Agreement. Lonza Information and the Manufacturing Process shall form part of, and be included in, Lonza&#8217;s Background Intellectual Property. Customer&#8217;s Background Intellectual Property shall exclude any Intellectual Property licensed (whether under this or any other agreement) to Customer or any Affiliate of Customer by Lonza or any Affiliate of Lonza.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Batch&#8221;&#160;&#160;&#160;&#160;the Product derived from a single run of the Manufacturing Process. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Batch Record&#8221;&#160;&#160;&#160;&#160;means the executed version of a given Master Batch Record pertaining to a given Batch </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Binding Order&#8221;&#160;&#160;&#160;&#160;means a binding order on the Parties made in accordance with Clause 6.1.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Cancellation Fee&#8221;&#160;&#160;&#160;&#160;has the meaning given in Clause 6.2.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Capital Equipment&#8221;&#160;&#160;&#160;&#160;means those certain pieces of new equipment described in the Project Plan which are to be acquired and paid for on terms to be agreed in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Cell Bank&#8221;&#160;&#160;&#160;&#160;means the Customer&#8217;s Cell Bank or cell stock of rodent and&#47;or human cell line in accordance with the Project Plan.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Cell Bank Storage&#8221;&#160;&#160;&#160;&#160;means the storage of Customer&#8217;s Cell Bank in accordance with Clause 2.11 of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Cell Line&#8221;&#160;&#160;&#160;&#160;means the cell line, particulars of which are set out in the applicable Project Plan.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Certificate of Analysis&#8221;&#160;&#160;&#160;&#160;means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, the Specification and test results.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Certificate of Compliance&#8221;&#160;&#160;&#160;&#160;means a document prepared by Lonza&#58; (i) listing the manufacturing date, unique Batch number and concentration of Product in such Batch&#59; and (ii) certifying that such Batch was manufactured in accordance with the Master Batch Record and cGMP, if applicable.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;cGMP&#8221;&#160;&#160;&#160;&#160;means those laws and regulations applicable in the United States, the European Union and the European Economic Area, the United Kingdom, Switzerland and any other countries the Parties may mutually agree upon in writing, relating to the manufacture of medicinal products for human use, including current good manufacturing practices as specified in the ICH guidelines, including ICH Q7A &#8220;ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients&#8221;, US Federal Food </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directives 2001&#47;83&#47;EC and 2003&#47;94&#47;EC.  For the avoidance of doubt, Lonza&#8217;s operational quality standards are defined in internal cGMP policy documents.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;cGMP Drug Product Batch&#8221;&#160;&#160;&#160;&#160;means a Batch of Drug Product which is required under the Project Plan to be manufactured in accordance with cGMP.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;cGMP Drug Substance Batch&#8221;&#160;&#160;&#160;&#160;means a Batch of Drug Substance which is required under the Project Plan to be manufactured in accordance with cGMP.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Change&#8221;&#160;&#160;&#160;&#160;means any change to the Services, pricing, Project Plan or scope of work incorporated into a written amendment to the Agreement in accordance with Clause 16.5 or effected in accordance with the Quality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Commencement Date&#8221;&#160;&#160;&#160;&#160;means the date of removal of the vial of cells from frozen storage for the production of a Batch or, in the case of other Services, the date of commencement of such Services.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Confidential Information&#8221;&#160;&#160;&#160;&#160;means Customer Information and&#47;or Lonza Information, as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Corruption Laws&#8221;&#160;&#160;&#160;&#160;means all anti-bribery and anti-corruption laws and regulations in the US, UK and EU including but not limited to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and the Organization for Economic Co-operation and Development Convention on Combating Bribery and Foreign Public Officials in International Business Transactions.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Customer Information&#8221;&#160;&#160;&#160;&#160;means all technical and other information that is proprietary to Customer or any Affiliate of Customer (including any and all Customer know-how and trade secrets and Customer Background Intellectual Property) or not known to Lonza and&#47;or not in the public domain relating to the Cell Line, Customer&#8217;s business, and the Product, in each case from time to time supplied by or on behalf of the Customer to Lonza.  Customer Information shall exclude any Lonza Information provided (whether under this or any other agreement) to Customer or any Affiliate of Customer by Lonza or any Affiliate of Lonza in connection with the Services.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Customer Materials&#8221;&#160;&#160;&#160;&#160;means any Raw Materials, components of Product, or other materials of any nature, in each case provided by or on behalf of Customer.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Delivery&#8221;&#160;&#160;&#160;&#160;shall have the meaning set out at Clause 7.1.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Development Work&#8221;&#160;&#160;&#160;&#160;means all activities other than the manufacture of Pilot Batches and cGMP Batches.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Drug Product&#8221;&#160;&#160;&#160;&#160;means the formulation of the Drug Substance in its final dosage form to be manufactured by Lonza under the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Drug Substance&#8221;&#160;&#160;&#160;&#160;means the Product in bulk drug substance form.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;EMA&#8221;&#160;&#160;&#160;&#160;means the European Medicines Agency, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;External Laboratories&#8221;&#160;&#160;&#160;&#160;means any Third Party instructed by Lonza, with Customer&#8217;s prior written consent, to conduct certain activities not customarily performed by Lonza which are required to complete the Services.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Facility&#8221;&#160;&#160;&#160;&#160;means&#58; (i) in respect of development and manufacturing of Pilot Drug Substance Batches and&#47;or cGMP Drug Substance Batches, Lonza&#8217;s facility in Slough, UK, Visp, Switzerland, Singapore, and&#47;or Hayward, California, USA&#59; (ii) in respect of Pilot Drug Product Batches and&#47;or cGMP Drug Product Batches at a Lonza facility as may be agreed by the Parties. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Failed Drug Product Batch&#8221; &#160;&#160;&#160;&#160;shall have the meaning set out in Clause 7.5.3.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Failed Drug Substance Batch&#8221;&#160;&#160;&#160;&#160;shall have the meaning set out in Clause 7.4.3.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;FDA&#8221;&#160;&#160;&#160;&#160;means the United States Food and Drug Administration, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;GDPR&#8221;&#160;&#160;&#160;&#160;means the European Union General Data Privacy Regulations.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;GS&#8221;&#160;&#160;&#160;&#160;means the glutamine synthetase expression system of which Lonza is the proprietor.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;GS Licence&#8221;&#160;&#160;&#160;&#160;means a licence granted by Lonza in respect of the use of GS.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Handling Fee&#8221;&#160;&#160;&#160;&#160;means (i) the procurement and handling fee of &#91;***&#93; percent (&#91;***&#93;%) of the acquisition cost of Raw Materials by Lonza that is charged to the Customer in addition to the cost of such Raw Materials and (ii) for the management and handling of activities performed by the External Laboratories, a fee of &#91;***&#93; percent (&#91;***&#93;%) of the cost that is charged to the Customer in addition to the charge for such External Laboratories.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Intellectual Property&#8221;&#160;&#160;&#160;&#160;means&#58; (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered&#59; (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing sub-clause (i)&#59; and (iii) all rights and applications that are similar or equivalent to the rights and application described in the foregoing sub-clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;International Trade Restrictions&#8221;&#160;&#160;&#160;&#160;means all applicable United States, United Nations, and European Union export control, trade, and financial sanctions laws, rules, and regulations.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Latent Defect&#8221;&#160;&#160;&#160;&#160;means any instance where a Drug Substance or Drug Product Batch fails to comply with Specification, and which could not be discovered by reasonable and customary observation or inspection pursuant to Clauses 7.4.1 and 7.5.1.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8220;Lonza Information&#8221;&#160;&#160;&#160;&#160;means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Customer under or in connection with this Agreement, including any and all Lonza know-how and trade secrets and Lonza Background Intellectual Property and Lonza Operating Documents.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Lonza Operating Documents&#8221;&#160;&#160;&#160;&#160;means the corporate standards, standard operating procedures, standard manufacturing procedures, Lonza-customized manufacturing procedures developed prior to the Effective Date or outside the scope of this Agreement, electronic programs and files, raw material specifications, protocols, Lonza validation documentation, and supporting documentation used by Lonza, such as, without limitation, environmental monitoring, for operation and maintenance of the Facility and Lonza equipment used in the process of producing the Product. Lonza Operating Documents shall be regarded as Lonza Information. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Lonza Responsibility&#8221;&#160;&#160;&#160;&#160;means a failure solely due to Lonza&#8217;s negligence, intentional misconduct, or material breach of its obligations hereunder.  Lonza Responsibility shall not include any failure due to a biological reason.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Manufacturing Process&#8221;&#160;&#160;&#160;&#160;means, as the context requires&#58; (i) the production process for the manufacture of Drug Substance&#59; and&#47;or (ii) the production process for the manufacture of Drug Product from Drug Substance, in each instance pursuant to the Services hereunder as such process may be improved or modified from time to time by agreement of the Parties in writing.  For clarity, the Manufacturing Process (to the extent not incorporating any Customer Intellectual Property, Customer Information and&#47;or Customer Background Intellectual Property) shall be Lonza&#8217;s Background Intellectual Property. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Master Batch Record&#8221;&#160;&#160;&#160;&#160;means the document which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;New Customer Intellectual Property&#8221;&#160;&#160;&#160;&#160;has the meaning given in Clause 10.2.</font></div><div style="padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;New Lonza Intellectual</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property&#8221;&#160;&#160;&#160;&#160;has the meaning given in Clause 10.3.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Party&#8221;&#160;&#160;&#160;&#160;means each of Lonza and Customer and, together, the &#8220;Parties&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Pilot Drug Product Batch&#8221; &#160;&#160;&#160;&#160;means a Batch of Drug Product which is designated as a pilot Batch and which shall not comply with cGMP and is not required to meet the Specification.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Pilot Drug Substance Batch&#8221;&#160;&#160;&#160;&#160;means a Batch of Drug Substance which is designated as a pilot Batch and which shall not comply with cGMP and is not required to meet the Specification.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Price&#8221;&#160;&#160;&#160;&#160;means the price for the Batches (including Pilot Drug Substance Batches, Pilot Drug Product Batches, cGMP Drug Substance Batches and cGMP Drug Product Batches), Services and Products as set out in the applicable Project Plan (the Price excludes the cost of the Raw Materials and the Handling Fee).</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Product&#8221;&#160;&#160;&#160;&#160;means the Product identified in the Project Plan.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Project Plan&#8221;&#160;&#160;&#160;&#160;means the plan describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time. The Project Plan are incorporated into and shall be an integral part of this Agreement. The initial Project Plan is attached hereto as Appendix A. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Quality Agreement&#8221;&#160;&#160;&#160;&#160;means the quality agreement, which shall be attached hereto as Appendix C, setting out the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">responsibilities of the Parties in relation to quality as required for compliance with cGMP. The Quality Agreement is incorporated into and shall be an integral part of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Raw Materials&#8221;&#160;&#160;&#160;&#160;means all ingredients, solvents, primary packaging materials, filter, single-use liquid-paths and other components of the Product required to perform the Manufacturing Process or Services set forth in the bill of materials detailing the same (&#8220;Raw Materials&#8221; includes Resins and single use bags, but excludes any consumables or wearables). </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Regulatory Authority&#8221;&#160;&#160;&#160;&#160;means the FDA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Release&#8221;&#160;&#160;&#160;&#160;has the meaning given in Clause 7.1.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Resin&#8221;&#160;&#160;&#160;&#160;means the chromatographic media and UF membranes intended to refine or purify the Product, as specified in the Master Batch Record.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Services&#8221;&#160;&#160;&#160;&#160;means all or any part of the services to be performed by Lonza (including, process and analytical method transfer, process development, process optimization, validation, clinical and commercial manufacturing of Batches, as well as quality control and quality assurance activities) under this Agreement, particulars of which are set out in the Project Plan.  </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Services Data&#8221;         &#160;&#160;&#160;&#160;means any and all data obtained by Lonza or any Affiliate, contractor or External Laboratories of Lonza in the course of performing the Services.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Specifications&#8221;&#160;&#160;&#160;&#160;means the specifications of the Product as specified in the applicable Project Plan or as otherwise agreed in writing between the Parties, which may be agreed and amended from time to time in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Specification (Drug Product)&#8221;&#160;&#160;&#160;&#160;means the specification of the Drug Product with regard to sterility and fill volume only as specified in the applicable Project Plan or as otherwise agreed in writing between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Stage of Work&#8221;&#160;&#160;&#160;&#160;means the individual stages of the Services as set out in the Project Plan.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Storage Requirements&#8221; &#160;&#160;&#160;&#160;means the Cell Bank storage requirements as set out in the Project Plan or as agreed between the Parties in writing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Subcontractors&#8221; &#160;&#160;&#160;&#160;means any Third Party selected and approved by Lonza which Lonza instructs to perform any part of the Service which Lonza customarily offers to customers. </font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Term&#8221;&#160;&#160;&#160;&#160;has the meaning given in Clause 14.1.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify;text-indent:-216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Third Party&#8221;&#160;&#160;&#160;&#160;means any party other than Customer, Lonza and their respective Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In this Agreement references to the Parties are to the Parties to this Agreement,  headings are used for convenience only and do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word &#8220;including&#8221; are to be construed without limitation.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Performance of Services</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.&#160;&#160;&#160;&#160;Lonza AG, Lonza Sales AG, and Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:63.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.1 Lonza AG shall be independently accountable for the performance of the Services under this Agreement performed or to be performed by Lonza in Switzerland and such performance shall be subject to the terms of this Agreement. Lonza Sales AG shall have no responsibility with respect to the performance of said Services and Lonza AG shall under no circumstance be deemed a subcontractor of Lonza Sales AG. </font></div><div style="margin-bottom:12pt;padding-left:63.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.2 Lonza Sales AG shall be independently accountable for the performance of the Services under this Agreement performed or to be performed by Lonza outside of Switzerland and such performance shall be subject to the terms of this Agreement. Lonza AG shall have no responsibility with respect to the performance of Services by Lonza Sales AG and Lonza Sales AG shall under no circumstance be deemed a subcontractor of Lonza AG. </font></div><div style="margin-bottom:12pt;padding-left:63.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.3&#160;&#160;&#160;&#160;Lonza AG, Lonza Sales AG, or any of their respective Affiliates may execute a Project Plan or Statement of Work with Customer pursuant to this Agreement and submit invoices to Customer under such Project Plan or Statement of Work. In such circumstances all references in this Agreement to Lonza shall be deemed to be applicable to the relevant Affiliate of Lonza with respect to that particular Project Plan or Statement of Work. Such Affiliate shall be entitled to enforce this Agreement with respect to such Project Plan or Statement of Work in its own name as an intended third party beneficiary and the Affiliate shall be solely liable to Customer (under the terms of this Agreement) for any obligations and liabilities undertaken pursuant to such Project Plan or Statement of Work.&#160;</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.&#160;&#160;&#160;&#160;Customer hereby retains Lonza to perform the Services set out in the Project Plan. Subject to the provisions of Clause 2, Lonza shall itself and through its Affiliates, diligently carry out the Services set out in the Project Plan and use commercially reasonable efforts to perform the Services without any material defect and according to the estimated timelines set out in the Project Plan. Owing to the unpredictable nature of the biological processes involved in the Services, the timescales set down for the performance of the Services are estimated only.  Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subcontracting and External Laboratories.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Lonza may subcontract or delegate any of its rights or obligations under this Agreement to perform the Services and Lonza </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be responsible for the acts and omissions of its Subcontractors. Lonza may engage an External Laboratory to provide some of the Services and Lonza shall be responsible for the acts and omissions of such External Laboratories chosen or nominated by Lonza.  Lonza shall not be responsible for services performed by, nor for any acts and&#47;or omissions whatsoever of, any Subcontractors or External Laboratories chosen or nominated by Customer.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Supply of Customer Information and Customer Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Customer is providing Customer Background Intellectual Property, Customer Information, Customer Materials, the Cell Line, and&#47;or other information or materials that may be reasonably required to be provided by or on behalf of Customer to Lonza and&#47;or its Affiliates for Lonza and&#47;or its Affiliates to perform the Services to Lonza, the Parties agree that they shall work together to transfer (as described in the Project Plan) the Customer Background Intellectual Property, Customer Information, Customer Materials, the Cell Line, and&#47;or other information or materials that may be reasonably required to be provided by or on behalf of Customer to Lonza and&#47;or its Affiliates or Lonza and&#47;or its Affiliates to perform the Services to the Facility, including implementing the technology transfer plan set out in the Project Plan.  Customer shall fully support such technology transfer as reasonably requested by Lonza.  Customer shall (by such date as agreed between the Parties) supply to Lonza all such relevant Customer Background Intellectual Property, Customer Information, Customer Materials, the Cell Line, and&#47;or other information or materials that may be reasonably required to be provided by or on behalf of Customer to Lonza and&#47;or its Affiliates for Lonza and&#47;or its Affiliates to perform the Services.  Lonza shall not be responsible for any delays arising out of Customer&#8217;s failure to provide such Customer Background Intellectual Property, Customer Information, Customer Materials, the Cell Line, and&#47;or other information and&#47;or materials reasonably required to be provided by or on behalf of Customer for Lonza to perform and&#47;or its Affiliates the Services, and any unreasonable delay shall be deemed a cancellation and Customer shall pay the Cancellation Fee in respect of such cancelled Services and shall pay for all additional reasonable costs and expenses arising out of such delay.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pilot Drug Substance Batches and Pilot Drug Product Batches</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Lonza shall manufacture, or procure the manufacture of, the Pilot Drug Substance Batch(es) and the Pilot Drug Product Batch(es) in accordance with the Project Plan, but shall have no obligation to meet Specifications or Specification (Drug Product) or comply with cGMP in relation to the Pilot Drug Substance Batch(es) or the Pilot Drug Product Batch(es) (and Lonza makes no warranty in this regard).  Customer shall have the right to make whatever use of the Pilot Drug Substance Batch(es) and the Pilot Drug Product Batch(es) as it shall determine, provided that Customer pays Lonza for such Pilot Drug Substance Batch(es) and Pilot Drug Product Batch(es), and such use is not for human use and does not violate any laws.  Unless Lonza and Customer agree otherwise, all Pilot Drug Substance Batches and Pilot Drug Product Batches shall be promptly shipped to Customer.  </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6.&#160;&#160;&#160;&#160;Prior to commencement of cGMP manufacturing pursuant to Clause 2.7, Lonza shall review the process assumptions.  If there is a material difference in the process assumptions as compared with the results demonstrated during the manufacture of the applicable Pilot Drug Substance Batch(es) or Pilot Drug Product Batch(es), the Parties shall meet to discuss in good faith the consequences of such changes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">cGMP Drug Substance Batches and cGMP Drug Product Batches.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Lonza will, in accordance with the terms of this Agreement and the Quality Agreement and subject to Clause 2.7.3&#58;</font></div><div style="margin-bottom:12pt;padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7.1.&#160;&#160;&#160;&#160;Manufacture and Release to Customer cGMP Drug Substance Batches in accordance with cGMP and which meet the applicable Specifications, together with a Certificate of Analysis&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7.2.&#160;&#160;&#160;&#160;Manufacture cGMP Drug Product Batches in accordance with cGMP and which meet the Specifications (Drug Product), and shall Release the cGMP Drug Product Batches together with a Certificate of Analysis if such cGMP Drug Product Batch meets the applicable Specifications (provided that Lonza&#8217;s liability for such cGMP Drug Product shall be as set out in Clause 2.7.3 below)&#59; </font></div><div style="margin-bottom:12pt;padding-left:61.2pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7.3.&#160;&#160;&#160;&#160;In each case (clause 2.7.1 and 2.7.2), Lonza shall use reasonable commercial endeavours to meet the Specifications and Specification (Drug Product), provided that Lonza shall not charge the Customer for&#58; (i) any cGMP Drug Substance Batches failing to meet Specification&#59; or (ii) any cGMP Drug Product Batch failing to meet the Specification (Drug Product), if, in each case due to Lonza&#8217;s negligence or failure to use commercially reasonable endeavours. For clarity, if a cGMP Drug Product Batch meets the Specifications (Drug Product) but no other applicable Specifications, then Customer shall be required to pay for such cGMP Drug Product Batch notwithstanding the fact that it only met the Specification (Drug Product) and not any other Specifications. Notwithstanding the foregoing, Lonza shall not be responsible for any failure to meet the Specifications and the Specification (Drug Product) in respect of, and Customer shall pay for&#58;</font></div><div style="margin-bottom:12pt;padding-left:103.5pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the first &#91;***&#93; cGMP Drug Substance Batches and the first &#91;***&#93; cGMP Drug Product Batches manufactured&#59; and&#47;or</font></div><div style="margin-bottom:12pt;padding-left:103.5pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;in respect of the &#91;***&#93; cGMP Drug Substance Batch and the &#91;***&#93; cGMP Drug Product Batch manufactured following any material change in the Manufacturing Process agreed to or requested by Customer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">However, Lonza shall comply with its performance obligations set out in Clause 2.2 and shall in relation to all cGMP Batches of Product be responsible for meeting such Specifications as may be agreed in writing prior to commencement of the Services in respect of the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) For cGMP Drug Substance Batches&#58;</font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-indent:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;Bioburden&#59;</font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-indent:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">II.&#160;&#160;&#160;&#160;Mycoplasmas&#59;</font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-indent:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">III.&#160;&#160;&#160;&#160;In Vitro tests (3 cell lines)&#59; </font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-indent:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IV.&#160;&#160;&#160;&#160;Endotoxins&#59; and</font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-indent:7.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">V.&#160;&#160;&#160;&#160;Minute virus of mice (MVM)</font></div><div style="margin-bottom:12pt;padding-left:63.25pt;text-align:justify;text-indent:4.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) For cGMP Drug Product Batches&#58; Specification (Drug Product).</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7A&#160;&#160;&#160;&#160;Lonza shall not have any obligation to comply with cGMP nor achieve any Specifications with regard to the Development Work or any other non-manufacturing services. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7B&#160;&#160;&#160;&#160;Prior to Customer&#8217;s submission of any information to the Regulatory Authority related in any way to Lonza or the Services provided under this Agreement (including information related to a Regulatory Authority&#8217;s request for additional information or an inspection, and Customer&#8217;s answer or other response thereto), Customer shall provide to Lonza, for Lonza&#8217;s review, copies thereof.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Raw Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials.  Customer shall be responsible for payment for all consumables and Raw Materials (together with the Handling Fee).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9.&#160;&#160;&#160;&#160;Promptly following the Effective Date the Customer shall supply to Lonza the Customer Information, together with full details of any known hazards relating to the Cell Line, and the Customer Materials, their storage and use.  On review and approval by Lonza&#8217;s safety committee of this Customer Information and hazards information, the Cell Line (if applicable), the Customer Materials, Customer Background Intellectual Property, and any other necessary Intellectual Property shall be provided to Lonza (or, as the case may be, rights thereto shall be secured by Customer and conveyed to Lonza) at Lonza&#8217;s reasonable request.  </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GS Licence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Where the Cell Line uses GS, the Customer acknowledges that it will require a GS Licence from Lonza prior to receipt of the Product or in vivo clinical studies or any other commercial use or sale of the Product.  The terms of such GS Licence shall be negotiated in good faith.   </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cell Bank Storage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.1.&#160;&#160;&#160;&#160;Cell Bank Storage shall commence at a time agreed between the Parties and shall continue, unless otherwise terminated in accordance with Clause 2.11.5, for &#91;***&#93; years (the &#8220;Initial Storage Term&#8221;). Thereafter, if Customer wishes Lonza to continue Cell Bank Storage, the Parties shall enter into a separate agreement.  Lonza shall store the Cell Bank in accordance with the Storage Requirements and Lonza shall not transfer the Cell Bank to a Third Party (other than an Affiliate of Lonza) without Customer&#8217;s prior written consent. Lonza reserves the right to perform testing of the Cell Bank which Lonza requires for QA, regulatory or safety purposes.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.2.&#160;&#160;&#160;&#160;Cell Banks stored at Lonza shall at all times remain Customer&#8217;s property (subject always to the terms of any other agreements or licences with Lonza, and subject to any Third Party Intellectual Property rights), save that the Cell Bank shall be subject to a lien in respect of any sums owed under any agreement by Customer to Lonza. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.3.&#160;&#160;&#160;&#160;Notwithstanding any other provisions of this Agreement, the price of Cell Bank Storage is calculated and shall be payable on a &#91;***&#93; month basis. Payment shall be made before Cell Bank Storage commences, and thereafter, &#91;***&#93; months prior to each anniversary of such commencement. Customer shall not be entitled to any refund in respect of any partial use of Cell Bank Storage. The initial price for Cell Bank Storage is set out in the Project Plan and shall be subject to review in accordance with Clause 8.8. If Customer does not pay for Cell Bank Storage by the due date, Lonza shall not be obliged to continue the Cell Bank Storage and Customer shall be required within &#91;***&#93; days of Lonza&#8217;s written notice to arrange collection and shipping of the Cell Bank.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.4.&#160;&#160;&#160;&#160;Lonza shall use reasonable endeavours to protect the Cell Bank from destruction, theft or loss during Cell Bank Storage. Notwithstanding any other provision of this Agreement, risk of loss or damage to the Cell Bank shall remain with Customer at all times. Notwithstanding Clause 12.5, other than in instances of gross negligence, the total aggregate liability of Lonza and its Affiliates for all claims (whether in contract, tort, negligence, breach of statutory duty, under indemnity, for any strict liability or otherwise) in connection with or arising out of Cell Bank Storage shall not exceed in the aggregate an amount equal to &#91;***&#93; the total Price paid by Customer for Cell Bank Storage for the Initial Storage Term.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.5.&#160;&#160;&#160;&#160;Either Party may terminate the Cell Bank Storage on giving &#91;***&#93; months prior written notice to the other. Customer shall not be entitled to any refunds in respect of any unused element of Cell Bank Storage for any such termination initiated by Customer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11.6.&#160;&#160;&#160;&#160;Upon termination of this Agreement or termination of the Cell Bank Storage pursuant to Clause 2.11.5 above and, in either case, upon payment of all sums due to Lonza, Customer shall either arrange for collection of the Cell Bank or instruct Lonza to destroy it. If the Customer has not collected the Cell Bank within &#91;***&#93; days from the date of termination of this Agreement or termination of the Cell Bank Storage, Lonza shall upon giving Customer a further &#91;***&#93; days written notice, arrange for the Cell Bank to be destroyed, in which case Customer shall pay Lonza the reasonable costs of such destruction. </font></div><div style="padding-left:35.45pt;text-indent:-35.45pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">3.&#160;&#160;&#160;&#160;Project Management </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Project Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As at the date of this Agreement, the initial Project Plan is set out in Appendix A. Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, (including draft Specifications (Drug Product)), a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for the relevant Services.  In the event of a conflict between the terms of a Project Plan and the terms of this Agreement, the terms of this Agreement will govern. If the Parties agree any additional work to be added to the Project Plan under and subject to this Agreement (&#8220;Additional Work&#8221;) it shall be subject to price and terms to be agreed in writing. Once the Additional Work has been added, the pricing for such Additional Work shall be subject to review in accordance with the provisions of Clause 8.8. If Customer wishes Lonza to perform a new project it shall notify Lonza and Lonza shall decide whether or not it is able to accept such new project. If Lonza has capacity for, and is willing to accept such new project the Parties shall negotiate a new Project Plan (which shall be subject to the terms of this Agreement and attached hereto as an Appendix) for such project. Lonza shall not be obligated to perform any services on any additional project unless and until a new Project Plan is agreed and signed by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Project Management</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Project Plan, each party will appoint a project manager who will be responsible for overseeing the Project Plan.  </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Person in Plant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Customer shall be permitted to have, at no additional cost, &#91;***&#93; employee or consultant at the Facility as reasonably requested by Customer, at any time during the Manufacturing Process for the purpose of observing, reporting on, and consulting as to the performance of the Services as may be approved in writing in advance by Lonza (such approval not to be unreasonably withheld, conditioned or delayed).  Such employee or consultant shall be subject to and agree to abide by confidentiality obligations and Lonza&#8217;s customary practices, operating procedures and security procedures regarding persons in plant, and such employee or consultant agrees to comply with all instructions of Lonza&#8217;s employees at the Facility.  Customer&#8217;s employee(s) or consultant(s) working at the Facility shall be and remain employees or consultant(s) of Customer, and Customer shall be solely responsible for the payment of compensation for such Customer employee (including applicable federal, state and local withholding, and other payroll taxes, workers&#8217; compensation insurance, health insurance, and other similar statutory and fringe benefits) or consultant.  Customer covenants and agrees to maintain workers&#8217; compensation benefits and employers&#8217; liability insurance as required by applicable laws with respect to all Customer employees working at the Facility.  </font></div><div style="padding-left:35.45pt;text-indent:-35.45pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">4.&#160;&#160;&#160;&#160;Quality</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;Responsibility for quality assurance and quality control of Product shall be allocated between Customer and Lonza as set forth in the Quality Agreement and in Lonza&#8217;s standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of the Quality Agreement shall prevail for matters relating solely to the quality and disposition of the Product, and this Agreement shall prevail for all other matters. If the Quality Agreement is not in place at the Effective Date, Lonza and Customer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Lonza will maintain accurate records for the production of the Product, as required by Applicable Laws. Lonza will retain possession of the Master Batch Record and Batch Records and Lonza Operating Documents and will make copies of the Master Batch Record and Batch Records available to Customer (in each case excluding any Lonza Information and Lonza Background Intellectual Property). Lonza Operating Documents will remain Lonza Information. Lonza will make Lonza Operating Documents available during site visits by Customer but Customer will not be permitted to make copies of and&#47;or remove Lonza Operating Documents from the Lonza site. In connection with a filing for Regulatory Approval of the Product, Lonza will provide the Lonza Operating Documents and any Lonza Information directly to the Regulatory Authority. </font></div><div style="padding-left:35.45pt;text-indent:-35.45pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">5.&#160;&#160;&#160;&#160;Insurance</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Each Party shall for itself and all of its applicable Affiliates, during the Term and for &#91;***&#93; years after &#91;***&#93;, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance in the amount of at least &#91;***&#93; US Dollars per claim made and &#91;***&#93; US Dollars in the annual aggregate. In addition, Customer shall during the Term and for &#91;***&#93; years after &#91;***&#93;, obtain and maintain at its own cost and expense from a qualified insurance company, product liability coverage in the amount of at least &#91;***&#93; US Dollars per claim made and in the annual aggregate.  Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request.</font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">6.&#160;&#160;&#160;&#160;Ordering and Cancellation</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Commitment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The Parties&#8217; binding commitment in respect of the Services is set out in the Project Plan and this shall be regarded as a Binding Order. Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement and&#47;or similar standardised form given and&#47;or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cancellation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Customer wishes to cancel any Stage of Work then it shall notify Lonza in writing and Customer shall be liable to pay (other than as set forth in Section 14.3(e)) a cancellation fee (a &#8220;Cancellation Fee&#8221;) as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development Work</font><font style="background-color:#e6e6e6;color:#2b579a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Customer provides written notice of cancellation of any Development Work Customer shall pay for any of the cancelled Development Work Lonza performed prior to the date of notification of cancellation and for any of such cancelled Development Work which would (were it not for the cancellation) have been performed during the period of &#91;***&#93; days post cancellation notification.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pilot Drug Substance Batch(es) &#47; Pilot Drug Product Batch(es)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; If Customer provides written notice of cancellation of any Pilot Drug Substance Batch and&#47;or any Pilot Drug Product Batch less than or equal to &#91;***&#93; months prior to the Commencement Date of such Pilot Drug Substance Batch or Pilot Drug Product Batch or at any time after, then a Cancellation Fee of &#91;***&#93; percent (&#91;***&#93;%) of the Price of each such Pilot Drug Substance Batch(es) and &#91;***&#93; percent (&#91;***&#93;%) of the Price of each such Pilot Drug Product Batch(es) cancelled is payable.  If Customer provides written notice of cancellation of any Pilot Drug Substance Batch and&#47;or any Pilot Drug Product Batch more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">than &#91;***&#93; months prior to the Commencement Date of such Pilot Drug Substance Batch or Pilot Drug Product Batch, then &#91;***&#93; is payable. </font></div><div style="margin-bottom:12pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">cGMP Drug Substance Batches&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If Customer provides written notice of cancellation of any cGMP Drug Substance Batch of Product&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)     less than or equal to &#91;***&#93; months prior to the Commencement Date of such cGMP Drug Substance Batch or at any time after, then a Cancellation Fee of &#91;***&#93; percent (&#91;***&#93;%) of the applicable Price of each such cGMP Drug Substance Batch cancelled is payable&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;more than &#91;***&#93; months but less than or equal to &#91;***&#93; months prior to the Commencement Date of one or more such cGMP Drug Substance Batches, then a Cancellation Fee of &#91;***&#93; percent (&#91;***&#93;%) of the Price of each such cGMP Drug Substance Batch cancelled is payable.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;more than &#91;***&#93; months prior to the Commencement Date of one or more such cGMP Drug Substance Batches, then &#91;***&#93; is payable.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">cGMP Drug Product Batches&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If Customer provides written notice of cancellation of any cGMP Drug Product Batch to Lonza&#58; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;less than or equal to &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">months prior to the Commencement Date of one or more such cGMP Drug Product Batch or at any time after, then a Cancellation Fee of &#91;***&#93; percent (&#91;***&#93;%) of the Price of each such cGMP Drug Product Batch cancelled is payable&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;more than &#91;***&#93; months but less than or equal to &#91;***&#93; months prior to the Commencement Date of one or more such cGMP Drug Product Batches, then a Cancellation Fee of &#91;***&#93; percent (&#91;***&#93;%) of the Price of each such cGMP Drug Product Batch cancelled is payable.</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;more than &#91;***&#93; months prior to the Commencement Date of one or more such cGMP Drug Product Batches, then &#91;***&#93; is payable.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mitigation of Batch Cancellation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Following the cancellation of a Batch pursuant to Clauses 6.2.2, 6.2.3 or 6.2.4, Lonza will use commercially reasonable efforts to secure a replacement batch for a new project (but excluding any batch and&#47;or project then under contract with Lonza) for the cGMP manufacturing capacity, and for the same dates and duration that would have been occupied by the cancelled Batch. If Lonza is successful in securing such a replacement batch, the applicable Cancellation Fee for the cancelled Batch may be reduced accordingly by an amount equal to &#91;***&#93; percent (&#91;***&#93;%) of the production fees associated with such replacement but in no event shall such reduction exceed the Price of the cancelled Batch. </font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Cancellation Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Cancellation Fees and the amounts payable pursuant to Clause 6.2.7 shall be payable following Lonza&#8217;s efforts to mitigate subject to Clause 6.2.5, but in any event no later than &#91;***&#93; days following the applicable written notice of cancellation, provided Lonza shall promptly refund Customer for any such payment(s) should Lonza&#8217;s mitigation efforts be successful.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Costs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> In addition to any Cancellation Fee, Customer shall pay for all costs associated with the cancelled Service and&#47;or Batch that Lonza has incurred, or is irrevocably committed to pay, including the cost of any External Laboratories (and the applicable Handling Fee) and Raw Materials and Resins (and the applicable Handling Fee) which Lonza has purchased or in respect to which Lonza has become irrevocably committed and which cannot be reused or returned to the supplier for a full refund&#59; provided Lonza shall promptly refund Customer for any partial refund Lonza may receive. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon cancellation of any part of the Services and&#47;or any Batch, all Raw Materials and External Laboratories fees shall be paid for by Customer within &#91;***&#93; days of invoice and, with respect to Raw Materials, at Customer&#8217;s option will either be&#58; (a) delivered to Customer&#59; or (b) disposed of by Lonza.</font></div><div style="padding-left:35.45pt;text-indent:-35.45pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Delivery and Acceptance</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All Product shall be delivered &#91;***&#93; (as defined by Incoterms&#174; 2020) &#91;***&#93; (&#8220;Delivery&#8221; or &#34;Delivered&#8221;).&#160; Lonza shall deliver to Customer the Certificate of Analysis and such other documentation as is reasonably required to meet all applicable regulatory requirements of the Regulatory Authorities (the &#8220;Release&#8221;) not later than the date of Delivery of Batches.&#160; With respect to any Customer Materials, title and risk of loss shall remain with the Customer and shall not transfer to Lonza.&#160; With respect to Product, title and risk of loss shall transfer to Customer upon &#91;***&#93; in accordance with this provision. Risk of loss to Product during shipping between Lonza Facilities shall be Lonza&#8217;s. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;If requested in writing by Customer, Lonza will (acting as agent of Customer for such purpose) arrange the transportation of Product &#91;***&#93;.  All additional costs and expenses of whatever nature reasonably incurred by Lonza in arranging such transportation and insurance shall be charged to Customer in addition to the Price. Transportation of Product shall be at the sole risk of &#91;***&#93; who shall be deemed to have full knowledge of the carrier&#8217;s terms and conditions of carriage. Customer shall, as appropriate, observe, perform and be subject to the carriage terms in relation to the transportation of the Product. Where Lonza has made arrangements for the transportation of Product, Customer shall diligently examine the Product as soon as practicable after receipt.&#160; Notice of all claims (time being of the essence) arising out of&#58; (a)&#160;visible damage to or total or partial loss of Product in transit shall be given in writing to Lonza and the carrier within &#91;***&#93; days of receipt by Customer&#59; (b)&#160;non-Delivery shall be given in writing to Lonza within &#91;***&#93; days after the date of the despatch notice&#59; or (c) with respect to a Latent Defect </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7.4.1 and 7.5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall apply. Customer shall make damaged Product and associated packaging materials available for inspection and shall comply with the requirements of any insurance policy covering the Product notified by Lonza to Customer.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Storage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Customer shall arrange for shipment and take delivery of such Batch from the Facility, at &#91;***&#93; expense, within &#91;***&#93; days after issue of the invoice under clause 8.5.2 or pay the storage costs set out in the applicable project plan.  Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to &#91;***&#93; days&#59; provided that any additional storage beyond &#91;***&#93; days will be subject to availability and, if available, will be charged to Customer at Lonza&#8217;s then current standard rates and will be subject to a separate agreement.&#160; In addition to Clause 8.3, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage.&#160; Notwithstanding anything to the contrary contained in this Agreement, in no event shall Lonza be required to store any Batch for more than &#91;***&#93; calendar days after issue of the invoice under clause 8.5.2.  Within &#91;***&#93; business days following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance&#47;Rejection of cGMP Drug Substance Batches</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4.1&#160;&#160;&#160;&#160;Promptly following Release of cGMP Drug Substance Batch(es) (whether or not the cGMP Drug Substance Batch was actually shipped to Customer or was stored at Lonza or shipped to another Lonza Facility for manufacture of the cGMP Drug Product Batch), which was required pursuant to the terms of this Agreement to meet Specifications, Customer shall inspect such cGMP Drug Substance Batch(es) and shall have the right to test any such cGMP Drug Substance Batches to determine compliance with the Specifications. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lonza shall provide samples of the Drug Substance Batch to Customer or Customer&#8217;s designated testing lab within &#91;***&#93; business days of Lonza&#8217;s receipt of Customer&#8217;s request for such samples. Customer shall notify Lonza in writing of any rejection of a cGMP Drug Substance Batch (which was required to meet the Specifications) based on any claim that it fails to meet Specifications within &#91;***&#93; days of Release, after which time all unrejected cGMP Drug Substance Batches shall be deemed accepted.  Notwithstanding the foregoing should any cGMP Drug Substance Batch Released hereunder have a Latent Defect, Customer shall notify Lonza of such Latent Defect within &#91;***&#93; days after Customer becomes aware of such Latent Defect and in any event no later than &#91;***&#93; months after delivery of the applicable Batch&#59; provided that such Latent Defect was not reasonably detectable by inspection within &#91;***&#93; days of Release.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4.2&#160;&#160;&#160;&#160;If Lonza believes that a cGMP Drug Substance Batch, which was required by the terms of this Agreement to meet Specifications, has been incorrectly rejected, Lonza may require that Customer provides samples to Lonza for testing.  Lonza may retain and test such samples.  If there is a discrepancy between Customer&#8217;s and Lonza&#8217;s test results such that Lonza&#8217;s test results fall within the relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall appoint an independent laboratory promptly to review records, test data and perform comparative tests and&#47;or analyses on samples of the cGMP Drug Substance Batch that allegedly fails to conform to Specifications.  Such independent laboratory shall be mutually agreed upon by the Parties.  The independent laboratory&#8217;s results shall be in writing and shall be final and binding save for manifest error.  Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4.3&#160;&#160;&#160;&#160;If it is determined (by the Parties or the independent laboratory) that a rejected cGMP Drug Substance Batch (where such cGMP Drug Substance Batch was required pursuant to the terms of this Agreement to have been compliant with cGMP and&#47;or met the Specifications) failed to conform with the Specifications (such Batch being a &#8220;Failed Drug Substance Batch&#8221;), then to the extent this was solely a Lonza Responsibility, Lonza shall, at Customer&#8217;s discretion, either&#58;</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;refund Customer the amount paid by Customer in respect of such Failed Drug Substance Batch and associated Raw Materials, to the extent paid by Customer&#59; or </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;schedule a replacement cGMP Drug Substance Batch to be manufactured (the timing of which shall be subject always to available capacity in the Facility, provided Lonza shall use reasonable efforts to expedite any such timing), and Customer shall pay for such replacement cGMP Drug Substance Batch and Raw Materials and Resins used therein (and any money it paid towards the Failed Drug Substance Batch shall be credited to the Price of such replacement cGMP Drug Substance Batch).</font></div><div style="padding-left:99.25pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance&#47;Rejection of cGMP Drug Product Batches</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.1&#160;&#160;&#160;&#160;Promptly following Delivery of cGMP Drug Product Batch(es) (whether or not the cGMP Drug Product Batch was actually shipped to Customer or was stored at Lonza), which was required pursuant to the terms of this Agreement to meet Specification (Drug Product) Customer shall inspect such cGMP Drug Product Batch(es) and shall have the right to test any such cGMP Drug Product Batches to determine compliance with the Specification (Drug Product).  Customer shall notify Lonza in writing of any rejection of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">cGMP Drug Product Batch which was required pursuant to the terms of this Agreement to meet Specification (Drug Product) based on any claim that it fails to meet Specification (Drug Product) within &#91;***&#93; days of Release Delivery, after which time all unrejected cGMP Drug Product Batches shall be deemed accepted.  Customer may not reject any cGMP Drug Product Batch on the grounds that it fails any Specifications other than Specification (Drug Product), and Customer must pay for all such cGMP Drug Product Batches, provided that they meet the Specification (Drug Product). Notwithstanding the foregoing should any cGMP Drug Product Batch Released hereunder have a Latent Defect, Customer shall notify Lonza of such Latent Defect within &#91;***&#93; days after Customer becomes aware of such Latent Defect  and in any event no later than &#91;***&#93; months after delivery of the applicable Batch&#59; provided that such Latent Defect was not reasonably detectable by inspection within &#91;***&#93; days of Release.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.2&#160;&#160;&#160;&#160;If Lonza believes that a cGMP Drug Product Batch which was required pursuant to the terms of this Agreement to meet Specification (Drug Product) has been incorrectly rejected, Lonza may require that Customer provides samples to Lonza for testing.  Lonza may retain and test such samples.  If there is a discrepancy between Customer&#8217;s and Lonza&#8217;s test results such that Lonza&#8217;s test results show that the cGMP Drug Product Batch meet the relevant Specification (Drug Product), or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party the Parties shall appoint an independent laboratory promptly to review records, test data and perform comparative tests and&#47;or analyses on samples of the cGMP Drug Product Batch that allegedly fails to conform to Specification (Drug Product).  Such independent laboratory shall be mutually agreed upon by the Parties.  The independent laboratory&#8217;s results shall be in writing and shall be final and binding save for manifest error.  Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5.3&#160;&#160;&#160;&#160;If it is determined (by the Parties or the independent laboratory) that a rejected cGMP Drug Product Batch (where such cGMP Drug Product Batch, was required pursuant to the terms of this Agreement to have been compliant with cGMP and&#47;or met the Specification (Drug Product)) failed to conform with the Specification (Drug Product) (such Batch being a &#8220;Failed Drug Product Batch&#8221;), then to the extent this was solely a Lonza Responsibility, Lonza shall, at Customer&#8217;s discretion, either&#58;</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">refund Customer the amount paid by Customer in respect of such Failed Drug Product Batch and associated Raw Materials, to the extent paid by Customer&#59; or </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;schedule a replacement cGMP Drug Product Batch to be manufactured (the timing of which shall be subject always to available capacity in the Facility, provided Lonza shall use reasonable efforts to expedite any such timing), and Customer shall pay for such replacement cGMP Drug Product Batch and Raw Materials and Resins used therein (and any money it paid towards the Failed Drug Product Batch shall be credited to the Price of such replacement cGMP Drug Product Batch).</font></div><div><font><br></font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity in the event that a cGMP Drug Product Batch meets the Specifications (Drug Product) but not any other Specifications, Customer must still pay in full for such cGMP Drug Product Batch. Customer may only reject a cGMP Drug Product Batch on the grounds that it failed to meet cGMP or the Specification (Drug Product) in each case solely due to a Lonza Responsibility (notwithstanding that such cGMP Drug Product Batch may not meet any other Specifications).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:99.25pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;Except if due to Lonza&#8217;s gross negligence, nothing in Clause 7.4 or 7.5 shall oblige Lonza to replace or refund any Drug Substance material produced by a cGMP Drug Substance Batch (or manufacture an additional cGMP Drug Substance Batch) or any other drug substance that may be required to produce any replacement cGMP Drug Product Batch. Clauses 7.4 and 7.5 shall always be subject to the provisions of Clauses 12.4 and 12.5.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;Customer acknowledges and agrees that its sole remedy with respect to a Failed Drug Substance Batch and&#47;or Failed Drug Product Batch that is a Lonza Responsibility is as set forth in Clauses 7.4 and 7.5.  Accordingly, other than if due to Lonza&#8217;s gross negligence or intentional breach, Customer hereby waives all other remedies at law or in equity regarding the foregoing claims.  Except if due to Lonza&#8217;s gross negligence Lonza shall not be responsible for (i) the cost of Raw Materials (except to the extent set forth in Clauses 7.4.3 and 7.5.3), Customer Materials, Drug Substance required for the manufacture of a cGMP Drug Product Batch, and&#47;or (ii) starting materials consumed in any Failed Drug Substance Batch or Failed Drug Product Batch.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8&#160;&#160;&#160;&#160;The Parties further agree that in the event that any Batch is a Failed Drug Substance Batch or a Failed Drug Product Batch and such failure is caused by any defect in any Customer Information, Customer Material, Cell Line, Customer Background Intellectual Property, and&#47;or any other information, material or Intellectual Property supplied by or on behalf of the Customer, then Lonza shall not have any liability with regard to such Failed Drug Substance Batch or Failed Drug Product Batch. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9&#160;&#160;&#160;&#160;Any cGMP Drug Substance Batch or any cGMP Drug Product Batch that is not required by this Agreement to meet Specifications or Specification (Drug Product) may not be rejected and Lonza shall not have any replacement or refund obligations in respect thereto, except if due to Lonza&#8217;s gross negligence. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8 &#160;&#160;&#160;&#160;Price and Payment</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pricing</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Subject to the provisions of this Agreement, Customer shall pay for all of the Services and the Batches (including Pilot Drug Substance Batches, Pilot Drug Product Batches, all cGMP Drug Substance Batches and all cGMP Drug Product Batches).  Pricing for the Services and the Batches (including Pilot Drug Substance Batches, Pilot Drug Product Batches, all cGMP Drug Substance Batches and all cGMP Drug Product Batches) manufactured by Lonza are set out in, and based on the assumptions and information set out in, the applicable Project Plan.  In the event of Changes based on Customer&#8217;s request, Customer shall bear all additional costs.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Raw Materials, Resins and Handling Fees, External Laboratory and Handling Fee.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> In addition to Clause 8.1, Customer shall also pay for all Raw Materials, Resins, single use bags, consumables and the Handling Fee, and External Laboratory Charges and the Handling Fee. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import duties and fees of whatever nature imposed by or under the authority of any government or public authority and all such charges applicable to the Services shall be paid by Customer, other than relevant income taxes of Lonza that shall be the responsibility of Lonza.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;When sending payment to Lonza, the Customer shall quote the relevant invoice number in its remittance advice.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.1&#160;&#160;&#160;&#160;For Stages of Work of less than &#91;***&#93;  (or equivalent in the applicable currency)&#58; Unless otherwise agreed in writing Lonza shall issue invoices to Customer for &#91;***&#93; percent (&#91;***&#93;%) of the Price upon completion of that Stage of Work. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.2&#160;&#160;&#160;&#160;For Stages of Work of &#91;***&#93; or more (or equivalent in the applicable currency)&#58; Unless otherwise agreed in writing Lonza shall issue all invoices to Customer for &#91;***&#93; percent (&#91;***&#93;%) of the Price for Product or Services upon commencement thereof and &#91;***&#93; percent (&#91;***&#93;%) upon Release of applicable Batches or completion of applicable Services, unless otherwise stated in the Project Plan.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.3&#160;&#160;&#160;&#160;Unless otherwise agreed in writing the Raw Materials (including media and feeds, but excluding Resins) and the applicable Handling Fee for each Batch shall be invoiced &#91;***&#93; percent (&#91;***&#93;%) upon the Commencement Date of the Batch, or the applicable Stage of Work, plus the Handling Fees. Resins and the Handling Fee in respect thereof, shall be invoiced on the placement of purchase orders by Lonza for such Resins. External Laboratory Charges and the Handling Fee shall be invoiced on completion of the applicable Stage of Work. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.4&#160;&#160;&#160;&#160;If the Certificate of Analysis requires the Customer to provide one or more elements of the Specification, but the Customer has not provided such information within the time agreed, then provided Lonza has completed those elements of the Certificate for Analysis for which it is responsible, Lonza can issue the applicable invoice at such time as set out in Clause 8. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.5&#160;&#160;&#160;&#160;All invoices are strictly net and payment must be made within &#91;***&#93; days of Customer&#8217;s receipt of invoice.  Payment shall be made without deduction, deferment, set-off, lien or counterclaim. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5.6&#160;&#160;&#160;&#160;For Services performed in Switzerland, invoices may be issued in the name of Lonza AG. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;If Customer fails to pay any undisputed invoice within the time set out in Clause 8.5.4 then Lonza shall have the option to change the payment terms such that &#91;***&#93; percent (&#91;***&#93;%) of the Price for any Stage of Work shall be payable on commencement and the price for Raw Materials and the Handling Fee shall also be payable &#91;***&#93; percent (&#91;***&#93;%) on commencement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;If in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of&#58; </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) the rate of &#91;***&#93; percent (&#91;***&#93;%) per month above the applicable currency below&#58; </font></div><div style="margin-bottom:12pt;padding-left:94.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">Swiss Average Rate Overnight (SARON) (for invoices in CHF)&#59;</font></div><div style="margin-bottom:0.12pt;padding-left:94.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">the Secured Overnight Financing Rate (SOFR) (for invoices in USD)&#59; </font></div><div style="margin-bottom:0.12pt;padding-left:85.05pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:94.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">the Euro Interbank Offered Rate (EURIBOR) (for invoices in EUR)&#59; and </font></div><div style="margin-bottom:0.12pt;padding-left:85.05pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:94.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.15pt">the Sterling Overnight Index Average (SONIA) (for invoices in GBP)&#59; </font></div><div style="margin-bottom:0.12pt;padding-left:85.05pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (ii) the maximum rate allowable by the governing law of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest shall accrue on a day to day basis until full payment.  Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services and&#47;or delivery of Product until all undisputed overdue amounts have been paid in full including interest for late payments and Customer shall be liable for any and all costs reasonably incurred by Lonza from any such delay to the Services.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Price adjustments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.8.1&#160;&#160;&#160;&#160;Not more than once per calendar year and with effect from the first anniversary of the Effective Date, and then on each subsequent anniversary, Lonza may adjust the Prices as follows upon at least &#91;***&#93; days prior written notice to Customer (provided that in the event of any negative change in the applicable index there shall not be any negative change to the Prices)&#58; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;In respect of Services performed in the UK&#58; the higher of&#58; (i) the change from the previous calendar year of the index of labour costs per hour for private sector companies (ILCH) as published by the Office of National Statistics of the United Kingdom (or any successor index)&#59; or (ii) &#91;***&#93; percent (&#91;***&#93;%)&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In respect of Singapore&#58; the higher of&#58; (i) the change from the previous calendar year of the UBCIMI index (https&#58;&#47;&#47;data.gov.sg) (or any successor index)&#59; or (ii) &#91;***&#93; percent (&#91;***&#93;%)&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;In respect of Services performed in Switzerland&#58; the higher of&#58; (i) the change from the previous calendar year of the Swiss Producer Prices index (or any successor index)&#59; or (ii) &#91;***&#93; percent (&#91;***&#93;%)&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;In respect of Services performed in USA&#58; the higher of&#58; (i) the change from the previous calendar year of the US Department of Labor&#8217;s Bureau of Labor Statistics Other Biological Product Manufacturing, ethical PCU 325414 index (or any successor index)&#59; or (ii) &#91;***&#93; percent (&#91;***&#93;%).  </font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The new Price reflecting such adjusted Price shall be effective for any Services and&#47;or Batch for which the Commencement Date is on or after the date of Lonza&#8217;s notice to Customer of the applicable Price adjustment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.8.2&#160;&#160;&#160;&#160;In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer (providing reasonable detail in support thereof), to reflect&#58; (i) an increase in variable costs (such as energy or Raw Materials) by more than &#91;***&#93; percent (&#91;***&#93;%) (based on the initial Price or any previously amended Price)&#59; (ii) material process adjustment or assumption changes&#59; and&#47;or (iii) any material change in an environmental, safety or regulatory standard that substantially impacts Lonza&#8217;s cost and&#47;or ability to perform the Services. </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">9.&#160;&#160;&#160;&#160;Capital Equipment</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Any Capital Equipment required for the performance of the Services shall be acquired on terms to be reasonably agreed by the Parties prior to commencement of the relevant Services, which terms shall also specify ownership, risk of loss, and maintenance requirements of such Capital Equipment. </font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">10.&#160;&#160;&#160;&#160;Intellectual Property</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.1&#160;&#160;&#160;&#160;Neither Party nor any of their Affiliates will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party or any of its Affiliates.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.2&#160;&#160;&#160;&#160;Subject to Clause 10.3, Customer shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and&#47;or its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Customer or others, in the course of the performance of the Services to the extent that it is both&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.2.1&#160;&#160;&#160;&#160;solely a direct derivative of or improvement to Customer Information and&#47;or Customer Background Intellectual Property, or directly relies on or incorporates any Customer Information and&#47;or Customer Background Intellectual Property&#59; and </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.2.2&#160;&#160;&#160;&#160;severable from and does not utilise, disclose or reveal any Lonza Background Intellectual Property, Lonza Information, and&#47;or New Lonza Intellectual Property&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the &#8220;New Customer Intellectual Property&#8221;).  For the avoidance of doubt, &#8220;New Customer Intellectual Property&#8221; shall include any material, processes or other items that solely embody, or that solely are claimed or covered by, any of the foregoing new Intellectual Property, but excluding any New Lonza Intellectual Property.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.3&#160;&#160;&#160;&#160;Notwithstanding Clause 10.2, Lonza shall own all right, title and interest in Intellectual Property that Lonza and&#47;or its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, or first reduces to practice or makes, solely or jointly with Customer or others, in the course of the performance of the Services, that is either&#58;</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.3.1&#160;&#160;&#160;&#160;generally applicable to the development or manufacture of chemical or biological products or products components&#59; or </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.3.2&#160;&#160;&#160;&#160;an improvement to, or derivative of, any Lonza Background Intellectual Property, and&#47;or Lonza Information&#59; </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;New Lonza Intellectual Property&#8221;).  For the avoidance of doubt, &#8220;New Lonza Intellectual Property&#8221; shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property. </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.4&#160;&#160;&#160;&#160;Lonza hereby assigns to Customer all of its right, title and interest in any New Customer Intellectual Property. Lonza shall execute, and shall require its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute any documents reasonably required to confirm Customer&#8217;s ownership of the New Customer Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Customer Intellectual Property. To the extent that Customer has or obtains any rights, title or interest in New Lonza Intellectual Property, Customer hereby assigns to Lonza all of its right, title and interest in any New Lonza Intellectual Property.  Customer shall execute, and shall require its personnel as well as its Affiliates, or contractors or agents and their personnel involved in the performance of the Services, to execute, any documents reasonably required to confirm Lonza&#8217;s ownership of the New Lonza Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Lonza Intellectual Property.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.5&#160;&#160;&#160;&#160;Customer hereby grants Lonza and its Affiliates, sub-contractors and the External Laboratories the non-exclusive right to use the Customer Information, Customer Background Intellectual Property, Customer Materials, New Customer Intellectual Property, the Cell Line, and any and all other Intellectual Property, information or materials supplied by or on behalf of the Customer, during the Term solely for the purpose of fulfilling their obligations under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.6&#160;&#160;&#160;&#160;The transfer of the Manufacturing Process to either Customer and&#47;or any Third Party manufacturer, for the manufacture of the Product (and no other products), shall be subject to Lonza&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed) and shall occur only pursuant to reasonable terms governing such technology transfer in a separate technology transfer agreement based on the Outline Terms for Technology Transfer Agreement set out in Appendix D, which may include a reasonable licensing fee applicable to such technology transfer. Customer shall reimburse Lonza for any reasonable costs (based on a full-time employee rate for such support) and expenses for any such transfer, as shall be set forth in such separate technology transfer agreement. If the Parties are unable to agree to such technology transfer terms, then the parties shall refer the matter to senior executives of both Parties in order to resolve any open issues and shall continue to negotiate and discuss in good faith.  Thereafter, if the Parties are still unable to agree to such terms, Lonza shall be under no obligation to transfer the Manufacturing Process to Customer or any Third Party. </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Prosecution of Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.  </font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.7.1&#160;&#160;&#160;&#160;Subject to the following subsection, Customer will have the sole right and discretion to file (or not file), prosecute and maintain patent applications and patents claiming the New Customer Intellectual Property, at Customer&#8217;s expense. Lonza will cooperate with Customer, at Customer&#8217;s expense, to file, prosecute, maintain, defend, and enforce patent applications and patents claiming any New Customer Intellectual Property.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.7.2&#160;&#160;&#160;&#160;Unless the Parties agree otherwise, at least &#91;***&#93; days prior to filing any application disclosing or claiming any New Customer Intellectual Property, Customer shall provide a draft thereof to Lonza, for Lonza&#8217;s prior review and approval. Within &#91;***&#93; days of receipt of such an application (&#8220;Lonza Review Period&#8221;), Lonza shall notify Customer of any Lonza Background Intellectual Property, Lonza Information or any information that could be considered New Lonza Intellectual Property and, on Lonza&#8217;s instruction, Customer shall either delete any information in such application that Lonza has reasonably identified within the Lonza Review Period as Lonza Background Intellectual Property, Lonza Information and&#47;or delay the filing of the application until such time that it can be concurrently filed with a patent application from Lonza claiming such New Lonza Intellectual Property.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.7.3&#160;&#160;&#160;&#160;Lonza will have the sole right and discretion to file (or not file), prosecute and maintain patent applications and patents claiming the New Lonza Intellectual Property, at Lonza&#8217;s expense. Customer will cooperate with Lonza, at Lonza&#8217;s expense, to file, prosecute, maintain, defend, and enforce patent applications and patents claiming any New Lonza Intellectual Property. Unless the Parties agree otherwise, at least &#91;***&#93; days prior to filing any application disclosing or claiming any New Lonza Intellectual Property, Lonza shall provide a draft thereof to Customer, for Customer&#8217;s prior review and approval. Within &#91;***&#93; days of receipt of such an application (&#8220;Customer Review Period&#8221;), Customer shall notify Lonza of any Customer Background Intellectual Property, Customer Information or any information that could be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">considered New Customer Intellectual Property and, on Customer&#8217;s instruction, Lonza shall either delete any information in such application that Customer has reasonably identified within the Customer Review Period as Customer Background Intellectual Property, Customer Information and&#47;or delay the filing of the application until such time that it can be concurrently filed with a patent application from Customer claiming such New Customer Intellectual Property.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Services Data.</font></div><div style="padding-left:81.85pt"><font><br></font></div><div style="padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the confidentiality provisions of Clause 13 (Confidentiality) as they may relate to the use of Services Data, the Parties agree that all Services Data may be collected, aggregated, hosted, mined or otherwise stored and maintained by Lonza and its Affiliates, contractors and External Laboratories. Both Lonza and its Affiliates, and Customer and its Affiliates, may use the Services Data, in any manner that is not inconsistent with the intellectual property-ownership terms set forth in this Clause 10, for further research, development, commercialization of, and securing rights to, development, manufacturing and testing systems, platforms, and service offerings, provided that said data shall be anonymized when used externally.</font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">11.&#160;&#160;&#160;&#160;Warranties</font></div><div style="margin-bottom:12pt;padding-left:21pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lonza warrants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1.1&#160;&#160;&#160;&#160;the Services shall be performed in accordance with all Applicable Laws&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1.2&#160;&#160;&#160;&#160;it or any of its Affiliates hold all necessary permits, approvals, consents and licenses to enable it to perform the Services at the Facility (subject always to Clause 11.2.4)&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1.3&#160;&#160;&#160;&#160;it has the necessary corporate authorisations to enter into and perform this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1.4&#160;&#160;&#160;&#160;in connection with its performance of the Services, Lonza shall take appropriate technical and organizational measures to ensure compliance with the applicable requirements of GDPR. Lonza shall act in compliance with GDPR as well as on Customer&#8217;s request, destroy all personal data, unless applicable law prevents Lonza from such destruction. Lonza confirms that any personal data that Lonza shares with Customer is done in accordance with applicable GDPR requirements GDPR&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1.5&#160;&#160;&#160;&#160;in connection with its performance of the Services, Lonza shall comply with, and shall cause its Affiliates, subsidiaries, subcontractors, directors, officers, employees, agents or any other person acting on behalf of Lonza to comply with, all applicable Corruption Laws and International Trade Restrictions. Lonza&#8217;s performance of the Services shall be in accordance with Applicable Laws, Corruption Laws and International Trade Restrictions and the laws of the countries in which the Services are performed.</font></div><div style="margin-bottom:12pt;padding-left:21pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Customer warrants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.1&#160;&#160;&#160;&#160;Customer has all the rights necessary to permit Lonza (and its relevant Affiliates any Subcontractors, and the External Laboratories) to perform the Services without infringing the Intellectual Property rights or other rights of any Third Party&#59; and Customer warrants that the performance of the Services will not infringe, misappropriate or violate (as the case may be) any Intellectual Property rights or other rights of any Third Party&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.2&#160;&#160;&#160;&#160;Customer will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Customer Information, Customer Background Intellectual Property, Customer Materials, New Customer Intellectual Property, the Cell Line, and&#47;or any and all other information, materials and Intellectual Property supplied by or on behalf of the Customer, or that the supply to and&#47;or use by Lonza (and&#47;or its relevant Affiliates, any Subcontractors, and the External Laboratories) thereof for the provision of the Services, infringes any Intellectual Property rights or other rights of any Third Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.3&#160;&#160;&#160;&#160;all Raw Materials and Customer Materials actually supplied by Customer shall be provided with a certificate of analysis or other relevant documentation demonstrating that such Raw Materials and Customer Materials meet the following Lonza acceptance criteria&#58; (i) are not contaminated, (ii) test negative for mycoplasma and bioburden (if applicable), (iii) have been manufactured in accordance with cGMP (if applicable), (iv) are free from all liens, charges, or encumbrances, and (v) meet other testing requirements and&#47;or specifications as may be agreed in writing by the Parties.  In addition, Customer has provided any environmental, health and safety information related to the Raw Materials and Customer Materials (including employee health and safety, of the handling, manufacture, distribution, use and disposal of the Raw Materials and Customer Materials), and will update, clarify, correct, supplement and amend such information as necessary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.4&#160;&#160;&#160;&#160;Customer has all the rights necessary to provide and permit Lonza and its Affiliates, any Subcontractors, and the External Laboratories to use, for the purposes of this Agreement, the Customer Information, Customer Background Intellectual Property, Customer Materials, New Customer Intellectual Property, the Cell Line, and any and all other information, materials and Intellectual Property supplied by or on behalf of the Customer&#59; and Customer warrants that the use of anything referred to in this Clause 11.2.4 will not infringe, misappropriate or violate the Intellectual Property rights or other rights of any Third Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.5&#160;&#160;&#160;&#160;Customer has the necessary corporate authorisations to enter into this Agreement and it has the full power and right to enter into this Agreement and that there are no outstanding agreements, assignments, licenses, encumbrances or rights of any kind, that would breach the provisions of this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.6&#160;&#160;&#160;&#160;in connection with its receipt and usage of the Services and Products, Customer shall take appropriate technical and organizational measures to ensure compliance with the applicable requirements of GDPR. Customer shall act in compliance with GDPR as well as on Lonza&#8217;s request, destroy all personal data, unless applicable law prevents Customer from such destruction. Customer confirms that any personal data that Customer shares with Lonza is done in accordance with applicable GDPR requirements&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.7&#160;&#160;&#160;&#160;in connection with its receipt and usage of the Services and Products, Customer shall comply with, and shall cause its Affiliates, subsidiaries, subcontractors, directors, officers, employees, agents or any other person acting on behalf of Customer to comply with, all applicable Corruption Laws and International Trade Restrictions. Customer&#8217;s receipt and usage of the Services and Products shall be in accordance with Applicable Laws, Corruption Laws and International Trade Restrictions and the laws of the countries in which the Product is sold&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2.8&#160;&#160;&#160;&#160;Customer warrants that as at the time that the Quality Agreement is signed, Customer will have an appropriate Quality function to ensure Customer&#8217;s ongoing compliance with cGMP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;Disclaimer&#58;  The warranties expressly set forth in this Agreement are in lieu of all other warranties, and all other warranties, both express and implied, are expressly disclaimed, including any warranty of merchantability or fitness for a particular purpose.  </font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">12.&#160;&#160;&#160;&#160;Indemnification and Liability</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Lonza</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Clauses 12.4 and 12.5, Lonza shall indemnify the Customer, its Affiliates, and the respective officers, employees and agents of Customer and&#47;or its Affiliates (&#8220;Customer Indemnitees&#8221;) from and against  any loss, damage, costs, liability and&#47;or expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of&#58; </font></div><div style="margin-bottom:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1.1&#160;&#160;&#160;&#160;any material breach of the warranties given by Lonza in Clause 11.1 above&#59; and&#47;or </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1.2&#160;&#160;&#160;&#160;any claim that the performance of the Services (excluding use by Lonza, Lonza&#8217;s Affiliates, Lonza Indemnitees, Lonza contractors, and&#47;or the External Laboratories of Customer Information, Customer Background Intellectual Property, Customer Materials, New Customer Intellectual Property, the Cell Line, and&#47;or any and all information, materials and other Intellectual Property supplied by or on behalf of the Customer) infringe any Intellectual Property rights of a Third Party&#59;</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">except, in each case (12.1.1 and&#47;or 12.1.2), to the extent that such claims resulted from the negligence and&#47;or breach of this Agreement and&#47;or intentional misconduct by any Customer Indemnitees.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Customer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Clause 12.4, Customer shall indemnify Lonza, Lonza&#8217;s Affiliates, and the respective officers, employees and agents of Lonza and&#47;or its Affiliates (&#8220;Lonza Indemnitees&#8221;) from and against any loss, damage, costs, liability and&#47;or expenses (including reasonable attorney fees) that any Lonza Indemnitees may suffer as a result of any Third Party claim arising directly out of&#58; </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2.1&#160;&#160;&#160;&#160;any material breach of the warranties given by Customer in Clause 11.2 above&#59; and&#47;or</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2.2&#160;&#160;&#160;&#160;any allegation that the performance of Services infringes any Intellectual Property rights of Third Parties&#59; and&#47;or</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2.3&#160;&#160;&#160;&#160;the manufacture, use, sale, processing, storage, packaging, labelling, marketing, promotion, or distribution of any Product (or any product that contains the Product), including but not limited to any claims of product liability&#59; and&#47;or</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2.4&#160;&#160;&#160;&#160;the supply to, and&#47;or use by, Lonza, any of Lonza&#8217;s Affiliates, Lonza Indemnitees, any Lonza contractors, any External Laboratory, and&#47;or any Third Party of any Customer Information, Customer Background Intellectual Property, Customer Materials, New Customer Intellectual Property, the Cell Line, and&#47;or any other information, materials or Intellectual Property provided by or on behalf of Customer (including any claim or allegation that such supply and&#47;or use of any of the foregoing infringes any Intellectual Property rights or other rights of any Third Party)&#59; </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;except, in each case (12.2.1, 12.2.2, 12.2.3 and&#47;or 12.2.4), to the extent that such claims resulted from the negligence and&#47;or breach of this Agreement and&#47;or intentional misconduct by any Lonza Indemnitees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in writing of such claim.  The indemnitor shall have the right to control the defence and&#47;or settlement thereof&#59; provided, however, that any indemnitee shall have the right to retain its own counsel at its own expense.  The indemnitee, its employees and agents shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12.  The failure to deliver prompt written notice to the indemnitor of any claim, to the extent that it is prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12. The Party seeking indemnification shall not settle any claim in respect of which it will seek indemnification without the prior written consent of the indemnifying Party (not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclaimer of certain damages</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In no event shall either Party and&#47;or any of its Affiliates be liable (in each case whether in contract, tort, negligence, breach of statutory duty, under any indemnity, or otherwise howsoever arising) for any (i) (direct or indirect) loss of profits, loss of business, loss of revenues, loss of goodwill, loss of reputation, or (ii) for any incidental, indirect, special, punitive or consequential losses or damages, arising from or related to this Agreement&#59; provided that this Clause 12.4 shall not preclude any claim by Lonza and&#47;or any of its Affiliates for any unpaid invoices (including the profit element of its charges) and&#47;or the Cancellation Fees and&#47;or termination fees and provided that this Clause 12.4 shall not preclude any claim by Lonza and&#47;or any of its Affiliates for the profit element of its charges&#59; &#91;***&#93;.</font></div><div style="padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject always to Clause 12.6 &#91;***&#93;, the aggregate liability of Lonza and its Affiliates under or in relation to this  Agreement and the Project Plans (whether in contract, tort, negligence, breach of statutory duty, under indemnity, or otherwise howsoever arising) shall not exceed, in the aggregate, an amount equal to &#91;***&#93; under this Agreement by Customer to Lonza, &#91;***&#93;. For the avoidance of doubt this limitation of liability shall be an aggregate limitation of liability which is shared between Lonza and all of its Affiliates (including Lonza AG and Lonza Sales AG), and there shall not be a separate limit of liability for each separate Lonza entity.</font></div><div><font><br></font></div><div style="margin-bottom:24pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6&#160;&#160;&#160;&#160;Nothing in this Agreement shall operate so as to exclude or in any way limit any liability for fraud, or for death or personal injury, or for gross negligence or intentional misconduct, or for any liability that may not be excluded or limited as a matter of English law. Nothing in this Agreement shall exclude or limit Customer&#8217;s liability to pay invoices and&#47;or the Cancellation Fees, termination fees or agreed capital expenditure. For clarity, it is not the intention that this Clause 12.6 should apply to negligence which is not gross negligence and negligence which is not gross negligence shall be subject to Clauses 12.4 and (in the case of Lonza and its Affiliates) 12.5.</font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">13.&#160;&#160;&#160;&#160;Confidentiality</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;A Party receiving Confidential Information (the &#8220;Receiving Party&#8221;) agrees to strictly keep secret any and all Confidential Information received during the Term from, or disclosed on behalf of, the other Party (the &#8220;Disclosing Party&#8221;), as well as the terms of this Agreement, using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts.  Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to, or observed or learned by, the Receiving Party or its Affiliates, or its or their Affiliate&#8217;s, employees, agents, consultants, or representatives including any persons on plant (in each case such employees, agents, consultants, or representatives, or persons on plant, of Customer or any of its Affiliates), under or in relation to this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary, as well as the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Receiving Party may disclose to any courts and&#47;or other authorities and&#47;or any stock exchange upon which that Party&#8217;s securities are then listed (except to any governmental patent office) Confidential Information of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Disclosing Party which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order. In such case the Receiving Party will, to the extent legally permitted, inform the Disclosing Party promptly in writing, which may include by email (in the case of Context) to Lonza&#8217;s then current program manager (unless an out of office response is received by Customer&#59; in which case Customer shall contact Lonza to confirm an alternative), and reasonably cooperate with the Disclosing Party in seeking to minimise the extent of Confidential Information of the Disclosing Party which is required to be disclosed to the courts and&#47;or other authorities and&#47;or any stock exchange. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information of the Disclosing Party, which&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3.1&#160;&#160;&#160;&#160;at the time of disclosure was publicly available&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3.2&#160;&#160;&#160;&#160;is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3.3&#160;&#160;&#160;&#160;which the Receiving Party can establish by contemporaneous written records was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3.4&#160;&#160;&#160;&#160;which the Receiving Party can establish by contemporaneous written records is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party&#59; or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3.5&#160;&#160;&#160;&#160;which the Receiving Party can establish by contemporaneous written records is developed by the Receiving Party independently from and without use of the Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;The Receiving Party will use Confidential Information of the Disclosing Party only for the purposes of this Agreement and will not make any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including with respect to research or product development or any reverse engineering or similar testing.  The Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party&#8217;s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the Receiving Party in its confidential files for record keeping purposes only.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5&#160;&#160;&#160;&#160;Each Party will restrict the disclosure of the other Party&#8217;s Confidential Information to its Affiliates, and such officers, employees, consultants and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement.  Prior to disclosure to such persons, the Receiving Party shall bind itself and its Affiliates&#8217; officers, agents, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth herein.  The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorised use or disclosure of the Confidential Information of the Disclosing Party. Lonza may disclose the Customer&#8217;s Confidential Information to Lonza&#8217;s Affiliates, Subcontractors and the External Laboratories, in each case for the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.6&#160;&#160;&#160;&#160;The Receiving Party shall at all times be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, officers, agents, consultants and representatives of itself or its Affiliates including any persons on plant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.7&#160;&#160;&#160;&#160;Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach.  In the event of any breach and&#47;or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party.</font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">14.&#160;&#160;&#160;&#160;Term and Termination</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall commence on the Effective Date and shall end on the date of completion of the Services unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the &#8220;Term&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement or any Project Plan may be terminated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.1&#160;&#160;&#160;&#160;If it becomes apparent to either Lonza or the Customer at any stage in the provision of the Services that it will not be possible to complete the Services for a material scientific or material technical reasons, a &#91;***&#93; day period shall be allowed for good faith discussion and attempts to resolve such problems.  If such problems are not resolved within such period, Lonza and the Customer shall each have the right to terminate the applicable Project Plan (or if there is only one Project Plan, this Agreement) forthwith by notice in writing&#59;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.2&#160;&#160;&#160;&#160;by either Party, immediately, if the other Party commits a material breach of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the non-breaching Party within &#91;***&#93; days (&#91;***&#93; days for non-payment) following written notification of such breach from the non-breaching party to the breaching party&#59; provided, however, that such &#91;***&#93; day period shall be extended as agreed by the Parties if the identified breach is incapable of cure within &#91;***&#93; days and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure (it being understood that this extended period shall be unavailable for any breach regarding non-payment)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.3&#160;&#160;&#160;&#160;by either Party, immediately, if the other Party enters into administration, becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has an administrator or receiver appointed for a substantial part of its assets&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2.4&#160;&#160;&#160;&#160;by either Party pursuant to Clause 15.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Consequences of Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of termination of this Agreement all Services and Batches which have been ordered, or to which the Customer is committed, in accordance with this Agreement (including those in the Project Plan to which the Parties are committed) shall be deemed to have been cancelled and Customer shall, within &#91;***&#93; days of such termination, pay Lonza for&#58;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;all Services commenced up to the date of termination, including in respect of any Product in-process&#59; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;all costs incurred through the date of termination, including all Raw Materials and Resins costs (and Handling Fees for Raw Materials and Resins) used or purchased or to which Lonza is irrevocably committed for use in connection with the Project Plan, and External Laboratory costs (and Handling Fees)&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;all unused Raw Materials and Resins shall be paid for by Customer within &#91;***&#93; days of invoice and at Customer&#8217;s option and cost will either be&#58; (i) held by Lonza for future use for the production of Product&#59; (ii) delivered to Customer&#59; or (iii) disposed of by Lonza&#59;</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;all unreimbursed Capital Equipment and related decommissioning charges incurred pursuant to Clause 9&#59; and</font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Cancellation Fees in respect of all Batches and&#47;or Services which have been ordered in accordance with this Agreement (including those in the Project Plan to which the Parties are committed) calculated in accordance with Clause 6.2 (other than in the event of termination by Customer pursuant to Clause 14.2.2 (material breach), or by either Party for an agreed scientific or technical reason pursuant to Clause 14.2.1 or by either Party pursuant to Clause 14.2.4 (Force Majeure), where in such instances no Cancellation Fees shall be payable). In the case of termination by Lonza for Customer&#8217;s material breach, Cancellation Fees shall be calculated as of the date of written notice of termination.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing in this Agreement shall require Customer to pay a Cancellation Fee more than once in respect for the same cancelled Stage of Work. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither the termination nor expiration of this Agreement shall affect the liability of a Party for breach of this Agreement. Notwithstanding anything contained in Clause 14, the rights and obligations of each Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 5, 10-13 (inclusive) and 16 (to the extent relevant). Termination of this Agreement (including the consequences of termination set out in this Clause 14) shall not affect the accrued rights or liabilities of either Party and shall not preclude either Party from pursuing any remedies it may have hereunder, or at law or in equity, with respect to any breach of, or default under, this Agreement (subject always to Clauses 12.4 and 12.5). All confidentiality obligations set out in this Agreement shall survive termination or expiry of this Agreement. </font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">15.&#160;&#160;&#160;&#160;Force Majeure</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;If either Party or any of its Affiliates is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure (other than Customer&#8217;s inability to make payments hereunder) and gives written notice thereof to the other Party specifying the matters constituting Force Majeure together with such evidence as such Party reasonably can give to the other Party and specifying the period for which it is estimated that such prevention or delay will continue, such Party shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue.  Provided that, if such Force Majeure persists for a period of &#91;***&#93; months or more, either Party may terminate&#58; (i) the affected Project Plan&#59; or (ii) in the event that the Force Majeure event prevents the performance of the entire Agreement, this Agreement&#59; in each case by delivering written notice to the other.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;The Parties acknowledge that the COVID-19 virus is currently causing global disruption, and that there is a significant risk that Lonza&#8217;s or Customer&#8217;s performance under this Agreement may be affected by consequences of the COVID-19 virus, including but not limited to any measures taken by authorities, and&#47;or the availability of human resources and raw materials, and that any such event shall be deemed a Force Majeure event.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;&#8220;Force Majeure&#8221; shall be deemed to include any reason or cause beyond a Party&#8217;s reasonable control affecting the performance by such Party of its obligations under the Agreement, including, but not limited to, any cause arising from or attributable to acts of God, epidemic, pandemic, strike, lockouts, labour troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorists acts, or as regards Lonza the inability of Lonza to obtain any required raw material, energy source, equipment, labour or transportation, at prices and on terms deemed by Lonza to be reasonably practicable, from Lonza&#8217;s usual sources of supply or, in the case of Lonza, the detection of a viral, bacterial or mycoplasmal contamination that causes a shutdown of the Facility or any part thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;With regard to Lonza, any such event of Force Majeure affecting services or Production at its Affiliates or suppliers shall be regarded as an event of Force Majeure.</font></div><div><font><br></font></div><div style="margin-bottom:4pt;margin-top:2pt;padding-left:14.2pt;text-indent:-14.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Contractors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Parties is an independent contractor and nothing herein contained shall be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties (save as set out in Clause 7.2).  Neither Party shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">No Presumption Against Drafter.  Each Party and its legal counsel have reviewed and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> revised this Agreement.  The rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter shall be waived by both Parties in the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The failure of any Party at any time or times to require performance of any provision of this Agreement (including any Appendix hereto) will in no manner affect its rights at a later time to enforce the same.  No waiver by any Party of any term, provision or condition contained in this Agreement (including any Appendix hereto), whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement (including any Appendix hereto).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby.  The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far as possible commercially equivalent considering the legal interests and the purpose.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Modifications and&#47;or amendments of this Agreement must be in writing and signed by the Parties. The Parties may amend this Agreement without the consent of the Affiliates of either Party.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Delegation &#47; Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza&#8217;s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations (subject to clause 2.1).  Subject thereto, neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that&#58;</font></div><div style="margin-bottom:12pt;padding-left:70.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1) (a) Lonza may, without the consent of the Customer, assign this Agreement to&#58; (i) any Affiliate of Lonza&#59; or (ii) any third party in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business related to the Facility or providing the Services&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:70.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) Lonza shall be entitled to sell, assign and&#47;or transfer its trade receivables resulting from this Agreement without the consent of the Customer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:70.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2) Customer may assign this Agreement without the consent of Lonza, to&#58; &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purposes of this Clause 16.6, the terms &#8220;assign&#8221; and &#8220;assignment&#8221; shall include&#58; (i)&#160;the sale of fifty percent (50%) or more of the outstanding stock of such Party to an Affiliate of such Party or an unrelated entity or natural person&#59; (ii) the sale or transfer or other assignment of all or substantially all of the assets of the Party or the line of business or Product to which this Agreement relates&#59; and (iii) a merger, consolidation, acquisition or other form of business combination.  Any purported assignment without a required consent shall be void.  No assignment shall relieve any Party of responsibility for the performance of any obligation or liability that accrued prior to the effective date of such assignment. Subject to the foregoing, this Agreement shall be binding on the successors and permitted assignees of each Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices (including any notice of cancellation or termination given in accordance with the terms of this Agreement) must be written and sent to the address of the Party first set forth above (or such other address as a Party may provide notice of to the other Party).  All notices must be given (a) by personal delivery, with receipt acknowledged, or (b) by prepaid certified or registered mail, return receipt requested, or (c) by prepaid recognised next business day delivery service.  Notices will be effective upon receipt or at a later date stated in the notice. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law&#47;Jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is governed in all respects by the laws of the State of New York. USA. The Parties agree to submit to the jurisdiction of the courts located within or jurisdiction over the State of New York, USA.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties to this Agreement do not intend that any term hereof should be enforceable by any person who is not a party to this Agreement, save that Affiliates of Lonza may rely on and enforce the indemnities granted to them and limitations and exclusions of liability contained herein and Affiliates of Lonza which have executed a Statement of Work or Project Plan under this Agreement shall be entitled to enforce this Agreement with respect to such Project Plan or Statement of Work in its own name as an intended third party beneficiary. This Agreement may be amended without the consent of any Affiliates of Lonza.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Announcements &#47; Press Releases</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Party shall make any press release or announcement regarding the subject matter of this Agreement without the prior written consent of the other, except that either Party may make an applicable filing concerning the existence or terms of this Agreement, and&#47;or the relationship between the Parties in accordance with Section 13.2. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement contains the entire agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof.  Nothing in this Agreement (or any Project Plan entered into pursuant to this Agreement) shall supersede, amend or otherwise modify any terms or conditions or other provisions of any other unrelated agreement between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document.  Each party acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for the purposes of this Agreement.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:35.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each of the Parties hereto has caused this Agreement to be executed by its duly authorised representative effective as of the date written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:35.3pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LONZA SALES AG<br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Albert Pereda&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name  Albert Pereda</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title  Associate General Counsel</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marc Augustin&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name  Marc Augustin</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title  VP Finance Biologics</font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LONZA AG<br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Albert Pereda&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name  Albert Pereda</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title  Associate General Counsel</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marc Augustin&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name  Marc Augustin</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title  VP Finance Biologics</font></div><div style="margin-bottom:18pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTEXT THERAPEUTICS INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Martin Lehr&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name Martin Lehr</font></div><div style="margin-bottom:18pt;padding-left:234pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title  CEO</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:9.07pt;padding-right:9.07pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">APPENDIX A</font></div><div style="padding-left:9.07pt;padding-right:9.07pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Product and Project Plan</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">APPENDIX B<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Pricing</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">APPENDIX C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Quality Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">APPENDIX D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Outline Terms For Technology Transfer Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;License to Lonza Intellectual Property</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-exclusive license, including the right to grant sublicense to an identified third party contract manufacturer, under the Lonza Confidential Information and Lonza Background Intellectual Property, to the extent necessary to manufacture, have manufactured and to supply the Product, but no other product, using the Manufacturing Process.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Price and payment</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#163;750,000 one-time fee, which shall be reduced &#91;***&#93;. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>context-lonzalicenseagreem.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie8cc55e9f3874c799dee67906b7e7ed4_1"></div><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">LICENCE AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">between</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">LONZA SALES AG</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">and</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTEXT THERAPEUTICS INC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">INDEX</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CLAUSE </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TITLE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PAGE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">1.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions and Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Supply of System Know-How, GS piggyBac&#174; Know-How and CDACF System</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">3.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Property and Intellectual Property</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Licences</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Procedures</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">7.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Liability and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property Enforcement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">10.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">11.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">12.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Dispute Resolution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">14.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Illegality</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">15.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">16.</a></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a href="#ie8cc55e9f3874c799dee67906b7e7ed4_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">APPENDIX</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#160;&#160;&#160;&#160;Patent Rights</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;&#160;&#160;&#160;CDACF Base Powders</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#160;&#160;&#160;&#160;CDACF Supplements, Media and Feeds</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#160;&#160;&#160;&#160;CDACF Know-How</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#160;&#160;&#160;&#160;Vectors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#160;&#160;&#160;&#160;GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7&#160;&#160;&#160;&#160;Pre-Approved Affiliates </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AGREEMENT is made the 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of November 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LONZA SALES AG</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lonza</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;), and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONTEXT THERAPEUTICS INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, incorporated and registered in USA whose registered office is at 2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103 USA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(hereinafter referred to as &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Licensee and Lonza shall jointly be referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and individually as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A&#160;&#160;&#160;&#160;Lonza is the proprietor of the System and the CDACF System and has the right to grant certain Intellectual Property Rights in relation thereto (all as defined below).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Lonza and Licensee intend to enter in a Manufacturing Services Agreement on or about the Effective Date, pursuant to which Lonza shall use and&#47;or may use the System and CDACF System to construct the Transfected Cell Line and manufacture Product on behalf of Licensee (such terms as defined below).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;The Licensee now wishes to take a licence under Intellectual Property Rights of which Lonza is the proprietor in order to continue using the System and CDACF System (together with the Transfected Cell Line) to develop, and commercially exploit the Product (as defined below) on the terms set out in this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE the Parties hereby agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Definitions and Interpretation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;In this Agreement the following words and phrases shall have the following meanings&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any company, corporation, limited liability company, partnership or other entity which directly or indirectly controls, is controlled by or is under common control, directly or indirectly, with the relevant Party to this Agreement. &#34;Control&#34; means the ownership of more than fifty percent (50%) of the issued share capital of the entity in question or the legal power to direct or cause the direction of the general management and policies of the entity in question. Such entity shall be deemed an Affiliate only so long as it satisfies the foregoing definition.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:35.45pt;text-align:justify;text-indent:0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a product sold by a Third Party in a Sales Country (as defined in Clause 5.2) that&#58; </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;has received all necessary approvals by the applicable regulatory authorities in such Sales Country to market and sell such product as a pharmaceutical product&#59; </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;such Third Party has not obtained the rights to market or sell such product as a licensee, sublicensee or distributor of Licensee (or any of its Affiliates, licensees or sublicensees) with respect to such product&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;is approved as&#58; (i) a &#8220;biosimilar&#8221; (in the United States) of the Product, (ii) a &#8220;similar biological medicinal product&#8221; (in the EU) with respect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">which the Product is the &#8220;reference medicinal product&#8221; or (iii) if not in the US or EU, the equivalent of a &#8220;biosimilar&#8221; or &#8220;similar biological medicinal product&#8221; of the Product&#59; in each case for use in such Sales Country pursuant to an expedited regulatory approval process governing approval of generic biologics based on the then-current standards for regulatory approval in such country and where such regulatory approval was based in significant part upon clinical data generated on the Product.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF Base Powders&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the applicable version of the powders set out in Appendix 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF Feeds&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the applicable version of the concentrated nutrient solutions used in order to maintain the growth and productivity of mammalian cells, as more fully set out in Appendix 3.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF Know-How&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any Know-How specifically relating to the applicable version of the CDACF Base Powders, CDACF Feeds, CDACF Media or the CDACF Supplements used either in combination or individually, as set out in Appendix 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF Media&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the applicable version of the solutions of nutrients used in mammalian cell culture, as more fully set out in Appendix 3.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF Supplements&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the applicable version of the supplement solutions, as more fully set out in Appendix 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;CDACF System&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the CDACF Base Powders, CDACF Feeds, CDACF Media, CDACF Know-How and the CDACF Supplements used either in combination or individually.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:35.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Cell Line&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means Lonza&#8217;s CHOK1SV GS-KO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> cell line. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any Know-How and confidential information (in any format and on any media) disclosed by one Party to the other in connection with this Agreement including for the avoidance of doubt the terms of this Agreement itself. In the case of Lonza, Confidential Information shall mean all information relating to the System and&#47;or CDACF System and any other materials, specifications or information which is provided and&#47;or disclosed by Lonza, its Affiliates and their respective officers, employees, agents and advisors to the Licensee and its officers, employees, agents and advisors, whether directly or indirectly, including, without limitation, all agreements, research databases, trade secrets, Intellectual Property Rights, business and&#47;or commercial and&#47;or financial data, specifications, technical designs, documents and drawings which are related to the System, the CDACF System and&#47;or Lonza&#8217;s business. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Effective Date&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the date first above written.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;First Commercial Sale&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the date of the first sale or other disposal of Product to a Third Party for consideration by or on behalf of Licensee in that particular country following regulatory approval in such country.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Lonza&#8217;s gene delivery system known as GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for use in the GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Field consisting of the GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials and the GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Know-How, whether used individually or in combination with each other. For the avoidance of doubt, any gene or genes proprietary to Licensee inserted into GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> do not form part of GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-0.55pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Field</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the use of Cell Line and the production and use of Vectors and&#47;or the GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials to produce biological molecules for all </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">All trade marks (&#174;) are registered in CH, EU or USA</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">purposes directly related to the production of human therapeutic products only (not for animal therapeutic products).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-0.55pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Know-How relating directly or indirectly to GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> known to Lonza, or its Affiliates, from time to time of which Lonza, or its Affiliates, is the proprietor or in which Lonza, or its Affiliates, has certain rights including for use in the GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Field and which at all times vests in Lonza.</font></div><div style="padding-left:35.45pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those materials referred to in Appendix 6.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Initiation&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means, with respect to any clinical trial, the first date that a human subject is dosed in such clinical trial.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Intellectual Property Rights&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means all rights, title and interests, vested and&#47;or arising out of any industrial or intellectual property, whether protected at common law or under statute, which includes (without limitation) any rights and interests in patents, copyrights, designs, trademarks, service marks, trade-names, technology, business names, logos, commercial symbols, processes, developments, licenses, trade secrets, goodwill, drawings, computer software, formulae, technical information, research data, procedures, Confidential Information and any other knowledge of any nature whatsoever throughout the world whether in existence today or which will come into existence in the future, and including all applications for patents, copyrights, trademarks, trade names, rights to apply and any amendments&#47;modifications or renewals thereto&#59; and all other intellectual property rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Know-How&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any technical and other information, whether patented or unpatented, including, but without prejudice to the generality of the foregoing, ideas, concepts, trade secrets, know-how, inventions, discoveries, data, formulae, specifications, processes, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification techniques and assay protocols.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Licensed Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the System Know-How, GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Know-How and CDACF Know-How.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Net Sales&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means all revenues recorded by or on behalf of Licensee or its Sublicensees for Product sold in the Territory (including without limitation where such sales are made by way of an alternative fee arrangement or commission arrangement when and to the extent that such selling entity recognises the applicable revenue under GAAP). The permitted deductions booked on an accrual basis by Licensee and its Sublicensees under their respective accounting standards to calculate the recorded net sales from gross sales are as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-35.9pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-35.9pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-35.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;&#91;***&#93;. </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-35.9pt"><font><br></font></div><div style="padding-left:36.1pt;text-align:justify;text-indent:1.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such permitted deductions shall not include, without limitation, &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Subject to the qualification stated below, &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding anything contained in this Agreement to the contrary, &#91;***&#93; shall not be included in this provision.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If the Product is sold as a combined product that consists of Product together with another therapeutically active ingredient or product (a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Combination&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Net Sales will be calculated by multiplying the Net Sales of the Combination (as defined using the Net Sales definition above) by the fraction, A&#47;(A+B) where A is the weighted (by sales volume) average sale price of the Product in the relevant country, and B is the weighted average sale price (by sales volume) in that country of the product(s) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">containing the other component(s) in finished form. Regarding prices comprised in the weighted average price when sold separately referred to above, if these are available for different dosages from the dosages of Product and other components that are included in the Combination, then the Parties shall mutually agree on the appropriate proportional adjustment to such prices in calculating the royalty-bearing Net Sales of the Combination. If the weighted average sale price cannot be determined for the Product or other component(s), the calculation of Net Sales for a Combination will be mutually agreed upon by the Parties based on the relative value contributed by each component, such agreement to be negotiated in good faith without unreasonable delay. If agreement on this basis cannot be reached, then the Parties will refer to the relative pricing of dosages as observed for biosimilar products in the same country. For the avoidance of doubt, in no event will a bioconjugate be deemed to be a Combination for the purposes of this Agreement. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Patent Rights (Lonza)&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the patents and applications, short particulars of which are set out in Appendix 1A, and all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition, and including any divisions, renewals, continuations, continuations in part, reissues, patent disclosures, improvements and extensions of reissue thereof.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Patent Rights (Third Party)&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the patents and applications, short particulars of which are set out in Appendix 1B, and to the extent granted to Lonza by the owners of the Patent Rights (Third Party), all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition, and including any divisions, renewals, continuations, continuations in part, reissues, patent disclosures, improvements and extensions of reissue thereof.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Pre-Approved Affiliates&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall mean those entities set out in Appendix 7. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Product&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means Licensee&#8217;s Claudin 6 x CD3 (&#8220;CLDN6xCD3&#8221;) bispecific antibody in which Licensee has Proprietary Rights and which (or a component of which) is obtained by the expression of any one gene or of any combination of genes by use of the System and&#47;or CDACF System, or any formulation containing the same.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:35.45pt;text-align:justify;text-indent:0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Proprietary Rights&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means sole or co-ownership, or an exclusive or sole licence, or those rights obtained by Licensee or its Affiliate pursuant to that certain Research Collaboration and License Agreement, as may be amended, with Integral Molecular, Inc. entered into on 6 April 2021.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">      </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Royalty Term&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall have the meaning ascribed to it in Clause 5.3.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Strategic Partner&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means a person or entity after the Effective Date&#58; (i) &#91;***&#93;&#59; and (ii) &#91;***&#93;. In no event may any entity whose role in the relationship is &#91;***&#93;.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Sublicensee&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any Strategic Partner or other Third Party to which Licensee grants a sublicence of the rights granted to Licensee pursuant to this Agreement.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;System&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means Lonza&#8217;s &#91;***&#93; gene expression system known as GS Xceed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">consisting of the System Materials, the System Know-How and GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(whether used individually or in combination with each other) and including any part of such system that is embodied within or otherwise used to create the Transfected Cell Line(s). For the avoidance of doubt, any gene in which Licensee has Proprietary Rights inserted into the System for the purposes of producing Product does not form part of the System.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;System Know-How&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means Know-How relating directly or indirectly to the System known to Lonza from time to time, of which Lonza is the proprietor (including, without limitation&#58; (i) manuals of operating procedures for the System&#59; (ii) regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">information supplied in connection with the System&#59; (iii) vector nucleotide sequences&#59; (iv) Know-How concerning the composition of the System&#59; and (v) any such Know-How that is otherwise embodied within one or more component(s) of the System).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;System Materials&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the Cell Line and Vectors.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Territory&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means worldwide.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Third Party&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means any individual or entity other than Lonza and Licensee. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:35.4pt;padding-right:-2.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Transfected Cell Line(s)&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means the Cell Line transfected by or on behalf of Licensee and which expresses Product.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Valid Claim&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means a claim within the Patent Rights (Lonza) or the Patent Rights (Third Party) (including any re-issued and unexpired claims) which, but for the licence and other rights granted pursuant to Clauses 4.1 to 4.4 hereof, would be infringed by the manufacture, use, sale, offer for sale, exportation or importation of Product by Licensee or its Sublicensees and which&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.57pt">has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal&#59; and</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.57pt">has not been finally revoked, held invalid or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Vectors&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> means Lonza&#8217;s &#91;***&#93; vectors set out in Appendix 5.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;The headings of this Agreement are inserted only for convenience and shall not affect the construction hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3&#160;&#160;&#160;&#160;Where appropriate words denoting a singular number only shall include the plural and vice versa.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160;References to the recitals, clauses and appendices shall be deemed to be a reference to the recitals, clauses and appendices to this Agreement and shall form an integral part of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;References to any statute or statutory provision include a reference to the statute or statutory provision as from time to time amended, extended or re-enacted.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;Reference in this Agreement to Lonza shall, unless repugnant to the subject or context thereof, include its Affiliates, successors and assigns. </font></div><div style="margin-top:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Supply of System Know-How, GS piggyBac&#174; Know-How and CDACF System </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Unless previously supplied by Lonza under a separate agreement, Lonza shall, if requested by Licensee in writing, supply further System Know-How as required by Licensee solely for regulatory purposes (and which shall only be supplied directly to the regulatory agency by Lonza). Any such System Know-How provided hereunder (together with all other applicable components of the System previously received by Licensee) shall be used strictly in accordance with the terms of this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;In relation to the CDACF System, Lonza shall following signature of this Agreement&#58; (a) provide Licensee with details of how to purchase the CDACF Base Powders and CDACF Supplements to enable Licensee to make CDACF Feeds and CDACF Media&#59; and (b) if requested in writing by Licensee and required for use under this Agreement, supply Licensee with the CDACF Know-How.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;Should any transportation of the System and&#47;or CDACF System be arranged by Lonza on behalf of Licensee such transportation shall be made at the sole risk of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee. The Licensee shall indemnify Lonza against all losses, expenses, demands, claims, actions, judgments, assessments, damages, liabilities, fines, penalties, costs and fees incurred by Lonza by reason of such transportation, other than such losses directly attributable to Lonza&#8217;s negligence or wilful misconduct.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Ownership of Property and Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;Save for any Intellectual Property Rights licensed to Lonza, it is hereby acknowledged and agreed that as between the Parties any and all property and Intellectual Property Rights in the System and the CDACF System is vested in Lonza. Similarly it is hereby acknowledged as between the Parties any and all Intellectual Property Rights in the Product and any gene proprietary to Licensee (or any of its licensors or sublicensees) inserted into the System, or used with the System and&#47;or CDACF System, for the purpose of producing Product is vested in Licensee (or its applicable licensors and sublicensees) to the extent that this is severable from and does not utilise, disclose, infringe or reveal any Intellectual Property Rights of Lonza.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Licences</font></div><div style="padding-right:-2.25pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Commercial Activities Licence</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;Lonza hereby grants to Licensee on the Effective Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.1&#160;&#160;&#160;&#160;a worldwide non-exclusive licence under the System, CDACF System, and the Patent Rights (Lonza) (with the right to sublicence, subject to Clause 4.2 below)&#59; and</font></div><div style="padding-left:36.75pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.2 &#160;&#160;&#160;&#160;a worldwide non-exclusive sublicence under the Patent Rights (Third Party) (with the right to sublicense, subject to Clause 4.2 below),</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in each case Clause 4.1.1 and Clause 4.1.2 to &#91;***&#93;, market, sell, offer for sale, distribute, import and export Product in the Territory (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;Subject to the provisions of this Clause 4.2 and the terms and conditions of this Agreement, Licensee shall be entitled to grant a sublicence to the rights (excluding the right to grant additional tiers of sublicences) granted by Clause 4.1 (each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Activities Sublicence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to any one or more Third Parties for the purposes of any such Third Party undertaking Commercial Activities for or on behalf of Licensee (each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Activities Sublicensee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) provided always&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.1&#160;&#160;&#160;&#160;Licensee shall ensure such Commercial Activities Sublicensee&#8217;s use of the Product is undertaken solely for undertaking Commercial Activities for or on behalf of Licensee&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.2&#160;&#160;&#160;&#160;The Commercial Activities Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or implied, to the System, CDACF System, Patent Rights (Lonza) and the Patent Rights (Third Party) other than for undertaking Commercial Activities for or on behalf of Licensee. Licensee agrees to ensure that such Commercial Activities Sublicensee shall not assign, transfer, further sublicense or otherwise make over the benefit or the burden of the rights granted to it pursuant to the Commercial Activities Sublicence&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.3&#160;&#160;&#160;&#160;Licensee shall notify Lonza in writing within a period of &#91;***&#93; days of granting a Commercial Activities Sublicence under this Agreement. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-right:-2.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Activities Licence&#58;</font></div><div style="padding-right:-2.25pt;text-align:justify"><font><br></font></div><div style="padding-right:-2.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Lonza hereby grants to Licensee on the Effective Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.1&#160;&#160;&#160;&#160;a non-exclusive licence under the System, CDACF System, and the Patent Rights (Lonza) (with the right to sublicence, subject to Clause 4.4 below)&#59; and</font></div><div style="padding-left:36.75pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.2 &#160;&#160;&#160;&#160;a non-exclusive sublicence under the Patent Rights (Third Party) (with the right to sublicense, subject to Clause 4.4 below), </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in each case 4.3.1 and 4.3.2 to use, develop and manufacture Product (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at Licensee&#8217;s premises located at 2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103 USA, or such other premises approved in writing by Lonza under the terms of this Agreement, such approval not to be unreasonably withheld, conditioned or delayed. It is agreed between the Parties that Lonza shall be considered to be reasonably withholding its consent if it holds commercial concerns as to protection of its Intellectual Property Rights and confidentiality should Manufacturing Activities be carried out at Licensee&#8217;s proposed premises.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;Subject to the provisions of this Clause 4.4 and the terms and conditions of this Agreement, Licensee shall be entitled to grant a sublicence to the rights (excluding the right to further sublicense) granted by Clause 4.3 (each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Sublicence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to any one or more Third Parties for the purposes of any such Third Party undertaking Manufacturing Activities at a facility owned or controlled by such Third Party(ies) for or on behalf of Licensee (each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Sublicensee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) provided always&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.1&#160;&#160;&#160;&#160;Licensee shall ensure such Manufacturing Sublicensee&#8217;s use of the System, the CDACF System and Lonza&#8217;s Intellectual Property Rights (subject always to Clause 4.6) is undertaken solely for undertaking Manufacturing Activities for or on behalf of Licensee&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.2&#160;&#160;&#160;&#160;The Manufacturing Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or implied, under any patent or proprietary right vested in Lonza or otherwise, to use the System, the CDACF System, Lonza&#8217;s Intellectual Property Rights or the Product other than for undertaking Manufacturing Activities for or on behalf of Licensee. Licensee agrees to ensure that such Manufacturing Sublicensee shall not assign, transfer, further sublicense or otherwise make over the benefit or the burden of the rights granted to it pursuant to this Agreement&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.3&#160;&#160;&#160;&#160;Prior to the grant of any Manufacturing Sublicence pursuant to this Clause 4, subject to Clause 4.4.4 below, Licensee shall obtain the written consent of Lonza (such consent not to be unreasonably withheld, conditioned or delayed) to the grant of such sublicence. It is agreed between the Parties that Lonza shall be considered to be reasonably withholding its consent if it holds commercial concerns as to protection of its Intellectual Property Rights and confidentiality should Lonza&#8217;s Intellectual Property Rights be sub-licensed to the proposed Manufacturing Sublicensee. The Licensee shall notify Lonza in writing within a period of &#91;***&#93; days of granting each Manufacturing Sublicence under this Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.4&#160;&#160;&#160;&#160;Notwithstanding Clause 4.4.3, Lonza hereby grants its consent to the grant of a Manufacturing Sublicence by Licensee to &#91;***&#93;. For the avoidance of doubt, such consent shall extend only to the location of the &#91;***&#93;. In the event that &#91;***&#93; intends to carry out Manufacturing Activities in any other location such location shall be subject to the prior written consent of Lonza in accordance with Clause 4.4.3&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4.5&#160;&#160;&#160;&#160;Within &#91;***&#93; business days following termination of this Agreement or termination or expiry of Licensee&#8217;s arrangements with any such Manufacturing Sublicensee (whichever occurs earlier), Licensee shall confirm in writing to Lonza that Transfected Cell Lines and Licensed Know-How (including materials provided to Manufacturing Sublicensee relating directly or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">indirectly to the System or the CDACF System) are destroyed and&#47;or returned to Licensee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">General Licence Restrictions (Commercial Activities and Manufacturing Activities) </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;Any Manufacturing Sublicence or Commercial Activities Sublicence granted by Licensee shall be granted expressly subject to the terms of this Agreement, and it shall be Licensee&#8217;s responsibility to ensure the strict adherence by each Manufacturing Sublicensee and Commercial Activities Sublicensee hereunder to the terms and conditions of this Agreement. Licensee shall be responsible and liable for the acts or omissions of each Manufacturing Sublicensee and Commercial Activities Sublicensee herein and Licensee shall indemnify Lonza against all costs, expenses, claims, loss or damage incurred or suffered by Lonza, or for which Lonza may become liable arising out of any act or omission of any Sublicensee, including any product liability claim relating to Product manufactured, supplied or put into use by the Sublicensee, except in all instances if directly related to the gross negligence or wilful misconduct of Lonza.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;Notwithstanding any other provision, Licensee shall not transfer the Cell Lines and&#47;or Vectors and&#47;or GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials to any Third Party without Lonza&#8217;s prior and express written consent (such consent not to be unreasonably withheld, conditioned or delayed), provided, however, that Licensee is allowed to transfer the Transfected Cell Lines to a Manufacturing Sublicensee for the purposes of and subject to Clause 4.4. It is agreed between the Parties that Lonza shall be considered to be reasonably withholding its consent if it holds commercial concerns as to protection of its Intellectual Property Rights and confidentiality should Lonza&#8217;s Intellectual Property Rights be transferred to the proposed recipient of such materials.  Licensee shall not transfer any Licensed Know-How without prior written approval by Lonza, which shall only be granted to the extent strictly required for Manufacturing Activities.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;Licensee hereby undertakes that it will neither reverse engineer nor make any modifications, adaptations or improvements to the System and&#47;or the CDACF System and&#47;or Transfected Cell Lines (including for the avoidance of doubt but not by way of limitation, inserting alternate cell lines and&#47;or vectors) without Lonza&#8217;s prior written consent, except and only to the extent that such activity is expressly permitted by applicable law notwithstanding this limitation. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;Licensee shall use the System only in accordance with the licences granted under Clause 4, and shall not use, cause the use of or permit to be used the System for any purpose not directly authorised by this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;The CDACF System may only be used in conjunction with the System and may not be used in conjunction with any other gene expression system or for any other purpose whatsoever.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;If, on a country-by-country basis, any granted patents that form part of the Patent Rights (Lonza) or Patent Rights (Third Party) (including any re-issued patents and unexpired patents), subsequently expire or no longer contain a Valid Claim such Patent Rights (Lonza) or Patent Rights (Third Party) shall automatically fall outside the scope of this Agreement for that particular country and the provisions of Clauses 4.1 to 4.9 shall only apply in that particular country, with respect to granted patents, to those granted patents which contain a Valid Claim and form part of the Patent Rights (Lonza) or Patent Rights (Third Party) for as long as those granted patents remain in force.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;Notwithstanding Clause 4.10, on a country-by-country basis, where no Valid Claim remains in force, the provisions of Clauses 4.1 to 4.9 shall continue to apply with respect to&#58; (i) &#91;***&#93;&#59; and (ii) &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;No licence is granted save as expressly provided herein and no licence in addition thereto shall be deemed to have arisen or be implied by way of estoppel or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Additional Licensee Obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;Licensee shall notify Lonza within &#91;***&#93; days of when Product changes its phase of clinical trial and&#47;or when it is first offered for commercial sale.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee shall obtain at its own expense all licences, permits and consents necessary for the provision of Product in the Territory. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.15&#160;&#160;&#160;&#160;Licensee acknowledges and agrees that the exercise of the licence granted to the Licensee under this Agreement is subject to all applicable laws, enactments, regulations and other similar instruments in the Territory, and the Licensee understands and agrees that it shall at all times be solely liable and responsible for such due observance and performance.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.16&#160;&#160;&#160;&#160;Licensee represents and warrants it has all the requisite authority and rights in Product to enter into this Agreement and exercise the rights being granted to it under this Agreement, other than any rights as may be required from Lonza.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Payments</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;In consideration of the licences granted to Licensee pursuant to Clauses 4.1 and 4.3 above, and in consideration for the right to sublicence the rights granted by Clauses 4.1 and 4.3, pursuant to Clauses 4.2 and 4.4 respectively, Licensee shall pay Lonza as follows, subject to the adjustment as set forth in Clause 5.2 and Clause 5.5 (as applicable)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.1&#160;&#160;&#160;&#160;in respect of Product manufactured by Lonza, a royalty of &#91;***&#93; percent (&#91;***&#93;%) of Net Sales&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.2&#160;&#160;&#160;&#160;where &#91;***&#93; manufactures Product (whether for clinical or commercial purposes)&#58; </font></div><div style="padding-left:120.5pt;text-align:justify;text-indent:-49.6pt"><font><br></font></div><div style="padding-left:120.5pt;text-align:justify;text-indent:-49.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.2.1&#160;&#160;&#160;&#160;a payment of &#91;***&#93; (&#91;***&#93;) due annually during the course of this Agreement, and being first payable upon &#91;***&#93; and thereafter on each anniversary of such date&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-73.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.2.2&#160;&#160;&#160;&#160;a royalty of &#91;***&#93; percent (&#91;***&#93;%) of Net Sales of Product&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.3&#160;&#160;&#160;&#160;where any person or entity other than &#91;***&#93; manufactures Product (whether for clinical or commercial purposes) (&#8220;&#91;***&#93;&#8221;)&#58;</font></div><div style="padding-left:72pt;padding-right:-2.35pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:120.5pt;text-align:justify;text-indent:-49.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.3.1&#160;&#160;&#160;&#160;a payment of &#91;***&#93; (&#91;***&#93;) &#91;***&#93; due annually during the course of such &#91;***&#93; (irrespective as to the years of manufacture), and being first payable on the commencement date of the relevant &#91;***&#93;&#59; and</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-73.1pt"><font><br></font></div><div style="padding-left:120.5pt;text-align:justify;text-indent:-49.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.3.2&#160;&#160;&#160;&#160;a royalty of &#91;***&#93; percent (&#91;***&#93;%) of Net Sales of Product.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-73.1pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;If, on a country-by-country basis, neither (i) the use, sale, offer for sale or import of the Product in a particular country (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Country</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) nor (ii) the manufacture and&#47;or export for sale of the Product in the country of its manufacture (whether in the Sales Country or otherwise) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture Country</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are covered by a Valid Claim (either because no patent or application was ever filed for any such country or the patent or application is no longer of effect) then in respect of sales in that Sales Country&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.1&#160;&#160;&#160;&#160;the royalties referred to in Clauses 5.1.1 and 5.1.2.2 shall be at the rate of &#91;***&#93; percent (&#91;***&#93;%) and &#91;***&#93; percent (&#91;***&#93;%) respectively of the Net Sales in that Sales Country&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.2&#160;&#160;&#160;&#160;the royalties referred to in Clause 5.1.3.2 shall be at the rate of &#91;***&#93; percent (&#91;***&#93;%) of the Net Sales in that Sales Country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;Any royalty payments due under this Clause 5 shall be required in each country of the world on a country-by-country basis until the later of&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.1&#160;&#160;&#160;&#160;expiry of the last Valid Claim in that particular Sales Country&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify;text-indent:-34.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.2&#160;&#160;&#160;&#160;expiry of the last Valid Claim in the Manufacture Country&#59; and </font></div><div style="padding-left:70.9pt;text-align:justify;text-indent:-34.9pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.3&#160;&#160;&#160;&#160;ten (10) years from the First Commercial Sale of the Product in that particular Sales Country,</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For the avoidance of doubt, (i) upon expiration of a Royalty Term in any individual country, all other terms and conditions of this Agreement shall remain in full force and effect, and (ii) there should be no payments due hereunder pursuant to Clauses 5.1.2.2 or 5.1.3.2. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;The Royalty Term for a particular country shall end earlier than as set out in Clause 5.3 in the event that, and on the date upon such receipt by Licensee, Licensee receives either&#58; (i) &#91;***&#93;&#59; (ii) &#91;***&#93;&#59; or (iii) &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5.1&#160;&#160;&#160;&#160;In the event that, on a country-by-country basis&#58; (i) &#91;***&#93;&#59; (ii) &#91;***&#93;&#59; and (iii) &#91;***&#93;&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:70.66pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.728%"><tr><td style="width:1.0%"></td><td style="width:24.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Product manufactured by Lonza (Clause 5.1.1)</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Product manufactured by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#160;(Clause 5.1.2.2)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Product manufactured by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(Clause 5.1.3.2)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></div><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></div><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font><br></font></div><div style="padding-left:1.62pt;padding-right:1.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5.2&#160;&#160;&#160;&#160;In the event that, following the expiry of a Royalty Term in a country in the Approved Territory, a &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5.3&#160;&#160;&#160;&#160;The &#91;***&#93; set out in Clauses 5.5.1 and 5.5.2 above shall be conditional on Licensee giving written notice to Lonza regarding &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;The provisions of this Clause 5 shall remain in effect notwithstanding termination of this Agreement until the settlement of all subsisting claims by Lonza.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Royalty Procedures</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;Licensee shall, and shall ensure that its Sublicensees shall, keep true and accurate records and books of account (including but not limited to easily accessible electronic database records) containing all data necessary for the calculation of royalties payable to Lonza and in accordance with accounting best practice. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;Licensee shall prepare a statement in respect of each calendar quarter which shall show for the immediately preceding quarter details of the sales of Product on a country-by-country basis, including a full list of all of the permitted deductions which have been applied by Licensee when calculating the Net Sales from the gross sales, and the royalty due and payable to Lonza thereon. Such statement shall be submitted to Lonza within &#91;***&#93; days after the end of the calendar quarter to which it relates, together with a remittance for the royalties due to Lonza to which Lonza shall issue a receipted invoice in return.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;The records and books of account referred to in Clause 6.1 shall, upon reasonable notice having been given by Lonza (which in no event shall be less than &#91;***&#93; days prior notice), be open at all reasonable times during regular business hours for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">inspection by independent auditors selected by Lonza and reasonably acceptable to Licensee. The audit shall take place where the Licensee maintains such records and books of account. In the event that a visit to a separate location is required for the purpose of conducting the audit, Licensee will reimburse Lonza for any additional costs reasonably incurred by the auditors as a result. The auditors shall be entitled to take copies as reasonably necessary in order for the auditor to carry out its audit effectively of Licensee&#8217;s records and books of account. Such independent auditors shall agree to maintain the confidentiality of the information and materials disclosed during the audit. Any such audit shall be conducted in a manner that does not interfere unreasonably with the operations of Licensee&#8217;s business. Lonza may perform an audit no more than &#91;***&#93;. Each audit shall begin upon the date specified by Lonza and shall be completed as soon as reasonably practicable. Lonza shall pay the costs of the independent auditors conducting such audit, unless the results of the audit reveal an underpayment of &#91;***&#93; percent (&#91;***&#93;%) or more by Licensee, in which case Licensee shall pay the reasonable costs of the independent auditors. If an audit concludes that an underpayment has occurred during the audited period, such underpayment shall be remitted by the Licensee to Lonza within &#91;***&#93; days after the date such auditor&#8217;s written report identifying the underpayment is delivered to the Licensee. If an audit concludes that an overpayment has occurred during the audited period, such overpayment shall be carried forward and offset against future amounts payable by Licensee to Lonza, or otherwise promptly refunded to Licensee if no additional payments are due at the time such audit is concluded or otherwise anticipated to become due to cover such amount. Receipt or acceptance by Lonza of royalty statements or payments due from Licensee pursuant to this Agreement shall not preclude Lonza from later questioning the accuracy or completeness of such statements. The Licensee shall procure that its Sublicensees shall grant rights directly to Lonza corresponding to those granted by the Licensee under this Clause 6.3.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;All sums due under this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.4.1&#160;&#160;&#160;&#160;shall be paid in &#91;***&#93; to Lonza&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4.2&#160;&#160;&#160;&#160;are exclusive of any value added tax or of any other applicable taxes, levies, imposts, duties and fees of whatever nature imposed by or under the authority of any government or public authority, which shall be paid by Licensee (other than taxes on Lonza&#8217;s income)&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4.3&#160;&#160;&#160;&#160;shall be paid free and clear and without deduction for any present and future taxes imposed by any taxing authority. If Licensee is required by law to deduct or withhold taxes from sums due to Lonza under this Agreement, Licensee shall pay to Lonza such additional amounts as are necessary to ensure receipt by Lonza of the full amount which Lonza would have received but for the deduction or withholding, other than for payments related to Lonza&#8217;s income. If such additional amounts can be reduced or eliminated under local or treaty law, Lonza shall cooperate with Licensee in obtaining such deduction or exemption, it being understood that the primary responsibility for completion and timely filing of any applicable forms in this respect resides with Licensee and any withholding tax that could not be reduced or eliminated is to be born and paid by Licensee.</font></div><div style="padding-left:72pt;padding-right:-2.35pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;To the extent that Licensee reports Net Sales otherwise than in United States Dollars then royalty payments due to Lonza shall be first calculated in the local currency in which Net Sales are reported and then shall be converted to a United States Dollars value at the rate of exchange first published in the Financial Times (London) on the first business day after the relevant quarterly reporting period.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;Where Lonza does not receive payment of any sum by the due date, interest shall accrue thereafter on the sum due and owing to Lonza at the rate of &#91;***&#93; percent (&#91;***&#93;%) per annum over the base rate from time to time of National Westminster </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank plc, interest to accrue on a day-to-day basis without prejudice to Lonza&#8217;s right to receive payment on the due date.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Liability and Warranties</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;Lonza warrants that the patents included in the Patent Rights (Lonza) and Patent Rights (Third Party) are the only patents that must be licensed or sub-licensed from Lonza and&#47;or its Affiliates in order to operate the System in accordance with the terms of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;Subject to Clause 7.1, Lonza gives no representation or warranty that the Patent Rights (Lonza) or Patent Rights (Third Party) which are patent applications will be granted or if granted will be valid nor that the exercise of the rights granted to Licensee hereunder will not infringe other patent rights or intellectual property rights vested in Lonza or any Third Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;The Licensee hereby acknowledges&#58; (i) this is a licence to the Licensed Know-How, Patent Rights (Lonza) and the Patent Rights (Third Party) and not to any other Lonza Intellectual Property Rights&#59; and (ii) that in order to exploit the rights granted herein the Licensee may require licences under Lonza Intellectual Property Rights (other than those herein licensed) or under Third Party patent rights (including those vested in Affiliates of Lonza) that may be infringed by the use by the Licensee of the rights licensed herein. It is hereby agreed that it shall be the Licensee's responsibility to satisfy itself as to the need for such licences and if necessary to obtain such licences&#59; provided that where any such Intellectual Property Rights vested in Lonza or its Affiliates would prevent the Licensee and its Sublicensees from operating the System as permitted by the terms of this Agreement, then such patent rights shall be automatically included within the Intellectual Property Rights licensed to Licensee hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;Each Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall indemnify and hold harmless the other Party and its Affiliates, and their respective officers, employees and agents (each an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at all times in respect of any and all losses, damages, costs and expenses (collectively &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) suffered or incurred as a result of any contractual, tortious or other claims or proceedings by Third Parties (collectively &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) against Indemnified Party arising out of the Indemnifying Party&#8217;s breach of this Agreement, including breach of representations or warranties, violation of applicable law, negligence or wilful misconduct&#59; provided that with respect to any Third Party Claim for which each Party is entitled hereunder to seek indemnification from the other Party, each Party as the Indemnifying Party shall indemnify the other Party for its Losses only to the extent of the Indemnifying Party&#8217;s relative responsibility for the facts underlying the Third Party Claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;With respect to product liability claims or proceedings, the following shall apply&#58; (a) except to the extent provided in (b) below, Licensee shall indemnify and hold harmless Lonza, its Affiliates and their respective officers, employees and agents at all times in respect of any and all losses, damages, costs and expenses suffered or incurred as a result of any tortious claims or proceedings of death or bodily injury relating to the Product, and (b) Lonza shall indemnify and hold harmless Licensee, its Affiliates and their respective officers, employees and agents at all times in respect of any and all losses, damages, costs and expenses suffered or incurred as a result of any tortious claims or proceedings of death or bodily injury relating to the Product to the extent such claims or proceedings result directly from defects in the Cell Lines, Vectors or GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;Any condition or warranty other than those relating to title which might otherwise be implied or incorporated within this Agreement by reason of statute or common law or otherwise is hereby expressly excluded.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;EXCEPT FOR EITHER PARTY&#8217;S BREACH OF CLAUSE 8 HEREOF SUBJECT TO CLAUSE 7.8, IN NO EVENT SHALL EITHER PARTY AND&#47;OR THEIR RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY, THEIR AFFILIATES AND THEIR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RESPECTIVE OFFICERS, EMPLOYEES AND AGENTS WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT WHETHER IN CONTRACT IN TORT IN NEGLIGENCE OR FOR BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY LOSS OF PROFITS, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8&#160;&#160;&#160;&#160;Nothing in this Agreement shall exclude or limit the liability of either Party for fraud or for death or personal injury caused by its negligence or for wilful or deliberate breach of this Agreement or for any other liability that may not be limited or excluded as a matter of law. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Confidentiality</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Licensee expressly acknowledges that Confidential Information disclosed by Lonza pursuant to this Agreement is supplied in circumstances imparting an obligation of confidence and Licensee shall keep such Confidential Information secure, secret and confidential and undertakes to respect Lonza&#8217;s proprietary rights therein and to use the same for the sole purpose of this Agreement and not during the period of this Agreement or at any time for any reason whatsoever to disclose, cause or permit to be disclosed such Confidential Information to any Third Party other than its Sublicensee hereunder for use in accordance with and subject to the terms of this Agreement. Licensee shall procure that only its employees and employees of its Sublicensee hereunder shall have access to Confidential Information and then only on a need-to-know basis and that all such employees shall be informed of their secret and confidential nature and shall be subject to the same obligations as Licensee and its Sublicensee hereunder pursuant to this Clause 8.1.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;Lonza expressly acknowledges and undertakes that any Confidential Information disclosed by the Licensee to Lonza pursuant to this Agreement is disclosed in circumstances imparting an obligation of confidence and Lonza shall keep such Licensee's Confidential Information secure, secret and confidential and undertakes to respect Licensee&#8217;s proprietary rights therein and to use the same for the sole purpose of this Agreement and not during the period of this Agreement or at any time for any reason whatsoever to disclose and&#47;or cause and&#47;or permit to be disclosed such Licensee's Confidential Information to any Third Party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;Each Party will restrict the disclosure of the terms of this Agreement to such officers, employees, professional advisers, finance-providers, and consultants of itself and its Affiliates (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Representatives&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) who have been informed of the confidential nature of the same and who have a need to know such terms. Prior to disclosure to such persons, the Party in receipt of the Confidential Information shall bind its and its Affiliates&#8217; Representatives to confidentiality and non-use obligations no less stringent than those set forth herein. The receiving Party shall notify the disclosing Party as promptly as practicable of any unauthorized use or disclosure. To the extent that either Party wishes to disclose any other Confidential Information to any of its Representatives, save as expressly permitted by this Clause 8, this shall be subject to obtaining the prior written consent of the other Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;The obligations of confidence referred to in this Clause 8 shall not extend to any information which the receiving Party demonstrates&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4.1&#160;&#160;&#160;&#160;is or shall become generally available to the public otherwise than by reason of a breach by the recipient Party of such information of the provisions of this Clause 8&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4.2&#160;&#160;&#160;&#160;is known to the recipient Party of such information and is at its free disposal prior to its receipt from the other&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4.3&#160;&#160;&#160;&#160;is subsequently disclosed to the recipient Party without obligations of confidence by a Third Party owing no such obligation of confidentiality to the disclosing Party&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4.4&#160;&#160;&#160;&#160;can be demonstrated by competent written evidence as having been independently developed by the recipient of the information in question without access to or use or knowledge of the information of the disclosing Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;Notwithstanding the foregoing it is acknowledged between the Parties that Lonza or Licensee may be required to disclose Confidential Information and&#47;or this Agreement to a government agency for the purpose of any statutory, regulatory or similar legislative requirement applicable to Licensee and&#47;or the production of Product, or to a court of law or to meet the requirements of any Stock Exchange to which a Party may be subject. In such circumstances the disclosing Party will inform the other Party prior to disclosure being made as to the nature of the required disclosure, shall only make the disclosure to the extent legally required and shall seek to impose obligations of secrecy and&#47;or confidential treatment wherever possible. Notwithstanding such disclosure such Confidential Information shall otherwise remain subject to this Clause 8. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;Each Party expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided hereunder by a Party may cause irreparable harm to the other Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and that money damages may not provide a sufficient remedy to the Non-Breaching Party for any breach or threatened breach. In the event of any breach and&#47;or threatened breach, then in addition to all other remedies available at law or in equity, the Non-Breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the Non-Breaching Party. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Intellectual Property Enforcement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;Lonza hereby undertakes and agrees that at its own discretion and expense it will&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1.1&#160;&#160;&#160;&#160;prosecute or procure prosecution of such of the Patent Rights (Lonza) which are patent applications diligently so as to secure the best commercial advantage obtainable, as determined by Lonza in its commercially reasonable discretion, and will pursue, as determined by Lonza in its commercially reasonable discretion, all necessary actions against any Third Party that Lonza reasonably believes is infringing, misappropriating or violating any Lonza Intellectual Property Rights&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1.2&#160;&#160;&#160;&#160;pay or procure payment of all renewal fees in respect of the Patent Rights (Lonza) for the full term thereof and in particular will procure such renewal of the registrations thereof as may be necessary from time to time so far as it is reasonable to do so with particular reference to Lonza&#8217;s commercial considerations.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;Licensee shall promptly notify Lonza in writing of any infringement or improper or unlawful use of or of any challenge to the validity of the Patent Rights (Lonza) and&#47;or Licensed Know-How. Lonza undertakes and agrees to take all such steps and proceedings and to do all other acts and things as may in Lonza&#8217;s sole discretion be necessary to restrain any such infringement or improper or unlawful use or to defend such challenge to validity and Licensee shall permit Lonza to have the sole conduct of any such steps and proceedings including the right to settle them whether or not Licensee is a party to them. Licensee shall have the right at its own cost and for its own benefit to initiate, prosecute and control the enforcement of the Patent Rights (Lonza) against infringement by a Third Party in the Territory if all of the following conditions are fulfilled (a) the product manufactured through the infringing activity is a competing product to the Product, (b) Lonza has not granted rights to Third Parties which prevent Lonza from granting such a right to enforce to Licensee, and (c) Lonza does not take steps to enforce its rights within &#91;***&#93; days of being requested to do so by Licensee. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Term and Termination</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;This Agreement shall commence on the Effective Date and shall continue in full force and effect in each country of the world unless terminated earlier in accordance with the provisions of this Clause 10 or Clause 13.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;Licensee may terminate this Agreement by giving &#91;***&#93; days&#8217; notice in writing to Lonza.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;Either Lonza or Licensee may terminate this Agreement forthwith by notice in writing to the other upon the occurrence of any of the following events&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3.1&#160;&#160;&#160;&#160;if the other commits a material breach of this Agreement which is irremediable or (in the case of a breach capable of remedy) shall not have been remedied within &#91;***&#93; days of the receipt by the other of a notice identifying the breach and requiring its remedy&#59; or </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3.2&#160;&#160;&#160;&#160;if the other is unable to pay its debts or enters into compulsory or voluntary liquidation (other than for the purpose of effecting a reconstruction or amalgamation in such manner that the company resulting from such reconstruction or amalgamation if a different legal entity shall agree to be bound by and assume the obligations of the relevant Party under this Agreement) or compounds with or convenes a meeting of its creditors or has a receiver or administrator appointed over all or any part of its assets or takes or suffers any similar action in consequence of a debt, or ceases for any reason to carry on business.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4 &#160;&#160;&#160;&#160;Without prejudice to any rights that have accrued under this Agreement or any of its rights or remedies, Lonza may terminate this Agreement immediately by giving written notice to Licensee if&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.1&#160;&#160;&#160;&#160;the Licensee contests the secret or substantial nature of the Licensed Know-How.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.2&#160;&#160;&#160;&#160;there is a change of control of Licensee (within the meaning of section 1124 of the Corporation Tax Act 2010) in circumstances where&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.57pt">&#91;***&#93;&#59; or</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.57pt">&#91;***&#93;&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;If this Agreement is terminated for any reason any and all licences and sublicences granted hereunder shall terminate with effect from the date of termination and Licensee shall destroy (or otherwise procure the destruction of) all System Materials, Transfected Cell Lines, GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Materials and Product and all Confidential Information which is provided by Lonza (including all Know-How, all System Know-How, all GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Know-How and all CDACF System Know-How) forthwith and shall certify such destruction immediately thereafter in writing to Lonza&#59; provided, however, that the Licensee and its Sublicensees shall have the right to sell or otherwise dispose of all Product then on hand, subject to the payment of royalties and the other terms of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;Termination for whatever reason of this Agreement shall not affect the accrued rights of the Parties arising in any way out of this Agreement as at the date of termination. The right to recover damages against the other and all provisions which are expressed to survive this Agreement shall remain in full force and effect.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7&#160;&#160;&#160;&#160;The terms of Clauses 3, 4.5 to 4.9 (subject always to the consequences of termination in Clause 10.5), 5, 6, 7, 8, 10, 11, 12, 14, 15 and 16 shall survive termination of this Agreement for whatever reason. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Assignment</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;Subject to Licensee&#8217;s rights to sublicence in accordance with Clause 4 and subject to Clause 11.2 below, neither Party shall be entitled to assign, transfer, charge or in any way make over the benefit and&#47;or the burden of this Agreement without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;Lonza shall be entitled without the prior written consent of Licensee to assign, transfer, charge, sub-contract, deal with or in any other manner make over the benefit and&#47;or burden of this Agreement&#58; (i) to an Affiliate&#59; (ii) to any joint venture company of which Lonza is the beneficial owner of at least fifty percent (50%) of the issued share capital thereof&#59; (iii) to any company with which Lonza may merge&#59; or (iv) to any company to which Lonza may transfer its assets and undertaking.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;Licensee shall be entitled to assign, transfer, deal with or in any other manner make over the benefit and&#47;or burden of this Agreement without the prior written consent of Lonza but on giving written notice&#58; &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;This Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns provided always that nothing herein shall permit any assignment by either Party except as expressly provided herein.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Governing Law and Dispute Resolution</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;This Agreement shall be governed by and construed in accordance with the laws of England and Wales.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;Any dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration under the London Court of International Arbitration (LCIA) Rules, which Rules are deemed to be incorporated by reference into this Clause, by a panel of three (3) arbitrators appointed in accordance with the said Rules. The seat, or legal place of arbitration shall be London, England and the arbitration shall be conducted in the English language. The arbitrator&#8217;s award shall be final and binding. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Force Majeure</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;Neither Party shall be in breach of this Agreement if there is any total or partial failure of performance by it of its duties and obligations under this Agreement occasioned by any act of God, fire, act of government or state, war, civil commotion, insurrection, embargo, prevention from or hindrance in obtaining any raw materials, energy or other supplies, labour disputes of whatever nature and any other reason beyond the reasonable control of that Party. If that Party is unable to perform its duties and obligations under this Agreement as a direct result of the effect of one of the reasons set out in this Clause 13 such Party shall give written notice to the other of such inability stating the reason in question. The operation of this Agreement shall be suspended during the period (and only during the period) in which the reason continues. Forthwith upon the reason ceasing to exist the Party relying upon it shall give written notice to the other of this fact. If the reason continues for a period of more than &#91;***&#93; days and substantially affects the commercial basis of this Agreement the Party not claiming under this Clause 13 shall have the right to terminate this Agreement by giving &#91;***&#93; days written notice of such termination to the other Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;Illegality</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;If any provision or term of this Agreement or any part thereof shall become or be declared illegal, invalid or unenforceable for any reason whatsoever including but without limitation by reason of the provisions of any legislation or other provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">having the force of law or by reason of any decision of any Court or other body or authority having jurisdiction over the Parties or this Agreement (including the EC Commission or the European Court of Justice, to the extent applicable)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:71.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.46pt">such provision shall, so far as it is illegal, invalid or unenforceable, be given no effect by the Parties and shall be deemed not to be included in this Agreement&#59; </font></div><div style="padding-left:71.45pt;text-align:justify"><font><br></font></div><div style="padding-left:71.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.46pt">the other provisions of this Agreement shall be binding on the Parties as if such provision was not included therein&#59; and</font></div><div style="padding-left:71.45pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1.3&#160;&#160;&#160;&#160;the Parties agree to negotiate in good faith to amend such provision to the extent possible for incorporation herein in such reasonable manner as most closely achieves the intention of the Parties without rendering such provision invalid or unenforceable. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;Miscellaneous</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;This Agreement embodies and sets forth the entire agreement and understanding of the Parties and supersedes all prior oral and written agreements, representations, misrepresentations (where innocently or negligently made), understandings or arrangements relating to the subject matter of this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Understandings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Neither Party shall be entitled to rely on any Understandings which are not expressly set forth in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;This Agreement shall not be amended, modified, varied or supplemented except in writing signed by duly authorised representatives of the Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;No failure or delay on the part of either Party to exercise any right or remedy under this Agreement shall be construed or operated as a waiver thereof nor shall any single or partial exercise of any right or remedy under this Agreement preclude the exercise of any other right or remedy or preclude the further exercise of such right or remedy as the case may be. The rights and remedies provided in this Agreement are cumulative and are not exclusive of any rights or remedies provided by law.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;Except as required by law, the text of any press release or other communication to be published by or in the media whether of a scientific nature or otherwise and concerning the terms of this Agreement (or Lonza&#8217;s System and&#47;or CDACF System) shall require the prior written approval of both Parties. &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;It is agreed and declared that the relationship between the Parties is on a principal-to-principal basis. Nothing contained in this Agreement shall constitute either Party as the legal representative and&#47;or agent of the other Party, nor shall either Party have the right and&#47;or authority to assume, create and&#47;or incur any liability and&#47;or obligation, express and&#47;or implied in the name of or on behalf of the other Party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6&#160;&#160;&#160;&#160;Each of the Parties shall be responsible for its respective legal and other costs incurred in relation to the preparation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7&#160;&#160;&#160;&#160;The Parties do not intend that any term hereof should be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999, or by any other statute or common-law principle, by any person who is not a party to this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.8&#160;&#160;&#160;&#160;This Agreement may be executed in two (2) counterparts and by each Party on a separate counterpart, each of which when executed and delivered shall constitute an original, but both counterparts shall together constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by electronic imaging means (e.g., &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;Notice</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;Any notice or other document to be given under this Agreement shall be in writing and shall be deemed to have been duly given if sent by registered post or by a reputable overnight courier or by email to a Party or delivered in person to a Party at the address set out below for such Party or such other address as the Party may from time to time designate by written notice to the other&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Address of Lonza</font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lonza Sales AG, Muenchensteinerstrasse 38 CH-4002, Basel, Switzerland</font></div><div style="padding-left:70.9pt;text-align:justify"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy to&#58; &#160;&#160;&#160;&#160;Lonza Biologics Plc </font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;228 Bath Road, Slough, Berkshire SL1 4DX, UK</font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;E-mail&#58; &#91;***&#93; </font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the attention of the Head of Legal Services</font></div><div style="padding-left:70.9pt;text-align:justify"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Address of Licensee</font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit 15, Philadelphia, PA 19103 USA  Attn&#58; &#91;***&#93;, SVP, Operations</font></div><div style="padding-left:70.9pt;text-align:justify"><font><br></font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy to&#58; &#160;&#160;&#160;&#160;Context Therapeutics Inc.</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2001 Market Street, Suite 3915, Unit 15 </font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19103 USA</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93; </font></div><div style="padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the attention of the Chief Legal Officer</font></div><div style="padding-left:70.9pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;All such notices and documents shall be in the English language. Any such notice or other document shall be deemed to have been received by the addressee &#91;***&#93; days following the date of dispatch of the notice or other document by post or, where the notice or other document is delivered by hand, at the time of such delivery or if by email simultaneously with the transmission. To prove the giving of a notice or other document it shall be sufficient to show that it was dispatched.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AS WITNESS the hands of the duly authorised representatives of the Parties hereto</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed for and on behalf of&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marc Augustin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LONZA SALES AG</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Head Finance Biologics.................  TITLE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed for and on behalf of&#160;&#160;&#160;&#160;&#47;s&#47; Albert Pereda</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LONZA SALES AG</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Associate General Counsel...........  TITLE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed for and on behalf of&#160;&#160;&#160;&#160;&#47;s&#47; Martin Lehr</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONTEXT THERAPEUTICS INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;CEO...............................................  TITLE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</font></div></div></div><div id="ie8cc55e9f3874c799dee67906b7e7ed4_4"></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 1A</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PATENT RIGHTS (LONZA)</font></div><div style="padding-left:134.7pt;text-align:justify;text-indent:-134.7pt"><font><br></font></div><div style="padding-left:134.7pt;text-align:justify;text-indent:-134.7pt"><font><br></font></div><div style="padding-right:-169.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;***&#93;</font></div><div style="padding-right:-169.2pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-180pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 1B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PATENT RIGHTS (THIRD PARTY)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center;text-indent:-216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center;text-indent:-216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center;text-indent:-216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center;text-indent:-216pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">CDACF BASE POWDERS</font></div><div style="padding-right:-1.17pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 3</font></div><div style="padding-right:-1.17pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">CDACF SUPPLEMENTS, MEDIA AND FEEDS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">CDACF KNOW-HOW</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 5 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">VECTORS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 6 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GS piggyBac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Materials</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX 7 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Approved Affiliates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>cntx-20220930x10qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i512b80004fea4de8825020328a0143bd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXHIBIT&#160;31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Martin Lehr, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Context Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; November 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Martin Lehr</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>cntx-20220930x10qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i50e7220e134f4dd590cd5bd8c60fe109_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXHIBIT&#160;31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Jennifer Minai-Azary, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Context Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; November 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jennifer Minai-Azary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>cntx-20220930x10qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8ccdc455e8434f528474e2113eb472dc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXHIBIT&#160;32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">STATEMENT PURSUANT TO 18 U.S.C. &#167; 1350</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirement set forth in Rule&#160;13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Martin Lehr, Chief Executive Officer (Principal Executive Officer) of Context Therapeutics Inc. (the &#8220;Company&#8221;) and Jennifer Minai-Azary, Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2022, to which this Certification is attached as Exhibit&#160;32.1 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; November 9, 2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer (Principal Executive Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; November 9, 2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer (Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Context Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#8221;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cntx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cntx="http://www.contexttherapeutics.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.contexttherapeutics.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.contexttherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlowsUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000008 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidity" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity">
        <link:definition>0000009 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000012 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePromissoryNotesandOtherDebt" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt">
        <link:definition>0000013 - Disclosure - Convertible Promissory Notes and Other Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStock" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock">
        <link:definition>0000014 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation">
        <link:definition>0000015 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies">
        <link:definition>0000016 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.contexttherapeutics.com/role/SubsequentEvents">
        <link:definition>0000017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000019 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>0000020 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables">
        <link:definition>0000022 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>0000023 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>0000024 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidityNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails">
        <link:definition>0000025 - Disclosure - Risks and Liquidity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>0000027 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
        <link:definition>0000028 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000029 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePromissoryNotesandOtherDebtDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails">
        <link:definition>0000030 - Disclosure - Convertible Promissory Notes and Other Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails">
        <link:definition>0000031 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails">
        <link:definition>0000032 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>0000034 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
        <link:definition>0000035 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofShareBasedActivityDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails">
        <link:definition>0000036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesOperatingLeaseDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails">
        <link:definition>0000037 - Disclosure - Commitment and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesEmployeeBenefitPlansDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails">
        <link:definition>0000038 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesCollaborationAgreementsDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails">
        <link:definition>0000039 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cntx_FairValueAdjustmentOnConvertibleDebt" abstract="false" name="FairValueAdjustmentOnConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_RedeemableCommonStockMember" abstract="true" name="RedeemableCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_IssuedInConnectionWithIPOMember" abstract="true" name="IssuedInConnectionWithIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_IntegralMolecularIncMember" abstract="true" name="IntegralMolecularIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_DeferredOfferingCostIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_PaymentProtectionProgramLoanMember" abstract="true" name="PaymentProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_December2021PrivatePlacementWarrantsMember" abstract="true" name="December2021PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_PatentCostsPolicyPolicyTextBlock" abstract="false" name="PatentCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_December2021PrivatePlacementAgentWarrantsMember" abstract="true" name="December2021PrivatePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp300KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_DebtConversionConvertedInstrumentPricePerShare" abstract="false" name="DebtConversionConvertedInstrumentPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cntx_ContextTherapeuticsLLCMember" abstract="true" name="ContextTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" abstract="true" name="WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_IssuedToPlacementAgentsMember" abstract="true" name="IssuedToPlacementAgentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityOfferingCosts" abstract="false" name="TemporaryEquityOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cntx_IssuedToSeriesAStockholdersMember" abstract="true" name="IssuedToSeriesAStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_RisksAndLiquidityTextBlock" abstract="false" name="RisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_IssuedForServicesMember" abstract="true" name="IssuedForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" abstract="false" name="TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_RisksAndLiquidityAbstract" abstract="true" name="RisksAndLiquidityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cntx_IssuedForProfessionalConsultingServicesMember" abstract="true" name="IssuedForProfessionalConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" abstract="false" name="TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" abstract="false" name="IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityDecreaseDueToConversionToWarrants" abstract="false" name="TemporaryEquityDecreaseDueToConversionToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp100KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_SeniorConvertibleNotesApril2020Member" abstract="true" name="SeniorConvertibleNotesApril2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_SeriesSeedPreferredStockMember" abstract="true" name="SeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cntx_PlacementAgentsWarrantsMember" abstract="true" name="PlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TyligandBioscienceShanghaiLimitedMember" abstract="true" name="TyligandBioscienceShanghaiLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cntx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98917ed3-bb00-4d4e-99fe-580be4d1ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5fe04cf5-a13c-46ff-aa67-aa206e57d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98917ed3-bb00-4d4e-99fe-580be4d1ebce" xlink:to="loc_us-gaap_PreferredStockValue_5fe04cf5-a13c-46ff-aa67-aa206e57d93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c830f86c-ae7b-42f8-98eb-5074cfbdb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98917ed3-bb00-4d4e-99fe-580be4d1ebce" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c830f86c-ae7b-42f8-98eb-5074cfbdb17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d20a06d7-5031-483f-910f-b32d95ddbb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98917ed3-bb00-4d4e-99fe-580be4d1ebce" xlink:to="loc_us-gaap_CommonStockValue_d20a06d7-5031-483f-910f-b32d95ddbb2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab917b13-e8d8-4481-8d5f-2bf2a7a564c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98917ed3-bb00-4d4e-99fe-580be4d1ebce" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab917b13-e8d8-4481-8d5f-2bf2a7a564c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_65a39e75-197e-4eec-8600-4ff4f4e058ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81435152-5a81-4a23-8f7f-1f6d82ea5e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65a39e75-197e-4eec-8600-4ff4f4e058ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81435152-5a81-4a23-8f7f-1f6d82ea5e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1db21b77-03f1-49f0-94b1-2ba95dad8516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65a39e75-197e-4eec-8600-4ff4f4e058ee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1db21b77-03f1-49f0-94b1-2ba95dad8516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e133e723-f6ed-4cd7-b947-094617d9f423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4db2669-7745-46ea-9417-d8e5d0e17a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e133e723-f6ed-4cd7-b947-094617d9f423" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4db2669-7745-46ea-9417-d8e5d0e17a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c49d552a-3b14-485d-8e33-8da3116ff19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c49d552a-3b14-485d-8e33-8da3116ff19e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ac8ed72-382c-408c-878d-8ab9d1fe947b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:to="loc_us-gaap_AssetsCurrent_7ac8ed72-382c-408c-878d-8ab9d1fe947b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed3a8f72-074a-4e92-a192-67aa5c2409cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed3a8f72-074a-4e92-a192-67aa5c2409cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_97fbe34d-f67b-4429-9ec1-5f745b6ab929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_97fbe34d-f67b-4429-9ec1-5f745b6ab929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_906056b1-f43b-4d46-97a1-961ca0c36285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2591d05e-7581-41ff-9d81-c6397e7452f0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_906056b1-f43b-4d46-97a1-961ca0c36285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c73e1be5-918d-47b8-a9d1-156aa056a28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_826a11aa-f593-4e97-b59e-2c5485a5c998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c73e1be5-918d-47b8-a9d1-156aa056a28c" xlink:to="loc_us-gaap_Liabilities_826a11aa-f593-4e97-b59e-2c5485a5c998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28d12a70-692b-426b-a133-189adc557c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c73e1be5-918d-47b8-a9d1-156aa056a28c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28d12a70-692b-426b-a133-189adc557c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_00389f1d-3284-4468-8476-638a345d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c73e1be5-918d-47b8-a9d1-156aa056a28c" xlink:to="loc_us-gaap_StockholdersEquity_00389f1d-3284-4468-8476-638a345d1871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_003f7af8-09d7-40a0-a5ef-747615cfb197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dc52102c-7a70-4f19-9ce0-eafeef6c8949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_003f7af8-09d7-40a0-a5ef-747615cfb197" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dc52102c-7a70-4f19-9ce0-eafeef6c8949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5ca41a81-9218-4c1d-b944-a31415249a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_003f7af8-09d7-40a0-a5ef-747615cfb197" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5ca41a81-9218-4c1d-b944-a31415249a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f36b35e6-6cca-4a20-91aa-68a38d154b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_003f7af8-09d7-40a0-a5ef-747615cfb197" xlink:to="loc_us-gaap_AccountsPayableCurrent_f36b35e6-6cca-4a20-91aa-68a38d154b96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f724d5e-6a23-430b-b4fc-b9ce9718879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_339295b6-5c56-4672-a3e7-223456c9c8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f724d5e-6a23-430b-b4fc-b9ce9718879e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_339295b6-5c56-4672-a3e7-223456c9c8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b7112e76-9f2b-4ddb-9e77-24e4dabc7404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f724d5e-6a23-430b-b4fc-b9ce9718879e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b7112e76-9f2b-4ddb-9e77-24e4dabc7404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_237a2dc2-3afa-4471-b3f1-68b6a62bb79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f724d5e-6a23-430b-b4fc-b9ce9718879e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_237a2dc2-3afa-4471-b3f1-68b6a62bb79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab440da4-a557-47d8-b4ed-6600ece8839a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_03755326-75ed-4440-ad69-d631cf48246b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab440da4-a557-47d8-b4ed-6600ece8839a" xlink:to="loc_us-gaap_OperatingIncomeLoss_03755326-75ed-4440-ad69-d631cf48246b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_07f17ed4-8e1c-4fa4-bb0a-419d4430a60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab440da4-a557-47d8-b4ed-6600ece8839a" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_07f17ed4-8e1c-4fa4-bb0a-419d4430a60e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_53b512ea-0b62-40ad-a4ad-8e12556dcc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab440da4-a557-47d8-b4ed-6600ece8839a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_53b512ea-0b62-40ad-a4ad-8e12556dcc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_f36b10b9-f151-453c-9c5e-072e879c18fb" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ab440da4-a557-47d8-b4ed-6600ece8839a" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_f36b10b9-f151-453c-9c5e-072e879c18fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1adf8a1-b753-45f5-9106-393ddd38195f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_53587719-90b5-4d85-a276-4ee560d530b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1adf8a1-b753-45f5-9106-393ddd38195f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_53587719-90b5-4d85-a276-4ee560d530b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_fb0f0490-dcfd-4788-8d94-237632e39dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1adf8a1-b753-45f5-9106-393ddd38195f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_fb0f0490-dcfd-4788-8d94-237632e39dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfaee601-9bac-4698-89d0-ff3221e3eca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_66f7a103-cbd3-4d20-8c42-e0c64190c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfaee601-9bac-4698-89d0-ff3221e3eca3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_66f7a103-cbd3-4d20-8c42-e0c64190c07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_dbfa3e28-35fd-47f8-8850-c8f4f3608302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfaee601-9bac-4698-89d0-ff3221e3eca3" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_dbfa3e28-35fd-47f8-8850-c8f4f3608302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_211d45aa-4c3d-459f-9905-cd5bff390ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_211d45aa-4c3d-459f-9905-cd5bff390ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98d391db-98ca-4b59-9c94-2bbc3a7d44f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_98d391db-98ca-4b59-9c94-2bbc3a7d44f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b552023-a1f0-4beb-afc1-8f2fe340ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_NetIncomeLoss_9b552023-a1f0-4beb-afc1-8f2fe340ee9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_fc3cce5c-a681-4954-9cfe-5df105c14c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_fc3cce5c-a681-4954-9cfe-5df105c14c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95bfca2c-9a53-4fa1-a178-c271d69dfcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_95bfca2c-9a53-4fa1-a178-c271d69dfcb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_63746457-ec69-4379-8f9f-f5d06502a4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_63746457-ec69-4379-8f9f-f5d06502a4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_43b0878e-fd99-4b49-b46f-1641dafc2560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_43b0878e-fd99-4b49-b46f-1641dafc2560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c82bbaae-d7f2-4ce0-943f-b61efe3d5f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c82bbaae-d7f2-4ce0-943f-b61efe3d5f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_5afc1d63-cf59-4639-bd0d-2bbf2ed27e93" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_5afc1d63-cf59-4639-bd0d-2bbf2ed27e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_440d1c42-293e-4013-aa23-883301615028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_440d1c42-293e-4013-aa23-883301615028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_90a79c68-26c4-442b-b106-241425f1cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_90a79c68-26c4-442b-b106-241425f1cc6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c9cdbd5-3361-4743-a551-d49315c611c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_ShareBasedCompensation_6c9cdbd5-3361-4743-a551-d49315c611c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3319b9cb-8339-4de3-ab39-b28621872661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_PaidInKindInterest_3319b9cb-8339-4de3-ab39-b28621872661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_693558ea-f312-430d-835b-0cb0c840045e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57e73f0-d938-4f09-bb6d-4043476d3a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_693558ea-f312-430d-835b-0cb0c840045e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51acf080-8db0-4edc-8ace-46a95121f2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_207cfb65-2826-4397-b1d5-41cc7d463623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51acf080-8db0-4edc-8ace-46a95121f2c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_207cfb65-2826-4397-b1d5-41cc7d463623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7de484-a907-47b6-9ebe-94240a049687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51acf080-8db0-4edc-8ace-46a95121f2c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7de484-a907-47b6-9ebe-94240a049687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0da058fb-ebba-40bf-868c-7c2e132ddc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51acf080-8db0-4edc-8ace-46a95121f2c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0da058fb-ebba-40bf-868c-7c2e132ddc80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8bdba037-a346-4ae7-99c9-b884bf63ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_eda0df01-8778-46e6-8123-00b7a5ef6c56" xlink:href="cntx-20220930.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bdba037-a346-4ae7-99c9-b884bf63ee00" xlink:to="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_eda0df01-8778-46e6-8123-00b7a5ef6c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3d3c67e0-c20d-4f04-8596-3b9085d15164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bdba037-a346-4ae7-99c9-b884bf63ee00" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3d3c67e0-c20d-4f04-8596-3b9085d15164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef8dcb91-8312-4841-9fd9-f862f68559ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bdba037-a346-4ae7-99c9-b884bf63ee00" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef8dcb91-8312-4841-9fd9-f862f68559ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_71b51c7f-1f37-48da-9598-60d1f9a81e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8bdba037-a346-4ae7-99c9-b884bf63ee00" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_71b51c7f-1f37-48da-9598-60d1f9a81e39" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cntx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended" id="i23c6006bec3845ce9e4bcf828fb5398d_CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_35617604-f9ae-43d0-aaa4-24a7d9d7e181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_35617604-f9ae-43d0-aaa4-24a7d9d7e181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c971d3bd-4e11-4a88-af69-a802bbd3b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c971d3bd-4e11-4a88-af69-a802bbd3b146" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0532de1-e732-4982-b572-757fdd650a94" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0532de1-e732-4982-b572-757fdd650a94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4c7e53a3-f7c5-48a6-85ee-e626ba801bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4c7e53a3-f7c5-48a6-85ee-e626ba801bc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4ed4a172-a85b-481b-9265-3cdd28c2b22d" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4ed4a172-a85b-481b-9265-3cdd28c2b22d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_480f919b-a077-4567-9e37-6c3ec569c996" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_480f919b-a077-4567-9e37-6c3ec569c996" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_42f46a03-9910-4cf5-94fa-331a3568a918" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_42f46a03-9910-4cf5-94fa-331a3568a918" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_24fee616-000a-48c7-8b75-1179a057e589" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_24fee616-000a-48c7-8b75-1179a057e589" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_dfe6e879-13c1-4576-a74d-9fd4ab399741" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_dfe6e879-13c1-4576-a74d-9fd4ab399741" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_eff27371-ef64-4bad-89c4-0f6a618f2c73" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_eff27371-ef64-4bad-89c4-0f6a618f2c73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_015f1321-9112-48d7-bc84-dac5330e3bab" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_015f1321-9112-48d7-bc84-dac5330e3bab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_96cb7b58-641f-450d-9e00-ffe576436341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7bd62c74-b33f-4709-bd72-5438e7525446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_de720460-5f73-4cc5-81f0-23158ee3452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_SharesOutstanding_de720460-5f73-4cc5-81f0-23158ee3452d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_063a8b6b-e16e-48ee-a6bc-053c6e9859a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockholdersEquity_063a8b6b-e16e-48ee-a6bc-053c6e9859a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_25b25ca5-90f3-4bf6-bf59-ba8a03ecd3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_25b25ca5-90f3-4bf6-bf59-ba8a03ecd3d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1eab2ee1-9291-4114-9ea8-1e78943cf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1eab2ee1-9291-4114-9ea8-1e78943cf8c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_9da41cb8-d1f1-4e90-8a2d-da35c90b640e" xlink:href="cntx-20220930.xsd#cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_9da41cb8-d1f1-4e90-8a2d-da35c90b640e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_6e00e296-6975-4d9f-9f43-0b17ac7425ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_6e00e296-6975-4d9f-9f43-0b17ac7425ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_bcce45d7-4a27-4661-9410-5d726ac19f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_bcce45d7-4a27-4661-9410-5d726ac19f34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae16e4f8-a847-4498-bde3-1241af28641a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae16e4f8-a847-4498-bde3-1241af28641a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_28b1b1a7-c96f-4bc9-9117-fc2542d45364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_28b1b1a7-c96f-4bc9-9117-fc2542d45364" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdb5195e-46d2-4987-8fe5-416ae3a0013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_NetIncomeLoss_fdb5195e-46d2-4987-8fe5-416ae3a0013b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_200d4315-3da7-4d6c-8c49-59cffdab73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_557dcb3b-1d7e-4c76-8cd7-fb84dee30256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:to="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f917e65a-988d-4277-b40d-d59c04e7c1c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:to="loc_us-gaap_EquityComponentDomain_f917e65a-988d-4277-b40d-d59c04e7c1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:to="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_905ffa0e-7d90-48ee-92c1-bde5f7d2b04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_CommonStockMember_905ffa0e-7d90-48ee-92c1-bde5f7d2b04f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2c937b04-1cc0-468e-ae01-26bca1a5d291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2c937b04-1cc0-468e-ae01-26bca1a5d291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_801a574e-29f0-4c30-9736-ab91ebbdc357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_RetainedEarningsMember_801a574e-29f0-4c30-9736-ab91ebbdc357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e72a6a9-70a8-458d-bddb-7865d2291f05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:to="loc_us-gaap_ClassOfStockDomain_1e72a6a9-70a8-458d-bddb-7865d2291f05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:to="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ae1933bd-d304-4f94-903d-f5d330db2fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ae1933bd-d304-4f94-903d-f5d330db2fe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_6653ec60-eea6-4aa9-9374-fcc536489e28" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_6653ec60-eea6-4aa9-9374-fcc536489e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_9e1ef17f-3ede-4bb7-9751-49244bcde7f3" xlink:href="cntx-20220930.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_cntx_RedeemableCommonStockMember_9e1ef17f-3ede-4bb7-9751-49244bcde7f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_03c6d4ac-428f-452c-a2b9-e883edb76360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_03c6d4ac-428f-452c-a2b9-e883edb76360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_55b63890-73b2-497d-aae4-dd473f942343" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_55b63890-73b2-497d-aae4-dd473f942343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_05449c54-603f-4d1d-982d-f2dbcee45783" xlink:href="cntx-20220930.xsd#cntx_IssuedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:to="loc_cntx_IssuedForServicesMember_05449c54-603f-4d1d-982d-f2dbcee45783" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended" id="ic74e3aa452ee4cf9a04c8a3b06fbc26f_CondensedConsolidatedStatementofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_709ed675-08fa-42eb-9cbf-1a354e44675e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_NetIncomeLoss_709ed675-08fa-42eb-9cbf-1a354e44675e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9836b159-520b-422c-beba-baa43cc3fcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9836b159-520b-422c-beba-baa43cc3fcef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b31ccd8d-3f15-44e1-9f52-6b75cc570378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b31ccd8d-3f15-44e1-9f52-6b75cc570378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b32ddfc8-e55d-413f-8e7b-1f4d618c258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_ShareBasedCompensation_b32ddfc8-e55d-413f-8e7b-1f4d618c258f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b43c4f27-6448-4a21-8351-0a2bb6c396b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b43c4f27-6448-4a21-8351-0a2bb6c396b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_de99bea5-b860-4eff-ba64-009db626659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_PaidInKindInterest_de99bea5-b860-4eff-ba64-009db626659d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_84d45a92-620b-40a3-a9f3-aecccea2e6e0" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_84d45a92-620b-40a3-a9f3-aecccea2e6e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27549ff0-3242-4607-bff3-5355eec9a06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27549ff0-3242-4607-bff3-5355eec9a06c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8b01d79f-c05b-4432-ba06-7802b3ef4aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8b01d79f-c05b-4432-ba06-7802b3ef4aa7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78f665bb-4b60-4a07-bfc6-23e657a9f3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78f665bb-4b60-4a07-bfc6-23e657a9f3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97bc0e3f-0674-4422-b399-94ab5d337530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97bc0e3f-0674-4422-b399-94ab5d337530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3989eb08-f2ad-4297-b52f-a5f435a1c1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3989eb08-f2ad-4297-b52f-a5f435a1c1f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_686329a8-562b-449f-ae6a-26c479f6019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_686329a8-562b-449f-ae6a-26c479f6019a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f50e58ea-b984-4443-ab68-7b42271531f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f50e58ea-b984-4443-ab68-7b42271531f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0574e8d5-3d37-47db-8934-1d6eee86d492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0574e8d5-3d37-47db-8934-1d6eee86d492" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_77475e87-6870-479f-b449-31e7455294a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_77475e87-6870-479f-b449-31e7455294a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116f9f63-f646-4ac0-8227-18afd7ff699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116f9f63-f646-4ac0-8227-18afd7ff699b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_819ba161-89ef-4ddc-a09a-b826e88c292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_819ba161-89ef-4ddc-a09a-b826e88c292d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5eda067-4ea0-457b-9b63-463e56d21a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5eda067-4ea0-457b-9b63-463e56d21a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_b2a5cf77-4283-48bb-888e-6cc1217b2bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_b2a5cf77-4283-48bb-888e-6cc1217b2bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_902b1365-34d4-4af7-bc71-958d2ac7de74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_902b1365-34d4-4af7-bc71-958d2ac7de74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ceaec7b-a971-463a-bfda-b925d7508245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ceaec7b-a971-463a-bfda-b925d7508245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6268360-3b2f-4220-98f1-05529a1645c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6268360-3b2f-4220-98f1-05529a1645c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5eeef4bc-32ca-4119-b160-6e714d809c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3ec518b6-0278-46cd-88dc-f05f37a37de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3ec518b6-0278-46cd-88dc-f05f37a37de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_73a7d071-8d1b-4071-8fd4-a83bd80f9996" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_WarrantsIssued_73a7d071-8d1b-4071-8fd4-a83bd80f9996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_023276a6-3782-4914-81fd-6fb50aacef15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_StockIssued1_023276a6-3782-4914-81fd-6fb50aacef15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_8e17492a-f888-415b-a9ce-25edfcb93fe2" xlink:href="cntx-20220930.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_8e17492a-f888-415b-a9ce-25edfcb93fe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_7ff2c344-920f-45ad-b149-12e7794ad457" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d996ddd9-b5e2-4d71-a550-364ae2ec11f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d996ddd9-b5e2-4d71-a550-364ae2ec11f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_68870cb0-8fb2-4899-b00b-f5a30ba8c2a0" xlink:href="cntx-20220930.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_68870cb0-8fb2-4899-b00b-f5a30ba8c2a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cd11d4d3-2313-4935-afc7-4d56a0508241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cd11d4d3-2313-4935-afc7-4d56a0508241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_e1fc4e5f-a1ed-4693-8016-b10128f94707" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_e1fc4e5f-a1ed-4693-8016-b10128f94707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_a1f4b838-56d4-4baf-a47f-27f9fec7befc" xlink:href="cntx-20220930.xsd#cntx_IssuedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:to="loc_cntx_IssuedForServicesMember_a1f4b838-56d4-4baf-a47f-27f9fec7befc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82668788-9090-4b59-b67a-845e9dcbfc47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82668788-9090-4b59-b67a-845e9dcbfc47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a354290c-5942-4189-8603-9758dd5a94c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:to="loc_us-gaap_PrivatePlacementMember_a354290c-5942-4189-8603-9758dd5a94c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f4d35347-1b01-4c29-bb7b-3f21db3caaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:to="loc_us-gaap_IPOMember_f4d35347-1b01-4c29-bb7b-3f21db3caaed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended" id="iaea5108cf16d4bcda0f231126cb29f22_OrganizationandDescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8862e6d1-4fea-47ca-a957-9faeb251314f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8862e6d1-4fea-47ca-a957-9faeb251314f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:to="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:to="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_301c94b1-2c97-4e65-aa4b-80b4f6a4988c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:to="loc_srt_OwnershipDomain_301c94b1-2c97-4e65-aa4b-80b4f6a4988c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:to="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember_87620e24-77b1-4bec-a233-9ea92c4c357d" xlink:href="cntx-20220930.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:to="loc_cntx_ContextTherapeuticsLLCMember_87620e24-77b1-4bec-a233-9ea92c4c357d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#RisksandLiquidityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="extended" id="i01ad23617847407a9e4a327707094cda_RisksandLiquidityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f1b8c6c-f841-4484-a172-6df11d008b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f1b8c6c-f841-4484-a172-6df11d008b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bdab9a9-a195-4321-9daf-038fad7e71e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bdab9a9-a195-4321-9daf-038fad7e71e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_961b933c-d723-45a3-b85e-6c9897882099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_961b933c-d723-45a3-b85e-6c9897882099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1d29c954-0619-4738-98bc-0e2a947dc4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1d29c954-0619-4738-98bc-0e2a947dc4f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf1ef1e7-1a17-4583-b3b9-311106161a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf1ef1e7-1a17-4583-b3b9-311106161a56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fc09dd7c-0959-4a5d-b925-d76504f4996d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fc09dd7c-0959-4a5d-b925-d76504f4996d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e5f1a08c-2b85-404b-9350-661971ed057c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e5f1a08c-2b85-404b-9350-661971ed057c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b4424bcf-bb89-4afc-8add-51b66eeb48c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b4424bcf-bb89-4afc-8add-51b66eeb48c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f8e325a-c9e0-4052-9dd1-b585591d726d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f8e325a-c9e0-4052-9dd1-b585591d726d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_bae8520f-85e1-41d2-9e6a-6d34a23218a0" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_bae8520f-85e1-41d2-9e6a-6d34a23218a0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8dac2d55-3818-4cdb-bc87-4cf817ef662c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8dac2d55-3818-4cdb-bc87-4cf817ef662c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9c6398db-4cf9-4f92-9525-557803977836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9c6398db-4cf9-4f92-9525-557803977836" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9db0b148-fea2-4240-880a-e1cfb50370a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9db0b148-fea2-4240-880a-e1cfb50370a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ad201aa-c1e9-4041-bed3-d10af1529ba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ad201aa-c1e9-4041-bed3-d10af1529ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c306e7c4-46e6-44fe-817d-9e92cd8d0123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:to="loc_us-gaap_IPOMember_c306e7c4-46e6-44fe-817d-9e92cd8d0123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_45d59e78-9156-442f-9f3c-64771f01325b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:to="loc_us-gaap_PrivatePlacementMember_45d59e78-9156-442f-9f3c-64771f01325b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_095ed0c7-45cf-4e07-9350-7851cb94eeaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_095ed0c7-45cf-4e07-9350-7851cb94eeaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember_dec733d5-cdc8-4aa7-a2cb-f1be69577517" xlink:href="cntx-20220930.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_PlacementAgentsWarrantsMember_dec733d5-cdc8-4aa7-a2cb-f1be69577517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_5dd7f898-7362-4ad3-83f0-08e2047f9966" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_5dd7f898-7362-4ad3-83f0-08e2047f9966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_ad022c90-2ffe-4f60-b38a-ab5b491a469e" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_ad022c90-2ffe-4f60-b38a-ab5b491a469e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7a5573c3-8d93-4ff6-9912-6f3a3d22047d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:to="loc_us-gaap_ClassOfStockDomain_7a5573c3-8d93-4ff6-9912-6f3a3d22047d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:to="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7779e352-a914-4984-81a7-ef97f9b0e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7779e352-a914-4984-81a7-ef97f9b0e3c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i4cb4be76cb2b412693814fb5e28137c1_BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_610629ff-3f71-4503-bfb7-2354f37ca3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_610629ff-3f71-4503-bfb7-2354f37ca3ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b9e91c5d-9adc-4c74-80c3-baf4ca026220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b9e91c5d-9adc-4c74-80c3-baf4ca026220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_ce702f2e-7508-43d1-9f77-3abf05a5afa5" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_ce702f2e-7508-43d1-9f77-3abf05a5afa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c203919d-cfc0-40b1-9a54-e1a70f429026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c203919d-cfc0-40b1-9a54-e1a70f429026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_87c4893d-a5d6-4178-922b-f0acba4bcedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_87c4893d-a5d6-4178-922b-f0acba4bcedf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a88d540c-cdb5-423b-8915-35daa38714ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a88d540c-cdb5-423b-8915-35daa38714ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_14b45181-6e72-4a9b-81d4-e3d2bf98546b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_WarrantMember_14b45181-6e72-4a9b-81d4-e3d2bf98546b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended" id="ic656627982ca4ba28de7292cb1a95ca9_FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3331dc79-3a5a-449d-80f4-683f94804bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3331dc79-3a5a-449d-80f4-683f94804bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_79f032bc-1de1-4e75-8418-62bb15cf6ae9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_79f032bc-1de1-4e75-8418-62bb15cf6ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e57fbff4-1460-4e42-ab73-7d313f2745f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e57fbff4-1460-4e42-ab73-7d313f2745f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1a820ff7-e97f-414a-b86f-3870eab6c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1a820ff7-e97f-414a-b86f-3870eab6c27b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8432da7a-6c03-4eb4-b82a-c76d0a852016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8432da7a-6c03-4eb4-b82a-c76d0a852016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc0a6b22-2425-4de1-a4f3-3f23eef7c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc0a6b22-2425-4de1-a4f3-3f23eef7c54d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2d78d57-aac4-4aea-a91b-2bfc1e669627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2d78d57-aac4-4aea-a91b-2bfc1e669627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_59b983f3-44d6-4b48-98cc-0a78664a8c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_59b983f3-44d6-4b48-98cc-0a78664a8c2a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePromissoryNotesandOtherDebtDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails" xlink:type="extended" id="iccd9b0cff4c24d67934a5a558c74a632_ConvertiblePromissoryNotesandOtherDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81d36f95-01cb-4156-b50a-0117fd90459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81d36f95-01cb-4156-b50a-0117fd90459d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e4d5e84b-67d9-4fcf-a6d1-bce77eb35ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_LongTermDebtFairValue_e4d5e84b-67d9-4fcf-a6d1-bce77eb35ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_94edba72-b269-4959-a47c-1778ca513b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_94edba72-b269-4959-a47c-1778ca513b4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_028425c1-cec3-40ad-8dcf-fdbfeec4443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_InterestExpense_028425c1-cec3-40ad-8dcf-fdbfeec4443e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_2425a0e6-615d-4392-be59-ae6361bdc9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_2425a0e6-615d-4392-be59-ae6361bdc9d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3d5bae5a-d9d5-4ced-a23c-25db3b4ffa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3d5bae5a-d9d5-4ced-a23c-25db3b4ffa3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_074e3952-660e-4f8c-a7c0-b27a8e3bc209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentTerm_074e3952-660e-4f8c-a7c0-b27a8e3bc209" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3f4b0e0-9f4d-4d15-ac6c-829bfacba205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3f4b0e0-9f4d-4d15-ac6c-829bfacba205" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d05a40ae-1c81-4e86-a023-68e5c774f0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d05a40ae-1c81-4e86-a023-68e5c774f0f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_83c553e9-d673-4743-b863-0f6250fdda02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_83c553e9-d673-4743-b863-0f6250fdda02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d5d4aa90-a663-4faf-ad8b-4aa4e5237919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d5d4aa90-a663-4faf-ad8b-4aa4e5237919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember_2448d40f-9db2-4eb6-a08d-756eeb77b0b3" xlink:href="cntx-20220930.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:to="loc_cntx_PaymentProtectionProgramLoanMember_2448d40f-9db2-4eb6-a08d-756eeb77b0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2074b96a-a00e-4c28-b0df-a4ee2dbbca86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2074b96a-a00e-4c28-b0df-a4ee2dbbca86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_3f292612-ec74-40d9-bebf-86a096c7ce2a" xlink:href="cntx-20220930.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_3f292612-ec74-40d9-bebf-86a096c7ce2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_19de576d-4192-4a7b-a3e3-6de3663c1738_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:to="loc_us-gaap_ClassOfStockDomain_19de576d-4192-4a7b-a3e3-6de3663c1738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:to="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f19eec47-9646-4dcb-84b2-1fdb4fc1a1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f19eec47-9646-4dcb-84b2-1fdb4fc1a1d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_058d4ace-8318-47c2-b968-ee787ac56acb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:to="loc_us-gaap_RelatedPartyDomain_058d4ace-8318-47c2-b968-ee787ac56acb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:to="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b76f5fca-4beb-433c-9ccd-fbf03f065940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:to="loc_srt_AffiliatedEntityMember_b76f5fca-4beb-433c-9ccd-fbf03f065940" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="extended" id="ibd1d93128b6e40f2b1f19973cb234829_ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7d37faaf-5397-4a92-9fde-1575396c1804" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7d37faaf-5397-4a92-9fde-1575396c1804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_abdea9b1-5433-4e3d-8e8f-121c04955542" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_abdea9b1-5433-4e3d-8e8f-121c04955542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e98fc7fb-6d2c-43d9-90c5-b7ff53b828a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e98fc7fb-6d2c-43d9-90c5-b7ff53b828a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_186a255d-aacc-4cf1-885c-de44b5bd0345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_186a255d-aacc-4cf1-885c-de44b5bd0345" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c1e8ee2f-1bc9-4e80-af07-37e431cb830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c1e8ee2f-1bc9-4e80-af07-37e431cb830f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_abecb514-1c93-45c7-a46c-4f507c3c3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_abecb514-1c93-45c7-a46c-4f507c3c3deb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dda4554f-6f30-4a5c-87a2-6fb1072e82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dda4554f-6f30-4a5c-87a2-6fb1072e82cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_d5989330-62b9-4d7c-b16a-d10cb7c854da" xlink:href="cntx-20220930.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_d5989330-62b9-4d7c-b16a-d10cb7c854da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3bc9f291-e6bc-4cd7-ac63-c0d4c30ef464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3bc9f291-e6bc-4cd7-ac63-c0d4c30ef464" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406cb32a-9e7d-43b5-85dc-8a04ebafd289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406cb32a-9e7d-43b5-85dc-8a04ebafd289" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dee8f66f-bb48-4ef6-b42d-5ecf448ff942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dee8f66f-bb48-4ef6-b42d-5ecf448ff942" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_612db7a9-ef08-4a08-943f-3928f79a9dfb" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_612db7a9-ef08-4a08-943f-3928f79a9dfb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fb688cb5-e164-4b35-9633-a71e164dcb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fb688cb5-e164-4b35-9633-a71e164dcb36" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abdffff2-1fd7-4e61-81da-438cd55648f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abdffff2-1fd7-4e61-81da-438cd55648f1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bd8db703-a49c-45be-89ed-72a2ba3228db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bd8db703-a49c-45be-89ed-72a2ba3228db" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ec0c4b2e-9eff-4c2f-ba05-3517d034030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ec0c4b2e-9eff-4c2f-ba05-3517d034030d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fea01e41-d461-4cce-a6a4-f3260054dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fea01e41-d461-4cce-a6a4-f3260054dbc8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bbdb066f-4626-4887-ba5f-049e7d4f1f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bbdb066f-4626-4887-ba5f-049e7d4f1f27" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:to="loc_us-gaap_ClassOfStockDomain_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:to="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b90f8f39-76a9-4115-86d1-d08550532c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b90f8f39-76a9-4115-86d1-d08550532c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_f6c8b50d-f0b3-4a92-b584-a162f4660335" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_f6c8b50d-f0b3-4a92-b584-a162f4660335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_521cd744-9a89-43cf-8e0c-8fbbc968b859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_us-gaap_CommonStockMember_521cd744-9a89-43cf-8e0c-8fbbc968b859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_a287fdc9-2eaa-4bb8-9350-06ce203efb8a" xlink:href="cntx-20220930.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_cntx_RedeemableCommonStockMember_a287fdc9-2eaa-4bb8-9350-06ce203efb8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca109273-aa24-4ed2-9946-12b695b51d78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca109273-aa24-4ed2-9946-12b695b51d78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_f4845e9e-8da3-4257-9513-c8545902e38a" xlink:href="cntx-20220930.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_f4845e9e-8da3-4257-9513-c8545902e38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_884f20ff-ba06-4dbf-87a7-7136d8f92eda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_884f20ff-ba06-4dbf-87a7-7136d8f92eda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c505fb9c-b520-4bde-a731-6cbc0a6128f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c505fb9c-b520-4bde-a731-6cbc0a6128f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d9ac8f1a-67b2-4830-a58e-2274d859a98e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d9ac8f1a-67b2-4830-a58e-2274d859a98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33944e53-3366-4102-a885-03e8007f5503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33944e53-3366-4102-a885-03e8007f5503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_69d10bc5-8029-4c22-8f4d-8b86ac55a304_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_69d10bc5-8029-4c22-8f4d-8b86ac55a304_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_44d3181c-d870-4a0e-8d71-757f4ecfd416" xlink:href="cntx-20220930.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_44d3181c-d870-4a0e-8d71-757f4ecfd416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember_c6651c23-2758-4dbe-ad7b-ba76de7c12e2" xlink:href="cntx-20220930.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedToSeriesAStockholdersMember_c6651c23-2758-4dbe-ad7b-ba76de7c12e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_939f1516-4eb0-45c2-bf74-fc5f6fce557a" xlink:href="cntx-20220930.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_939f1516-4eb0-45c2-bf74-fc5f6fce557a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_5f8dde41-6aa8-483e-8b79-ec3ebe6acdc9" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_5f8dde41-6aa8-483e-8b79-ec3ebe6acdc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_a7b7acae-33ec-4606-bbf6-ee7885d79b8f" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_a7b7acae-33ec-4606-bbf6-ee7885d79b8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_03f4a759-e673-472d-98cc-dd1b4b771cd6" xlink:href="cntx-20220930.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_03f4a759-e673-472d-98cc-dd1b4b771cd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_53f9eaaa-862a-4662-8084-eb4f0a94efa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:to="loc_us-gaap_IPOMember_53f9eaaa-862a-4662-8084-eb4f0a94efa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0bd27d47-54ed-455c-8440-d86c4d5f3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:to="loc_us-gaap_PrivatePlacementMember_0bd27d47-54ed-455c-8440-d86c4d5f3e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_802067be-1dbe-4e58-a67f-929035b8c97f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:to="loc_us-gaap_EquityComponentDomain_802067be-1dbe-4e58-a67f-929035b8c97f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:to="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_92f2e5af-c8a8-4930-8eac-ae3bf9d175fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:to="loc_us-gaap_CommonStockMember_92f2e5af-c8a8-4930-8eac-ae3bf9d175fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="extended" id="i4d2a2d28e0ba4b01a202a12b92eebb35_ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb0ed11a-6055-4075-9bf5-01f7b2bbddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb0ed11a-6055-4075-9bf5-01f7b2bbddb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_69aa8de0-656f-4d6b-be97-adcffaabcc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_69aa8de0-656f-4d6b-be97-adcffaabcc4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_de6d48b2-7b9e-400e-9301-33e1faf505e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_de6d48b2-7b9e-400e-9301-33e1faf505e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_9dbd5b96-6eb6-4cf8-90a4-3499b0906253" xlink:href="cntx-20220930.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_9dbd5b96-6eb6-4cf8-90a4-3499b0906253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_bbf44536-3e26-4682-8de8-e3b7abb5dff6" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_bbf44536-3e26-4682-8de8-e3b7abb5dff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_412f0918-715f-41a8-af87-598619422c69" xlink:href="cntx-20220930.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_412f0918-715f-41a8-af87-598619422c69" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i7e89bbcb9e15441493964edc3ead907f_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e69d0358-d4b5-42bd-824b-25c5448a33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e69d0358-d4b5-42bd-824b-25c5448a33ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_6f8d727b-4c5f-4e7f-89ee-349a165df546" xlink:href="cntx-20220930.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_6f8d727b-4c5f-4e7f-89ee-349a165df546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_82e4ce58-7a06-4a69-b036-935a34553a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_82e4ce58-7a06-4a69-b036-935a34553a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eefffadb-8ec6-4f98-9adc-54a468b7d04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eefffadb-8ec6-4f98-9adc-54a468b7d04c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b261662-6d72-4b34-a480-7534297fa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b261662-6d72-4b34-a480-7534297fa2cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c28ace78-e455-4ae5-a195-2b5c6dfe84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c28ace78-e455-4ae5-a195-2b5c6dfe84ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b3053a4-ebfb-4cff-99d7-5df49cd385b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b3053a4-ebfb-4cff-99d7-5df49cd385b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c33ed3a9-f9a1-4638-a8cc-b85aaa7fcef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c33ed3a9-f9a1-4638-a8cc-b85aaa7fcef9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc97dbc2-1d43-45b4-8204-66fe93ef8375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc97dbc2-1d43-45b4-8204-66fe93ef8375" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f341a3fe-f188-4968-956a-c13ac97ee18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f341a3fe-f188-4968-956a-c13ac97ee18d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:to="loc_us-gaap_ClassOfStockDomain_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:to="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e634eeb3-af78-40ca-93e7-8db772d57f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_CommonClassAMember_e634eeb3-af78-40ca-93e7-8db772d57f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_12b3dfd8-9772-4db7-a78b-18fc629d7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_12b3dfd8-9772-4db7-a78b-18fc629d7a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f4f9ae0c-a27b-4d8b-97cd-956425b7654b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f4f9ae0c-a27b-4d8b-97cd-956425b7654b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_602f60ba-9763-4455-bcd2-a66b44ecfeb8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:to="loc_srt_RangeMember_602f60ba-9763-4455-bcd2-a66b44ecfeb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:to="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d2d70c5-9e8c-4f12-bb5d-3ddac46785eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:to="loc_srt_MinimumMember_0d2d70c5-9e8c-4f12-bb5d-3ddac46785eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76fd6738-a210-4003-8f37-84b157babe3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:to="loc_srt_MaximumMember_76fd6738-a210-4003-8f37-84b157babe3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17f2e3e5-3987-4035-9506-4689f10204f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17f2e3e5-3987-4035-9506-4689f10204f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906fbdbe-7e87-4a47-9752-78a68a280cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906fbdbe-7e87-4a47-9752-78a68a280cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d1e61b9-6bef-4080-8e34-1e23950ca038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d1e61b9-6bef-4080-8e34-1e23950ca038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba31c3c-e84f-4346-9f93-c7943041459b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba31c3c-e84f-4346-9f93-c7943041459b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a0694163-34f7-4d69-8b72-a1c60dceea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a0694163-34f7-4d69-8b72-a1c60dceea21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i171f68100b8641cd8684a408d8d0fafe_SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3093573d-2d2d-4046-98fe-c9f48a63b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3093573d-2d2d-4046-98fe-c9f48a63b7b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d0937af1-2f04-49d2-b48d-fb68aff490cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d0937af1-2f04-49d2-b48d-fb68aff490cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ae284e59-6a4d-439d-b1f1-72b69a96963e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ae284e59-6a4d-439d-b1f1-72b69a96963e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_254bbd74-21ef-4238-a492-e32466625570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_254bbd74-21ef-4238-a492-e32466625570" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended" id="ie98f07f11a4445e08a5d936149011bbe_ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9ad1ce90-151e-4eb5-b271-a67daa73536d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9ad1ce90-151e-4eb5-b271-a67daa73536d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b9c6954-b29a-46bd-b8c2-20f266686fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b9c6954-b29a-46bd-b8c2-20f266686fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e5c050e0-7fe4-48a9-9c3d-77c448d9b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e5c050e0-7fe4-48a9-9c3d-77c448d9b4df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e384c3f-795f-4f00-8360-8a865dd9e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e384c3f-795f-4f00-8360-8a865dd9e5b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:to="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9f98e0b-5cc0-458b-98b2-c649a683a3d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9f98e0b-5cc0-458b-98b2-c649a683a3d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93fecb96-e988-4f0d-b0b1-0ee715cc77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93fecb96-e988-4f0d-b0b1-0ee715cc77d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#CommitmentandContingenciesCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="extended" id="i68456538b6de49eda6d9fb5bbe110e44_CommitmentandContingenciesCollaborationAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7017fed4-0514-4584-be5a-b03d1d5aad63" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7017fed4-0514-4584-be5a-b03d1d5aad63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_dbf50be5-d2ec-45ac-b2e6-49b781227991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_dbf50be5-d2ec-45ac-b2e6-49b781227991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ddab1843-6e87-4d82-bd97-a206d4eba086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ddab1843-6e87-4d82-bd97-a206d4eba086" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_a84da7af-fd76-43ce-ad32-1957c5554771" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_a84da7af-fd76-43ce-ad32-1957c5554771" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_c36ae485-3f1f-49b4-bb6f-11c500472223" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_c36ae485-3f1f-49b4-bb6f-11c500472223" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_76db4e27-d370-4653-a4cb-608a32d41dd7" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_76db4e27-d370-4653-a4cb-608a32d41dd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_4ff9643e-496c-49b8-b393-52b40094d779" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_4ff9643e-496c-49b8-b393-52b40094d779" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_87085a1b-90fb-4d78-b5f3-f49c31618ebb" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_87085a1b-90fb-4d78-b5f3-f49c31618ebb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_ea841119-dc6e-48c5-8088-f22c8879031f" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_ea841119-dc6e-48c5-8088-f22c8879031f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_e2338ced-bffd-440a-b094-908bcdbecd00" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_e2338ced-bffd-440a-b094-908bcdbecd00" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_54c4125c-caab-4f84-89fe-43d17dfb5319" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_54c4125c-caab-4f84-89fe-43d17dfb5319" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b7f29cd7-72e6-4c46-b645-d3c27040e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b7f29cd7-72e6-4c46-b645-d3c27040e2b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9698b1e6-27a9-432f-8ebf-bf62abaf3a46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:to="loc_us-gaap_ProjectMember_9698b1e6-27a9-432f-8ebf-bf62abaf3a46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:to="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_68118278-3b59-46dc-8732-076b78eae53d" xlink:href="cntx-20220930.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_68118278-3b59-46dc-8732-076b78eae53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_7938f194-9406-45a0-8451-86fd06eee6f1" xlink:href="cntx-20220930.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_7938f194-9406-45a0-8451-86fd06eee6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_082366bc-5ad2-431f-b786-cb5dbc72477e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_082366bc-5ad2-431f-b786-cb5dbc72477e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_aa6cc28e-1e3c-44fa-a56e-bb1fb73d4382" xlink:href="cntx-20220930.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_aa6cc28e-1e3c-44fa-a56e-bb1fb73d4382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_91591f7e-17ae-4b8d-bac0-485d13490eec" xlink:href="cntx-20220930.xsd#cntx_IntegralMolecularIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:to="loc_cntx_IntegralMolecularIncMember_91591f7e-17ae-4b8d-bac0-485d13490eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ffd8a9ec-fbef-4403-975d-e9567a710e3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:to="loc_us-gaap_ClassOfStockDomain_ffd8a9ec-fbef-4403-975d-e9567a710e3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:to="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5cdb9e7a-61bf-4367-88cc-224caf7c1110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5cdb9e7a-61bf-4367-88cc-224caf7c1110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0eea1f22-e102-4d21-82dc-33b68f76274c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0eea1f22-e102-4d21-82dc-33b68f76274c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cntx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2147565-ce62-4374-8f3a-91e137e1cf75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf3af374-130e-427c-99dd-81579f49d376_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b710d70b-276f-4ad5-b483-3ad78a835992_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d2648780-0dec-4aa8-9d8c-333ebd455cff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b93f1fe5-5070-49a0-a306-ac6c7531716b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_59d8ad5c-bcc0-4b81-a92b-0573ea381ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b610055c-2b3f-4513-8d52-80553b62395b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_06ec8205-8426-457b-9c93-654a86442cec_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c46d566c-ecba-4254-88d8-566f74351e9a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_a10ec447-bf43-4561-8e55-520e5dc0678d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_15495391-9116-4af5-aea3-4a4a2abe359c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93db8bc2-51bb-4038-911a-fb85d8fec834_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5a0d4105-b3f1-4311-9b5b-69e7f96395f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_927b9540-85b5-4439-9843-35f72aedfa41_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1ccbf066-1ba1-483c-a2cd-b7f337436734_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a070b69b-8892-4336-bea1-6aa9c85068dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f4dd0338-8f3d-48e9-b1e4-ad837c26dafc_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt to equity (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81885b3-fa74-4273-8aba-6387f60c4202_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_d3d049e5-d4cf-47fb-a10f-4b1b8c88c4d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7805f1ab-7529-42e0-b96c-230327876338_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6a581b3e-2270-4255-ad5f-1bda210830be_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9bb0d936-e509-487d-8776-4bac7c52d4b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_884e1e2a-7638-4815-9bc4-2774be9274b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_7904110e-7d32-4ef5-8271-23dd09d27619_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_label_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:to="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_f6c27334-44b6-45e3-83ea-4e99d1dd5d6e_terseLabel_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock</link:label>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_label_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_SeriesSeedPreferredStockMember" xlink:to="lab_cntx_SeriesSeedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_c3872b94-ba65-40c2-8930-31808afc1787_terseLabel_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan</link:label>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_label_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan [Member]</link:label>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_documentation_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember" xlink:href="cntx-20220930.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PaymentProtectionProgramLoanMember" xlink:to="lab_cntx_PaymentProtectionProgramLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_0f5fcf19-f203-44c6-84f3-03123aa62d08_terseLabel_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_label_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited [Member]</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_documentation_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:href="cntx-20220930.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:to="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_85cb5c25-b2cd-4c6c-a976-1664d090f3f3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f08df1a4-9c92-4330-acb3-0e615352ebb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8d2f63b7-ad33-4197-994a-e1e355abe4c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f7eff4ff-9244-4ef2-afea-ba3cf53e2000_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0d95f9ee-26c3-46f1-ad9c-9407af08601d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_80e5d43e-195b-4692-880d-e8eca405bfb0_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_08bd41b5-4af5-40dc-bdd8-1a1468361412_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ee2db15a-1a20-4e92-be71-61bcb6887fef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27fa626d-b157-46e5-9920-e538777d8b9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9781420f-4f52-4e92-a032-c329c25ab18f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_f0f3bda9-bd0a-4201-bc9f-04b487fb00c9_negatedTerseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued for services</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_label_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:to="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5142022d-75e7-4c06-9289-ec6332637aed_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_30ce8721-44dc-49b0-8ad3-08cc4f14139e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued for services</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4c253f93-91c3-4ed4-b6f9-7b2197d4b27e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants reclassified into additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ef48c056-2513-43f9-bda4-9325109050fe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_ae68208b-8480-4586-a946-7ad46086004e_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_8190f33a-4a2c-4d14-a38a-5d83c5ce8128_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f8e3ad15-3d05-4ebc-95b4-4aca85acb761_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5f9603b4-9f71-4e03-bf27-3288596c4938_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at September&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_06f9301f-686c-41db-b679-95bc5c511022_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_label_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityOfferingCosts" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityOfferingCosts" xlink:to="lab_cntx_TemporaryEquityOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_51adb376-7d49-448c-b987-f243845f360e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f590e209-78a4-47e9-8dd5-02ad2cb21068_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_67fb1409-2c04-41ea-95e0-0dbcf34695b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93911a19-5fa6-44f0-bc6f-d5d43ccde949_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_c66e21ca-2812-436b-bddc-0962512332fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RedeemableCommonStockMember_e233e557-3622-4910-a4d4-8ac2ae007a0a_terseLabel_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:label id="lab_cntx_RedeemableCommonStockMember_label_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock [Member]</link:label>
    <link:label id="lab_cntx_RedeemableCommonStockMember_documentation_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember" xlink:href="cntx-20220930.xsd#cntx_RedeemableCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RedeemableCommonStockMember" xlink:to="lab_cntx_RedeemableCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_WarrantsIssued_9232cabd-7a58-4b0f-b55a-3108e9155531_terseLabel_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in conjunction with Series A preferred stock</link:label>
    <link:label id="lab_cntx_WarrantsIssued_bdc6f688-cac2-4abf-9741-2aa986db1de8_verboseLabel_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants for services provided</link:label>
    <link:label id="lab_cntx_WarrantsIssued_label_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_cntx_WarrantsIssued_documentation_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_WarrantsIssued" xlink:to="lab_cntx_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_84118baf-0646-421b-977c-b9db46863f0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_16a7f783-3aa2-4601-aa9a-d5815040301f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_65b90ff3-af4f-481a-89d0-58da184a75f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b512d237-dd9e-4d62-b7c4-5e44551b0e59_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_00eec8fe-7a38-4cce-a052-3a9427a25a54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7cc704f6-7ae2-4c24-bcfe-8ddb147c391b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e7556f9d-3f02-492e-b831-d267790547d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_af1bc8d3-5b6c-4c30-adb5-96107ad0b407_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_7ae7bfb5-6a12-4405-a2de-5521dbcaabdf_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_57322748-0783-44ce-80f3-0b93d5c4ad99_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_8ebc3fcd-df4b-428b-b3b7-6a6fc1e760f4_terseLabel_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020</link:label>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_label_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020 [Member]</link:label>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_documentation_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member" xlink:href="cntx-20220930.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_SeniorConvertibleNotesApril2020Member" xlink:to="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_18293ace-e85e-4efd-9f71-840fc697dbcd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_226eb8e5-0acb-4d24-af7f-a9e65dacca76_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d8146ee2-6a2c-4f67-9d35-1f2cace9bd4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_6140b61b-836d-417f-a599-23b643b27d87_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_01190c05-8f29-4e6e-9a80-e5c78a8e291b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b1396eba-266e-4b44-bce8-9a4c83889288_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ddfa6263-4879-4f46-bffa-c8db8bec8b68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_a9c614fe-113d-4cee-8f4b-6b93cd8fc96c_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, percentage</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_22447435-d2c7-46a8-b321-8e29822c7a16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_c5935767-5894-4c1e-92a3-bd78334c7e89_terseLabel_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in connection with 2021 private placement</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_label_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:to="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_d9efcf4c-2a67-4588-8b7f-84d9d471420b_terseLabel_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC</link:label>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_label_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC [Member]</link:label>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember" xlink:href="cntx-20220930.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ContextTherapeuticsLLCMember" xlink:to="lab_cntx_ContextTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7f29f013-a77f-49b3-affa-565ff511e101_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3b3c6823-f1c7-46f3-b2b5-fac2d3f832dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7f2c0dd3-4774-4e75-b332-fb2f804142e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ed9430c9-20eb-4b83-b5ea-85bdeb4f26f1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6455f37e-b3a4-41a5-8213-eaea10fa3fdc_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_050d901d-03b3-4c47-8675-42c5410e7a12_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80e6208f-afc4-4fb9-9b1c-ea5474938f85_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_da1f7e85-c062-40aa-90b0-e9fea547b1cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84219910-b89a-4c1e-a6d3-7d4dad3fe7fa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e17c8ff1-bb1f-4b27-a1b7-78ce2646cd27_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0d67a76b-1803-4822-b20f-229c5a0e34c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5555101d-0ab8-4173-8aab-3e24217184fc_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_a352cf77-922f-43f9-951f-acbfbf9281eb_terseLabel_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="cntx-20220930.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b50ace81-e963-4ac5-ada3-ac0634319ee6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_c7a39e16-d9cd-48e5-bb10-8143b4042a0d_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e696f33-40a5-45f6-93b5-7edce7000bcb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d535cc8b-7294-4a7e-894d-f6138efdff4f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9489214e-72c8-4576-9929-33ff0c9cd654_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_98cc6928-126b-44af-88ab-ce83919bafb5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1440c3a9-9c15-4044-82a5-450fd039fb32_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c2a00ccc-ab46-4d11-bcde-9c7b16d17ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_9e1f319c-79f7-415e-b750-6c6dedcf3fb4_terseLabel_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_label_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Incurred but Not yet Paid</link:label>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:href="cntx-20220930.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:to="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d3cc4d4c-2e94-4333-857f-923241db6e62_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e9de9e7-6572-4772-b0b3-24709a898e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_89f2ae2f-1078-4db7-bb4a-6ea13a6ac66d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_edc33f8a-ff05-44b1-a8af-43142d4a8462_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9e74f6f3-56a3-491a-9c64-87cced927c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8506b60b-a16c-4546-867f-8046d344d224_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_2a20f6d9-4336-40be-8622-054cba27ac82_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5d69756e-4844-4035-8479-e7d0a4142452_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_55c40866-9573-4fe8-a5ed-b46a42c27fd6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da8aef22-d284-4589-bab1-fc518d6b7a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5c016f6c-0010-4542-85d5-d1f0015b6d20_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_84b067f6-13f9-41c8-a740-69d9c8eddf7e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1aa063b8-e3bc-4bd2-be28-de41730efaba_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_6928a618-0389-48a3-954e-a636d59f42fa_terseLabel_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_label_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_documentation_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:href="cntx-20220930.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:to="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_309be090-4d84-41ca-8f5a-e2890e3e4105_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fae979a1-ac27-4466-a32f-4f70821c5baa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_9460bea0-3599-4f65-af59-1e3bb3f2039d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_66a620df-e6bd-46ff-9fc0-0ed19b36aba3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66fb4ab3-ba8c-41b5-afd6-55decf587d68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_32b1080f-2cee-4bb3-bd63-aeedd119f452_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f11aa104-bb82-4d59-980b-71806785bdbc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f068c4d2-f541-461c-a8e8-82688efb7058_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_41a3f59d-68e7-4c56-9887-5d6ca8bd2acb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4cfeb358-1267-49f2-92d9-d53b8cd99b37_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1243bd08-6d87-4fbb-ab8c-286619ddf9fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ba0cde7f-238c-4631-9ffb-e22241461618_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_614f1bb1-527d-41b8-9579-9c014b8c7b09_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred shares and redeemable common shares</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:to="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c337bc74-af0b-4b64-87c7-4eecfb0f6afc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_dc77e71e-2471-444d-8d51-d9aa8caa2312_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_86150414-e3f4-4691-b3ed-98decb31a896_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_8d628611-4ba7-4b8c-a1ca-084bc1716aa3_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Issued For Services</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8be6e156-c6e1-4db2-9a84-0317bbfa36eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95466bbd-e01e-4d70-8017-402d1a668535_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Redeemable Common Stock and Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a84c7f21-31fe-4d1c-9c4d-ccb706528bfa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in the carrying amount of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_c43cb622-db6c-4383-8979-c137440a41f0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_11d5f5a7-567a-4e42-80c2-a1907d1d935f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes and Other Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2d366f2c-e1b4-41e0-bf16-95a91e16a377_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_d08cd710-7505-4ed9-a5ef-bb1bc84b2484_terseLabel_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agent Warrants</link:label>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_label_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_documentation_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agents Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember" xlink:href="cntx-20220930.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PlacementAgentsWarrantsMember" xlink:to="lab_cntx_PlacementAgentsWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ad6ecc8-73e8-4654-b90e-d92d23a4c82a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2fe88b7e-6303-4eb8-bbb5-8d49126e2f50_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_c9dd39bb-182c-483a-b15a-5ab38146fe6a_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_03ede772-c80d-4e82-8d42-012cc17cafe3_negatedTerseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued in conjunction with the Series A preferred stock</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_label_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Conversion To Warrants</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Conversion To Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:to="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IntegralMolecularIncMember_765269e3-1ef3-4b4a-b4c3-58beb4a3db0d_terseLabel_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_label_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc. [Member]</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_documentation_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember" xlink:href="cntx-20220930.xsd#cntx_IntegralMolecularIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IntegralMolecularIncMember" xlink:to="lab_cntx_IntegralMolecularIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_24436470-88f2-4d74-842d-22a615b6bfb9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_3ccd910a-9406-48c3-a58d-b26e7f105c08_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_02f8ec66-3d0d-4153-bb9c-76f18ded93c7_terseLabel_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_5e711f57-8297-4660-8424-27525d9365b4_negatedTerseLabel_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_label_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment On Convertible Debt</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_documentation_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment On Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:to="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_397d0204-9bb8-470f-a126-89d62ecdfeed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8c11bdff-4d4e-43f9-9d29-de83737da1ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_69424938-1a0f-4eea-b0db-79161ae2b725_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6f51bfaf-77d4-4d2e-a2d8-f4922292b5f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5aa05b5d-b5ef-486f-8d69-7ce7634b33ac_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d6c56fa6-d73f-4975-b7cc-1da3d2fe683f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_849009cc-21ec-493e-972e-96444eb35786_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_bbe582db-d75b-447c-a481-95c4cb31b648_terseLabel_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in connection with 2021 IPO</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_label_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents [Member]</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_documentation_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember" xlink:href="cntx-20220930.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedToPlacementAgentsMember" xlink:to="lab_cntx_IssuedToPlacementAgentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_599bf716-3a7b-432c-b61d-3ca058dd9a41_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_724d186b-f01c-4286-af9d-0fca37f39ac7_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum payments due</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5300ebe3-0295-447e-892a-b50bad00eb52_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f5276b9-21bb-4860-a89c-34d386616123_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fffe6e01-a119-4406-93d7-956192566baf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f039587a-68ac-4243-8828-7ecb8fa9cc7c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ca01652a-cd69-411d-bf33-21f43d515543_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_18088df1-ba77-4d59-9ef6-79a910b3fc46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_8eaf52b7-1dad-47f8-9285-22fe74a9837a_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 100 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20220930.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_527e89c8-03ab-461c-ae69-d0032d75456f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_c2293ed8-e87a-4aab-aef4-e36193316c84_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue date fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e7abc2b9-224b-4569-9609-cc44fdd42ecc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_eceafdff-c57c-4ec4-8fe8-1e544946ae7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_60fc522d-8e5c-47cb-a0bb-63852faea8d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0a88f31d-12d0-46f5-a4ba-2a103e220821_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2e722ff1-50bf-4daf-9267-ceb7cbb87fa9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_35956df3-675b-4868-ba52-9b320538bb41_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs incurred</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f29ef367-e687-425a-a964-5b572354f038_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9fb3412f-2c64-4a2f-bd4a-1ee8dbea58f4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7e3c369c-2b55-4fa8-9d6c-b99808bb92ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_0996018e-0b73-4a9b-942e-58ce5c4cc4e2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_b254243a-7aca-4f4a-8fb1-82356d4835c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_1472023b-b020-46f4-893a-0b8000147807_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e040311b-198b-49eb-a9a8-0975b4cee9bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_00fdd24a-a10d-421c-85cc-b36fc3ac88e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1013785e-14aa-446c-88a8-f7bcc220d89a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0aeeb983-2a68-4b58-bff3-c8733d5ab7e2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acea21c7-a904-40e9-8fdb-534150f3f375_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25caaac2-3c45-4258-afac-f4fc82c5c48b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d78f12c-6e88-47ad-a24f-fc33a0ff3908_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3dd0b212-8649-4d57-9dec-35bf86b9b004_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_405be4d3-bc3f-4c3d-84ab-91d01768168b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at September&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_7ea66542-0690-46f3-af73-39f577cde699_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a2b3b6dc-463c-4547-b5db-5165cd623bad_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_53d8b633-715d-4dd3-b693-83fdf8adf056_terseLabel_en-US" xlink:label="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued as placement agent fees</link:label>
    <link:label id="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_label_en-US" xlink:label="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Issued For Services</link:label>
    <link:label id="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_documentation_en-US" xlink:label="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrants Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:href="cntx-20220930.xsd#cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:to="lab_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ce62306b-1b5a-4a9c-9719-fa919d83ab55_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_08b27602-7fff-4598-a1e1-4de706714aaa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a299d106-382b-4a5f-b379-247971d8e08b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b41bc952-6bfe-4587-8367-8b364f1959c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43bb9f8e-80ee-4907-b2b6-7aa7a12255ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_02517ecb-7f5c-4a83-a5a0-8c47ec6fec0e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_75c01574-27a9-4f6e-9ff4-496f935ad5fe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense payable to related party</link:label>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_label_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2224728f-832e-428a-969b-3bf78952521f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_66c06239-9de8-47ed-be45-62e857b6dbaf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_a1ff94e9-7006-425b-bf7b-d105488e50ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A preferred stock issued for acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_30ce2f5c-c12a-4761-9bc2-4d13e61bfdad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b58ad216-aebd-402e-a19e-a1147e7413fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_6f2e4f68-8d0a-4507-8061-c5bdc04bdf32_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of warrants (in shares)</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_6d5a07d9-1300-4e26-8006-50492b1e40cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of Series A preferred stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2357ee77-fffc-43db-b2bb-42dadb02a176_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9d98b876-683a-41f6-879a-c71a7068056c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ae48f814-a4c7-4af5-b166-ef9da3251eec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ac3b5a4f-a8f7-42be-9446-52001f1d8632_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_eb38400a-73d6-40aa-b162-da9371546b8d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3710be2f-8cae-442d-b64c-94d1f6f3dccc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_33098ee1-9b3d-4d79-baca-885191336644_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0de5daa8-ee7c-4237-bb1c-13c62b8fc203_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_06b22fbb-a566-4adb-aa90-da7caeb75a97_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_494920a8-e32d-45c7-a5e4-5f12b6967493_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8f937561-dd7e-4c32-bdaf-91ab6c51ea9b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_44a57770-5838-44c6-ad13-47690c07977e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_0052f70c-3e93-4541-bbb9-5a1b7ae830f6_terseLabel_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in Connection with IPO</link:label>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_label_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in Connection with IPO [Member]</link:label>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_documentation_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in Connection with IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember" xlink:href="cntx-20220930.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedInConnectionWithIPOMember" xlink:to="lab_cntx_IssuedInConnectionWithIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_34dcff11-1d95-41d7-9905-43d09b0e70e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fa692ac9-c34f-45c8-83e6-6c5f9ae80d0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_af625753-5c7c-4dfe-bda3-90dab9795f97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_27279da5-118c-4ddc-9fac-3ca77443cbdd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e9897f8a-ac1b-4882-a133-e265de6c443e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c03b4afb-9e68-4d12-a3a1-314a394b17d5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_661d14a6-087a-4b91-aed8-d3b5883b61c0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_45a2f262-5d9d-4c58-af09-b0bc772f7ae7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3c36fcad-8e2b-4e71-bdb2-ddeb2d6616b2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_522d6778-17dd-493d-8d4a-c8592c4008f2_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation amount</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34777ba2-f633-44a6-b089-b92810c9d920_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a5fcfd89-86e3-475d-87e6-59aca008ea55_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_2337819c-ea99-4fed-8129-ecf418798ee2_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Issued For Services</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_8045f646-f513-422a-b9d6-ee03c9f49264_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, price per share (in dollars per share)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d026d9c6-88c1-4ac0-9db0-c924dd221831_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_17e2b62a-f52d-4f98-8edf-b0397ef50cff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bd3745e6-4e5f-43ef-9332-a8b600ebb76e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_cb2bd02d-9fa4-4aa8-892d-b8395f921646_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_9f3b8f72-193e-4d7e-ba09-dec26bc41c32_terseLabel_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Liquidity</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Text Block]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock" xlink:href="cntx-20220930.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityTextBlock" xlink:to="lab_cntx_RisksAndLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_789f6796-964b-4aa5-9e2d-2b9f17ea9475_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5333f0df-201a-4e26-bf53-5332b3f177aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_496a814c-80b0-493c-8ce3-1a2690d37e0f_terseLabel_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:href="cntx-20220930.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:to="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9581c809-c1bf-429a-b349-a5abb61f5354_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f6c0c20a-442a-47d5-99c0-e4a003d1e616_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ecf12b35-9989-4cb7-a32e-b981bfa00dda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51b253b1-aadb-411f-b5bf-daa6d8ce29c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2af1dbcb-dfd0-403b-ab20-f81af8eae9ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for offering costs related to the private placement sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_477f6e0b-cb69-44c9-b0a4-8b62ead83090_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f402024a-5747-4f80-ab0c-086a5a1fce75_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed856113-d11d-4232-8a30-a3fd64c4b7b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4c9af3d8-3406-429f-a40d-d49c507db10a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants for services provided</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b4bc120-63e3-4955-b8dd-5fa7a3304caa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_6ad2eb7a-396c-46f4-8b74-d1e2df58391f_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development and regulatory milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f0524afe-5af9-4437-b57a-0778b22798f8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_167956eb-e756-4f25-b810-8e667ca1c1be_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_56b88eb3-0e3a-4d22-8f88-01adc43e88d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2bde020d-d2cb-4ef7-8de5-8a94bb0745de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_cc0ef897-4478-4128-b5ec-bca9028b24aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e8f9edcb-0ca7-46b3-95ba-83cc94e5cdeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3bd4433e-f272-42b9-8ac8-480da1c89fa2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f9103533-0004-47d9-9471-9c51fb58edab_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6071ac15-3da7-4d07-8b25-d66cf3c1e9ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_39639f67-e81b-43db-bf68-9ea8eb989bdb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e0d71d43-3a5b-4af7-abd8-1559725199d3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForServicesMember_73854b91-0fdb-4a4c-aeab-2eeda1bc4478_terseLabel_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for services</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember" xlink:href="cntx-20220930.xsd#cntx_IssuedForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForServicesMember" xlink:to="lab_cntx_IssuedForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_468a48ff-3113-4f2e-8ee7-1ab83804f616_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c44edbc6-459c-409d-8756-711621653a03_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_44b05818-fa18-4c89-8e29-240865af4bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity new shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ffaecf1d-20f0-438f-8077-559e683263f9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_2f0f9273-ef2c-432d-8259-49d1cccc4860_terseLabel_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rate at which authorized shares of common stock increase</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_label_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_documentation_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:href="cntx-20220930.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:to="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_dfb3d271-cad3-41b0-9dfc-65da5bb50ae0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_35a6ac9a-f036-4b81-81d5-b39af4861fcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_093d219f-8919-4777-b227-0d5faf87f809_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd3b6ef6-6e44-4604-a212-b9350c4e3098_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8f39dc55-a15d-4643-b486-0df5fbde32f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_98d10281-e582-4c7b-804e-2cbe4ae82c08_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_28df089b-5121-4aaa-b9ea-2d1da235948c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_4ee32997-60c3-4313-8e49-d629b45d6c92_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_89f39621-e027-4d44-8cb8-094eb735a388_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b9bf9564-f302-4cf9-9845-92fe7ca11aa9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_99a1b639-0a72-4a61-8a36-f80b0a4341d8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1be98d75-b44f-4ef1-bfef-e8be24403d8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3cba8e24-f366-47c2-ab8e-e1975f0f1908_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52b26a48-2bff-4fde-a2c3-12a4b156f57c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_2da89802-e9cf-427b-860c-000275b1dff3_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 300 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20220930.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_25c9963b-f696-4d27-a8f1-b23d918a21ba_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_de8f2b21-b0d1-4a3c-8726-fc7cac7cbb07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b197286a-ae9b-4145-aed4-44457ae1d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_88b55bd6-a71c-475c-ae84-9205be3838fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_eeb8e383-54bd-4cb1-a713-e4bac401ce6b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4729cf5d-1f36-4e56-889e-55ec86c45291_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cd1641e4-e2fe-4bb1-8512-07fbdfb5d630_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ed658085-dec7-4fa6-bdda-63a0bbc02376_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9580df2-baf8-47c6-81fe-9d3c3545ebb8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e3684507-e0f4-4e63-b918-7b9c55a98dad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_323b56a0-f346-4c7e-9c04-f3d1c536030e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_202f4841-ccb8-4dee-8713-9e7c94b94411_terseLabel_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, price per share (in dollars per share)</link:label>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_label_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Price Per Share</link:label>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_documentation_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:href="cntx-20220930.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:to="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0fded164-c01b-4bec-8762-e4dbd2a057ab_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt to equity</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d67d6d3a-17ba-4ee9-b7a8-10f7fa02c387_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e7502a91-1727-47ad-9c2d-24047fc34ce9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d285b3ac-e8b8-4bb4-ae9c-fb2d5a30b629_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_c314c690-a170-4fc2-b961-f4cc61c88642_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, percent (up to)</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_95507d13-1b8f-4a0e-b6d0-9bb4364b04a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ebd25305-24c8-4f29-b8f1-b0d0748db857_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d59470ed-87cf-45e3-b218-8a4ddbae7670_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_5cfc5f4b-02a2-496c-80ef-cf45b6f1315a_terseLabel_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_label_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants [Member]</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_documentation_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_December2021PrivatePlacementWarrantsMember" xlink:to="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a1604d76-e822-4c99-9ae7-9ea6bd1d847a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b397cf34-bc85-4dbc-aba9-a09d588e2156_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d686f1ce-819b-4565-82b0-2814f4db2490_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c171e065-b94d-4147-b4ff-5380356907eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c0beb09c-22cc-4ad3-888a-03fdbbf19dff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_604290bb-b97d-4a7d-aa03-3388ae507ff3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_48aef61f-6646-488f-9939-6a462a04d190_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0bfcc224-d806-4eb5-af39-98ac12318e4d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7d21b4c0-2d68-4246-9062-2a3170b03f3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c3f08869-da23-486d-adcc-a66fa9413775_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_521b6b2e-c62f-44a5-a848-6f07e9fde2b8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_bceb945d-3d70-4786-bd57-6e142bd473c0_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, term from date of issuance</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_53658fcb-60e4-41c6-b0f3-fa4db9f1c4c7_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity new shares issued (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_003e89bb-2511-4cc1-b421-608427f56fba_terseLabel_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in 2022 for consulting services</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:href="cntx-20220930.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:to="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3e4f17e6-f18b-43dd-ae60-5e01aed8128b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbc20c16-4e3a-469a-8bd3-a1c8b5a3b960_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_6d722357-814b-4cd4-a3e4-a25d03b162e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_83249ee4-3106-49a2-8933-d883e5f6d557_terseLabel_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in conjunction with series A preferred stock</link:label>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_label_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued in Conjunction With Series A Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued in Conjunction With Series A Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:to="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3b31a23b-0fb0-4576-bf51-706a5682b6c9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed15dcc9-48cf-43b8-b370-b4817fdbaa3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_27109fdb-8bdb-4389-bb70-d3c312538107_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_3ee43a2e-a168-45d1-be33-a85d9a69a9e9_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sales milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b896be7-a8d7-4230-b7e5-8e08856ae732_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_fee1e31c-d188-4f3a-a02f-2dfbe6ac8909_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development charge</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a670fa56-6991-4e28-bc37-e36c5a1b812c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ca3b71c7-0c1d-4e22-9ade-98782ceccb4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_fe9908d7-4b98-4994-9cbd-994c248c581b_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_59746a42-1ff2-49a7-9c8b-181c5eaa4334_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b8f01297-d0b3-4c96-bf15-a2d644f8229e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_968b885d-66bd-4aec-a427-3c84a5bdd89c_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_209b446e-322a-4d99-b72c-847035cba032_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of grants during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7e7050a6-66cc-4b9c-9350-ebd61f895c3b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants prior to conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_321dbd9c-a5f3-4163-a463-9fe7ba5cffe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_f0f00c7e-38e8-4201-8c23-ce586ea76fa2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt beneficial conversion feature</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9f9593a9-bbea-4835-b07a-4443f627ddd8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3e336ba4-0cfc-4d97-87ac-17e4aeaef038_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_53ceaf76-5f5b-4399-855b-09e0b99e3259_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a556482b-34fd-44c2-b374-b70c3df7d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a4036bc9-6b9c-4c0d-a15a-7bfb1e2b4a30_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_14170be1-2925-4b9b-b5bc-ea09b1baa54f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1311b517-199b-4b5e-8c4a-3b79bfbd5381_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2cf43da4-7461-4ce4-a8ad-0f5f4bf0b584_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_a8e74922-5675-4db5-98b1-35129869ebb2_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, period of payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Payment Period</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_220831ed-81fd-4ab3-b4c3-ebbf4220cba6_terseLabel_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders</link:label>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_label_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders [Member]</link:label>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_documentation_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember" xlink:href="cntx-20220930.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedToSeriesAStockholdersMember" xlink:to="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ee7a650c-d35a-4fc7-979b-5d3806148287_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2d39c67c-ff7a-49f2-a978-eb9e04f65e5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as a result of converted debt (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c56a3f78-115a-4f73-98b6-d166545e47ca_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_de0afe18-791d-47c0-8ea1-bd96f8947d24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1630c9bb-c0fa-4b35-a379-ec7e6e9b741c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Abstract]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract" xlink:href="cntx-20220930.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityAbstract" xlink:to="lab_cntx_RisksAndLiquidityAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cntx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ec4fc5f3-40c3-4ce8-b261-b7543d6ca0a8,g:6354369b-e6d8-4c65-8fe7-4a86d7bb73a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/Cover" xlink:type="simple" xlink:href="cntx-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b5faab4c-365a-4bdc-bea0-585e3ae5db92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentType_b5faab4c-365a-4bdc-bea0-585e3ae5db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_82ae9087-8085-417e-8a11-d9b882eda933" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentQuarterlyReport_82ae9087-8085-417e-8a11-d9b882eda933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_617163c6-a68e-4a82-abe2-ec7205a22fb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentPeriodEndDate_617163c6-a68e-4a82-abe2-ec7205a22fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f632bf6f-5f1c-469d-b3f8-37ee107cfa14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentTransitionReport_f632bf6f-5f1c-469d-b3f8-37ee107cfa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b4b05f12-e340-47df-99cd-2f3828bddcc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityFileNumber_b4b05f12-e340-47df-99cd-2f3828bddcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3983ae0e-84a0-43c0-8bb0-3dd5a9acd3b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityRegistrantName_3983ae0e-84a0-43c0-8bb0-3dd5a9acd3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_32ba22f7-d11b-4461-8c92-2c1070b1347d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityIncorporationStateCountryCode_32ba22f7-d11b-4461-8c92-2c1070b1347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a987ab29-4826-454d-927e-8728835392df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityTaxIdentificationNumber_a987ab29-4826-454d-927e-8728835392df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cbefc4d6-ca43-4b71-aee2-649ba51c7d3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityAddressAddressLine1_cbefc4d6-ca43-4b71-aee2-649ba51c7d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_44081798-f6a9-4c0d-ad4b-d69eb347fa4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityAddressAddressLine2_44081798-f6a9-4c0d-ad4b-d69eb347fa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_27622a3e-02fb-4927-8d86-d80c6deb8830" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityAddressCityOrTown_27622a3e-02fb-4927-8d86-d80c6deb8830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_34d78ef4-f2b5-4b50-a1b3-a6bab7984de4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityAddressStateOrProvince_34d78ef4-f2b5-4b50-a1b3-a6bab7984de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4044b1cf-67a0-40cf-939d-43ebb20bc26c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityAddressPostalZipCode_4044b1cf-67a0-40cf-939d-43ebb20bc26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_724b1761-589e-4668-bc4e-a2cb896a231b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_CityAreaCode_724b1761-589e-4668-bc4e-a2cb896a231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8c92b932-5b8f-4c88-a729-c25b039e3e61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_LocalPhoneNumber_8c92b932-5b8f-4c88-a729-c25b039e3e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9f176ee0-3f8c-41e3-b6e2-5f10d3b8b4e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_Security12bTitle_9f176ee0-3f8c-41e3-b6e2-5f10d3b8b4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2db24222-f252-413f-bae5-2c7d4e21511f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_TradingSymbol_2db24222-f252-413f-bae5-2c7d4e21511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41d6f196-add2-4373-81fc-9171e5478f36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_SecurityExchangeName_41d6f196-add2-4373-81fc-9171e5478f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3b934c8a-8995-4849-8a52-55feeb294049" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityCurrentReportingStatus_3b934c8a-8995-4849-8a52-55feeb294049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aa198058-da62-44a2-9aed-4756662c9c4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityInteractiveDataCurrent_aa198058-da62-44a2-9aed-4756662c9c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c9a26bb1-a688-448e-9903-bde0b7cb6618" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityFilerCategory_c9a26bb1-a688-448e-9903-bde0b7cb6618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_176ce6a0-a896-4173-b4bf-bc81ef1b4300" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntitySmallBusiness_176ce6a0-a896-4173-b4bf-bc81ef1b4300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_500346ec-79da-40e2-8ffe-0e10760eb642" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityEmergingGrowthCompany_500346ec-79da-40e2-8ffe-0e10760eb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e7f1d82d-7c91-44f9-88ac-bdb4293e5eab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityExTransitionPeriod_e7f1d82d-7c91-44f9-88ac-bdb4293e5eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_67008b5a-e123-41b6-b852-738b002366d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityShellCompany_67008b5a-e123-41b6-b852-738b002366d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b5516d1f-8829-4bc9-a2a4-fa7479ed2ff4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b5516d1f-8829-4bc9-a2a4-fa7479ed2ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f3d87941-fad2-4b32-90b9-a886b0fadaee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_AmendmentFlag_f3d87941-fad2-4b32-90b9-a886b0fadaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6ec8a2d3-547d-4584-ba77-4553d66bb9f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentFiscalYearFocus_6ec8a2d3-547d-4584-ba77-4553d66bb9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_195b1b38-0327-4c13-b1cd-ab9361fa4ba1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_DocumentFiscalPeriodFocus_195b1b38-0327-4c13-b1cd-ab9361fa4ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f13ef624-7c50-4a1b-b2b0-ffb1a97de1b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_EntityCentralIndexKey_f13ef624-7c50-4a1b-b2b0-ffb1a97de1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_84e934e1-7289-47ad-9cfa-e2f26966b8fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dec516f-fea7-406f-b843-1539021ff663" xlink:to="loc_dei_CurrentFiscalYearEndDate_84e934e1-7289-47ad-9cfa-e2f26966b8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_22b19ade-3155-4af4-9889-ab6cd4be24eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22b19ade-3155-4af4-9889-ab6cd4be24eb" xlink:to="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1c9a9b65-94be-4d43-9421-55be6badfe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1c9a9b65-94be-4d43-9421-55be6badfe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c6c10c2-e005-4074-a89a-db32d1ff1666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c9a9b65-94be-4d43-9421-55be6badfe7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c6c10c2-e005-4074-a89a-db32d1ff1666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d938a8f-3fed-41fa-98e6-aefe512ba39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c9a9b65-94be-4d43-9421-55be6badfe7b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d938a8f-3fed-41fa-98e6-aefe512ba39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6f842877-8931-4fa1-9336-72278b8577fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1c9a9b65-94be-4d43-9421-55be6badfe7b" xlink:to="loc_us-gaap_AssetsCurrent_6f842877-8931-4fa1-9336-72278b8577fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_397301ec-a681-4147-b8a6-021cddf1df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_397301ec-a681-4147-b8a6-021cddf1df5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1fe3b811-1cc1-4a28-a48e-6e160cc3c632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1fe3b811-1cc1-4a28-a48e-6e160cc3c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_19c1bba0-cc27-4a8f-8f65-b15b16610269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_19c1bba0-cc27-4a8f-8f65-b15b16610269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f024966e-6784-4bc4-b85c-e6d1f7fe7cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f024966e-6784-4bc4-b85c-e6d1f7fe7cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0b969ebe-2be6-40b0-9470-6b49c47a9f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e137a06-c79d-4328-91cd-8db251c29fe6" xlink:to="loc_us-gaap_Assets_0b969ebe-2be6-40b0-9470-6b49c47a9f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22b19ade-3155-4af4-9889-ab6cd4be24eb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b11f3f3e-57a6-484b-95b6-52ca98c47470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:to="loc_us-gaap_AccountsPayableCurrent_b11f3f3e-57a6-484b-95b6-52ca98c47470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3782ae4-e593-46c4-9104-04753987bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c3782ae4-e593-46c4-9104-04753987bc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_da6f8a3b-bd87-4e69-a52f-001bbaf2dc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_da6f8a3b-bd87-4e69-a52f-001bbaf2dc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_967290a0-aeaf-46d0-9cf8-f4cef99ee885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50a29081-d545-4661-bb3b-ed501ce6d0e4" xlink:to="loc_us-gaap_LiabilitiesCurrent_967290a0-aeaf-46d0-9cf8-f4cef99ee885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14bc5a13-5855-4eb0-a32a-26591b8d084a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:to="loc_us-gaap_Liabilities_14bc5a13-5855-4eb0-a32a-26591b8d084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_60b5080d-48fe-480d-8905-06bde99101b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_60b5080d-48fe-480d-8905-06bde99101b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fd6817a7-ee79-4f0f-9f1e-3cbeb00131ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:to="loc_us-gaap_PreferredStockValue_fd6817a7-ee79-4f0f-9f1e-3cbeb00131ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2cf6d98d-dbdd-4b89-80e4-e41f7bab5b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:to="loc_us-gaap_CommonStockValue_2cf6d98d-dbdd-4b89-80e4-e41f7bab5b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_18d82644-67bb-4149-ab07-5bd23c2baa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_18d82644-67bb-4149-ab07-5bd23c2baa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e8f6335c-3a64-4691-b660-8dc0a1d73e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e8f6335c-3a64-4691-b660-8dc0a1d73e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49ee9fe2-6f68-4167-95ac-bf6e23713d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d565da5b-05e9-4731-b56a-57645e88b5e0" xlink:to="loc_us-gaap_StockholdersEquity_49ee9fe2-6f68-4167-95ac-bf6e23713d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_53448d69-36c4-429c-8d3f-f7edd067e318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59f44742-1da7-4f69-a354-f9f95d2ebbc5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_53448d69-36c4-429c-8d3f-f7edd067e318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6e94f54a-958b-4c86-9084-62dfac1341ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6e94f54a-958b-4c86-9084-62dfac1341ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ea1d50be-ce2a-47d8-b0e3-ead1b445b64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ea1d50be-ce2a-47d8-b0e3-ead1b445b64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_23fa125d-8ba8-4e43-a26e-fe5e7cbaf708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_23fa125d-8ba8-4e43-a26e-fe5e7cbaf708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a161bcc8-0b78-4d83-ad12-4b34aa8b09e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a161bcc8-0b78-4d83-ad12-4b34aa8b09e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b68049c5-5ce7-48cf-84b5-c370e63b0305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b68049c5-5ce7-48cf-84b5-c370e63b0305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_68b01d1b-8034-4c92-b28c-a48910c79754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_68b01d1b-8034-4c92-b28c-a48910c79754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_444b1a2c-699b-4c78-99ee-7b9c39c6cbde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_CommonStockSharesIssued_444b1a2c-699b-4c78-99ee-7b9c39c6cbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_492a2f16-4c63-4fd7-b64e-02fa8a666373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce948569-db6a-46d8-a5ec-de946e37a0fa" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_492a2f16-4c63-4fd7-b64e-02fa8a666373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ddf5d6db-f37a-4672-a871-1cea2e8249fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ddf5d6db-f37a-4672-a871-1cea2e8249fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_940682cd-ec7c-4d95-bcb9-6ae00b96eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ddf5d6db-f37a-4672-a871-1cea2e8249fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_940682cd-ec7c-4d95-bcb9-6ae00b96eb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_39b4fb49-6dda-41be-b9d0-f6e62035d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ddf5d6db-f37a-4672-a871-1cea2e8249fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_39b4fb49-6dda-41be-b9d0-f6e62035d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c5e668a7-71b2-42b4-994d-9b2206a5feac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ddf5d6db-f37a-4672-a871-1cea2e8249fa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c5e668a7-71b2-42b4-994d-9b2206a5feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bfd6bd95-4530-425b-b57a-7754efcf4f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_OperatingIncomeLoss_bfd6bd95-4530-425b-b57a-7754efcf4f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_321b9c21-f6c2-4d65-94c9-e4458003240e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_321b9c21-f6c2-4d65-94c9-e4458003240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_7ca04c12-d770-438b-836a-e01b992aac11" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_7ca04c12-d770-438b-836a-e01b992aac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_84d48697-2fec-4400-9936-4bc79f6506bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_84d48697-2fec-4400-9936-4bc79f6506bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a63920b0-e1ec-4254-ba48-ca8d56a5284b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_NetIncomeLoss_a63920b0-e1ec-4254-ba48-ca8d56a5284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3c95bc91-decd-4b75-864b-3e35cfe42f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_EarningsPerShareBasic_3c95bc91-decd-4b75-864b-3e35cfe42f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1a1f1750-469e-4005-9048-2fc308668df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1a1f1750-469e-4005-9048-2fc308668df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f0104c4-1021-4054-8ee9-192682eaf9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f0104c4-1021-4054-8ee9-192682eaf9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_632e9d1f-ece3-40b3-97a9-4a30f32129ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db5c3838-b7a8-4830-9a64-69f868ed7eb3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_632e9d1f-ece3-40b3-97a9-4a30f32129ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c6d6eb6-0371-409c-bfa8-48112cbd1497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c6d6eb6-0371-409c-bfa8-48112cbd1497" xlink:to="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f917e65a-988d-4277-b40d-d59c04e7c1c8" xlink:to="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_905ffa0e-7d90-48ee-92c1-bde5f7d2b04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_CommonStockMember_905ffa0e-7d90-48ee-92c1-bde5f7d2b04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2c937b04-1cc0-468e-ae01-26bca1a5d291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2c937b04-1cc0-468e-ae01-26bca1a5d291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_801a574e-29f0-4c30-9736-ab91ebbdc357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8d19a333-89a4-4533-a2dc-ce4730f8ab8d" xlink:to="loc_us-gaap_RetainedEarningsMember_801a574e-29f0-4c30-9736-ab91ebbdc357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e72a6a9-70a8-458d-bddb-7865d2291f05" xlink:to="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ae1933bd-d304-4f94-903d-f5d330db2fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ae1933bd-d304-4f94-903d-f5d330db2fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_6653ec60-eea6-4aa9-9374-fcc536489e28" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_6653ec60-eea6-4aa9-9374-fcc536489e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_9e1ef17f-3ede-4bb7-9751-49244bcde7f3" xlink:href="cntx-20220930.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26ca1ae4-63d1-44d4-82ff-e9c5a9a976c8" xlink:to="loc_cntx_RedeemableCommonStockMember_9e1ef17f-3ede-4bb7-9751-49244bcde7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_03c6d4ac-428f-452c-a2b9-e883edb76360" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_55b63890-73b2-497d-aae4-dd473f942343" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_55b63890-73b2-497d-aae4-dd473f942343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_05449c54-603f-4d1d-982d-f2dbcee45783" xlink:href="cntx-20220930.xsd#cntx_IssuedForServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_429b5c1a-5b51-4926-83bb-cd57688d1a13" xlink:to="loc_cntx_IssuedForServicesMember_05449c54-603f-4d1d-982d-f2dbcee45783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9a16bbd-7f37-499e-82f5-61361c014e49" xlink:to="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_35617604-f9ae-43d0-aaa4-24a7d9d7e181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_35617604-f9ae-43d0-aaa4-24a7d9d7e181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c971d3bd-4e11-4a88-af69-a802bbd3b146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c971d3bd-4e11-4a88-af69-a802bbd3b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0532de1-e732-4982-b572-757fdd650a94" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0532de1-e732-4982-b572-757fdd650a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4c7e53a3-f7c5-48a6-85ee-e626ba801bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4c7e53a3-f7c5-48a6-85ee-e626ba801bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4ed4a172-a85b-481b-9265-3cdd28c2b22d" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4ed4a172-a85b-481b-9265-3cdd28c2b22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_480f919b-a077-4567-9e37-6c3ec569c996" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_480f919b-a077-4567-9e37-6c3ec569c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_42f46a03-9910-4cf5-94fa-331a3568a918" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_42f46a03-9910-4cf5-94fa-331a3568a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_24fee616-000a-48c7-8b75-1179a057e589" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_24fee616-000a-48c7-8b75-1179a057e589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_dfe6e879-13c1-4576-a74d-9fd4ab399741" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_dfe6e879-13c1-4576-a74d-9fd4ab399741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_eff27371-ef64-4bad-89c4-0f6a618f2c73" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_eff27371-ef64-4bad-89c4-0f6a618f2c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_015f1321-9112-48d7-bc84-dac5330e3bab" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_015f1321-9112-48d7-bc84-dac5330e3bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_96cb7b58-641f-450d-9e00-ffe576436341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_96cb7b58-641f-450d-9e00-ffe576436341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7bd62c74-b33f-4709-bd72-5438e7525446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_741863a4-9ded-4371-8c18-b6a93beefefb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7bd62c74-b33f-4709-bd72-5438e7525446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ed15678b-3f1c-4135-bc0d-fddb8b24fef7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_de720460-5f73-4cc5-81f0-23158ee3452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_SharesOutstanding_de720460-5f73-4cc5-81f0-23158ee3452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_063a8b6b-e16e-48ee-a6bc-053c6e9859a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockholdersEquity_063a8b6b-e16e-48ee-a6bc-053c6e9859a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_25b25ca5-90f3-4bf6-bf59-ba8a03ecd3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_25b25ca5-90f3-4bf6-bf59-ba8a03ecd3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1eab2ee1-9291-4114-9ea8-1e78943cf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1eab2ee1-9291-4114-9ea8-1e78943cf8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_9da41cb8-d1f1-4e90-8a2d-da35c90b640e" xlink:href="cntx-20220930.xsd#cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices_9da41cb8-d1f1-4e90-8a2d-da35c90b640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_6e00e296-6975-4d9f-9f43-0b17ac7425ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_6e00e296-6975-4d9f-9f43-0b17ac7425ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_bcce45d7-4a27-4661-9410-5d726ac19f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_bcce45d7-4a27-4661-9410-5d726ac19f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae16e4f8-a847-4498-bde3-1241af28641a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae16e4f8-a847-4498-bde3-1241af28641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_28b1b1a7-c96f-4bc9-9117-fc2542d45364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_28b1b1a7-c96f-4bc9-9117-fc2542d45364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdb5195e-46d2-4987-8fe5-416ae3a0013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_NetIncomeLoss_fdb5195e-46d2-4987-8fe5-416ae3a0013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_200d4315-3da7-4d6c-8c49-59cffdab73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_SharesOutstanding_200d4315-3da7-4d6c-8c49-59cffdab73e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_557dcb3b-1d7e-4c76-8cd7-fb84dee30256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c0148f2-7870-4a9a-b1d4-3b4b50ab1f36" xlink:to="loc_us-gaap_StockholdersEquity_557dcb3b-1d7e-4c76-8cd7-fb84dee30256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_14763070-0ca9-4316-9cd4-6ffe63b3af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityOfferingCosts_18cfce46-3116-413c-b6fc-155763bf611c" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_14763070-0ca9-4316-9cd4-6ffe63b3af1c" xlink:to="loc_cntx_TemporaryEquityOfferingCosts_18cfce46-3116-413c-b6fc-155763bf611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20220930.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a31c2d59-07f5-4234-a9dd-9b54ce1b8f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a31c2d59-07f5-4234-a9dd-9b54ce1b8f93" xlink:to="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cd11d4d3-2313-4935-afc7-4d56a0508241" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_e1fc4e5f-a1ed-4693-8016-b10128f94707" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_e1fc4e5f-a1ed-4693-8016-b10128f94707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_a1f4b838-56d4-4baf-a47f-27f9fec7befc" xlink:href="cntx-20220930.xsd#cntx_IssuedForServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3145dabe-c34c-4208-abde-3c4445102edb" xlink:to="loc_cntx_IssuedForServicesMember_a1f4b838-56d4-4baf-a47f-27f9fec7befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_82668788-9090-4b59-b67a-845e9dcbfc47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a354290c-5942-4189-8603-9758dd5a94c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:to="loc_us-gaap_PrivatePlacementMember_a354290c-5942-4189-8603-9758dd5a94c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f4d35347-1b01-4c29-bb7b-3f21db3caaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1b08de-781c-44cd-b174-b10c6e1af789" xlink:to="loc_us-gaap_IPOMember_f4d35347-1b01-4c29-bb7b-3f21db3caaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6bf39a8e-f598-4eaf-87ce-5234d18d22e2" xlink:to="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_709ed675-08fa-42eb-9cbf-1a354e44675e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_NetIncomeLoss_709ed675-08fa-42eb-9cbf-1a354e44675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9836b159-520b-422c-beba-baa43cc3fcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9836b159-520b-422c-beba-baa43cc3fcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b31ccd8d-3f15-44e1-9f52-6b75cc570378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b31ccd8d-3f15-44e1-9f52-6b75cc570378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b32ddfc8-e55d-413f-8e7b-1f4d618c258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_ShareBasedCompensation_b32ddfc8-e55d-413f-8e7b-1f4d618c258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b43c4f27-6448-4a21-8351-0a2bb6c396b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b43c4f27-6448-4a21-8351-0a2bb6c396b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_de99bea5-b860-4eff-ba64-009db626659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_PaidInKindInterest_de99bea5-b860-4eff-ba64-009db626659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_84d45a92-620b-40a3-a9f3-aecccea2e6e0" xlink:href="cntx-20220930.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_84d45a92-620b-40a3-a9f3-aecccea2e6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27549ff0-3242-4607-bff3-5355eec9a06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27549ff0-3242-4607-bff3-5355eec9a06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8b01d79f-c05b-4432-ba06-7802b3ef4aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8b01d79f-c05b-4432-ba06-7802b3ef4aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6eb80d94-9ccc-49a9-af6c-89c8b41c4002" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78f665bb-4b60-4a07-bfc6-23e657a9f3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78f665bb-4b60-4a07-bfc6-23e657a9f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97bc0e3f-0674-4422-b399-94ab5d337530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97bc0e3f-0674-4422-b399-94ab5d337530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3989eb08-f2ad-4297-b52f-a5f435a1c1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3989eb08-f2ad-4297-b52f-a5f435a1c1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_686329a8-562b-449f-ae6a-26c479f6019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_686329a8-562b-449f-ae6a-26c479f6019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f50e58ea-b984-4443-ab68-7b42271531f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2cdbb88-f61f-4db7-a8b6-6d5a20f2ca2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f50e58ea-b984-4443-ab68-7b42271531f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0574e8d5-3d37-47db-8934-1d6eee86d492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e860f06e-74d8-4cc1-89e7-ce4d1b3f37ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0574e8d5-3d37-47db-8934-1d6eee86d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_77475e87-6870-479f-b449-31e7455294a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_77475e87-6870-479f-b449-31e7455294a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116f9f63-f646-4ac0-8227-18afd7ff699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_116f9f63-f646-4ac0-8227-18afd7ff699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_819ba161-89ef-4ddc-a09a-b826e88c292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_251cf55e-00a2-4b1b-bae5-da5495939931" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_819ba161-89ef-4ddc-a09a-b826e88c292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5eda067-4ea0-457b-9b63-463e56d21a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5eda067-4ea0-457b-9b63-463e56d21a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_b2a5cf77-4283-48bb-888e-6cc1217b2bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_b2a5cf77-4283-48bb-888e-6cc1217b2bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_902b1365-34d4-4af7-bc71-958d2ac7de74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14774b8a-b3fb-45ce-bf2c-d430db6ca228" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_902b1365-34d4-4af7-bc71-958d2ac7de74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ceaec7b-a971-463a-bfda-b925d7508245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7ceaec7b-a971-463a-bfda-b925d7508245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6268360-3b2f-4220-98f1-05529a1645c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6268360-3b2f-4220-98f1-05529a1645c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5eeef4bc-32ca-4119-b160-6e714d809c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5eeef4bc-32ca-4119-b160-6e714d809c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffaad6ab-ce1a-4b87-84fd-260d0d91cfc6" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3ec518b6-0278-46cd-88dc-f05f37a37de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3ec518b6-0278-46cd-88dc-f05f37a37de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_73a7d071-8d1b-4071-8fd4-a83bd80f9996" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_WarrantsIssued_73a7d071-8d1b-4071-8fd4-a83bd80f9996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_023276a6-3782-4914-81fd-6fb50aacef15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_StockIssued1_023276a6-3782-4914-81fd-6fb50aacef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_8e17492a-f888-415b-a9ce-25edfcb93fe2" xlink:href="cntx-20220930.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_8e17492a-f888-415b-a9ce-25edfcb93fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_7ff2c344-920f-45ad-b149-12e7794ad457" xlink:href="cntx-20220930.xsd#cntx_WarrantsIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_WarrantsIssued_7ff2c344-920f-45ad-b149-12e7794ad457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d996ddd9-b5e2-4d71-a550-364ae2ec11f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d996ddd9-b5e2-4d71-a550-364ae2ec11f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_68870cb0-8fb2-4899-b00b-f5a30ba8c2a0" xlink:href="cntx-20220930.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_14bd4cb7-766e-4a0e-b909-f0551bd9d224" xlink:to="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_68870cb0-8fb2-4899-b00b-f5a30ba8c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="cntx-20220930.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a4b3246-ae79-4179-82ca-de764dcc9617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_9fa1902d-99e4-4cac-ac3b-091625173f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a4b3246-ae79-4179-82ca-de764dcc9617" xlink:to="loc_us-gaap_NatureOfOperations_9fa1902d-99e4-4cac-ac3b-091625173f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="simple" xlink:href="cntx-20220930.xsd#RisksandLiquidity"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_22d104bf-03cc-4145-91bc-27d43bc5594b" xlink:href="cntx-20220930.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock_7326db9d-a666-4066-b721-5fee796b7d87" xlink:href="cntx-20220930.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_22d104bf-03cc-4145-91bc-27d43bc5594b" xlink:to="loc_cntx_RisksAndLiquidityTextBlock_7326db9d-a666-4066-b721-5fee796b7d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e311edc1-6e72-4427-bbe4-58cad529844b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_17e76a2f-1faa-480c-82c0-1674f1a76d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e311edc1-6e72-4427-bbe4-58cad529844b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_17e76a2f-1faa-480c-82c0-1674f1a76d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cntx-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c40795ad-3af0-48aa-aa1e-ea24f544c8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3c4b74e0-f596-47a0-93ad-a5ff1642a60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c40795ad-3af0-48aa-aa1e-ea24f544c8c0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3c4b74e0-f596-47a0-93ad-a5ff1642a60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cntx-20220930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8a7b8cd0-bef7-4c31-addb-1b40f6f5ff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f904852b-ef2f-49f6-9dc3-5629deb8450d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8a7b8cd0-bef7-4c31-addb-1b40f6f5ff19" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f904852b-ef2f-49f6-9dc3-5629deb8450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePromissoryNotesandOtherDebt"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3fc86911-e725-4a5d-999f-99d37763994a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_c0e936b7-5c06-4b57-92f6-bfd586309801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3fc86911-e725-4a5d-999f-99d37763994a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_c0e936b7-5c06-4b57-92f6-bfd586309801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStock"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_65be819c-926e-444c-b4c3-b61146bea20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c989f85b-3495-4325-a521-b9f5134fe5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_65be819c-926e-444c-b4c3-b61146bea20a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c989f85b-3495-4325-a521-b9f5134fe5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69184c37-1c2c-461d-9eb3-a38ad44c34fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4e99b7-8a60-4ee4-99bc-73c1f1b62baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69184c37-1c2c-461d-9eb3-a38ad44c34fa" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4e99b7-8a60-4ee4-99bc-73c1f1b62baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="cntx-20220930.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3b9f44a1-5428-4c70-92ac-d9f709fe8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_988d29fa-d424-4e05-9ea9-c247dbc42631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3b9f44a1-5428-4c70-92ac-d9f709fe8cea" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_988d29fa-d424-4e05-9ea9-c247dbc42631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cntx-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_efa1dc2a-7009-4099-93c0-f1006825b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_45e75a48-8aab-4aea-8258-db97fd333c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_efa1dc2a-7009-4099-93c0-f1006825b1ae" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_45e75a48-8aab-4aea-8258-db97fd333c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2de484ed-d4ee-4961-93a9-7b379e53b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2de484ed-d4ee-4961-93a9-7b379e53b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_61f10a93-9689-42ad-9584-b444106f6922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_61f10a93-9689-42ad-9584-b444106f6922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bdac4160-e337-4302-acb8-0b0742ab63b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_UseOfEstimates_bdac4160-e337-4302-acb8-0b0742ab63b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e4486be3-8504-43b0-a443-04ad81ab772d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e4486be3-8504-43b0-a443-04ad81ab772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccf3ed81-481b-40d9-a1a4-d41952460e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccf3ed81-481b-40d9-a1a4-d41952460e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c80f3207-2ac4-4b60-9344-dc57716e505f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c80f3207-2ac4-4b60-9344-dc57716e505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_69b60199-a2df-410b-b228-038944adb5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_69b60199-a2df-410b-b228-038944adb5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8680fdbd-0366-4919-a23b-568023044194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8680fdbd-0366-4919-a23b-568023044194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5e5d4dec-8b8b-40f0-991d-5341910dc84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5e5d4dec-8b8b-40f0-991d-5341910dc84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock_9e41b5f3-b257-4e92-89ab-d87afbfbf6a8" xlink:href="cntx-20220930.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_cntx_PatentCostsPolicyPolicyTextBlock_9e41b5f3-b257-4e92-89ab-d87afbfbf6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_612cf818-c292-4384-92b9-ff49017ea5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_612cf818-c292-4384-92b9-ff49017ea5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8d187e5c-2cb6-486a-9832-56cf33b605be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8d187e5c-2cb6-486a-9832-56cf33b605be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_495c7bea-e63d-40dd-9466-a1143684c005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e5a0452-c190-4783-88c3-53cdfec543b2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_495c7bea-e63d-40dd-9466-a1143684c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c47b74ff-19e1-4781-b0b0-df6a568decc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_59c9adfe-2dc8-41f8-82f2-c8f480d08f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c47b74ff-19e1-4781-b0b0-df6a568decc1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_59c9adfe-2dc8-41f8-82f2-c8f480d08f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cntx-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9d80dceb-cfda-43b2-b94a-16591ba8da9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_30a406bc-672f-486a-8d98-579ebb6b0c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9d80dceb-cfda-43b2-b94a-16591ba8da9c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_30a406bc-672f-486a-8d98-579ebb6b0c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cntx-20220930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a3a8f2ea-7306-4020-8296-2bdb52037094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ea82a27d-6ace-44d1-bdb5-d451478b35f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a3a8f2ea-7306-4020-8296-2bdb52037094" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ea82a27d-6ace-44d1-bdb5-d451478b35f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_3c58481d-f98d-4f0d-92e1-5afa791088c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_dfcd9ffe-dae3-4136-a9e8-ae91607b4204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_3c58481d-f98d-4f0d-92e1-5afa791088c5" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_dfcd9ffe-dae3-4136-a9e8-ae91607b4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff333ba9-197a-453a-847c-6731f70471f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0f813ef9-bcf0-4b1f-a21d-fde8e07bf091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff333ba9-197a-453a-847c-6731f70471f5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0f813ef9-bcf0-4b1f-a21d-fde8e07bf091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_06f96df8-a7c1-4def-921f-459996789222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff333ba9-197a-453a-847c-6731f70471f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_06f96df8-a7c1-4def-921f-459996789222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3c42bb8e-7102-440c-a003-4452973303d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff333ba9-197a-453a-847c-6731f70471f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3c42bb8e-7102-440c-a003-4452973303d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257d75a3-7b8d-4fb8-a66c-7afb2709eec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257d75a3-7b8d-4fb8-a66c-7afb2709eec2" xlink:to="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:to="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_301c94b1-2c97-4e65-aa4b-80b4f6a4988c" xlink:to="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember_87620e24-77b1-4bec-a233-9ea92c4c357d" xlink:href="cntx-20220930.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_62776b00-cd76-41c5-a5f2-46ef49553409" xlink:to="loc_cntx_ContextTherapeuticsLLCMember_87620e24-77b1-4bec-a233-9ea92c4c357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_95f584b1-2904-4c9b-886f-da4c2922daf0" xlink:to="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8862e6d1-4fea-47ca-a957-9faeb251314f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_88d6837f-5641-4c8a-a89b-db6969c49b75" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_8862e6d1-4fea-47ca-a957-9faeb251314f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#RisksandLiquidityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_10daed96-1bbe-4964-867c-1899da0c6ccb" xlink:href="cntx-20220930.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_10daed96-1bbe-4964-867c-1899da0c6ccb" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ad201aa-c1e9-4041-bed3-d10af1529ba9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c306e7c4-46e6-44fe-817d-9e92cd8d0123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:to="loc_us-gaap_IPOMember_c306e7c4-46e6-44fe-817d-9e92cd8d0123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_45d59e78-9156-442f-9f3c-64771f01325b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d93d2c50-8687-4c94-871e-59f5b07a2cb7" xlink:to="loc_us-gaap_PrivatePlacementMember_45d59e78-9156-442f-9f3c-64771f01325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_095ed0c7-45cf-4e07-9350-7851cb94eeaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember_dec733d5-cdc8-4aa7-a2cb-f1be69577517" xlink:href="cntx-20220930.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_PlacementAgentsWarrantsMember_dec733d5-cdc8-4aa7-a2cb-f1be69577517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_5dd7f898-7362-4ad3-83f0-08e2047f9966" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_5dd7f898-7362-4ad3-83f0-08e2047f9966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_ad022c90-2ffe-4f60-b38a-ab5b491a469e" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_340fc3c5-c7ca-4a49-9f3c-0aa01a788751" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_ad022c90-2ffe-4f60-b38a-ab5b491a469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a5573c3-8d93-4ff6-9912-6f3a3d22047d" xlink:to="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7779e352-a914-4984-81a7-ef97f9b0e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9d1fdfaf-e012-482f-a3b0-21d955f5ec9a" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7779e352-a914-4984-81a7-ef97f9b0e3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_d57b8aba-0293-49bb-8c35-452c52bff297" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f1b8c6c-f841-4484-a172-6df11d008b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f1b8c6c-f841-4484-a172-6df11d008b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bdab9a9-a195-4321-9daf-038fad7e71e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bdab9a9-a195-4321-9daf-038fad7e71e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_961b933c-d723-45a3-b85e-6c9897882099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_961b933c-d723-45a3-b85e-6c9897882099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1d29c954-0619-4738-98bc-0e2a947dc4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1d29c954-0619-4738-98bc-0e2a947dc4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf1ef1e7-1a17-4583-b3b9-311106161a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf1ef1e7-1a17-4583-b3b9-311106161a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fc09dd7c-0959-4a5d-b925-d76504f4996d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fc09dd7c-0959-4a5d-b925-d76504f4996d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e5f1a08c-2b85-404b-9350-661971ed057c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e5f1a08c-2b85-404b-9350-661971ed057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b4424bcf-bb89-4afc-8add-51b66eeb48c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b4424bcf-bb89-4afc-8add-51b66eeb48c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f8e325a-c9e0-4052-9dd1-b585591d726d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f8e325a-c9e0-4052-9dd1-b585591d726d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_bae8520f-85e1-41d2-9e6a-6d34a23218a0" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_bae8520f-85e1-41d2-9e6a-6d34a23218a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8dac2d55-3818-4cdb-bc87-4cf817ef662c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8dac2d55-3818-4cdb-bc87-4cf817ef662c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9c6398db-4cf9-4f92-9525-557803977836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9c6398db-4cf9-4f92-9525-557803977836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9db0b148-fea2-4240-880a-e1cfb50370a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_e4933f70-d2e0-4f0c-b998-ae126e801ff2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9db0b148-fea2-4240-880a-e1cfb50370a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c168ca6f-f731-4ba7-aaf8-750d0c3b7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6c671859-2826-4b44-97b1-7d25b7a80f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c168ca6f-f731-4ba7-aaf8-750d0c3b7d84" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6c671859-2826-4b44-97b1-7d25b7a80f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9f14d69f-695a-47c9-a278-9f415a2fccfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f14d69f-695a-47c9-a278-9f415a2fccfd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9e91c5d-9adc-4c74-80c3-baf4ca026220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_ce702f2e-7508-43d1-9f77-3abf05a5afa5" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_ce702f2e-7508-43d1-9f77-3abf05a5afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c203919d-cfc0-40b1-9a54-e1a70f429026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c203919d-cfc0-40b1-9a54-e1a70f429026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_87c4893d-a5d6-4178-922b-f0acba4bcedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_87c4893d-a5d6-4178-922b-f0acba4bcedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a88d540c-cdb5-423b-8915-35daa38714ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a88d540c-cdb5-423b-8915-35daa38714ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_14b45181-6e72-4a9b-81d4-e3d2bf98546b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_28dfe133-2d00-477b-9c40-66b30489a4d6" xlink:to="loc_us-gaap_WarrantMember_14b45181-6e72-4a9b-81d4-e3d2bf98546b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ec71373-4506-4289-97db-a64cc32f3031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_610629ff-3f71-4503-bfb7-2354f37ca3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c7a1487-f77e-4511-aa8f-e217e7c86c19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_610629ff-3f71-4503-bfb7-2354f37ca3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ebeda6a2-fa39-43cd-ba3c-0d32b1cdda21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ebeda6a2-fa39-43cd-ba3c-0d32b1cdda21" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_79f032bc-1de1-4e75-8418-62bb15cf6ae9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e57fbff4-1460-4e42-ab73-7d313f2745f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba412d2-b494-482c-9f6b-55c7043634f5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e57fbff4-1460-4e42-ab73-7d313f2745f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ddf2375c-e9c3-4ce3-ad0c-800a53225f5d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1a820ff7-e97f-414a-b86f-3870eab6c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10efbf0d-e621-4b45-8f0e-3997343540ec" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1a820ff7-e97f-414a-b86f-3870eab6c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8432da7a-6c03-4eb4-b82a-c76d0a852016" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc0a6b22-2425-4de1-a4f3-3f23eef7c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc0a6b22-2425-4de1-a4f3-3f23eef7c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2d78d57-aac4-4aea-a91b-2bfc1e669627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2d78d57-aac4-4aea-a91b-2bfc1e669627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_59b983f3-44d6-4b48-98cc-0a78664a8c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e4bc88f-3ca4-4dcb-a116-587f4a212049" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_59b983f3-44d6-4b48-98cc-0a78664a8c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_113a77b5-a040-48f9-88cf-5af20d7af86b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb8e94af-21c4-4bcc-b2b1-661f0824d1e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3331dc79-3a5a-449d-80f4-683f94804bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_581ce4ef-3a0d-4f3a-80c4-62e729abaa51" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3331dc79-3a5a-449d-80f4-683f94804bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bb35b0b-6913-43ed-aa23-e159ce744da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bb35b0b-6913-43ed-aa23-e159ce744da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_c7b7aa87-977f-4cd4-bae7-012bc66d7cfd" xlink:href="cntx-20220930.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:to="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_c7b7aa87-977f-4cd4-bae7-012bc66d7cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b9c4f6f9-28df-406a-8bef-570a4f185fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b9c4f6f9-28df-406a-8bef-570a4f185fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e8c6d535-4051-42cb-9a0a-6f749faaf7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e8c6d535-4051-42cb-9a0a-6f749faaf7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8b8c4473-838b-44a1-bdd5-219dd7d31b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e74f756e-7a47-4ac5-8c5d-6291dbf03d86" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8b8c4473-838b-44a1-bdd5-219dd7d31b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePromissoryNotesandOtherDebtDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_482d051b-ba0b-44d2-9218-6a8620e7b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_482d051b-ba0b-44d2-9218-6a8620e7b422" xlink:to="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83c553e9-d673-4743-b863-0f6250fdda02" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_d5d4aa90-a663-4faf-ad8b-4aa4e5237919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_d5d4aa90-a663-4faf-ad8b-4aa4e5237919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember_2448d40f-9db2-4eb6-a08d-756eeb77b0b3" xlink:href="cntx-20220930.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba10ac8d-5350-495d-891e-c3b3312e9417" xlink:to="loc_cntx_PaymentProtectionProgramLoanMember_2448d40f-9db2-4eb6-a08d-756eeb77b0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2074b96a-a00e-4c28-b0df-a4ee2dbbca86" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_3f292612-ec74-40d9-bebf-86a096c7ce2a" xlink:href="cntx-20220930.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d82ddc6-2d2c-41a1-a82d-679bec10ae1f" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_3f292612-ec74-40d9-bebf-86a096c7ce2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19de576d-4192-4a7b-a3e3-6de3663c1738" xlink:to="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f19eec47-9646-4dcb-84b2-1fdb4fc1a1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f534bd68-b298-4943-8ad2-646a64ee1445" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f19eec47-9646-4dcb-84b2-1fdb4fc1a1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_058d4ace-8318-47c2-b968-ee787ac56acb" xlink:to="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b76f5fca-4beb-433c-9ccd-fbf03f065940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cb219162-f523-4c0a-94c4-da24cededa01" xlink:to="loc_srt_AffiliatedEntityMember_b76f5fca-4beb-433c-9ccd-fbf03f065940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce7c3132-3130-488e-9386-904974c79dd4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81d36f95-01cb-4156-b50a-0117fd90459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81d36f95-01cb-4156-b50a-0117fd90459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e4d5e84b-67d9-4fcf-a6d1-bce77eb35ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_LongTermDebtFairValue_e4d5e84b-67d9-4fcf-a6d1-bce77eb35ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_94edba72-b269-4959-a47c-1778ca513b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_94edba72-b269-4959-a47c-1778ca513b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_028425c1-cec3-40ad-8dcf-fdbfeec4443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_InterestExpense_028425c1-cec3-40ad-8dcf-fdbfeec4443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_2425a0e6-615d-4392-be59-ae6361bdc9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_2425a0e6-615d-4392-be59-ae6361bdc9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3d5bae5a-d9d5-4ced-a23c-25db3b4ffa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3d5bae5a-d9d5-4ced-a23c-25db3b4ffa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_074e3952-660e-4f8c-a7c0-b27a8e3bc209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentTerm_074e3952-660e-4f8c-a7c0-b27a8e3bc209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3f4b0e0-9f4d-4d15-ac6c-829bfacba205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3f4b0e0-9f4d-4d15-ac6c-829bfacba205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d05a40ae-1c81-4e86-a023-68e5c774f0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2ae462fa-fa5c-4ea3-8beb-089d01fd0b40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d05a40ae-1c81-4e86-a023-68e5c774f0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_430555eb-6a47-46fa-a699-ceedcc483cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_430555eb-6a47-46fa-a699-ceedcc483cd7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_32ed6e90-9b91-4ae2-9294-cc15ec6b5d1b" xlink:to="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b90f8f39-76a9-4115-86d1-d08550532c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b90f8f39-76a9-4115-86d1-d08550532c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_f6c8b50d-f0b3-4a92-b584-a162f4660335" xlink:href="cntx-20220930.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_f6c8b50d-f0b3-4a92-b584-a162f4660335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_521cd744-9a89-43cf-8e0c-8fbbc968b859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_us-gaap_CommonStockMember_521cd744-9a89-43cf-8e0c-8fbbc968b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_a287fdc9-2eaa-4bb8-9350-06ce203efb8a" xlink:href="cntx-20220930.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a0522b5-f98c-4c99-9d2a-46e9a5a588e2" xlink:to="loc_cntx_RedeemableCommonStockMember_a287fdc9-2eaa-4bb8-9350-06ce203efb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca109273-aa24-4ed2-9946-12b695b51d78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_f4845e9e-8da3-4257-9513-c8545902e38a" xlink:href="cntx-20220930.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5e8c6f8-f1b5-4146-b46d-c6b7786d75cd" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_f4845e9e-8da3-4257-9513-c8545902e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_884f20ff-ba06-4dbf-87a7-7136d8f92eda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c505fb9c-b520-4bde-a731-6cbc0a6128f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_370cd674-d5cc-4416-8c08-d4d42fd06746" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c505fb9c-b520-4bde-a731-6cbc0a6128f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9ac8f1a-67b2-4830-a58e-2274d859a98e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33944e53-3366-4102-a885-03e8007f5503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_572864d6-30d7-41c4-82e7-1a0e3ef70188" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33944e53-3366-4102-a885-03e8007f5503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69d10bc5-8029-4c22-8f4d-8b86ac55a304" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_44d3181c-d870-4a0e-8d71-757f4ecfd416" xlink:href="cntx-20220930.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_44d3181c-d870-4a0e-8d71-757f4ecfd416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember_c6651c23-2758-4dbe-ad7b-ba76de7c12e2" xlink:href="cntx-20220930.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedToSeriesAStockholdersMember_c6651c23-2758-4dbe-ad7b-ba76de7c12e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_939f1516-4eb0-45c2-bf74-fc5f6fce557a" xlink:href="cntx-20220930.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_939f1516-4eb0-45c2-bf74-fc5f6fce557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_5f8dde41-6aa8-483e-8b79-ec3ebe6acdc9" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_5f8dde41-6aa8-483e-8b79-ec3ebe6acdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_a7b7acae-33ec-4606-bbf6-ee7885d79b8f" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_a7b7acae-33ec-4606-bbf6-ee7885d79b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_03f4a759-e673-472d-98cc-dd1b4b771cd6" xlink:href="cntx-20220930.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a5acf890-ac06-423c-a4ba-ef43a8b0b891" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_03f4a759-e673-472d-98cc-dd1b4b771cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2de3ec6-b5a8-41e9-ad7e-bf444ea455e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_53f9eaaa-862a-4662-8084-eb4f0a94efa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:to="loc_us-gaap_IPOMember_53f9eaaa-862a-4662-8084-eb4f0a94efa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0bd27d47-54ed-455c-8440-d86c4d5f3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ffc0e603-6145-4f6f-9683-5bc27d445a7f" xlink:to="loc_us-gaap_PrivatePlacementMember_0bd27d47-54ed-455c-8440-d86c4d5f3e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_802067be-1dbe-4e58-a67f-929035b8c97f" xlink:to="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_92f2e5af-c8a8-4930-8eac-ae3bf9d175fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39902c2d-b603-44fa-8487-9ec4ecacdbe7" xlink:to="loc_us-gaap_CommonStockMember_92f2e5af-c8a8-4930-8eac-ae3bf9d175fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_09aae981-f934-47d9-bc74-a23734522291" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7d37faaf-5397-4a92-9fde-1575396c1804" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7d37faaf-5397-4a92-9fde-1575396c1804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_abdea9b1-5433-4e3d-8e8f-121c04955542" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_abdea9b1-5433-4e3d-8e8f-121c04955542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e98fc7fb-6d2c-43d9-90c5-b7ff53b828a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e98fc7fb-6d2c-43d9-90c5-b7ff53b828a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_186a255d-aacc-4cf1-885c-de44b5bd0345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_186a255d-aacc-4cf1-885c-de44b5bd0345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c1e8ee2f-1bc9-4e80-af07-37e431cb830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c1e8ee2f-1bc9-4e80-af07-37e431cb830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_abecb514-1c93-45c7-a46c-4f507c3c3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_abecb514-1c93-45c7-a46c-4f507c3c3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dda4554f-6f30-4a5c-87a2-6fb1072e82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dda4554f-6f30-4a5c-87a2-6fb1072e82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_d5989330-62b9-4d7c-b16a-d10cb7c854da" xlink:href="cntx-20220930.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_d5989330-62b9-4d7c-b16a-d10cb7c854da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3bc9f291-e6bc-4cd7-ac63-c0d4c30ef464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3bc9f291-e6bc-4cd7-ac63-c0d4c30ef464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406cb32a-9e7d-43b5-85dc-8a04ebafd289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406cb32a-9e7d-43b5-85dc-8a04ebafd289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dee8f66f-bb48-4ef6-b42d-5ecf448ff942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dee8f66f-bb48-4ef6-b42d-5ecf448ff942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_612db7a9-ef08-4a08-943f-3928f79a9dfb" xlink:href="cntx-20220930.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_612db7a9-ef08-4a08-943f-3928f79a9dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fb688cb5-e164-4b35-9633-a71e164dcb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fb688cb5-e164-4b35-9633-a71e164dcb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abdffff2-1fd7-4e61-81da-438cd55648f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abdffff2-1fd7-4e61-81da-438cd55648f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bd8db703-a49c-45be-89ed-72a2ba3228db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bd8db703-a49c-45be-89ed-72a2ba3228db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ec0c4b2e-9eff-4c2f-ba05-3517d034030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ec0c4b2e-9eff-4c2f-ba05-3517d034030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fea01e41-d461-4cce-a6a4-f3260054dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fea01e41-d461-4cce-a6a4-f3260054dbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bbdb066f-4626-4887-ba5f-049e7d4f1f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d53ddfb0-a860-4998-b543-e2af31a2472e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bbdb066f-4626-4887-ba5f-049e7d4f1f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_ee1d4988-8c71-4f5a-90dc-1b36eb3fe969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_ee1d4988-8c71-4f5a-90dc-1b36eb3fe969" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de6d48b2-7b9e-400e-9301-33e1faf505e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_9dbd5b96-6eb6-4cf8-90a4-3499b0906253" xlink:href="cntx-20220930.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_9dbd5b96-6eb6-4cf8-90a4-3499b0906253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_bbf44536-3e26-4682-8de8-e3b7abb5dff6" xlink:href="cntx-20220930.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_bbf44536-3e26-4682-8de8-e3b7abb5dff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_412f0918-715f-41a8-af87-598619422c69" xlink:href="cntx-20220930.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffb3c049-ce6c-4018-ac9e-5d2c91fb2228" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_412f0918-715f-41a8-af87-598619422c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_992d9530-2203-4f13-8c58-ac3a90f39adc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb0ed11a-6055-4075-9bf5-01f7b2bbddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cb0ed11a-6055-4075-9bf5-01f7b2bbddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_69aa8de0-656f-4d6b-be97-adcffaabcc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_66e81a75-7c9e-4952-9f36-a5aee67dbde1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_69aa8de0-656f-4d6b-be97-adcffaabcc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7e66a1-7b13-48f8-af64-6e7f8a8ab017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7e66a1-7b13-48f8-af64-6e7f8a8ab017" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96fbf4d9-3bcd-46bd-bfd1-d3dd2e15004e" xlink:to="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e634eeb3-af78-40ca-93e7-8db772d57f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_CommonClassAMember_e634eeb3-af78-40ca-93e7-8db772d57f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_12b3dfd8-9772-4db7-a78b-18fc629d7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_12b3dfd8-9772-4db7-a78b-18fc629d7a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f4f9ae0c-a27b-4d8b-97cd-956425b7654b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_56f57271-5998-40fc-9360-d2cb9f76ef9d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f4f9ae0c-a27b-4d8b-97cd-956425b7654b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_602f60ba-9763-4455-bcd2-a66b44ecfeb8" xlink:to="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0d2d70c5-9e8c-4f12-bb5d-3ddac46785eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:to="loc_srt_MinimumMember_0d2d70c5-9e8c-4f12-bb5d-3ddac46785eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76fd6738-a210-4003-8f37-84b157babe3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_164088a2-a2ec-40b5-b035-1bd8d201b9f4" xlink:to="loc_srt_MaximumMember_76fd6738-a210-4003-8f37-84b157babe3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17f2e3e5-3987-4035-9506-4689f10204f1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906fbdbe-7e87-4a47-9752-78a68a280cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906fbdbe-7e87-4a47-9752-78a68a280cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d1e61b9-6bef-4080-8e34-1e23950ca038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d04326f8-7e6c-4ca5-9ee4-9ffdad16229e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d1e61b9-6bef-4080-8e34-1e23950ca038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7ba31c3c-e84f-4346-9f93-c7943041459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a0694163-34f7-4d69-8b72-a1c60dceea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aba86d4-6792-402e-b88e-9e474dab6b6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a0694163-34f7-4d69-8b72-a1c60dceea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_473e794d-2499-4709-a880-c616dc07f813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e69d0358-d4b5-42bd-824b-25c5448a33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e69d0358-d4b5-42bd-824b-25c5448a33ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_6f8d727b-4c5f-4e7f-89ee-349a165df546" xlink:href="cntx-20220930.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_6f8d727b-4c5f-4e7f-89ee-349a165df546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_82e4ce58-7a06-4a69-b036-935a34553a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_82e4ce58-7a06-4a69-b036-935a34553a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eefffadb-8ec6-4f98-9adc-54a468b7d04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eefffadb-8ec6-4f98-9adc-54a468b7d04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b261662-6d72-4b34-a480-7534297fa2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b261662-6d72-4b34-a480-7534297fa2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c28ace78-e455-4ae5-a195-2b5c6dfe84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c28ace78-e455-4ae5-a195-2b5c6dfe84ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b3053a4-ebfb-4cff-99d7-5df49cd385b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b3053a4-ebfb-4cff-99d7-5df49cd385b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c33ed3a9-f9a1-4638-a8cc-b85aaa7fcef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c33ed3a9-f9a1-4638-a8cc-b85aaa7fcef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc97dbc2-1d43-45b4-8204-66fe93ef8375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cc97dbc2-1d43-45b4-8204-66fe93ef8375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f341a3fe-f188-4968-956a-c13ac97ee18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c26251f-9eef-41c1-9b5c-a26f18cab23a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f341a3fe-f188-4968-956a-c13ac97ee18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_740d2569-db29-4688-a7c3-b9dd36b8932d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_740d2569-db29-4688-a7c3-b9dd36b8932d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0937af1-2f04-49d2-b48d-fb68aff490cf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ae284e59-6a4d-439d-b1f1-72b69a96963e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ae284e59-6a4d-439d-b1f1-72b69a96963e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_254bbd74-21ef-4238-a492-e32466625570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e88f211b-848d-46e7-9b73-8062621526ef" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_254bbd74-21ef-4238-a492-e32466625570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3388ab38-c543-43f6-bcee-ed499d95b73f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3093573d-2d2d-4046-98fe-c9f48a63b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59688275-ddd8-4f34-8482-3d06958bb94a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3093573d-2d2d-4046-98fe-c9f48a63b7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d52149f5-a444-4fc4-950d-1509adbcedd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d52149f5-a444-4fc4-950d-1509adbcedd9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:to="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9f98e0b-5cc0-458b-98b2-c649a683a3d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_93fecb96-e988-4f0d-b0b1-0ee715cc77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28fc8db4-7519-4ce0-8244-882053d6edc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_93fecb96-e988-4f0d-b0b1-0ee715cc77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1cf5a98f-b17b-4bfc-97f9-e2ea6c62ca61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9ad1ce90-151e-4eb5-b271-a67daa73536d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9ad1ce90-151e-4eb5-b271-a67daa73536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b9c6954-b29a-46bd-b8c2-20f266686fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0b9c6954-b29a-46bd-b8c2-20f266686fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e5c050e0-7fe4-48a9-9c3d-77c448d9b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e5c050e0-7fe4-48a9-9c3d-77c448d9b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e384c3f-795f-4f00-8360-8a865dd9e5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0127632-d5f3-45d6-8ea2-9475a57c84eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e384c3f-795f-4f00-8360-8a865dd9e5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#ShareBasedCompensationScheduleofShareBasedActivityDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c004b9fc-609b-4fa9-9dd1-3dbe807157de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c004b9fc-609b-4fa9-9dd1-3dbe807157de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb463436-51ad-49f1-b062-8d8a710ea6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb463436-51ad-49f1-b062-8d8a710ea6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e8198f59-964f-4ca0-a17a-810db4e7af35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e8198f59-964f-4ca0-a17a-810db4e7af35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14e73fe8-4773-4054-a62b-99303a3a0abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4579e9d0-4223-4e99-bca4-4d09f89f2d95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14e73fe8-4773-4054-a62b-99303a3a0abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e96e935-3847-4f2b-bd4d-cc7b18f82d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5e96e935-3847-4f2b-bd4d-cc7b18f82d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e63a5357-cdb7-4483-b8cb-0620d2da5106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e63a5357-cdb7-4483-b8cb-0620d2da5106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1d513b27-aed3-475d-8e4d-fc030ff2bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1d513b27-aed3-475d-8e4d-fc030ff2bce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b8b948d6-c039-4b16-95db-f620e657e9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b8b948d6-c039-4b16-95db-f620e657e9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cbdca574-644c-4617-8031-b86a85b6b97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cbdca574-644c-4617-8031-b86a85b6b97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d2ed436-e7e7-4ff5-8c9f-7397c773b00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce095244-5161-45f4-9012-7bd63fd5df58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d2ed436-e7e7-4ff5-8c9f-7397c773b00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eac27757-3889-437b-94b9-78191ab9f69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eac27757-3889-437b-94b9-78191ab9f69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_105d44cb-b866-493b-9032-f4e2a5befb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_105d44cb-b866-493b-9032-f4e2a5befb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6784ea0-9959-4f85-ac92-1b5111b2478f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3d5585e8-a435-4035-8393-d50a36ed5efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3d5585e8-a435-4035-8393-d50a36ed5efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f33912b8-7a8b-4de5-b880-473f4a4cad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f33912b8-7a8b-4de5-b880-473f4a4cad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_08febcc5-25d7-47c8-ac03-c2f08bbf5640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_08febcc5-25d7-47c8-ac03-c2f08bbf5640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78805378-f63d-4e18-8631-279bcea9f769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4fafd10-4e7d-4ed3-bbb1-d8f7a7fc9019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_78805378-f63d-4e18-8631-279bcea9f769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#CommitmentandContingenciesOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6223d3ad-1b62-48cb-9e8f-b17d448585b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6223d3ad-1b62-48cb-9e8f-b17d448585b5" xlink:to="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c2e317-bb79-45cc-adbf-53febc54cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_35c2e317-bb79-45cc-adbf-53febc54cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_655b4e6d-5b95-48c3-89d8-8de8ae4f019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_OperatingLeaseLiability_655b4e6d-5b95-48c3-89d8-8de8ae4f019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4388fee4-3d0f-42cd-a164-55296685025e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4388fee4-3d0f-42cd-a164-55296685025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_80828703-5090-4441-ac83-df66a2998cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_80828703-5090-4441-ac83-df66a2998cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_99ec38b2-df8a-43b5-9cea-fe42c9c3d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_OperatingLeaseCost_99ec38b2-df8a-43b5-9cea-fe42c9c3d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0477e819-61aa-4519-bbf5-4d585631a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5212072-2fea-42f7-ae5e-fc8adcaa0c9e" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0477e819-61aa-4519-bbf5-4d585631a75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#CommitmentandContingenciesEmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c530c173-43b0-43bf-8e6c-52c0a3e44941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_251a08fe-21ca-4a18-a102-105f65a8e5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c530c173-43b0-43bf-8e6c-52c0a3e44941" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_251a08fe-21ca-4a18-a102-105f65a8e5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_68bdfb42-c7d2-4dcd-ab86-9f92595194de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c530c173-43b0-43bf-8e6c-52c0a3e44941" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_68bdfb42-c7d2-4dcd-ab86-9f92595194de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_10f474da-b5ce-45f4-9d9c-42a89ce379c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c530c173-43b0-43bf-8e6c-52c0a3e44941" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_10f474da-b5ce-45f4-9d9c-42a89ce379c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="simple" xlink:href="cntx-20220930.xsd#CommitmentandContingenciesCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc33543-1acd-4f30-83c5-de170dd8f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc33543-1acd-4f30-83c5-de170dd8f14d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9698b1e6-27a9-432f-8ebf-bf62abaf3a46" xlink:to="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_68118278-3b59-46dc-8732-076b78eae53d" xlink:href="cntx-20220930.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_68118278-3b59-46dc-8732-076b78eae53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_7938f194-9406-45a0-8451-86fd06eee6f1" xlink:href="cntx-20220930.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_dcf14403-ec0c-4685-9551-f8ee30061299" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_7938f194-9406-45a0-8451-86fd06eee6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_082366bc-5ad2-431f-b786-cb5dbc72477e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_aa6cc28e-1e3c-44fa-a56e-bb1fb73d4382" xlink:href="cntx-20220930.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_aa6cc28e-1e3c-44fa-a56e-bb1fb73d4382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_91591f7e-17ae-4b8d-bac0-485d13490eec" xlink:href="cntx-20220930.xsd#cntx_IntegralMolecularIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_769e6ea4-20cd-4e96-81da-59308341f1b8" xlink:to="loc_cntx_IntegralMolecularIncMember_91591f7e-17ae-4b8d-bac0-485d13490eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd8a9ec-fbef-4403-975d-e9567a710e3a" xlink:to="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5cdb9e7a-61bf-4367-88cc-224caf7c1110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c67f3922-6dd7-456c-96cc-61d195bb62f6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5cdb9e7a-61bf-4367-88cc-224caf7c1110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_211b1aa9-cd53-4cf8-8c0e-849ebf00ae88" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0eea1f22-e102-4d21-82dc-33b68f76274c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_83c778b4-07ac-49df-a0e4-269ceeb5bafe" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0eea1f22-e102-4d21-82dc-33b68f76274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3883ff6f-0c09-4842-969e-b3e22af45219" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7017fed4-0514-4584-be5a-b03d1d5aad63" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7017fed4-0514-4584-be5a-b03d1d5aad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_dbf50be5-d2ec-45ac-b2e6-49b781227991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_dbf50be5-d2ec-45ac-b2e6-49b781227991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ddab1843-6e87-4d82-bd97-a206d4eba086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ddab1843-6e87-4d82-bd97-a206d4eba086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_a84da7af-fd76-43ce-ad32-1957c5554771" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_a84da7af-fd76-43ce-ad32-1957c5554771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_c36ae485-3f1f-49b4-bb6f-11c500472223" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_c36ae485-3f1f-49b4-bb6f-11c500472223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_76db4e27-d370-4653-a4cb-608a32d41dd7" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_76db4e27-d370-4653-a4cb-608a32d41dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_4ff9643e-496c-49b8-b393-52b40094d779" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_4ff9643e-496c-49b8-b393-52b40094d779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_87085a1b-90fb-4d78-b5f3-f49c31618ebb" xlink:href="cntx-20220930.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_87085a1b-90fb-4d78-b5f3-f49c31618ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_ea841119-dc6e-48c5-8088-f22c8879031f" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_ea841119-dc6e-48c5-8088-f22c8879031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_e2338ced-bffd-440a-b094-908bcdbecd00" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_e2338ced-bffd-440a-b094-908bcdbecd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_54c4125c-caab-4f84-89fe-43d17dfb5319" xlink:href="cntx-20220930.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_54c4125c-caab-4f84-89fe-43d17dfb5319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b7f29cd7-72e6-4c46-b645-d3c27040e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_5754b5b0-7afa-4495-8ea8-621ed9552977" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_b7f29cd7-72e6-4c46-b645-d3c27040e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M. -\B[XY4\(44K4[39Y)<7W@V=A?5UAAA9AZ^/KKKW?L4#Z8T1)/G#BQ./#
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MWS;=MQ[)NK-HU9;ZWC4+!;\BW"0@R$J_ZXKIB'47H;UT;^JD(P;$34<1Q,U
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MHJIU[?PQ(Z.5-F3(Z/"J^D'62+V(5I%)\>#&V="WE?T9JWHB QI6J2V1%IO
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M]79;)L7=M4R*6S<'974"^A'+ LD\B1*GOD<9@V,DD6*&[*FA,*S(/EAW;?%
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:EJWO[?\!L]GGA_MK9Y@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008514096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CONTEXT THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-3738787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2001 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 3915, Unit #15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">225-7416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001842952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008610656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,427,118<span></span>
</td>
<td class="nump">$ 49,635,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,512,076<span></span>
</td>
<td class="nump">1,620,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">41,939,194<span></span>
</td>
<td class="nump">51,255,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">73,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,762<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">39,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,083,021<span></span>
</td>
<td class="nump">51,305,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,494,995<span></span>
</td>
<td class="nump">1,826,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,438,319<span></span>
</td>
<td class="nump">1,207,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">78,197<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,011,511<span></span>
</td>
<td class="nump">3,033,415<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,011,511<span></span>
</td>
<td class="nump">3,033,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">15,966<span></span>
</td>
<td class="nump">15,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">78,589,142<span></span>
</td>
<td class="nump">77,510,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(40,533,598)<span></span>
</td>
<td class="num">(29,254,440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">38,071,510<span></span>
</td>
<td class="nump">48,272,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 42,083,021<span></span>
</td>
<td class="nump">$ 51,305,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008380928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008596864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 3,087,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,077,566<span></span>
</td>
<td class="nump">739,598<span></span>
</td>
<td class="nump">4,946,304<span></span>
</td>
<td class="nump">2,511,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,970,521<span></span>
</td>
<td class="nump">828,464<span></span>
</td>
<td class="nump">6,052,556<span></span>
</td>
<td class="nump">1,834,645<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,048,087)<span></span>
</td>
<td class="num">(1,568,062)<span></span>
</td>
<td class="num">(11,498,860)<span></span>
</td>
<td class="num">(7,433,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">192,245<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
<td class="nump">219,405<span></span>
</td>
<td class="num">(64,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_FairValueAdjustmentOnConvertibleDebt', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">126,531<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">124,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,854,310)<span></span>
</td>
<td class="num">$ (1,442,792)<span></span>
</td>
<td class="num">$ (11,279,158)<span></span>
</td>
<td class="num">$ (7,365,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (4.00)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (20.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (4.00)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (20.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">361,067<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">355,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">361,067<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">355,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_FairValueAdjustmentOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment On Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_FairValueAdjustmentOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741000186768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Warrants issued in conjunction with series A preferred stock</div></th>
<th class="th"><div>Issued for services</div></th>
<th class="th"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Series Seed Preferred Stock</div></th>
<th class="th"><div>Redeemable Common Stock</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Warrants issued in conjunction with series A preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Issued for services</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,715<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,935<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,034,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt to equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,728,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,508,633<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,992,208<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (16,921,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 1,876,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,797,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock</a></td>
<td class="nump">137,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices', window );">Fair value of warrants issued as placement agent fees</a></td>
<td class="nump">13,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</a></td>
<td class="nump">25,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">25,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(892,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(892,049)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="num">(17,478,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">2,211,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,689,619)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,715<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,935<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,212,543<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,641,005<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 82,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(16,921,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">1,876,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,797,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,365,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="num">(23,213,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">2,948,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,162,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,508,633<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,992,208<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,948,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,837,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,212,543<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,641,005<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 82,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="num">(17,478,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">2,211,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,689,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices', window );">Fair value of warrants issued as placement agent fees</a></td>
<td class="nump">30,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</a></td>
<td class="nump">119,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">119,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="num">(53,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,030,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,030,164)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">(22,304,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">2,414,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,719,783)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,212,543<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,641,005<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 82,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</a></td>
<td class="nump">161,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">161,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,442,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442,792)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="num">(23,213,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">2,948,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,162,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">48,272,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">77,510,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,254,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">214,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,438,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,438,337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">45,394,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,071,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,692,777)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">48,272,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">77,510,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,254,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,279,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">38,071,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,589,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,533,598)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">45,394,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,071,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,692,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">241,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,986,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,986,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">41,649,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,312,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,679,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">276,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,854,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,854,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 38,071,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">$ 78,589,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,533,598)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrants Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due To Conversion To Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityDecreaseDueToConversionToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741009514448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityOfferingCosts', window );">Offering costs</a></td>
<td class="nump">$ 96,948<span></span>
</td>
<td class="nump">$ 213,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741006529248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,854,310)<span></span>
</td>
<td class="num">$ (3,438,337)<span></span>
</td>
<td class="num">$ (1,442,792)<span></span>
</td>
<td class="num">$ (892,049)<span></span>
</td>
<td class="num">$ (11,279,158)<span></span>
</td>
<td class="num">$ (7,365,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">3,087,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,803<span></span>
</td>
<td class="nump">306,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_FairValueAdjustmentOnConvertibleDebt', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,736<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(891,912)<span></span>
</td>
<td class="num">(9,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,313)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,228)<span></span>
</td>
<td class="num">(179,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,728<span></span>
</td>
<td class="nump">20,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,619,561)<span></span>
</td>
<td class="num">(3,837,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,836)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(536,836)<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the sale of Series A preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,982,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash (used in) provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,071)<span></span>
</td>
<td class="nump">4,165,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,258,468)<span></span>
</td>
<td class="nump">78,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,685,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,037<span></span>
</td>
<td class="nump">49,685,586<span></span>
</td>
<td class="nump">341,037<span></span>
</td>
<td class="nump">$ 341,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 39,427,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,427,118<span></span>
</td>
<td class="nump">419,152<span></span>
</td>
<td class="nump">$ 49,685,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,866,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Series A preferred stock issued for acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,837,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_DeferredOfferingCostIncurredButNotYetPaid', window );">Deferred offering costs in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,004,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,488<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs related to the private placement sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs related to the private placement sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(816,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember', window );">Warrants issued in conjunction with series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants in conjunction with Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">309,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">309,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember', window );">Issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants in conjunction with Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,530<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DeferredOfferingCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Cost Incurred but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DeferredOfferingCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_FairValueAdjustmentOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment On Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_FairValueAdjustmentOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012562720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of BusinessContext Therapeutics Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction the condensed consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013069424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">Risks and Liquidity <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $40.5&#160;million as of September&#160;30, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company believes its cash and cash equivalents of $39.4 million as of September&#160;30, 2022 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first half of 2021, the Company raised $5.0&#160;million in net proceeds related to the sale of its Series A convertible preferred stock (&#8220;Series A Stock&#8221;) and warrants for common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company closed an initial public offering (&#8220;IPO&#8221;), in which it issued and sold 5,750,000 shares at a public offering price of $5.00 per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $6.25 per share and a term of five years from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and 480,415 warrants converted into 9,816 shares of common stock. The Company received net proceeds of approximately $24.4&#160;million as a result of the offering. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company sold 5,000,000 shares of its common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement and received net proceeds of approximately $28.9&#160;million. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $6.25 per share and a term of 5.5 years from the date of issuance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div>In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012392688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and its results of operations for the three and nine months ended September&#160;30, 2022 and 2021 and cash flows for the nine months ended September&#160;30, 2022 and 2021. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. The consolidated financial information as of December&#160;31, 2021 included herein has been derived from the annual audited consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of convertible debt and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintained approximately $50,000 as collateral for the Company&#8217;s credit card program at December 31, 2021, which is reported as restricted cash on its condensed consolidated balance sheets.  There were no amounts restricted as of September 30, 2022, as the collateral was released to the Company in the first quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Deferred Offering Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of office equipment, furniture, and leasehold improvements and is recorded at cost. Property and equipment is depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted share-based awards based on the grant date fair value of the awards.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:55.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.889%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series Seed convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,624,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,212,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">436,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">480,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,201,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,787,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts in the above table reflect common stock equivalents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Emerging Growth Company Status </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its condensed consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012423872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;3 &#8211; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,921,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,921,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,051,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,051,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012443504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:49.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">564,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">436,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,801,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">339,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">345,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">60,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">85,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,438,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,207,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012903728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Other Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Other Debt</a></td>
<td class="text">Convertible Promissory Notes and Other Debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Convertible Notes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company previously issued certain convertible promissory notes to various investors which were converted into Senior Convertible Notes (the &#8220;Senior Convertible Notes&#8221;, and collectively, the &#8220;Convertible Promissory Notes&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into 844,824 shares of Series A Stock in February 2021, of which 430,467 shares were issued to the Company's Chief Executive Officer and an immediate family member (the "Related Party"). Due to certain embedded features within the Senior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Senior Convertible Notes was $5.7 million and was reclassified to Series A Stock. The Company recorded a non-cash credit of $9,000 in the condensed consolidated statement of operations for the nine months ended September 30, 2021 related to the decrease in fair value of the Senior Convertible Notes. For the nine months ended September&#160;30, 2021, the Company recognized $46,000 of interest expense in connection with the Senior Convertible Notes, including $23,000 payable to the Related Party, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paycheck Protection Program </span></div>In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender for a loan in an aggregate principal amount of $0.1 million (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act implemented by the U.S. Small Business Administration.  In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that the Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#8217;s loan forgiveness covered period. The Loan was set to mature in two years and bore interest at a rate of 1.0% per year, with all payments deferred through September&#160;5, 2021. The outstanding principal balance of the Loan of $0.1&#160;million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the condensed consolidated statements of operations during the three and nine months ended September 30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013079248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock, Redeemable Common Stock and Common Stock</a></td>
<td class="text">Convertible Preferred Stock, Redeemable Common Stock and Common Stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series A convertible preferred stock and Series Seed convertible preferred stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February, March and April 2021, the Company sold 738,445 shares of Series A Stock for $7.168 per share for net proceeds of $5.0 million. The Company also issued 184,597 warrants to purchase common stock at an exercise price of $7.168 to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued 24,134 warrants to purchase common stock at an exercise price of $7.168 to placement agents as a part of the Series A Stock financing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, the Company converted $6.1 million of principal and interest related to Senior Convertible Notes into 844,824 shares of Series A Stock at a price of $7.168 per share. In addition, warrants with a fair value of $0.1 million associated with the Senior Convertible Notes were reclassified into additional paid-in capital. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the Company completed its IPO in which the Company sold 5,750,000 shares at a public offering price of $5.00 per share. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and all of the outstanding warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of the offering. The Company issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.0 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock and received net proceeds of $28.9&#160;million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. The Company also issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.5 years.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrants for Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At September&#160;30, 2022, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">360,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008693120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#8220;Share Limit&#8221;).  The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of September&#160;30, 2022, 546,535 shares remained available for future grants. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based awards generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfOTk5_9bce99fb-680f-4b4e-95c7-aea7eb7069f0">one</span> to four years, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is ten years. The expiration dates of the outstanding share-based awards range from January 2028 to August 2032. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation expense related to the issuance of stock options was as follows for the three and nine months ended September 30, 2022 and 2021: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:32.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">74,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">56,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">262,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">133,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">658,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">224,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">276,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">151,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">732,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">280,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the nine months ended September&#160;30, 2022 and 2021, respectively, were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"/><td style="width:66.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">87.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">97.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.03%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.77</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">506,691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">890,058</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(55,245)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.57pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">275,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average fair value of share-based awards granted during the nine months ended September&#160;30, 2022 and 2021 was $1.38 and $3.76, respectively. As of September&#160;30, 2022, the unrecognized compensation cost related to outstanding share-based awards was $1.9&#160;million and is expected to be recognized as expense over a weighted-average period of approximately 2.25 years. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company issues RSUs to employees and consultants that generally vest monthly over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjUxNQ_9f1ec537-f564-4137-94fe-554fb0d09f1f">one</span> to three-year periods. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded share-based compensation expense of approximately $10,000 and $25,000 in research and development expense for the three and nine months ended September&#160;30, 2021, respectively, related to RSUs. There were no RSUs outstanding as of September&#160;30, 2022 or December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012836304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2022, the operating lease right-of-use asset and the operating lease liabilities were $74,000 and $78,000, respectively. The weighted average discount rate used to account for the Company&#8217;s operating leases under Topic 842 is the Company&#8217;s estimated incremental borrowing rate of 5.0%. The remaining term of the Company&#8217;s noncancellable operating lease is 0.83 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rent expense related to the Company&#8217;s operating lease was approximately $23,000 and $60,000 for the three and nine months ended September&#160;30, 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future minimum lease payments under the sublease are $80,000 at September 30, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employee Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to 3% of employees&#8217; compensation. The Company generally assumes all administrative costs of the plan. For the three and nine months ended September&#160;30, 2022, the Company provided contributions of approximately $12,000 and $54,000, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company entered into a process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#8220;ONA-XR&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#8220;Tyligand License Agreement&#8221; and, together with the Tyligand Process Development Agreement, the &#8220;Tyligand Agreements&#8221;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company retains rights in the rest of the world to commercialize ONA-XR. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Tyligand Process Development Agreement, the Company paid Tyligand $0.8 million and issued 111,576 warrants to purchase shares of common stock at an exercise price of $7.17 per share upon successful completion of the manufacturing development plan in 2021.  The warrants were cancelled in connection with the Company&#8217;s IPO. In addition, $2.0 million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#8220;GMP&#8221;)-grade compound and $3.0 million upon the Company&#8217;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) 15 years after the date of the first commercial sale of product in the Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration and Licensing Agreement with Integral Molecular </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsAb&#8221;) for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $0.3 million, granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8 million, and expensed these costs to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $55&#160;million, sales milestone payments totaling up to $130.0 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. In the second quarter of 2022, the Company expensed $0.5&#160;million in acquired in-process research and development related to a development milestone achieved under the agreement with Integral.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require upfront payments and long-term commitments of cash.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013079248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Event<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 7, 2022, the Company entered into a Development and Manufacturing Services Agreement (the &#8220;Lonza Development Agreement&#8221;), with Lonza Sales AG (&#8220;Lonza Sales&#8221;) and Lonza AG (collectively, &#8220;Lonza&#8221;). Under the terms of the Lonza Development Agreement, Lonza will provide services relating to the development and manufacture of the Company&#8217;s anti-claudin 6 bispecific monoclonal antibody product (the &#8220;Product&#8221;) in accordance with the project plan attached to the Lonza Development Agreement and any other work as may be agreed to between the Company and Lonza. The Lonza Development Agreement will terminate upon the completion of the agreed upon services, unless earlier terminated by the Company or Lonza for uncured material breaches, insolvency of the other party, or if a party determines that it is not possible to complete the services for material scientific or material technical reasons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, on November 7, 2022, the Company entered into a License Agreement (the &#8220;Lonza License Agreement&#8221;) with Lonza Sales. Under the terms of the Lonza License Agreement, to the extent incorporated into the Product, Lonza granted the Company a non-exclusive license to use certain proprietary Lonza intellectual property and systems for the Company to develop, manufacture and commercially exploit the Product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008470928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div>In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and its results of operations for the three and nine months ended September&#160;30, 2022 and 2021 and cash flows for the nine months ended September&#160;30, 2022 and 2021. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. The consolidated financial information as of December&#160;31, 2021 included herein has been derived from the annual audited consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div>Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of convertible debt and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured </span></div>limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span>Property and equipment consist of office equipment, furniture, and leasehold improvements and is recorded at cost. Property and equipment is depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted share-based awards based on the grant date fair value of the awards.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">Recently Issued Accounting Pronouncements <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued ASU 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its condensed consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012825440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:55.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.889%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series Seed convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,624,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,212,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">436,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Unvested restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">480,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,201,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,787,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013086880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,921,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,921,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,051,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,051,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013027376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:49.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">564,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">436,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,801,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">339,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">345,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">60,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">85,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,438,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,207,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013167648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At September&#160;30, 2022, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">360,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008583568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">Share-based compensation expense related to the issuance of stock options was as follows for the three and nine months ended September 30, 2022 and 2021: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:32.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">74,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">56,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">262,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">133,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">658,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">224,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">276,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">151,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">732,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">280,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the nine months ended September&#160;30, 2022 and 2021, respectively, were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"/><td style="width:66.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">87.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">97.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.03%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.77</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-Based Award Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">506,691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">890,058</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(55,245)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.57pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">275,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013031440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br></strong></div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember', window );">Context Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740998080960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 29,254,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,533,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,635,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,427,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,853,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Shares issued upon conversion of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,948,309<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 3,034,526<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember', window );">December 2021 Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember', window );">Issued in connection with 2021 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issuance, consideration received</a></td>
<td class="nump">$ 28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741012838944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741008660080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">7,201,504<span></span>
</td>
<td class="nump">5,787,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,212,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">1,341,504<span></span>
</td>
<td class="nump">436,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741006391136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details) - Recurring - Money market funds - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,921,341<span></span>
</td>
<td class="nump">$ 49,051,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,921,341<span></span>
</td>
<td class="nump">49,051,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740997991632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 564,989<span></span>
</td>
<td class="nump">$ 436,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">1,801,041<span></span>
</td>
<td class="nump">339,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">345,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">60,289<span></span>
</td>
<td class="nump">85,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,438,319<span></span>
</td>
<td class="nump">$ 1,207,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741006452960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Other Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Issue date fair value</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Convertible debt beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020 | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020 | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020 | Series A Preferred Stock | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="nump">430,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember', window );">Payment Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740999144304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,866,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants reclassified into additional paid-in-capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,853,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares', window );">Conversion of preferred shares and redeemable common shares</a></td>
<td class="nump">4,853,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issuance, consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember', window );">Issued in connection with 2021 IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember', window );">Issued to Series A Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember', window );">Issued in Connection with IPO | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to preferred stock (in shares)</a></td>
<td class="nump">9,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember', window );">December 2021 Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember', window );">Issued in connection with 2021 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued in 2022 for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member', window );">Senior Convertible Notes, April 2020 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,351<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="nump">453,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare', window );">Temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,948,309<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 3,034,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Senior Convertible Notes, April 2020 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_DebtConversionConvertedInstrumentPricePerShare', window );">Debt conversion, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DebtConversionConvertedInstrumentPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DebtConversionConvertedInstrumentPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741000095408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember', window );">Issued in connection with 2021 IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">24,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember', window );">Issued in connection with 2021 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued in 2022 for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740998209088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock', window );">Annual rate at which authorized shares of common stock increase</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based award contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,521<span></span>
</td>
<td class="nump">$ 151,075<span></span>
</td>
<td class="nump">$ 732,803<span></span>
</td>
<td class="nump">$ 280,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of grants during period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,349<span></span>
</td>
<td class="nump">17,775<span></span>
</td>
<td class="nump">$ 74,256<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,172<span></span>
</td>
<td class="nump">133,300<span></span>
</td>
<td class="nump">$ 658,547<span></span>
</td>
<td class="nump">224,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">1,266,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock awards | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741006389600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 276,521<span></span>
</td>
<td class="nump">$ 151,075<span></span>
</td>
<td class="nump">$ 732,803<span></span>
</td>
<td class="nump">$ 280,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">14,349<span></span>
</td>
<td class="nump">17,775<span></span>
</td>
<td class="nump">74,256<span></span>
</td>
<td class="nump">56,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 262,172<span></span>
</td>
<td class="nump">$ 133,300<span></span>
</td>
<td class="nump">$ 658,547<span></span>
</td>
<td class="nump">$ 224,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741013287824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">87.02%<span></span>
</td>
<td class="nump">97.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.17%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740998198928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period ( in shares)</a></td>
<td class="nump">506,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted during the period (in shares)</a></td>
<td class="nump">890,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(55,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at period end (in shares)</a></td>
<td class="nump">1,341,504<span></span>
</td>
<td class="nump">506,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at period end (in shares)</a></td>
<td class="nump">275,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at period end (in shares)</a></td>
<td class="nump">1,341,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at period end (in dollars per share)</a></td>
<td class="nump">3.27<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at period end (in dollars per share)</a></td>
<td class="nump">5.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at period end (in dollars per share)</a></td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at beginning of period</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at September&#160;30, 2022</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at September&#160;30, 2022</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139740997945440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 73,752<span></span>
</td>
<td class="nump">$ 73,752<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum payments due</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741000109024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139741002516352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Collaboration Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,837,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember', window );">Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Maximum obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent', window );">Quarterly sales payment due upon completion, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod', window );">Quarterly sales payment due upon completion, period of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember', window );">Integral | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Maximum obligation amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum', window );">Maximum development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Maximum sales milestone payments</a></td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty payment, percent (up to)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember', window );">Integral | Series A Preferred Stock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares)</a></td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 100 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 300 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>cntx-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cntx="http://www.contexttherapeutics.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cntx-20220930.xsd" xlink:type="simple"/>
    <context id="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id897838cf09a4fb98dd25ffc123540c1_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="i061af97dccdb4fda98333d1bb3013560_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1081ba53b574bb2adf21cf126fc5f4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i02120c98aecd422bb636957763abc278_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78abb364b55c453cb3733b76148eb098_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91d778453bdd415ca0474d3b80c97e81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ab19c1394c44429ac9cf701c02bacd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8044192b7fa3405f8f099c5b69712352_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c7d6b0e50bc4558a6bf3ad8ad190e64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dbda5f1db214fb88786236031b5e24c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8d87d55ccb734efb9c7ed1999f656107_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d0f5d0c94a24a37bbe2603f3a941447_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0dff8bbfea2e482896c4ab248a7dda24_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9523681451b740f0a62eab036c049fcf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i23e70673670b454697bd3e735f7ead67_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab094eb4f1c449799a6a0a40dfaefe12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5e5be68e8b1d499185e82be5b03a485f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1985a71fd2e840d0a0b035d856815619_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i053e2d5b4fdd45cba9f89d705600f026_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3c334b6a33324fb8ab9e49483ece3d16_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibed9ebe777744942b2d52251d599962a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i469bd896d0404212882a523d504522da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2d5ed2cb14343529f70dad75a4e6f8d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i21e677df66a94349ade55221ca159924_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd6441b83d394e10b602af00c07a1e9a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf64ab93cf964595a69c22ef2bf1bbc3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8e4251d780d94171abc72a54e3f1d40b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i72999784f84f4f78976de510cce92938_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifb364b5e1db7443e829eab3187e71baf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibfd008432ea34dd495de31355c35c5b8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab1984306aeb45b086de0b8f791fa525_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if4538f14815a4c249d92da084a9a25ed_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i41ac2f42af1e46f28082b9e44edd8bd1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79bf85e416f34002b19f3f5ac5bdba47_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39eb46827db041658824ba64d452487b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ba3cd3b4cb54008bf47ddd2a959ae16_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i88cf0f3abb49481aa205ca8023e30fbc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia720be76271949ebb4bd4ecc9a63607a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic9faae0f7b5144a19efc12326f0f220e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib5595b49782e4a2696ca3a2a49ad6925_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd60ff9a89c748609e3e159d17b22413_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id904dd6c948942fa95d470d8f7fc4c71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i017447a0256f4196a4817dfa28f8e101_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90d3dccad9594e50872f23a00f725fff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57ab355349f74b32990f6a5b1420ee6e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf9a2c2fcc664d35b2b5d1dd7995760c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1810fec077b40c0930be13c655ee345_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e87e049d31a4a989377c27f50ee7a17_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i02ebe5df39614a3fa046b9dec55140fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i539fb2bc4bb345aabb6f8dfdd9ba6f6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i799f37f97f4a4744b4bc59d2d24293d4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6e9c37e644824b0d84879f473b9cf77e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib54220fa169e4707885970ecdc945467_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica83b1571ad4481baeba3aef75b2db8c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5486e6d972204740a82b09a1b927049f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d8d9514a6a745a0a488a3f6c4207777_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2f8b2d08e4604b7e9b651b2457ac44d6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i06b116b88064480fb840617b61eabdf0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i896495c2f35f47858d0e21309439c662_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaeaf8efe24bd416fa817b05f01fdc15f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3db5b6f078814f8e95ab6d13d23d25e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i38bed32e2197428db5b6ab17d60a789b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i065c7e802d2941d1a5f4e25656709a56_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i455a6e88e29d4ef2a78a2a38f261295b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i046810a1fd7d400da5a699c022e8d9f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5737c76ba5424054a9aeed887403599b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fdea296ead7488282261bdc319ef5d1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5dbc3701bbc4b54a21909b1998fe19c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0008c07757234399a7495a0798d22f5b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2471273c7ae344129757969381e9512f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6e9a07f9c2946a8b52c28630a825031_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cntx:ContextTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i18dfaee2fd0749dea6d251e8a01ce718_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i07512b61ceef49069b0fde3492828089_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ic464fb81556f45ecbf3818ed885dba50_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ifdb18b5ff7dd4565b0689e48dd33cb0f_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic30db45c99284874bb93ab62a6ede5bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic97c72893b0b45f9ac13a510ac0ce919_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7be4c088e38d48fca44ed64b3a9cc35b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba7c76c52c0843d4b179f34fcc164f44_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i661fcc5b4602480e8cc52211d82446d0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i855cb448971a4619b544a94285a0cc96_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad85129c8a58499f94bd8e3d2af6078f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8472e008fd846c1af7dbda2c91dddc6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5403ef21acee45fbab5d4ad32b444c79_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91b81907a7d94fc1a709a3a7f59a42f2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4603fb59699f4e428a7f38a3b3c0ae44_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if18940842a4d4141bb83557faaaa3f5d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9ea3bc90fc5e45babe9d16439371f804_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib9cfc17885754c02bf2915c69856a33b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibdfc0ddf63e14d7082cb9c967c847020_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if6eea0a991414c36a0929d31f1d3d7f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5916c4827b84fc8b33f7160c0b78aab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72e8a39dfcb84e878ff3f8aa02b39b95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefc04475ba4c443bb02c7f09ee9c52a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i52408a7bafe3490ea2b90900d2fd960a_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i27893806b30342149eb85b8143f8df92_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65e645342cf74ea6b3b63d9596768247_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88ad34f7e1fb4d8694c59f20b25c8ba6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaae18aea4a6d4d3c9f8d5c3d37e7307e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ib0ba8f04e8d44ad486f7a21607ab601a_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ie29255ae26c54473ad60f4e96b040b6a_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i02d517722f68464aa57cb746d8b6b0fc_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i37765677fef04878bfd307079cffd395_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i94a68f56ad3d4f398d8120b6f54fc354_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="iea511a0f86dd4c4daa7a2411ba8f627d_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ifb7a61f34a4b428e9a376347e43312f6_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iab205c27896840a48993517f0d658e53_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i88481b1f040d4ae9ab9358ec2a521621_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13ff4879231b4c58a0d8f431b824853d_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf6909f0d3984eef85455ec758334932_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i7142d15699314123900d44fdfb1d6fa7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0f0d08a54b2d45fcbab6217ef7c19f5c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b6b6924916f49cebf4a3197558fd9aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i44b557d2dee24d6d85852c77416f09b7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b03a95d6ac1446db1df7032d377d274_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i893010e7c4d84530bb4e535807bafd81_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6bfb3d422efb4a2184822401861fbbb9_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i9d27a8b650fb459ea73fa6afb06d6686_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i390779b4e1374f78a3d2ff4696312717_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3552069f01754175946fbde459157a66_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaac7d80114ef46d39ae9a53271640ba1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia3f47e32ce8e4ceab933f1129b620c5e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib73ab2ac402a4838afab49d9909a77b3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i452d4086812e4e2eb52bd1a594c530b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if870d3ee8de04697b45e9489a10d6c63_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia42107d884244b2ab5d0ba0cf3931add_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id527e215cc174d55a56cc5895cb43547_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3a3137493924173b60421527f2075d0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibffa84374b394851b73ca24a8916a301_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd804bfec7bc4f1d89cace194a5d9f99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia4a410a7e6134fa78385a8cc70a725e0_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i3aa6a3da81d5470497285d540411a506_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ib894c6511aad4955ac97436b31cd674f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89136a0062a546e4bba3db98f38f30c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i629d249a546f43ebb5ec4d9fc839c160_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb8fbecc9e72463d930d63daeec62a21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8773e0c5834143cbb0d43e34a17e2a92_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="ibc6ef50417cb4013b7ac39e1693b2f04_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibcabaf70069543ae99e3fe4be7d87d00_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ic7d331e039ce4907b44d8c6829eb96ab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf836415560143e7aa246d7036b09772_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN18zLTEtMS0xLTQ5NzEy_af830281-1932-429b-b13f-61feb33b050f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN180LTEtMS0xLTQ5NzEy_a9f4c4e8-382f-4241-94db-1efb7379573e">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN181LTEtMS0xLTQ5NzEy_694c2193-a4a7-4fac-bd5b-bdd6dcee51e0">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN182LTEtMS0xLTQ5NzEy_ff061ddd-1513-4fe9-ae9f-8c88fcea2010">0001842952</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180L2ZyYWc6YTFmZWU0MWQ5NjZiNDBhNWEyYWQwNTczODU5ODk1Y2EvdGFibGU6ZmI1NTRhYTY4ZWFlNGQ3M2I0NTBkM2MzNTQyMDE2MDcvdGFibGVyYW5nZTpmYjU1NGFhNjhlYWU0ZDczYjQ1MGQzYzM1NDIwMTYwN183LTEtMS0xLTQ5NzEy_5c08594f-49d5-4ea3-b99d-f148fc6139c5">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6bfb3d422efb4a2184822401861fbbb9_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfOTk5_9bce99fb-680f-4b4e-95c7-aea7eb7069f0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia4a410a7e6134fa78385a8cc70a725e0_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjUxNQ_9f1ec537-f564-4137-94fe-554fb0d09f1f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTYw_4de4dd48-715f-4804-9d34-3628a59ba706">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6ODQ0YjEyODk2MjhkNGU2NTkzM2E0ZjY1NWNjZjYxMWMvdGFibGVyYW5nZTo4NDRiMTI4OTYyOGQ0ZTY1OTMzYTRmNjU1Y2NmNjExY18wLTEtMS0xLTQ5NzEy_577051d8-18ff-4e1a-9a56-1495161c1546">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTM_2563fbd2-5def-43e9-bd53-484773d47885">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NzZlZjQ0ZGM0YzgzNDUyN2IzMTI2YjdlZmVjMmI4MzgvdGFibGVyYW5nZTo3NmVmNDRkYzRjODM0NTI3YjMxMjZiN2VmZWMyYjgzOF8wLTEtMS0xLTQ5NzEy_d572da6b-2f6c-460b-bff1-96ac5911e204">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU0_c4429d95-bfca-4f70-9055-127aa07cfe81">001-40654</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ5_20db404a-91ce-475f-a40a-afe65bfc1a0e">CONTEXT THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NGZhNWUzYzc4YjFmNDI5ZWI2NjVlNTI3M2ZlMjgwMjcvdGFibGVyYW5nZTo0ZmE1ZTNjNzhiMWY0MjllYjY2NWU1MjczZmUyODAyN18wLTAtMS0xLTQ5NzEy_a7ce617b-8e54-4d2c-acf1-ef5ffa85aa14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6NGZhNWUzYzc4YjFmNDI5ZWI2NjVlNTI3M2ZlMjgwMjcvdGFibGVyYW5nZTo0ZmE1ZTNjNzhiMWY0MjllYjY2NWU1MjczZmUyODAyN18wLTEtMS0xLTQ5NzEy_4695dd05-5e7f-4461-b4ff-c09d8fc6b334">86-3738787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUz_c7a51b91-268f-46d1-aac5-bab51f86b9d4">2001 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTYx_8005dd00-b537-421c-a2ce-d0499a27ee13">Suite 3915, Unit #15</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU3_96821f27-b9cd-476e-a444-6982c1e61b6a">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUx_b11ef277-d7f5-4f19-a6e6-893f46c60a24">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF81MTE_48b9f4b7-ad38-41e7-b3c3-2cc22eea6555">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF81Nzg_7b25c4db-01d7-4a28-85d6-c54f34d589d8">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ3_81426f8c-b5da-4f53-beb0-e3ccc2aa7512">225-7416</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTAtMS0xLTQ5NzEy_1751a0f8-bb29-4fb2-acfd-2f918ac7e7ff">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTEtMS0xLTQ5NzEy_03915ff1-bf96-43f0-b54b-ca2ba0cf0d86">CNTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6YjkxMDUzNjAxZTUxNDU5OThkZjIxYWU2MTA5ZWVlYmEvdGFibGVyYW5nZTpiOTEwNTM2MDFlNTE0NTk5OGRmMjFhZTYxMDllZWViYV8yLTItMS0xLTQ5NzEy_f9596a07-d76c-4f08-b27e-a79e677643c8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTQ4_a20de20c-5b12-4043-85db-0f99c2b93297">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTUy_6ad24768-d099-46b9-9079-150b3930a48b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18xLTAtMS0xLTQ5NzEy_6694b805-9a91-4a1d-8e4a-463c6b6d5c60">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18xLTQtMS0xLTQ5NzEy_852e4e3e-c33b-44ea-8e1c-d4ba9e6617e3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGFibGU6MmI1MTkzM2UyOWYxNGNkN2I4MDcxNmIzZThlN2E4ZWMvdGFibGVyYW5nZToyYjUxOTMzZTI5ZjE0Y2Q3YjgwNzE2YjNlOGU3YThlY18yLTQtMS0xLTQ5NzEy_a7eaa096-4cb6-438f-8532-4d364a60c15e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU4_347cd3f4-d248-41ae-9d68-19cb429ad862">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTU5_4598a963-1061-42be-96ad-73ab06f1b850">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id897838cf09a4fb98dd25ffc123540c1_I20221104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18xL2ZyYWc6YzM3M2JiOTAxZmQ4NDIxZGE5ZTM1ZDNlMTgxMDBmMTAvdGV4dHJlZ2lvbjpjMzczYmI5MDFmZDg0MjFkYTllMzVkM2UxODEwMGYxMF8yMTM2_a777224a-c6c0-4fdf-9440-cce338e43ca6"
      unitRef="shares">15966053</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNC0xLTEtMS00OTcxMg_713a9893-9586-4f9b-bfbe-9136002ff5e0"
      unitRef="usd">39427118</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNC0zLTEtMS00OTcxMg_64315d63-9a80-4efa-a05e-11a8f5b3d86e"
      unitRef="usd">49635197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNS0xLTEtMS00OTcxMg_46409073-af8a-4adf-a65c-3664281eed45"
      unitRef="usd">2512076</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNS0zLTEtMS00OTcxMg_c35e04e2-9fbc-48c6-84ab-8340d8a87326"
      unitRef="usd">1620164</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNi0xLTEtMS00OTcxMg_29b0b6e2-1456-4888-8a6e-f3ec9c6d6eba"
      unitRef="usd">41939194</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNi0zLTEtMS00OTcxMg_bc795ec6-4f1b-43ca-a11e-f07719088d85"
      unitRef="usd">51255361</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNy0xLTEtMS00OTcxMg_6b4c2220-fcb2-470a-894c-6e2e4cb9e14d"
      unitRef="usd">73752</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfNy0zLTEtMS00OTcxMg_2714bbe7-ba7e-4bf9-bcae-ff31c378935d"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOC0xLTEtMS00OTcxMg_e767fd3c-fc7b-4a43-83c1-c67f07357974"
      unitRef="usd">30762</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOC0zLTEtMS00OTcxMg_0905f010-9cba-4745-b41f-01271e8e8f85"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOS0xLTEtMS00OTcxMg_29fb71a6-551f-40c9-9402-d5364b084351"
      unitRef="usd">39313</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfOS0zLTEtMS00OTcxMg_dc6233f4-5053-4ef9-8bf0-36fd70942870"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTAtMS0xLTEtNDk3MTI_700edbf1-fb6d-4b6b-8bc1-155e7e8f8ece"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTAtMy0xLTEtNDk3MTI_28d86d01-2c58-4cfb-b517-fd5c6231fae7"
      unitRef="usd">50389</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTEtMS0xLTEtNDk3MTI_03ed4867-0ca2-469d-a519-7d3062d2d688"
      unitRef="usd">42083021</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTEtMy0xLTEtNDk3MTI_754e4397-cee3-4f64-b0d7-5d4af951e4eb"
      unitRef="usd">51305750</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTQtMS0xLTEtNDk3MTI_fa57f685-f1c2-4736-99fd-244ad6985315"
      unitRef="usd">1494995</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTQtMy0xLTEtNDk3MTI_8d7a1898-7c5a-48f5-95f7-b4b54c965c0b"
      unitRef="usd">1826294</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTUtMS0xLTEtNDk3MTI_3c3eac73-bfc7-47f7-b164-cc8f8da5b7d2"
      unitRef="usd">2438319</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTUtMy0xLTEtNDk3MTI_5d5e2dac-5cf0-47cb-bdda-099f29227799"
      unitRef="usd">1207121</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTYtMS0xLTEtNDk3MTI_21f96253-752f-4d6b-9704-bd52b51a5f84"
      unitRef="usd">78197</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTYtMy0xLTEtNDk3MTI_fa47fdd5-298b-4e94-a0ae-dee6ea1163ce"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTctMS0xLTEtNDk3MTI_5ea7117b-f383-4d98-85bf-4dd2473a3379"
      unitRef="usd">4011511</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTctMy0xLTEtNDk3MTI_d8323ee6-5466-41b6-ab40-c542c2e9aca9"
      unitRef="usd">3033415</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTktMS0xLTEtNDk3MTI_826ebea7-3b1c-4a6f-b67c-eca76565bea7"
      unitRef="usd">4011511</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMTktMy0xLTEtNDk3MTI_4cba41af-1add-40bf-a99d-62b74d920005"
      unitRef="usd">3033415</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjAtMS0xLTEtNDk3MTI_950a32ee-686b-4a6f-a5db-3a2ee82cad97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjAtMy0xLTEtNDk3MTI_f8a4690a-da19-4e24-ae79-058a85bd1ec6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8yMQ_a737279c-1313-4ccf-840a-4b9957d0cc6b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8yMQ_d325b640-f562-4350-8899-0cad2a27b4ca"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8zNQ_b4754ddc-ecba-4267-9ff7-dd3aee026cad"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV8zNQ_c4825cd1-7415-4f9e-b50f-5c280b0a0ae4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_5802f078-0785-431c-ba80-946facd12cd4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_7de1e803-5185-4da9-b9e5-00fb643eb0cf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_9ca7d8ac-2895-42d2-9e61-43238d8afd9d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjo3ZjVjZWU5OWMwMGI0MDI0OGRjZmMxMDI4MTY0NGQ2MV81Nw_cd529052-e105-48ce-bee4-668df48a979c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMS0xLTEtNDk3MTI_ec56b248-55b1-415a-ae01-fb2a5e5b9051"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjItMy0xLTEtNDk3MTI_9ebdfdcd-e688-40b3-9f04-d08508993c3d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8xOA_258f6e0a-3732-428b-b630-089456267097"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8xOA_f58133ab-e3d5-46e6-99b5-3f5e4543007f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8zMg_4661b880-a904-4966-9dc6-c808b9a24d3d"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV8zMg_9026d6a8-f2a2-4be3-b358-c6bc1b0e1dae"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_4e1cdd3c-1d10-4dc4-a964-81e75967eb56"
      unitRef="shares">15966053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_6bdfc8af-e75a-470c-89a7-b0f715fd1839"
      unitRef="shares">15966053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_9b432b29-2f45-48cb-b402-7ab709474eee"
      unitRef="shares">15966053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjpkNzdhMGYzMGJmOWQ0YWI0ODhmNTE2MzQ2YmZhNDQ4OV81NA_ee1678b4-28c3-415b-8e93-af1ab45fd526"
      unitRef="shares">15966053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMS0xLTEtNDk3MTI_6b7146f5-ce9b-42f2-8b68-633181d723db"
      unitRef="usd">15966</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjMtMy0xLTEtNDk3MTI_7e477ba8-c521-43c6-a577-6503eb796275"
      unitRef="usd">15966</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjQtMS0xLTEtNDk3MTI_71932b6e-8c1e-47c2-9f1d-be846450cb93"
      unitRef="usd">78589142</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjQtMy0xLTEtNDk3MTI_98a972e8-0cfc-4af7-84fa-4e6ceb0d8c15"
      unitRef="usd">77510809</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjUtMS0xLTEtNDk3MTI_136f98ff-446e-4d7c-9900-3e0121bd26ea"
      unitRef="usd">-40533598</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjUtMy0xLTEtNDk3MTI_83c4aae7-fe1b-4134-89b6-68bcdfcc1bb7"
      unitRef="usd">-29254440</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjYtMS0xLTEtNDk3MTI_696f0b53-0c2d-4f88-bd6b-ca3f95a73564"
      unitRef="usd">38071510</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjYtMy0xLTEtNDk3MTI_deba6bf5-c07e-495a-82ed-fe4183ac8766"
      unitRef="usd">48272335</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjctMS0xLTEtNDk3MTI_9699d476-0d86-48e5-9c02-c096c17c88da"
      unitRef="usd">42083021</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yMi9mcmFnOmRiZjU3MWE1NDA3MDQ4ZTlhODFiOGUzMjJkNWEyYTlmL3RhYmxlOjdiZjA3MjZiMWRiMDRhMDc4MDU5Nzg2YWE3OTBmOTU1L3RhYmxlcmFuZ2U6N2JmMDcyNmIxZGIwNGEwNzgwNTk3ODZhYTc5MGY5NTVfMjctMy0xLTEtNDk3MTI_9fadf479-d4cd-4c4c-8c34-d1ed523f5edc"
      unitRef="usd">51305750</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy0xLTEtMS00OTcxMg_923581f2-05c8-4a8b-8e8d-03b0e6476093"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy0zLTEtMS00OTcxMg_461e75da-f558-4806-ad8e-47c1a2cd0a20"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy01LTEtMS00OTcxMg_068d0f5b-6168-44ac-8d54-7bbc5d2771b3"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMy03LTEtMS00OTcxMg_ca647cb7-4d25-4bb0-947c-db938192c579"
      unitRef="usd">3087832</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC0xLTEtMS00OTcxMg_1fa241ab-0901-4b91-853a-88d0d26e2c24"
      unitRef="usd">2077566</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC0zLTEtMS00OTcxMg_49e02b83-9c59-4e18-86c8-41b12204e4cf"
      unitRef="usd">739598</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC01LTEtMS00OTcxMg_773f1b3c-fa2e-4c88-9c58-63f2ac8ba166"
      unitRef="usd">4946304</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNC03LTEtMS00OTcxMg_c5a36242-223b-4c20-a34f-3f55b6540ba3"
      unitRef="usd">2511438</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS0xLTEtMS00OTcxMg_ac70a21c-6535-4f25-b804-7019f302c73b"
      unitRef="usd">1970521</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS0zLTEtMS00OTcxMg_38806a74-4da8-4e33-a966-8cf10de4e863"
      unitRef="usd">828464</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS01LTEtMS00OTcxMg_57a3cd17-c053-4649-bb1d-2a0d3e985ad2"
      unitRef="usd">6052556</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNS03LTEtMS00OTcxMg_0cfe3518-05ce-4b0c-80fb-ffe21b7d62f4"
      unitRef="usd">1834645</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi0xLTEtMS00OTcxMg_4b0e3c2f-8a81-4f12-b4b1-e921fa45c2af"
      unitRef="usd">-4048087</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi0zLTEtMS00OTcxMg_6f441a10-734b-4f2e-aa9c-705b3123cc91"
      unitRef="usd">-1568062</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi01LTEtMS00OTcxMg_028e5797-1a0d-4ee1-b22f-e6f310866a84"
      unitRef="usd">-11498860</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNi03LTEtMS00OTcxMg_f23cb09b-bb4a-43ff-b21c-c4d317198a36"
      unitRef="usd">-7433915</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy0xLTEtMS00OTcxMg_a196acd3-0545-4a4b-b323-a9268de6dcd5"
      unitRef="usd">192245</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy0zLTEtMS00OTcxMg_01827078-a9b4-4055-befc-756d3aa034bf"
      unitRef="usd">-1261</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy01LTEtMS00OTcxMg_7b6d6295-4395-44ec-b924-60f7cb9655c2"
      unitRef="usd">219405</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfNy03LTEtMS00OTcxMg_f0ed5bcb-dc55-4834-a145-e804203675e1"
      unitRef="usd">-64555</us-gaap:InterestIncomeExpenseNet>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC0xLTEtMS00OTcxMg_46a2813e-c848-487d-9341-5ca6e2e86be5"
      unitRef="usd">0</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC0zLTEtMS00OTcxMg_a02ef09c-58bb-4ae2-8052-7ee15e84ca74"
      unitRef="usd">0</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC01LTEtMS00OTcxMg_a8182f6d-cbb1-4db1-9356-c51db94f0c97"
      unitRef="usd">0</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOC03LTEtMS00OTcxMg_5f1557c2-c21d-409a-b665-ae862ebf03eb"
      unitRef="usd">9317</cntx:FairValueAdjustmentOnConvertibleDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS0xLTEtMS00OTcxMg_b322d735-ca0d-4538-a90a-0f31240d54df"
      unitRef="usd">1532</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS0zLTEtMS00OTcxMg_c67fecf2-4f6c-4ce4-aeea-45be602c2eff"
      unitRef="usd">126531</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS01LTEtMS00OTcxMg_8ecd4cb8-7b5d-4ccf-84a6-d2e0fe9e59b7"
      unitRef="usd">297</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfOS03LTEtMS00OTcxMg_1291771a-df82-4d03-881f-a0dd0cfb4713"
      unitRef="usd">124148</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtMS0xLTEtNDk3MTI_989bbae3-09af-455b-a2e3-b140ab0b494d"
      unitRef="usd">-3854310</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtMy0xLTEtNDk3MTI_878e1968-4f4a-410e-b5fd-75b120200a7a"
      unitRef="usd">-1442792</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtNS0xLTEtNDk3MTI_972bf84c-4ba2-4438-8ef6-b93c905fc64c"
      unitRef="usd">-11279158</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTAtNy0xLTEtNDk3MTI_496aaa9d-2ca9-43b2-8d87-aaf75dd89e5c"
      unitRef="usd">-7365005</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMS0xLTEtNDk3MTI_0964f98c-37f0-43ad-9c92-bb3134f0d57c"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMS0xLTEtNDk3MTI_883c2eb6-758c-4238-9dbb-12917f175739"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMy0xLTEtNDk3MTI_e1323283-cc8b-441a-98a5-29aa8492c789"
      unitRef="usdPerShare">-4.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtMy0xLTEtNDk3MTI_ebea069b-aae3-4776-903d-0b5c00eb6108"
      unitRef="usdPerShare">-4.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNS0xLTEtNDk3MTI_6231ed5c-c4f4-4e63-a692-d80175410285"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNS0xLTEtNDk3MTI_b810ca34-3826-4683-b7f8-de5acc461c78"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNy0xLTEtNDk3MTI_985ef353-01fb-435f-8740-6c87d4976238"
      unitRef="usdPerShare">-20.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTEtNy0xLTEtNDk3MTI_dd6da342-4977-4d95-9c3f-68218bf2c5cf"
      unitRef="usdPerShare">-20.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMS0xLTEtNDk3MTI_7563f6eb-88f5-47b1-9168-2fcdb0077783"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMS0xLTEtNDk3MTI_b52672e6-0de4-4936-9b7b-8b4fcc3f49ad"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMy0xLTEtNDk3MTI_4001669d-eb20-49c4-85a2-c18a764c2dab"
      unitRef="shares">361067</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtMy0xLTEtNDk3MTI_6dd492a1-da8a-444a-9d6e-2bfc577a5b6d"
      unitRef="shares">361067</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNS0xLTEtNDk3MTI_c1c8c4a3-fc9c-4791-b105-6add37c2fe6c"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNS0xLTEtNDk3MTI_cbeb1744-0cbe-4135-8f18-82524f0c62ca"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNy0xLTEtNDk3MTI_920257d8-1056-4fba-a87b-e113a12aa6f9"
      unitRef="shares">355087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yNS9mcmFnOmU2NWE5ZjhkOGYyZjQzZWY4YTE2MjgyZjZlNWNiMmQ5L3RhYmxlOjMzOTEyNjQ3NjQ3YTQ5YzViODI1OGFhNGQxZDQ4M2ZjL3RhYmxlcmFuZ2U6MzM5MTI2NDc2NDdhNDljNWI4MjU4YWE0ZDFkNDgzZmNfMTMtNy0xLTEtNDk3MTI_a27dd9db-132f-4a93-8f38-3028d6b66ae4"
      unitRef="shares">355087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i91d778453bdd415ca0474d3b80c97e81_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xLTEtMS00OTcxMg_0f789e0f-c8bb-4ddc-876c-7d7d83478475"
      unitRef="shares">210715</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i91d778453bdd415ca0474d3b80c97e81_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0zLTEtMS00OTcxMg_666fa77b-6758-4ff9-9c73-55b3e0fcf220"
      unitRef="usd">1400935</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7ab19c1394c44429ac9cf701c02bacd3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi01LTEtMS00OTcxMg_20471bd9-1c38-4a08-817a-8e7a54b648bd"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7ab19c1394c44429ac9cf701c02bacd3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi03LTEtMS00OTcxMg_bb0ae81e-3aa1-4610-b469-fb31670fc033"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi05LTEtMS00OTcxMg_4e57054b-218d-4dcd-a8d1-47e1ba9f50c8"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i02b4e25e62db4e1b8735f0ca5a308f16_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xMS0xLTEtNDk3MTI_53c38111-b0d7-4189-9748-2ce205842c33"
      unitRef="usd">29000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xNC0xLTEtNDk3MTI_d7e39e4a-f5dc-4fbd-ab7d-4d7b743027a3"
      unitRef="shares">331789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifadbaed99b6d4f7ca0466880d9e9f239_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xNi0xLTEtNDk3MTI_b81bbbfe-df1a-49fd-9130-1c96004a355a"
      unitRef="usd">332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8044192b7fa3405f8f099c5b69712352_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0xOC0xLTEtNDk3MTI_44f7f4bb-3e40-4121-9125-b7df493ecd72"
      unitRef="usd">1876159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c7d6b0e50bc4558a6bf3ad8ad190e64_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0yMC0xLTEtNDk3MTI_4f6c03fb-1cc3-4bd5-b591-d519fae0c31c"
      unitRef="usd">-18797570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dbda5f1db214fb88786236031b5e24c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMi0yMi0xLTEtNDk3MTI_768da387-eb8b-44be-8838-cdc40332585b"
      unitRef="usd">-16921079</us-gaap:StockholdersEquity>
    <cntx:TemporaryEquityOfferingCosts
      contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0wLTEtMS00OTcxMi90ZXh0cmVnaW9uOjNkNzM0NTZkZGRlNTQ3NzM5YjM4ZmJjYmIxYmFmNWU0XzYz_971e83c3-7e83-4f17-9b75-f9ef97610915"
      unitRef="usd">213073</cntx:TemporaryEquityOfferingCosts>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0xLTEtMS00OTcxMg_2fafb12b-29a6-4987-87e1-d1bef8df0396"
      unitRef="shares">453094</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMy0zLTEtMS00OTcxMg_a9750c5a-7c39-4071-8b4b-09e3e984abd2"
      unitRef="usd">3034526</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0xLTEtMS00OTcxMg_0eeef742-2221-481e-bba8-ab22b88caa32"
      unitRef="shares">844824</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0zLTEtMS00OTcxMg_622c1dcb-2041-4fa9-812e-4190deabf23b"
      unitRef="usd">5728793</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0xOC0xLTEtNDk3MTI_63058e8a-a871-4607-ad4d-a32b60579ce9"
      unitRef="usd">137497</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNS0yMi0xLTEtNDk3MTI_92f7594c-8f97-4417-92f2-58e11a1230b7"
      unitRef="usd">137497</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrants
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0zLTEtMS00OTcxMg_f43c0de5-1a5a-4391-a5c2-9503b4209743"
      unitRef="usd">158658</cntx:TemporaryEquityDecreaseDueToConversionToWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i8d87d55ccb734efb9c7ed1999f656107_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0xOC0xLTEtNDk3MTI_5b45433b-ef28-43cd-9333-327f8e189494"
      unitRef="usd">158658</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i0d0f5d0c94a24a37bbe2603f3a941447_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNi0yMi0xLTEtNDk3MTI_8c061b53-aaba-4a63-8b90-2d7b36f55fa2"
      unitRef="usd">158658</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees
      contextRef="ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0zLTEtMS00OTcxMg_6a6c6484-99dd-4c15-9236-a6d1ec5e0984"
      unitRef="usd">13388</cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees>
    <cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices
      contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0xOC0xLTEtNDk3MTI_173263e6-8447-45f2-be17-0e8a1713ad5a"
      unitRef="usd">13388</cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices>
    <cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices
      contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfNy0yMi0xLTEtNDk3MTI_f9d1361d-9839-47e6-afcf-3208172118b5"
      unitRef="usd">13388</cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xNC0xLTEtNDk3MTI_3a42ab54-83b1-43fa-9db4-48697cd6b57a"
      unitRef="shares">4218</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i025d2aee2ee94517ad2b98ed900e2de7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xNi0xLTEtNDk3MTI_15c35ae9-6257-4852-b613-50833a71d77f"
      unitRef="usd">4</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i777d227b9bb249bfbe8e99621481cafa_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0xOC0xLTEtNDk3MTI_a2dd7d04-8505-4fb1-ad9e-d9c6c7851ce9"
      unitRef="usd">25509</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOC0yMi0xLTEtNDk3MTI_6e1f5348-839f-44cb-86a8-8072866eb642"
      unitRef="usd">25513</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:NetIncomeLoss
      contextRef="i0dff8bbfea2e482896c4ab248a7dda24_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOS0yMC0xLTEtNDk3MTI_8efe0d05-65af-484a-b278-11ff58b4e12a"
      unitRef="usd">-892049</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb7bdf97058a4abd92feaf9cc7e6057c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfOS0yMi0xLTEtNDk3MTI_440b8e89-2c21-4c10-87e1-33d27e725746"
      unitRef="usd">-892049</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9523681451b740f0a62eab036c049fcf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMS0xLTEtNDk3MTI_f7b00b6a-4556-4b5f-a2a4-364e92241074"
      unitRef="shares">1508633</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9523681451b740f0a62eab036c049fcf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMy0xLTEtNDk3MTI_fdb2ca2d-b785-4811-aa82-ec6b1b9a49f3"
      unitRef="usd">9992208</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i23e70673670b454697bd3e735f7ead67_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtNS0xLTEtNDk3MTI_a431267a-2593-44e8-aaea-9ca3bbed0200"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i23e70673670b454697bd3e735f7ead67_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtNy0xLTEtNDk3MTI_1c564e60-c502-4367-908e-445eeb365f8b"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iab094eb4f1c449799a6a0a40dfaefe12_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtOS0xLTEtNDk3MTI_d7bddee7-0408-4d77-9315-7617bdaf1c7e"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iab094eb4f1c449799a6a0a40dfaefe12_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTEtMS0xLTQ5NzEy_56ddcda2-07f2-48c0-a7f7-3a9b0ffa969b"
      unitRef="usd">29000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i5e5be68e8b1d499185e82be5b03a485f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTQtMS0xLTQ5NzEy_4b304cb6-17e3-4a59-985c-4e9ff36343f8"
      unitRef="shares">336007</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5e5be68e8b1d499185e82be5b03a485f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTYtMS0xLTQ5NzEy_0652b57f-78ec-4f65-bce8-23e9d4ffcc9d"
      unitRef="usd">336</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1985a71fd2e840d0a0b035d856815619_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMTgtMS0xLTQ5NzEy_20d1f16b-7ff3-43f2-811e-fb48facf7d1f"
      unitRef="usd">2211211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i053e2d5b4fdd45cba9f89d705600f026_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMjAtMS0xLTQ5NzEy_c0c07ed9-f12e-4f3a-80af-98f79fabbdef"
      unitRef="usd">-19689619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c334b6a33324fb8ab9e49483ece3d16_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTAtMjItMS0xLTQ5NzEy_9df26a76-3559-478d-95e0-8ef210eeade0"
      unitRef="usd">-17478072</us-gaap:StockholdersEquity>
    <cntx:TemporaryEquityOfferingCosts
      contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMC0xLTEtNDk3MTIvdGV4dHJlZ2lvbjphMDdjY2E4NzNkNzk0ZTdiOTQ1Y2UyNjM5YjJjMjBhNl82Mw_f5ddb8a2-f4c3-4f7a-ac98-f89e7d2e5f86"
      unitRef="usd">96948</cntx:TemporaryEquityOfferingCosts>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMS0xLTEtNDk3MTI_2a84cafb-5588-4f1d-b90e-1e4ef2384e0a"
      unitRef="shares">285351</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTEtMy0xLTEtNDk3MTI_3a30db1a-def5-49ce-b4b2-1a5b99670cb5"
      unitRef="usd">1948309</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTItMS0xLTEtNDk3MTI_bb6a46fd-5b59-4921-a9fd-d0c460c69d10"
      unitRef="shares">418559</cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTItMy0xLTEtNDk3MTI_fe63646b-326f-4243-ba6c-7022178fd8ac"
      unitRef="usd">2837832</cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrants
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMy0xLTEtNDk3MTI_7a956b0a-72cd-4f5b-900f-716f83c3e548"
      unitRef="usd">106935</cntx:TemporaryEquityDecreaseDueToConversionToWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i469bd896d0404212882a523d504522da_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMTgtMS0xLTQ5NzEy_95923447-be29-4d32-bafb-0e9e56c76baf"
      unitRef="usd">106935</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="id2d5ed2cb14343529f70dad75a4e6f8d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTMtMjItMS0xLTQ5NzEy_dd8e9371-087e-497b-aeac-cc9908511a23"
      unitRef="usd">106935</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees
      contextRef="i1476e493307e4b08b37ea40f6a957180_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMy0xLTEtNDk3MTI_9f39ecdd-34ea-43b9-b93b-e85aa91f37c9"
      unitRef="usd">30409</cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees>
    <cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices
      contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMTgtMS0xLTQ5NzEy_b5108b5e-b079-4442-ae0d-92261c6f0a0a"
      unitRef="usd">30409</cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices>
    <cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices
      contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTQtMjItMS0xLTQ5NzEy_7c6ce12b-217f-47fb-bc0e-6a2d37192f22"
      unitRef="usd">30409</cntx:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTQtMS0xLTQ5NzEy_d1540675-6b95-43ce-8258-0198ff6d42a8"
      unitRef="shares">6262</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i207306f2f0214f37ab5cf87cb1c5e66a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTYtMS0xLTQ5NzEy_20f5e916-9b09-4fe0-85d7-c3827385f3e4"
      unitRef="usd">6</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMTgtMS0xLTQ5NzEy_d96e0464-b154-4113-8ca3-d1bc57f6c944"
      unitRef="usd">119357</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTUtMjItMS0xLTQ5NzEy_3041b77c-8fb9-4c7c-b8f1-565e30f7a1b1"
      unitRef="usd">119363</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="ifd6441b83d394e10b602af00c07a1e9a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMTEtMS0xLTQ5NzEy_7c2a5107-bb9a-4f9c-8987-9f01b3c1e7ac"
      unitRef="usd">53330</cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i21e677df66a94349ade55221ca159924_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMTgtMS0xLTQ5NzEy_aff3f488-f3f3-400d-99e7-0dbed9e2cf8c"
      unitRef="usd">53330</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTYtMjItMS0xLTQ5NzEy_e0fb2cb4-898f-4e78-bfc6-eba372ba1ce3"
      unitRef="usd">53330</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="icf64ab93cf964595a69c22ef2bf1bbc3_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTctMjAtMS0xLTQ5NzEy_385daf5f-2a77-41d4-86d6-7e5c41eca846"
      unitRef="usd">-5030164</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibed9ebe777744942b2d52251d599962a_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTctMjItMS0xLTQ5NzEy_86696421-7946-4f21-83fa-b1fe09d1f0b0"
      unitRef="usd">-5030164</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8e4251d780d94171abc72a54e3f1d40b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMS0xLTEtNDk3MTI_bbddfc2a-599d-4134-aff5-8682f5e45ef7"
      unitRef="shares">2212543</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8e4251d780d94171abc72a54e3f1d40b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMy0xLTEtNDk3MTI_ef7255cb-7e43-4b25-b1c6-468be0655b5c"
      unitRef="usd">14641005</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i72999784f84f4f78976de510cce92938_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtNS0xLTEtNDk3MTI_7796f20d-84dc-43c6-90f9-9ad7e60b55a2"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i72999784f84f4f78976de510cce92938_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtNy0xLTEtNDk3MTI_dccc3ce9-ecf2-4877-9df4-51c8858bacce"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ifb364b5e1db7443e829eab3187e71baf_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtOS0xLTEtNDk3MTI_2ea6d635-ff0e-44a4-a358-fb7e36b5dc58"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ifb364b5e1db7443e829eab3187e71baf_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTEtMS0xLTQ5NzEy_e2b4980b-a002-47ce-8494-3a45990d5a78"
      unitRef="usd">82330</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTQtMS0xLTQ5NzEy_d0cdd8f7-f797-4498-87f1-0fee9f71b1cc"
      unitRef="shares">342269</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i70bb2f92ab7f4ec1bc1aa6198cc40eab_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTYtMS0xLTQ5NzEy_c1a4fcf5-5da6-4404-a0ac-6df75a0be807"
      unitRef="usd">342</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfd008432ea34dd495de31355c35c5b8_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMTgtMS0xLTQ5NzEy_fecdb11d-6ae3-45c4-84d2-30ce3f2c06f0"
      unitRef="usd">2414582</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab1984306aeb45b086de0b8f791fa525_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMjAtMS0xLTQ5NzEy_5d2ab032-ac64-4175-bf15-9738e5bba5fd"
      unitRef="usd">-24719783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4538f14815a4c249d92da084a9a25ed_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTgtMjItMS0xLTQ5NzEy_1595e473-536e-40fb-82eb-257f7d7668f6"
      unitRef="usd">-22304859</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i41ac2f42af1e46f28082b9e44edd8bd1_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTktMTgtMS0xLTUxNDIw_f5a83868-107c-48f3-8334-34617d8eafa3"
      unitRef="usd">371895</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i79bf85e416f34002b19f3f5ac5bdba47_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMTktMjItMS0xLTUxNDIw_0f1c99e7-9d30-411e-8601-d6f2fe8b6b1a"
      unitRef="usd">371895</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTQtMS0xLTUxNDIw_2c3e1a39-512c-48cb-92bb-a6ad2329789b"
      unitRef="shares">6262</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="icd6f168e660b49ca9caffef26e5668f8_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTYtMS0xLTUxNDIw_227801aa-55b3-437d-9e00-523932d2df66"
      unitRef="usd">6</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i39eb46827db041658824ba64d452487b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMTgtMS0xLTUxNDIw_a8a69c8e-1bc0-43da-a3a1-abeef4344421"
      unitRef="usd">161817</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjAtMjItMS0xLTUxNDIw_b5c2bfbb-20ca-4841-80f6-ec88cf9d8af0"
      unitRef="usd">161823</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:NetIncomeLoss
      contextRef="i3ba3cd3b4cb54008bf47ddd2a959ae16_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjEtMjAtMS0xLTUxNDIw_b3819e34-c804-4d03-b3c5-ff52117273e1"
      unitRef="usd">-1442792</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjEtMjItMS0xLTUxNDIw_683a522c-0b14-42d5-8c30-5aa8b19f0da9"
      unitRef="usd">-1442792</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMS0xLTEtNTE0MzI_bb543168-7754-41dd-94c6-859a4cb2a16d"
      unitRef="shares">2212543</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i480d2a99da5648cd8cc2ac7bcb0e9651_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMy0xLTEtNTE0MzI_822ec977-7ddc-47de-bbd7-1b64a5c681e9"
      unitRef="usd">14641005</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i88cf0f3abb49481aa205ca8023e30fbc_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItNS0xLTEtNTE0MzI_3207b941-6e96-421f-9845-80358c7cfd79"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i88cf0f3abb49481aa205ca8023e30fbc_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItNy0xLTEtNTE0MzI_56bfb606-d495-442f-a12b-ecf5ba9e36da"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItOS0xLTEtNTE0MzI_c7f49169-668d-4461-8b35-1b235559dae1"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ide1bfb5cab9b42c5ac68ecf110cf0f1a_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTEtMS0xLTUxNDMy_c5e5b5d0-b144-4fb0-a2ab-a9ec3a05907b"
      unitRef="usd">82330</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ia720be76271949ebb4bd4ecc9a63607a_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTQtMS0xLTUxNDMy_c2495526-2c7c-43f4-a955-bb15020224c2"
      unitRef="shares">348531</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia720be76271949ebb4bd4ecc9a63607a_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTYtMS0xLTUxNDMy_3f6a5014-b27f-4b7f-8b54-36f3425bca0c"
      unitRef="usd">348</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9faae0f7b5144a19efc12326f0f220e_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMTgtMS0xLTUxNDMy_fb689a47-26d1-47c8-ac64-2c61759935f9"
      unitRef="usd">2948294</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5595b49782e4a2696ca3a2a49ad6925_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMjAtMS0xLTUxNDMy_9766a434-0136-4ef7-a08c-23932b3eedee"
      unitRef="usd">-26162575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd60ff9a89c748609e3e159d17b22413_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18yOC9mcmFnOjQxMGE3Y2NjNTY0ZDRmNTY4MjQ2NmVlZTQ1NWM0OWViL3RhYmxlOjQ2ZmMyZjk3NzBlYzQzY2RiNzQ2ZGVkMmZiMWY4NTdhL3RhYmxlcmFuZ2U6NDZmYzJmOTc3MGVjNDNjZGI3NDZkZWQyZmIxZjg1N2FfMjItMjItMS0xLTUxNDMy_b0761558-c4b8-42a1-b20a-d2840b795fd8"
      unitRef="usd">-23213933</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi0xLTEtMS00OTcxMg_08a598b1-0cfb-42fb-a92f-0d76d3487b0d"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ief5ceba54f2a49a1956b1fae61c6d55f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi0zLTEtMS00OTcxMg_f4c753de-1249-4b6e-95df-c70ac3440ff6"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id904dd6c948942fa95d470d8f7fc4c71_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi01LTEtMS00OTcxMg_1a35adc5-2f07-4d39-9431-cf6d2a2be66a"
      unitRef="usd">77510809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i017447a0256f4196a4817dfa28f8e101_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi03LTEtMS00OTcxMg_0af2d8a2-6f18-45ba-8201-f062c46a6c6e"
      unitRef="usd">-29254440</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMi05LTEtMS00OTcxMg_268424dd-05b4-4596-a393-91c59da154ff"
      unitRef="usd">48272335</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i90d3dccad9594e50872f23a00f725fff_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMy01LTEtMS00OTcxMg_163d4d37-4a9e-447f-8ae0-ec38aea7f660"
      unitRef="usd">345530</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i57ab355349f74b32990f6a5b1420ee6e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMy05LTEtMS00OTcxMg_1e6ccb28-ea65-43f6-b2d8-c9578c9f636c"
      unitRef="usd">345530</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idf9a2c2fcc664d35b2b5d1dd7995760c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNC01LTEtMS00OTcxMg_13718dd4-1337-4a3f-b162-93d49267699d"
      unitRef="usd">214958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNC05LTEtMS00OTcxMg_a6e573b1-0621-41b2-88f4-f6214ac0b123"
      unitRef="usd">214958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ic1810fec077b40c0930be13c655ee345_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNS03LTEtMS00OTcxMg_cc451caf-2f21-49bd-a9cd-3d7c0ea8fb4c"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaded6707aedb428887caf7e734b3b9c0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNS05LTEtMS00OTcxMg_255e8768-19db-462a-b163-cee21b8bbbe6"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3e87e049d31a4a989377c27f50ee7a17_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi0xLTEtMS00OTcxMg_5edfc7bd-47ab-4483-83e8-f4374319095f"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3e87e049d31a4a989377c27f50ee7a17_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi0zLTEtMS00OTcxMg_0c1b12de-0aab-4309-909f-7b823c674194"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02ebe5df39614a3fa046b9dec55140fb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi01LTEtMS00OTcxMg_cb02dd28-89e4-4ba5-a07c-7c5ee9ff4fc7"
      unitRef="usd">78071297</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i539fb2bc4bb345aabb6f8dfdd9ba6f6b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi03LTEtMS00OTcxMg_a362b7c8-b393-4630-bc17-4f9e1ec2f509"
      unitRef="usd">-32692777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i799f37f97f4a4744b4bc59d2d24293d4_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNi05LTEtMS00OTcxMg_e0abc88f-fdef-4bb4-a23d-39951c4a8c54"
      unitRef="usd">45394486</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e9c37e644824b0d84879f473b9cf77e_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNy01LTEtMS00OTcxMg_b2a2df64-d581-4f3c-85df-05c05fdc9460"
      unitRef="usd">241324</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib54220fa169e4707885970ecdc945467_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfNy05LTEtMS00OTcxMg_00089e2e-f65b-45ed-8000-5ade45c87303"
      unitRef="usd">241324</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ica83b1571ad4481baeba3aef75b2db8c_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOC03LTEtMS00OTcxMg_2410d64a-d462-4c59-931d-07546130f2bd"
      unitRef="usd">-3986511</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib54220fa169e4707885970ecdc945467_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOC05LTEtMS00OTcxMg_19521edf-ed3c-46e1-b9c9-e6106637d0b2"
      unitRef="usd">-3986511</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5486e6d972204740a82b09a1b927049f_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS0xLTEtMS00OTcxMg_8dbae2e5-0c94-4248-be48-62b06b25c238"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5486e6d972204740a82b09a1b927049f_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS0zLTEtMS00OTcxMg_fdade631-560a-406c-bc5f-536c1e60c513"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d8d9514a6a745a0a488a3f6c4207777_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS01LTEtMS00OTcxMg_04c2a359-6f56-42c8-99c8-80c4c6bb49b9"
      unitRef="usd">78312621</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f8b2d08e4604b7e9b651b2457ac44d6_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS03LTEtMS00OTcxMg_60d02801-8af4-4b75-a0ba-3edc579a6976"
      unitRef="usd">-36679288</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06b116b88064480fb840617b61eabdf0_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfOS05LTEtMS00OTcxMg_3f522d6b-cde6-4a6d-98f3-bd37104ffd5e"
      unitRef="usd">41649299</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i896495c2f35f47858d0e21309439c662_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTAtNS0xLTEtNTE3MDI_b48b409a-2252-48d0-a5be-d33e0e7809d3"
      unitRef="usd">276521</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTAtOS0xLTEtNTE0NDM_4fb5c9fc-42dd-4143-b105-8a41490ac261"
      unitRef="usd">276521</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iaeaf8efe24bd416fa817b05f01fdc15f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTEtNy0xLTEtNTE3MTA_9b9888ab-26e7-41bf-900b-ad315f0f7423"
      unitRef="usd">-3854310</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTEtOS0xLTEtNTE0NDM_35034a90-5c00-415c-a1c7-778d3a811b6d"
      unitRef="usd">-3854310</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItMS0xLTEtNTE0NDM_dd3a479d-f3f0-4a74-84b6-3747196e908a"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b967bc3c52a4c4baa2255fc5bb13586_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItMy0xLTEtNTE0NDM_6b283ff9-8f8d-40a9-a523-d29beda38164"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3db5b6f078814f8e95ab6d13d23d25e9_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItNS0xLTEtNTE0NDM_9450a778-06db-4d20-8f4d-981104c6325e"
      unitRef="usd">78589142</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38bed32e2197428db5b6ab17d60a789b_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItNy0xLTEtNTE0NDM_eda08cd1-7da6-4c35-9a2c-b806280ab088"
      unitRef="usd">-40533598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zMS9mcmFnOmI3MjBiY2YwYTk2ZTRiZDhiYWFiZTA0NjgxZWE5NjhmL3RhYmxlOjA3OTAwY2NiYjczZTRhYjI4N2E4ZWMyY2RmMWUxZDE5L3RhYmxlcmFuZ2U6MDc5MDBjY2JiNzNlNGFiMjg3YThlYzJjZGYxZTFkMTlfMTItOS0xLTEtNTE0NDM_ba759316-db99-4996-b08d-97f47413fb24"
      unitRef="usd">38071510</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNC0xLTEtMS00OTcxMg_e3408d18-17e8-40d8-9dde-d10434f57764"
      unitRef="usd">-11279158</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNC0zLTEtMS00OTcxMg_9c696207-1556-469b-9c96-ece1ce6ea239"
      unitRef="usd">-7365005</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNi0xLTEtMS00OTcxMg_bffadea7-683a-496c-a887-1faaf07935d8"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNi0zLTEtMS00OTcxMg_6f893e65-3b34-4166-95bf-3aee8ca8ffcf"
      unitRef="usd">3087832</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNy0xLTEtMS00OTcxMg_18031e02-4b58-4e5b-b17d-4e59c40c743a"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNy0zLTEtMS00OTcxMg_aac513e9-b98f-43ed-99bc-286a796ac968"
      unitRef="usd">371895</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOC0xLTEtMS00OTcxMg_ed14e1d7-e9a6-4bf1-a188-2179322e8786"
      unitRef="usd">732803</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOC0zLTEtMS00OTcxMg_8d66f193-705d-41df-9332-8ec46e9c5d73"
      unitRef="usd">306699</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOS0xLTEtMS00OTcxMg_66208a6b-af6d-44f1-b348-2e04c479f2e1"
      unitRef="usd">6074</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfOS0zLTEtMS00OTcxMg_ba10660d-4164-4af3-af09-6713cababe92"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTAtMS0xLTEtNDk3MTI_1b7ad7ee-7be4-4f70-ad6b-3fc6ea1210bc"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTAtMy0xLTEtNDk3MTI_95cb89b2-eed3-4548-b740-43d06f579102"
      unitRef="usd">64555</us-gaap:PaidInKindInterest>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTEtMS0xLTEtNDk3MTI_e8c4639d-766a-4a9f-88e3-096e42d5eba2"
      unitRef="usd">0</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTEtMy0xLTEtNDk3MTI_3f4a4cd0-d286-4158-8acb-f794a99809c6"
      unitRef="usd">9317</cntx:FairValueAdjustmentOnConvertibleDebt>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTItMS0xLTEtNDk3MTI_edc122dc-5bea-41c5-8d9e-c4c16706b468"
      unitRef="usd">56736</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTItMy0xLTEtNDk3MTI_5fdaca14-f432-4ade-af7f-46f2488ed42a"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTMtMS0xLTEtNTI0NDE_e17bd808-a389-4741-93d5-f50e590f5a1f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTMtMy0xLTEtNTI0MjA_ceed27b1-5769-4ce7-94c5-4d9ba707b5ed"
      unitRef="usd">125577</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTQtMS0xLTEtNDk3MTI_da641b17-c67c-4027-ba84-7728d0cf8b01"
      unitRef="usd">891912</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTQtMy0xLTEtNDk3MTI_f9ad80bd-9bba-4d48-9208-9e22e45ec9e0"
      unitRef="usd">9707</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTUtMS0xLTEtNDk3MTI_0849e2a3-f9ab-4e68-88dc-20c0cf595c16"
      unitRef="usd">39313</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTUtMy0xLTEtNDk3MTI_219d4234-770d-4ddc-a799-7298fe219aa0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTYtMS0xLTEtNDk3MTI_707f8506-3f90-4fe2-b8d4-a860e6a26847"
      unitRef="usd">-229228</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTYtMy0xLTEtNDk3MTI_01e8d992-8a69-48c6-97bc-06334eaa3036"
      unitRef="usd">-179199</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTctMS0xLTEtNDk3MTI_c9552a4c-851a-4dc5-a46d-dce94d1e61f6"
      unitRef="usd">1576728</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTctMy0xLTEtNDk3MTI_6828d76b-eed4-48f6-85dd-768decb37a7a"
      unitRef="usd">20021</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTgtMS0xLTEtNDk3MTI_7e9f52b9-71ca-4e40-aac2-d6a83436b036"
      unitRef="usd">-52291</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTgtMy0xLTEtNDk3MTI_9bb09535-b2a0-4e4e-b43e-39f2c7f7e423"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTktMS0xLTEtNDk3MTI_e43b1ad5-b81d-493b-a219-d3d0850922ba"
      unitRef="usd">-9619561</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMTktMy0xLTEtNDk3MTI_1a681f86-c68e-4f60-a9e6-606acda09b82"
      unitRef="usd">-3837803</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjEtMS0xLTEtNDk3MTI_1ecc5157-c0b8-4a6d-82fe-9cd1f47a4e04"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjEtMy0xLTEtNDk3MTI_3d2b5918-c141-4396-8db8-8043ebfbe3e5"
      unitRef="usd">250000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjItMS0xLTEtNDk3MTI_624c38f7-cd56-4b4c-a3aa-22f168ce7c09"
      unitRef="usd">36836</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjItMy0xLTEtNDk3MTI_e2199a36-a286-485c-8a66-cc9ac1f4a1cc"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjMtMS0xLTEtNDk3MTI_2a5de524-f2f0-4268-9592-506bb32d09f1"
      unitRef="usd">-536836</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjMtMy0xLTEtNDk3MTI_9b5b1f0d-758c-40df-a841-dbc71677e053"
      unitRef="usd">-250000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i065c7e802d2941d1a5f4e25656709a56_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjUtMS0xLTEtNDk3MTI_47de4ecd-0006-4227-bdb1-9b40aee5bb38"
      unitRef="usd">102071</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i455a6e88e29d4ef2a78a2a38f261295b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjUtMy0xLTEtNDk3MTI_b394f57d-2873-45a3-9647-99a8eab39afc"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjYtMS0xLTEtNDk3MTI_3d3902cd-318b-48ad-89c1-a1b037c8f7df"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjYtMy0xLTEtNDk3MTI_33938b8c-2279-4b37-a4d3-0020509433f7"
      unitRef="usd">4982835</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i046810a1fd7d400da5a699c022e8d9f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMS0xLTEtNTI0MzA_ed1df21a-1936-4cf1-974a-1153b9e48de1"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5737c76ba5424054a9aeed887403599b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMy0xLTEtNTI0MzA_22450d30-34af-4a57-895d-4fec86cf253e"
      unitRef="usd">816917</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjctMS0xLTEtNDk3MTI_030442a9-a36b-4d20-8310-1d9b7f6c0563"
      unitRef="usd">-102071</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjctMy0xLTEtNDk3MTI_d44821e1-f570-489a-b47e-deaca171fab7"
      unitRef="usd">4165918</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjgtMS0xLTEtNDk3MTI_3cab3356-15a1-47dc-af71-4172aeb9dfb7"
      unitRef="usd">-10258468</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjgtMy0xLTEtNDk3MTI_8d4a64a6-5926-46a7-befe-36a81c4cb37f"
      unitRef="usd">78115</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMS0xLTEtNDk3MTI_fb07250f-e034-47e5-b350-1521031e2d4e"
      unitRef="usd">49685586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2dbda5f1db214fb88786236031b5e24c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMjktMy0xLTEtNDk3MTI_e0ffc535-751d-4211-a342-4b3f17d7b8f5"
      unitRef="usd">341037</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzAtMS0xLTEtNDk3MTI_25e500a4-5553-4ea2-94ff-b285f9ec7e33"
      unitRef="usd">39427118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifd60ff9a89c748609e3e159d17b22413_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzAtMy0xLTEtNDk3MTI_1850254d-0bd9-45aa-aee7-df3ab0a1db65"
      unitRef="usd">419152</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzMtMS0xLTEtNDk3MTI_10e9da6d-f24a-445b-9eb4-3948709c4564"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzMtMy0xLTEtNDk3MTI_a67e0dfa-4cbc-4962-a7b0-1fe68fff6de1"
      unitRef="usd">5866290</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <cntx:WarrantsIssued
      contextRef="i2fdea296ead7488282261bdc319ef5d1_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzQtMS0xLTEtNDk3MTI_800933e3-7d0c-4412-999b-311828d2eccf"
      unitRef="usd">0</cntx:WarrantsIssued>
    <cntx:WarrantsIssued
      contextRef="ia5dbc3701bbc4b54a21909b1998fe19c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzQtMy0xLTEtNDk3MTI_a68be806-0162-4fcd-aa9d-5eb64624b983"
      unitRef="usd">309390</cntx:WarrantsIssued>
    <us-gaap:StockIssued1
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzUtMS0xLTEtNDk3MTI_b459f268-2ef3-4a49-a33e-82b4014e398b"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzUtMy0xLTEtNDk3MTI_851a585e-210d-4acf-8f07-82c1981bea94"
      unitRef="usd">2837832</us-gaap:StockIssued1>
    <cntx:DeferredOfferingCostIncurredButNotYetPaid
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzYtMS0xLTEtNDk3MTI_173ebaf2-5ad4-4f4c-8891-eeb54b87f9c9"
      unitRef="usd">0</cntx:DeferredOfferingCostIncurredButNotYetPaid>
    <cntx:DeferredOfferingCostIncurredButNotYetPaid
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzYtMy0xLTEtNDk3MTI_6590a676-0f33-4531-9e20-46f77664b60f"
      unitRef="usd">1004856</cntx:DeferredOfferingCostIncurredButNotYetPaid>
    <cntx:WarrantsIssued
      contextRef="i0008c07757234399a7495a0798d22f5b_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzgtMS0xLTEtNDk3MTI_9059fc85-b086-4735-8255-946ed0862864"
      unitRef="usd">345530</cntx:WarrantsIssued>
    <cntx:WarrantsIssued
      contextRef="i2471273c7ae344129757969381e9512f_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzgtMy0xLTEtNDk3MTI_d2521830-9520-41cc-9ed5-275d9adc9fc0"
      unitRef="usd">0</cntx:WarrantsIssued>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzktMS0xLTEtNDk3MTI_3d6dbd92-81f4-4e61-947f-6b9ca521ecae"
      unitRef="usd">130488</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfMzktMy0xLTEtNDk3MTI_eb0bda00-7bef-475c-930f-7564fdea0d25"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNDAtMS0xLTEtNDk3MTI_ae3165cd-c1ab-4d4e-bb5d-59200325a00e"
      unitRef="usd">0</cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN18zNC9mcmFnOjRmOTA4NDE3ODZlZTRhNmY5ZTMzOGJiYmZkOTAzYTMyL3RhYmxlOjM2MDMzNTdjYzIxZTRlOWJiZGRmOWY4NzUwMWJlZjQxL3RhYmxlcmFuZ2U6MzYwMzM1N2NjMjFlNGU5YmJkZGY5Zjg3NTAxYmVmNDFfNDAtMy0xLTEtNDk3MTI_e80e957a-5a8b-4375-9d1c-e0e794432f9f"
      unitRef="usd">53330</cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <us-gaap:NatureOfOperations
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180MC9mcmFnOmYxZDUxOTIwZDM5OTRkYTdhOGQwMjIwNmI4N2YwOTMwL3RleHRyZWdpb246ZjFkNTE5MjBkMzk5NGRhN2E4ZDAyMjA2Yjg3ZjA5MzBfMTIzMw_f4950940-1f72-4316-a59f-a61e4d2ada44">Organization and Description of BusinessContext Therapeutics Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#x2019;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction the condensed consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie6e9a07f9c2946a8b52c28630a825031_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180MC9mcmFnOmYxZDUxOTIwZDM5OTRkYTdhOGQwMjIwNmI4N2YwOTMwL3RleHRyZWdpb246ZjFkNTE5MjBkMzk5NGRhN2E4ZDAyMjA2Yjg3ZjA5MzBfNDc5_de1f19da-bad0-4869-a0d1-b46d51417977"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <cntx:RisksAndLiquidityTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfNDcxMQ_544f48fd-1cbe-4085-bb79-1f0b2f773cfb">Risks and Liquidity &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $40.5&#160;million as of September&#160;30, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company believes its cash and cash equivalents of $39.4 million as of September&#160;30, 2022 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first half of 2021, the Company raised $5.0&#160;million in net proceeds related to the sale of its Series A convertible preferred stock (&#x201c;Series A Stock&#x201d;) and warrants for common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the Company closed an initial public offering (&#x201c;IPO&#x201d;), in which it issued and sold 5,750,000 shares at a public offering price of $5.00 per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent's warrants have an exercise price of $6.25 per share and a term of five years from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#x2019;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and 480,415 warrants converted into 9,816 shares of common stock. The Company received net proceeds of approximately $24.4&#160;million as a result of the offering. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company sold 5,000,000 shares of its common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement and received net proceeds of approximately $28.9&#160;million. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#x2019;s warrants have an exercise price of $6.25 per share and a term of 5.5 years from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#x2019;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#x2019;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#x2019;s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#x2019;s financial condition and future operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. &lt;/span&gt;&lt;/div&gt;In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#x2019;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#x2019;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#x2019;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#x2019;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</cntx:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTUy_70da8732-818b-487e-8436-374f3905bfbd"
      unitRef="usd">-40500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMzkz_091f83d8-0d71-4917-a13a-b54270aab61d"
      unitRef="usd">39400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i18dfaee2fd0749dea6d251e8a01ce718_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfODcw_bdd1ac88-cf6b-4bed-8af7-443caf775434"
      unitRef="usd">5000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTEwNA_cfbeac0b-34f4-449b-b4f9-802770a0ae18"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i07512b61ceef49069b0fde3492828089_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTE0NA_b23f72c6-f711-4ef4-9ad9-2e2aac655aa5"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTI0NA_8c655182-fc3d-4a39-aa0c-e2caa8f845ef"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTM2NA_708be903-7a4c-4151-8d75-38bc747c9bac"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic464fb81556f45ecbf3818ed885dba50_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTM5MQ_fb8d1ec3-33a5-40a2-aaea-505797504399">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTU2NQ_f5d73510-36f5-4c52-863d-5066a3bfead2"
      unitRef="shares">4853533</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifdb18b5ff7dd4565b0689e48dd33cb0f_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTU5NQ_0a504933-2a11-482a-9bfe-b8a4ac07b1a2"
      unitRef="shares">480415</us-gaap:ClassOfWarrantOrRightOutstanding>
    <cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTYyMg_ae7f2ac2-d1ea-436b-bf6a-f8639d6fc5dc"
      unitRef="shares">9816</cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTcwMA_ffefbcfc-a0df-4bba-9051-d42f52148645"
      unitRef="usd">24400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTc2OQ_5b3aa155-4a78-4458-8543-b7555d488e54"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTgzNA_7a64603f-2ba5-47c4-8897-96f363cc51e9"
      unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMTkyNg_c6508bf4-f1c0-4137-a2fe-204aff43f03b"
      unitRef="usd">28900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjAzMw_a3aead29-182f-4e10-a6ae-c5c28e62c71d"
      unitRef="usdPerShare">6.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjA2NQ_fa199a4a-1880-4902-9e6a-eb7e7a11cd48">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjA5Mw_f13b0577-6ec5-44a6-a98d-aee7afe0fa4d"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjIwNw_a8d3c593-42d0-49d2-a93b-ccb5c4610f37"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjMyNw_f13b0577-6ec5-44a6-a98d-aee7afe0fa4d"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180My9mcmFnOjZhZjQ0MDdiMzZjNzRkNzU4OGQxNjY2MGY5ZjhkOTliL3RleHRyZWdpb246NmFmNDQwN2IzNmM3NGQ3NTg4ZDE2NjYwZjlmOGQ5OWJfMjM1NA_fa199a4a-1880-4902-9e6a-eb7e7a11cd48">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODI_38f3acb5-27fa-4dfd-92ec-8466dcfa67b1">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2022, and its results of operations for the three and nine months ended September&#160;30, 2022 and 2021 and cash flows for the nine months ended September&#160;30, 2022 and 2021. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. The consolidated financial information as of December&#160;31, 2021 included herein has been derived from the annual audited consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of convertible debt and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amount of the Company&#x2019;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company maintained approximately $50,000 as collateral for the Company&#x2019;s credit card program at December 31, 2021, which is reported as restricted cash on its condensed consolidated balance sheets.  There were no amounts restricted as of September 30, 2022, as the collateral was released to the Company in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipmen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;t&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of office equipment, furniture, and leasehold improvements and is recorded at cost. Property and equipment is depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted share-based awards based on the grant date fair value of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Series Seed convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,624,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,212,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;436,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;33,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;480,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;7,201,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,787,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts in the above table reflect common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Emerging Growth Company Status &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its condensed consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzc_818d866c-5481-4447-b682-64534b389f6d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2022, and its results of operations for the three and nine months ended September&#160;30, 2022 and 2021 and cash flows for the nine months ended September&#160;30, 2022 and 2021. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2021. The consolidated financial information as of December&#160;31, 2021 included herein has been derived from the annual audited consolidated financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzg_b8063a10-602e-46ea-8bf8-fc6271b40487">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODY_7b5272ad-def0-49af-a310-3a9fc1b5ba7d">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of convertible debt and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODM_692affe1-55d1-457b-8f40-b41e31358751">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured &lt;/span&gt;&lt;/div&gt;limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODQ_5e1c0feb-3a50-4cce-9349-1ced343d26fe">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amount of the Company&#x2019;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTI_82470bd7-1758-4a39-af94-763133f27900">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfNDQyNw_c3d628ee-20c7-4e60-a197-5b31469ca303"
      unitRef="usd">50000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfNDU5OQ_ba36c5bb-727f-4db3-b7bf-353c174be7e5"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODA_2161a1db-72ed-46bb-aa9f-5152cb912d8f">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTM_064df7b9-4ec0-46cd-9b04-2bc163ca0c31">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipmen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;t&lt;/span&gt;Property and equipment consist of office equipment, furniture, and leasehold improvements and is recorded at cost. Property and equipment is depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4Nzk_2fecab80-c649-4b2c-9c20-fe8bfab1fdfa">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cntx:PatentCostsPolicyPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODc_688016e2-1e47-409e-a003-68ed86b9b069">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;</cntx:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODg_d00f1eab-d9a0-4f04-ba1c-3e0c7fcb17b7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted share-based awards based on the grant date fair value of the awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODU_ac60e336-36a4-45a0-a0a3-fb33dbedf924">Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4ODE_e6980917-0e8a-4e7e-b547-3c57755989ce">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Series Seed convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,624,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,212,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;436,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;33,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;480,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;7,201,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,787,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic97c72893b0b45f9ac13a510ac0ce919_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfMy0xLTEtMS00OTcxMg_4a647e4d-486b-4ec4-8593-91fa1eee2160"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7be4c088e38d48fca44ed64b3a9cc35b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfMy0zLTEtMS00OTcxMg_a32ca88a-0910-4113-a2b3-d5de5ee6eccc"
      unitRef="shares">2624324</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba7c76c52c0843d4b179f34fcc164f44_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNC0xLTEtMS00OTcxMg_28ce0e75-f324-4f51-996a-245759127c80"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i661fcc5b4602480e8cc52211d82446d0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNC0zLTEtMS00OTcxMg_f9f43430-2961-4988-8a20-32fec68f1782"
      unitRef="shares">2212543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i855cb448971a4619b544a94285a0cc96_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNS0xLTEtMS00OTcxMg_37767340-b35b-40c7-9d65-0fe6010101ce"
      unitRef="shares">1341504</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iad85129c8a58499f94bd8e3d2af6078f_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNS0zLTEtMS00OTcxMg_70091dd4-1492-4b5f-b75e-90c066e54dd0"
      unitRef="shares">436437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie8472e008fd846c1af7dbda2c91dddc6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNi0xLTEtMS00OTcxMg_4b60c486-6514-41a6-b24b-cf5489746ff8"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5403ef21acee45fbab5d4ad32b444c79_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNi0zLTEtMS00OTcxMg_6eff1c2c-daeb-4d5d-be49-2fdbb9a4da98"
      unitRef="shares">33397</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i91b81907a7d94fc1a709a3a7f59a42f2_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNy0xLTEtMS00OTcxMg_dd451a88-1dc8-4ce9-a0f1-93c3af4b8559"
      unitRef="shares">5860000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4603fb59699f4e428a7f38a3b3c0ae44_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfNy0zLTEtMS00OTcxMg_c12812e6-a0a3-4162-a451-476715f89c49"
      unitRef="shares">480415</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfOC0xLTEtMS00OTcxMg_b038f080-9f46-4a2a-a08c-90aae9de83e4"
      unitRef="shares">7201504</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RhYmxlOjU0ZTdmMzI1MWI3NzRjZTg5MmNjZjFiOTZmOGExZGI0L3RhYmxlcmFuZ2U6NTRlN2YzMjUxYjc3NGNlODkyY2NmMWI5NmY4YTFkYjRfOC0zLTEtMS00OTcxMg_696d7225-26e2-4788-a5ec-64c092509b4c"
      unitRef="shares">5787116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180Ni9mcmFnOjdlNmI3NGJmM2I3YTQzYWY5MzEwM2VjMTJjMWQxNzRiL3RleHRyZWdpb246N2U2Yjc0YmYzYjdhNDNhZjkzMTAzZWMxMmMxZDE3NGJfMTI4OTA_8b2fb37b-0c3f-4156-88f8-6e4ca6a790c1">Recently Issued Accounting Pronouncements &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its condensed consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RleHRyZWdpb246MGZmMmFjZjUyZGM4NGQ5MzhjZTY5ZDFhMTBkNGQxMmVfODQ0_8b7a66b8-d630-41e5-ae84-e2eb90a26319">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;1 &#x2013; Observable inputs such as quoted prices in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;2 &#x2013; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;3 &#x2013; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;br/&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,921,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,921,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,051,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,051,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RleHRyZWdpb246MGZmMmFjZjUyZGM4NGQ5MzhjZTY5ZDFhMTBkNGQxMmVfODQ1_142eb705-f730-4fa2-b15f-7b93386ce911">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;br/&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,921,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,921,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,051,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;49,051,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if18940842a4d4141bb83557faaaa3f5d_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy0xLTEtMS00OTcxMg_d5696b5c-c5df-4734-8a26-e49abdf6775d"
      unitRef="usd">1921341</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ea3bc90fc5e45babe9d16439371f804_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy0zLTEtMS00OTcxMg_035945d3-b50e-4bbc-8dbb-26bc45ba32fc"
      unitRef="usd">1921341</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib9cfc17885754c02bf2915c69856a33b_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy01LTEtMS00OTcxMg_fa35085a-e473-4b2f-9158-ea7d730f7237"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibdfc0ddf63e14d7082cb9c967c847020_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOjNjYzBmZTcyMjEzMjQ4YjA4OTJmMzdlMGRjODk3ZWJhL3RhYmxlcmFuZ2U6M2NjMGZlNzIyMTMyNDhiMDg5MmYzN2UwZGM4OTdlYmFfMy03LTEtMS00OTcxMg_b3eb07b6-e5ee-47bc-ab5e-7fc096e7b734"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6eea0a991414c36a0929d31f1d3d7f8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy0xLTEtMS00OTcxMg_bd261844-ead0-4b22-8e51-82b1a6e17377"
      unitRef="usd">49051061</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id5916c4827b84fc8b33f7160c0b78aab_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy0zLTEtMS00OTcxMg_ce3507a1-61f5-44b5-9d10-b2ab38e29cf0"
      unitRef="usd">49051061</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i72e8a39dfcb84e878ff3f8aa02b39b95_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy01LTEtMS00OTcxMg_fb77eb85-5f75-47e1-b370-64ede4858aa5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iefc04475ba4c443bb02c7f09ee9c52a0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN180OS9mcmFnOjBmZjJhY2Y1MmRjODRkOTM4Y2U2OWQxYTEwZDRkMTJlL3RhYmxlOmY0ZDZmMjA0ZjdhNTRkZGE4MTEzMzJmYjg3NWVmMzRhL3RhYmxlcmFuZ2U6ZjRkNmYyMDRmN2E1NGRkYTgxMTMzMmZiODc1ZWYzNGFfMy03LTEtMS00OTcxMg_0fdcb875-4344-43f7-be64-0909abecd8ff"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RleHRyZWdpb246NzBmZTJkMTk5Y2FjNDI1NGFjZjRiYzNiOWM2ZTQxZWNfMTMz_b612913c-b7b2-4c62-8010-8f3db8b72155">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;564,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;436,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,801,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;339,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;345,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;60,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;85,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,438,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,207,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RleHRyZWdpb246NzBmZTJkMTk5Y2FjNDI1NGFjZjRiYzNiOWM2ZTQxZWNfMTM0_06ca63a8-0bf6-46f4-8a81-d356f9103276">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;564,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;436,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,801,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;339,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;345,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;60,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;85,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,438,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,207,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMS0xLTEtMS00OTcxMg_55e875b7-c58d-48a9-9d29-ad4ee6dfd16a"
      unitRef="usd">564989</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMS0zLTEtMS00OTcxMg_3d380ed7-6d8a-4167-ab9c-0bf632efa05f"
      unitRef="usd">436990</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cntx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMi0xLTEtMS00OTcxMg_6a260099-96a0-4824-9ade-9fce578c4da2"
      unitRef="usd">1801041</cntx:AccruedResearchAndDevelopmentCostsCurrent>
    <cntx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMi0zLTEtMS00OTcxMg_13aa7105-62b9-463d-88aa-0b5eae5aa2d9"
      unitRef="usd">339072</cntx:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMy0xLTEtMS00OTcxMg_5940f8f6-af98-4158-92bc-8554e1e6f273"
      unitRef="usd">12000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfMy0zLTEtMS00OTcxMg_c23be5f7-ee75-44cc-9070-aa3720d3eb44"
      unitRef="usd">345530</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNC0xLTEtMS00OTcxMg_6681b63b-44bb-4d79-9f0e-440ccf864833"
      unitRef="usd">60289</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNC0zLTEtMS00OTcxMg_df906393-13f3-417c-87f6-3b83b15c7ddc"
      unitRef="usd">85529</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNS0xLTEtMS00OTcxMg_6c76960b-67fc-4bd6-9c0a-bb6a953aaf5a"
      unitRef="usd">2438319</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181Mi9mcmFnOjcwZmUyZDE5OWNhYzQyNTRhY2Y0YmMzYjljNmU0MWVjL3RhYmxlOjg0MDAxMDExZTQzYTRmZGI5MGM1MDdiZjQ5ZDkxYTdjL3RhYmxlcmFuZ2U6ODQwMDEwMTFlNDNhNGZkYjkwYzUwN2JmNDlkOTFhN2NfNS0zLTEtMS00OTcxMg_a1fdcb19-44de-4724-abce-774b75ada169"
      unitRef="usd">1207121</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjQxMQ_8e396ba4-4753-4b65-87c4-f5f557692e96">Convertible Promissory Notes and Other Debt&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Senior Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company previously issued certain convertible promissory notes to various investors which were converted into Senior Convertible Notes (the &#x201c;Senior Convertible Notes&#x201d;, and collectively, the &#x201c;Convertible Promissory Notes&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All of the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into 844,824 shares of Series A Stock in February 2021, of which 430,467 shares were issued to the Company's Chief Executive Officer and an immediate family member (the "Related Party"). Due to certain embedded features within the Senior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Senior Convertible Notes was $5.7 million and was reclassified to Series A Stock. The Company recorded a non-cash credit of $9,000 in the condensed consolidated statement of operations for the nine months ended September 30, 2021 related to the decrease in fair value of the Senior Convertible Notes. For the nine months ended September&#160;30, 2021, the Company recognized $46,000 of interest expense in connection with the Senior Convertible Notes, including $23,000 payable to the Related Party, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Paycheck Protection Program &lt;/span&gt;&lt;/div&gt;In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender for a loan in an aggregate principal amount of $0.1 million (the &#x201c;Loan&#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act implemented by the U.S. Small Business Administration.  In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that the Small Business Administration remits the borrower&#x2019;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#x2019;s loan forgiveness covered period. The Loan was set to mature in two years and bore interest at a rate of 1.0% per year, with all payments deferred through September&#160;5, 2021. The outstanding principal balance of the Loan of $0.1&#160;million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the condensed consolidated statements of operations during the three and nine months ended September 30, 2021.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfNDYz_600a0e62-67e3-43ac-afb9-371548288f69"
      unitRef="shares">844824</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i52408a7bafe3490ea2b90900d2fd960a_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfNTE4_d12d8f73-f954-430d-a790-dd105b51ee66"
      unitRef="shares">430467</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i27893806b30342149eb85b8143f8df92_I20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfOTAx_7827297c-2162-47e1-844d-2d284a9ac4c1"
      unitRef="usd">5700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTAwOA_549fafe3-ef08-4689-a6aa-e4363425658e"
      unitRef="usd">9000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:InterestExpense
      contextRef="i4f7ce9679d964bac81e3f64466d9687d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTIzNg_4b9e78bf-8502-46b6-9d5f-c629aa17337c"
      unitRef="usd">46000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i65e645342cf74ea6b3b63d9596768247_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTIzNg_e476a3b5-5b1a-48b6-85b5-a81405ecbf21"
      unitRef="usd">46000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="i88ad34f7e1fb4d8694c59f20b25c8ba6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTMxOA_a9eec32f-6a9f-4b4a-afa9-240895eb0e52"
      unitRef="usd">23000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="iaae18aea4a6d4d3c9f8d5c3d37e7307e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTMxOA_eee04279-d869-4dc2-96d7-90cf013369a8"
      unitRef="usd">23000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMTU1Nw_fbb06226-9a3d-4837-90ab-00747be70d12"
      unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="ib0ba8f04e8d44ad486f7a21607ab601a_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjE5Mw_fc852a86-609f-4527-85d3-3cf7de09784b">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07611a308e2c480eb6fdd59ebac3f2b9_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjIyNw_6e61bf66-adc4-4a4e-9af6-9c391436cc17"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie29255ae26c54473ad60f4e96b040b6a_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181NS9mcmFnOjVmZWFjNzFkMGE1YjQ2NDhhMDZkZDM2ZGQ2YTY3OTdmL3RleHRyZWdpb246NWZlYWM3MWQwYTViNDY0OGEwNmRkMzZkZDZhNjc5N2ZfMjE5OTAyMzI1OTQ3Nw_225e91ba-81d4-4572-a2f4-a6a8a8781b59"
      unitRef="usd">100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjY1MQ_ce258876-cf87-4559-97e4-9f0dca6603bd">Convertible Preferred Stock, Redeemable Common Stock and Common Stock&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Series A convertible preferred stock and Series Seed convertible preferred stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February, March and April 2021, the Company sold 738,445 shares of Series A Stock for $7.168 per share for net proceeds of $5.0 million. The Company also issued 184,597 warrants to purchase common stock at an exercise price of $7.168 to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued 24,134 warrants to purchase common stock at an exercise price of $7.168 to placement agents as a part of the Series A Stock financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2021, the Company converted $6.1 million of principal and interest related to Senior Convertible Notes into 844,824 shares of Series A Stock at a price of $7.168 per share. In addition, warrants with a fair value of $0.1 million associated with the Senior Convertible Notes were reclassified into additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the Company completed its IPO in which the Company sold 5,750,000 shares at a public offering price of $5.00 per share. Immediately prior to the completion of the IPO, all of the Company&#x2019;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and all of the outstanding warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of the offering. The Company issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock and received net proceeds of $28.9&#160;million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. The Company also issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Warrants for Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At September&#160;30, 2022, the Company had the following warrants outstanding to acquire common stock: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Exercise&#160;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Expiration&#160;dates &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in 2022 for consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;360,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEz_a4e2b89c-0bdb-473e-8f43-e5658fd84127"
      unitRef="shares">738445</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="i02d517722f68464aa57cb746d8b6b0fc_I20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjQ1_d1c62cba-c655-467a-a0cf-6d2c72c34b22"
      unitRef="usdPerShare">7.168</cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i718aa616c0d04160b6c70d8a853bf845_D20210201-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjc4_b180eebf-0bda-4cc1-b9c5-430407010e17"
      unitRef="usd">5000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i37765677fef04878bfd307079cffd395_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMzA2_6ab39b7c-fb9d-40c2-a42f-9d78899f9da3"
      unitRef="shares">184597</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i37765677fef04878bfd307079cffd395_I20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMzY3_277687f8-8c87-4f3c-8110-7ddbaa6c0541"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i94a68f56ad3d4f398d8120b6f54fc354_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNDcz_20b23783-1ff3-4187-845c-31ad2b0af0f3"
      unitRef="shares">24134</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i94a68f56ad3d4f398d8120b6f54fc354_I20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNTM0_3571e5c8-d785-4e3b-90ad-9b4198d9316d"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iea511a0f86dd4c4daa7a2411ba8f627d_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNjQx_bc0d5118-f882-4bea-b744-69d31cdd0434"
      unitRef="usd">6100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ia78dc4ebd9ca4882be974e5c7eb99b0a_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNzEx_7864292a-a4db-4f7f-a42d-e01da68bb593"
      unitRef="shares">844824</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <cntx:DebtConversionConvertedInstrumentPricePerShare
      contextRef="ifb7a61f34a4b428e9a376347e43312f6_I20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfNzUz_5b5cb989-745d-4cca-b11f-8025b67d3d49"
      unitRef="usdPerShare">7.168</cntx:DebtConversionConvertedInstrumentPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="iab205c27896840a48993517f0d658e53_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfODEw_ba472495-9690-4799-a86b-0984fc93625d"
      unitRef="usd">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6f2a5fbbda3a4260997ebb5507e0d17a_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfOTgz_976c63e7-96c1-46b9-a090-d35e1a320eba"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i07512b61ceef49069b0fde3492828089_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTAyMw_278d0883-b748-4834-af2d-789efeb6214d"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i88481b1f040d4ae9ab9358ec2a521621_D20210930-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTE4MQ_199b732d-f27f-46a3-b875-eb8d724ac172"
      unitRef="shares">4853533</cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i13ff4879231b4c58a0d8f431b824853d_D20210930-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTI1OA_c09e844c-7ed7-4fef-852c-3c4932886fdd"
      unitRef="shares">9816</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i5bffcb105fba4c288989c8360b034b50_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTMyMg_63b49a01-0b8a-4879-9cc6-2f94fb72454c"
      unitRef="usd">24400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iaf6909f0d3984eef85455ec758334932_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTM3Mw_6b2a8a57-06cb-4692-8870-43e01cdccdcc"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iaf6909f0d3984eef85455ec758334932_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTQ1Ng_df71647d-ab1e-436f-ae02-45f11315cd2b"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iaf6909f0d3984eef85455ec758334932_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTQ4Mw_c43dba84-d884-4921-b73a-2d20e856c902">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTUyMw_bfedc1d2-583b-4939-bb84-d809da073d4f"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTU4NA_4a2be141-3d65-45cd-993a-680db700a348"
      unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8a53c28e68fa412e957e3229c78a770d_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTYzOQ_4f80710d-de4f-4ef9-bd9a-5edfb0f3ef9d"
      unitRef="usd">28900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iedba3e5b6d9b4bbd9cdd3f4eb5c70b60_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTc2OQ_458f1bcd-3bf5-442d-885b-63595290460a"
      unitRef="usdPerShare">6.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTgwMQ_6247d32f-e693-4812-834d-4a03647bf3b0">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic30db45c99284874bb93ab62a6ede5bf_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTgyOQ_78067a26-31aa-4a66-ac71-323e6dae02c7"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTg2Nw_2ee73fdf-3871-4cf2-9cdf-672a67341a32"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTk1MA_79487c76-28e4-4fe7-8d81-eec784ca5ea7"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i693375af6c0e4e808d56df5c3d2c0d2d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMTk3Nw_66861e63-7de6-4864-aed7-5369a94cd11b">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjA0Mw_fea7605a-b895-4aec-b981-b4f1295f2985"
      unitRef="shares">360000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEwNg_d59e4877-30df-4c09-8130-fe2d5161b374"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i7142d15699314123900d44fdfb1d6fa7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjEzMw_7bcc91bb-0aa6-4867-940c-7bb346f067a8">P5Y9M3D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i0f0d08a54b2d45fcbab6217ef7c19f5c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjI1Mg_07512ce2-ed4e-45c6-b657-e9730bda2c37"
      unitRef="usd">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RleHRyZWdpb246NjQ3N2NjNGYwZTNkNDczMGFlOGQ4ZWQwOWNmZjQ4NTZfMjY1Mg_265cda74-a96d-421e-a6bf-170f9bbb8ed1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At September&#160;30, 2022, the Company had the following warrants outstanding to acquire common stock: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Exercise&#160;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Expiration&#160;dates &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in 2022 for consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;360,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2b6b6924916f49cebf4a3197558fd9aa_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMS0xLTEtMS00OTcxMg_317079a2-f0c6-4e40-832f-fc9c85db0599"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2b6b6924916f49cebf4a3197558fd9aa_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMS0zLTEtMS00OTcxMg_d63a83ad-b9ec-4d99-a9d2-0cb6d9dfbf67"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMi0xLTEtMS00OTcxMg_f28e7611-c39f-4861-95fa-a64a834eaa96"
      unitRef="shares">5250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibdea65afb4f94483b2f188e2e3aa35fd_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMi0zLTEtMS00OTcxMg_e51b0b5c-3b62-4e48-9dd9-b67826fa4e15"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i44b557d2dee24d6d85852c77416f09b7_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMy0xLTEtMS00OTcxMg_c70b1f0f-6d44-41b0-846e-2a1db2f62b9b"
      unitRef="shares">360000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i44b557d2dee24d6d85852c77416f09b7_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfMy0zLTEtMS00OTcxMg_e209b833-6686-4d3d-8ba0-3eef540b2ceb"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181OC9mcmFnOjY0NzdjYzRmMGUzZDQ3MzBhZThkOGVkMDljZmY0ODU2L3RhYmxlOmI4Yjg3ZjYwODJjMzQwNjhhYjlkNGE0MTFkMDBhYzQwL3RhYmxlcmFuZ2U6YjhiODdmNjA4MmMzNDA2OGFiOWQ0YTQxMWQwMGFjNDBfNC0xLTEtMS00OTcxMg_72738b3b-9743-4668-8b7c-53b462d472d0"
      unitRef="shares">5860000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1OQ_b3eadc36-7537-460d-a43f-2d72765a27d8">Share-based Compensation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#x201c;2021 Incentive Plan&#x201d;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#x201c;RSUs&#x201d;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#x201c;Share Limit&#x201d;).  The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of September&#160;30, 2022, 546,535 shares remained available for future grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based awards generally vest over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfOTk5_9bce99fb-680f-4b4e-95c7-aea7eb7069f0"&gt;one&lt;/span&gt; to four years, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is ten years. The expiration dates of the outstanding share-based awards range from January 2028 to August 2032. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#x2019; compensation is charged to general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based compensation expense related to the issuance of stock options was as follows for the three and nine months ended September 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;14,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;17,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;74,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;56,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;262,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;133,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;658,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;224,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;276,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;151,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;732,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;280,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the nine months ended September&#160;30, 2022 and 2021, respectively, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:51.3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;87.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;97.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.03%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the share-based award activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Number&#160;of&#160;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(years) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;506,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;890,058&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.05pt;margin-top:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(55,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.57pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and exercisable at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;275,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and expected to vest at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average fair value of share-based awards granted during the nine months ended September&#160;30, 2022 and 2021 was $1.38 and $3.76, respectively. As of September&#160;30, 2022, the unrecognized compensation cost related to outstanding share-based awards was $1.9&#160;million and is expected to be recognized as expense over a weighted-average period of approximately 2.25 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Restricted Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company issues RSUs to employees and consultants that generally vest monthly over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjUxNQ_9f1ec537-f564-4137-94fe-554fb0d09f1f"&gt;one&lt;/span&gt; to three-year periods. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded share-based compensation expense of approximately $10,000 and $25,000 in research and development expense for the three and nine months ended September&#160;30, 2021, respectively, related to RSUs. There were no RSUs outstanding as of September&#160;30, 2022 or December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2b03a95d6ac1446db1df7032d377d274_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMzQ5_dc6944e2-d2ba-44cc-8ed6-fc1ca101e801"
      unitRef="shares">1266092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock
      contextRef="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfNjQx_e607ec05-b727-4f84-bc4c-50f4d5a52952"
      unitRef="number">0.04</cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i893010e7c4d84530bb4e535807bafd81_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfODk3_c7c41c3f-5d11-4bd4-88d1-50bd7722dce0"
      unitRef="shares">546535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9d27a8b650fb459ea73fa6afb06d6686_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMTAwNQ_e0ec93b2-d1ae-4ac9-83d1-36f565312960">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMTE0NQ_23c9018c-5c9e-4742-8ac8-ba196e97f24e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk2MA_c2f33bc1-0866-4bf8-a3c4-7411bb80d84f">Share-based compensation expense related to the issuance of stock options was as follows for the three and nine months ended September 30, 2022 and 2021: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;14,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;17,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;74,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;56,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;262,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;133,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;658,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;224,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;276,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;151,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;732,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;280,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i390779b4e1374f78a3d2ff4696312717_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi0xLTEtMS00OTcxMg_cfcda6f3-b44f-4a33-9248-77d7830820ea"
      unitRef="usd">14349</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3552069f01754175946fbde459157a66_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi0zLTEtMS00OTcxMg_82f6bc85-9111-4754-b871-71a7772f573b"
      unitRef="usd">17775</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaac7d80114ef46d39ae9a53271640ba1_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi01LTEtMS00OTcxMg_869146d2-3e70-48a8-bad4-ac40a28f194a"
      unitRef="usd">74256</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia3f47e32ce8e4ceab933f1129b620c5e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMi03LTEtMS00OTcxMg_62e06fe6-93d9-4320-bb4e-cb58b20e3af2"
      unitRef="usd">56677</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib73ab2ac402a4838afab49d9909a77b3_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy0xLTEtMS00OTcxMg_d7231dcd-ffd3-4f72-aaf2-9eca366e5a7d"
      unitRef="usd">262172</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i452d4086812e4e2eb52bd1a594c530b4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy0zLTEtMS00OTcxMg_8f08e0a9-51b3-4a69-a158-812a731ecdcb"
      unitRef="usd">133300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if870d3ee8de04697b45e9489a10d6c63_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy01LTEtMS00OTcxMg_a6867df2-3d7c-40e1-b2a5-c87ce633ebd6"
      unitRef="usd">658547</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia42107d884244b2ab5d0ba0cf3931add_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfMy03LTEtMS00OTcxMg_fbc7fcb0-8c5f-43d5-992b-935e6408ff2b"
      unitRef="usd">224049</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC0xLTEtMS00OTcxMg_83d005cf-9079-408e-8d5b-96a4665c135d"
      unitRef="usd">276521</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i02120c98aecd422bb636957763abc278_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC0zLTEtMS00OTcxMg_cdea628b-4347-419e-bee9-7854cc1ddc88"
      unitRef="usd">151075</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC01LTEtMS00OTcxMg_0ac237f8-aee3-4457-a5f1-b114c6c031f2"
      unitRef="usd">732803</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjI2ZjExYTBlOTNjZDRiODFhNzZlY2JjOTg2NWJhNGU0L3RhYmxlcmFuZ2U6MjZmMTFhMGU5M2NkNGI4MWE3NmVjYmM5ODY1YmE0ZTRfNC03LTEtMS00OTcxMg_0eafc801-fceb-480c-8f63-cab45331a9c6"
      unitRef="usd">280726</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk2MQ_a1e7809f-c6b0-4ac4-860a-1ab229ccbd2d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the nine months ended September&#160;30, 2022 and 2021, respectively, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:51.3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;87.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;97.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.03%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.77&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMS0yLTEtMS00OTcxMg_89b01d21-f6e3-4c46-8f7b-55214418bb84"
      unitRef="number">0.8702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMS00LTEtMS00OTcxMg_66d413c1-b44d-4aae-a352-12bb63e75d4b"
      unitRef="number">0.9750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMi0yLTEtMS00OTcxMg_bb9859bc-6246-4306-aaa4-61387d9f15a0"
      unitRef="number">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMi00LTEtMS00OTcxMg_e1f16fa7-8b1d-4f17-9375-b7622dda6098"
      unitRef="number">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMy0yLTEtMS00OTcxMg_74eb2b6b-84c2-4a34-ab18-ad65e114b18d">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfMy00LTEtMS00OTcxMg_79456cdf-d98d-4ae5-8c04-41f4d8399e6a">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id527e215cc174d55a56cc5895cb43547_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfNC0yLTEtMS00OTcxMg_9e6068d3-1b8e-4bec-90e9-9660a316a833"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic3a3137493924173b60421527f2075d0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjkxMDc4NzQ4Nzg1ZTQ3NGU4ZjkxNjEzZjkzZmFlNjY5L3RhYmxlcmFuZ2U6OTEwNzg3NDg3ODVlNDc0ZThmOTE2MTNmOTNmYWU2NjlfNC00LTEtMS00OTcxMg_e81b262d-578b-4bf5-8427-94bfd08249a6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1Nw_457a6a51-1fa0-4d86-9054-d0b0402552ee">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the share-based award activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Number&#160;of&#160;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(years) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;506,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;890,058&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.05pt;margin-top:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(55,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.57pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and exercisable at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;275,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and expected to vest at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS0xLTEtMS00OTcxMg_6834ea30-4805-4ba0-b1a2-db130b7b333c"
      unitRef="shares">506691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if1081ba53b574bb2adf21cf126fc5f4a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS0zLTEtMS00OTcxMg_300895a4-3f76-436a-9551-3d9f14ad1548"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibffa84374b394851b73ca24a8916a301_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMS01LTEtMS00OTcxMg_ec9c629d-c3b6-4fd9-b066-33d951e2d725">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMi0xLTEtMS00OTcxMg_35bd2636-d5c3-4f0e-8d11-66a53958f1df"
      unitRef="shares">890058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMi0zLTEtMS00OTcxMg_34b4e7fa-b439-44f9-8191-9b82a7da58f2"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0xLTEtMS01MjU1MQ_feb6799e-db73-4e1d-9e0e-f86fc38e3ee7"
      unitRef="shares">55245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0zLTEtMS01MjU1MQ_175046f0-8ab2-4795-992b-111b1d98201e"
      unitRef="usdPerShare">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0xLTEtMS00OTcxMg_1b382d0c-723a-4bc7-9f60-546400a97e7b"
      unitRef="shares">1341504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy0zLTEtMS00OTcxMg_a5eb4775-1fbe-4a7a-a9b4-d9304f247697"
      unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfMy01LTEtMS00OTcxMg_28808637-2671-4c4b-b0f8-61e99b6f80d9">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC0xLTEtMS00OTcxMg_a00817ac-eb9b-4a10-b205-b16b1efdac8f"
      unitRef="shares">275061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC0zLTEtMS00OTcxMg_94521a11-0ded-40a6-80aa-02654a7a1182"
      unitRef="usdPerShare">5.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNC01LTEtMS00OTcxMg_cf81991a-2e8a-48b0-9ebb-8e12b35965f0">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS0xLTEtMS00OTcxMg_14f3e102-d69a-427b-a1ed-fbe2c25c8af0"
      unitRef="shares">1341504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS0zLTEtMS00OTcxMg_03279383-f026-4219-9b09-46cc7779e019"
      unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RhYmxlOjFiZmQ3YTFkOTg1ODQxMjI4MDBiNmE0MWQ5MWU4OGExL3RhYmxlcmFuZ2U6MWJmZDdhMWQ5ODU4NDEyMjgwMGI2YTQxZDkxZTg4YTFfNS01LTEtMS00OTcxMg_427a57a2-9b73-4ed5-9469-cad95f12fd4e">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjE4Mw_5f04b18b-ead0-41a9-8b1d-f08d8ab00f2d"
      unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i78abb364b55c453cb3733b76148eb098_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjE5MA_cd961160-ccd8-4b2b-80ea-498b16ed3632"
      unitRef="usdPerShare">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjI5OQ_6a5f57ce-68b9-474e-8ed6-6697e86ea0af"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibd804bfec7bc4f1d89cace194a5d9f99_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjM5NA_9d7db2f6-29a2-4ed7-8897-91ddb8bde884">P2Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3aa6a3da81d5470497285d540411a506_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjk1OA_89063d21-b052-4121-9f04-9493aa5ccb31">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib894c6511aad4955ac97436b31cd674f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjc5Mg_7807661f-2d27-41e4-9d78-da1bdc7f7a31"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89136a0062a546e4bba3db98f38f30c7_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjc5OQ_1eb28e49-1de4-421f-99cf-97c9d24f8079"
      unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i629d249a546f43ebb5ec4d9fc839c160_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjkwOA_050971a8-7a78-4b1a-84e6-827b3a64128f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icb8fbecc9e72463d930d63daeec62a21_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182MS9mcmFnOmQ5NGZmMTFhM2Q5ODQxY2ZhZGRmOTQ4OTgzYzI0MGQ2L3RleHRyZWdpb246ZDk0ZmYxMWEzZDk4NDFjZmFkZGY5NDg5ODNjMjQwZDZfMjkwOA_39c2ca3b-2ff8-4b77-9bb4-9ee2f5fcd937"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTk0Mw_2e3324c0-8b2f-49c3-9320-cba67be9e8df">Commitments and Contingencies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September&#160;30, 2022, the operating lease right-of-use asset and the operating lease liabilities were $74,000 and $78,000, respectively. The weighted average discount rate used to account for the Company&#x2019;s operating leases under Topic 842 is the Company&#x2019;s estimated incremental borrowing rate of 5.0%. The remaining term of the Company&#x2019;s noncancellable operating lease is 0.83 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rent expense related to the Company&#x2019;s operating lease was approximately $23,000 and $60,000 for the three and nine months ended September&#160;30, 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future minimum lease payments under the sublease are $80,000 at September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to 3% of employees&#x2019; compensation. The Company generally assumes all administrative costs of the plan. For the three and nine months ended September&#160;30, 2022, the Company provided contributions of approximately $12,000 and $54,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration Agreement with Tyligand Bioscience &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, the Company entered into a process development agreement (the &#x201c;Tyligand Process Development Agreement&#x201d;) with Tyligand Bioscience (Shanghai) Limited (&#x201c;Tyligand&#x201d;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#x201c;ONA-XR&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#x201c;Tyligand License Agreement&#x201d; and, together with the Tyligand Process Development Agreement, the &#x201c;Tyligand Agreements&#x201d;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#x201c;Territory&#x201d;). The Company retains rights in the rest of the world to commercialize ONA-XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the Tyligand Process Development Agreement, the Company paid Tyligand $0.8 million and issued 111,576 warrants to purchase shares of common stock at an exercise price of $7.17 per share upon successful completion of the manufacturing development plan in 2021.  The warrants were cancelled in connection with the Company&#x2019;s IPO. In addition, $2.0 million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#x201c;GMP&#x201d;)-grade compound and $3.0 million upon the Company&#x2019;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#x2019;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) 15 years after the date of the first commercial sale of product in the Territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration and Licensing Agreement with Integral Molecular &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#x201c;Integral&#x201d;) for the development of an anti-claudin 6 (&#x201c;CLDN6&#x201d;) bispecific monoclonal antibody (&#x201c;BsAb&#x201d;) for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $0.3 million, granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8 million, and expensed these costs to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $55&#160;million, sales milestone payments totaling up to $130.0 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. In the second quarter of 2022, the Company expensed $0.5&#160;million in acquired in-process research and development related to a development milestone achieved under the agreement with Integral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.05pt;margin-top:0.05pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;require upfront payments and long-term commitments of cash.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzgy_6a3df771-1d89-4966-8719-bdf0fcf872ce"
      unitRef="usd">74000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzg5_9c2299c2-6924-44b2-bdf8-1c7f46afc1df"
      unitRef="usd">78000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTY2_6173a73b-ad9b-4276-adc6-406166578020"
      unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNjQw_d4c4b7a2-8551-4fd3-9c81-bcbf85f50523">P0Y9M29D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNzE3_1735e1c7-c3cb-41d3-af6a-b1f053047f84"
      unitRef="usd">23000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNzI0_87fc8064-07c3-4cee-84e0-3a5b9e459568"
      unitRef="usd">60000</us-gaap:OperatingLeaseCost>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i061af97dccdb4fda98333d1bb3013560_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfOTc0_e7ee869c-e930-4046-bd2c-5e182d937ba6"
      unitRef="usd">80000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTE0OQ_b5b4c1d9-2e93-4864-bdbd-4f044c51b635"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTMwMw_1d76d59a-b5a7-4196-9ecb-109dda9fc6b8"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTQ5Mw_2575fc03-2441-426a-baea-996a8bbc7d7b"
      unitRef="usd">12000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMTUwMA_879e074a-cef1-40aa-9cee-dd0511056cdc"
      unitRef="usd">54000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i8773e0c5834143cbb0d43e34a17e2a92_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjUxMA_f0ee5811-2f53-40d0-9d31-66e47ffe640b"
      unitRef="usd">800000</cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjUyNA_57c8524e-3ca3-42e5-86d8-3080d2e04d59"
      unitRef="shares">111576</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7fc2f8dbffb14da8bb6fe2a753aecebe_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjU5NQ_45646acf-2844-46ec-a016-c41e30899685"
      unitRef="usdPerShare">7.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="ibc6ef50417cb4013b7ac39e1693b2f04_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjc2Mg_9629f533-4c47-4ddc-856b-c507f4fc414d"
      unitRef="usd">2000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="ibcabaf70069543ae99e3fe4be7d87d00_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMjkxNA_2f94c38b-d552-4118-b80c-eec3ba4f9d0f"
      unitRef="usd">3000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent
      contextRef="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzE5NA_2dcc9340-433c-42f2-bb25-9e396af583ec"
      unitRef="number">0.01</cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod
      contextRef="ief71d6e238744c8db6fa5c4029185461_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfMzc4Mw_ca011791-f8fd-44f6-8850-e2bb317ebb8b">P15Y</cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod>
    <cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDYwMw_fcc96258-a475-461b-8854-411d7b2aad92"
      unitRef="usd">300000</cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDYxOA_1f72eeb3-adb1-4ce5-b69d-4b9396b8ac84"
      unitRef="shares">418559</cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices
      contextRef="i90b1fc71421840c8810cc95467a88ab5_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDY4OA_cdb676ad-7d2f-497f-bea1-4bcbe0be3356"
      unitRef="usd">2800000</cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices>
    <cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum
      contextRef="ic7d331e039ce4907b44d8c6829eb96ab_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDk0Nw_5f195a21-ee4c-4f33-a446-a02c378d3794"
      unitRef="usd">55000000</cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNDk5MQ_e3f77fdd-bbeb-461e-bf0e-2ae1f99eb6de"
      unitRef="usd">130000000</cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="ia2ebeb11a4d148d68f523754c98b6a3e_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTAyNQ_f90c4dc4-8e34-4d96-929f-ec84e7bc542c"
      unitRef="number">0.12</cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ibf836415560143e7aa246d7036b09772_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN182NC9mcmFnOjQyMjJhOTYzNmEwNDQ1MjY5OGZkZGY0NDkzNDNjMThmL3RleHRyZWdpb246NDIyMmE5NjM2YTA0NDUyNjk4ZmRkZjQ0OTM0M2MxOGZfNTE0NQ_233cbe05-df1a-45fd-9583-da47a97c974b"
      unitRef="usd">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjYxMjhlZjI3MTY1ZDQwNjZhOTU1YTg1OWI0YjBlZTI3L3NlYzo2MTI4ZWYyNzE2NWQ0MDY2YTk1NWE4NTliNGIwZWUyN181MTQvZnJhZzozMDZlZjNhNjEyNWU0Yzg0YTY5Yzg2MmNhZDUzZDlhMi90ZXh0cmVnaW9uOjMwNmVmM2E2MTI1ZTRjODRhNjljODYyY2FkNTNkOWEyXzIxOTkwMjMyNTY5NzA_f75ed3c3-6a8e-4160-a512-4eb79cbb895f">Subsequent Event&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On November 7, 2022, the Company entered into a Development and Manufacturing Services Agreement (the &#x201c;Lonza Development Agreement&#x201d;), with Lonza Sales AG (&#x201c;Lonza Sales&#x201d;) and Lonza AG (collectively, &#x201c;Lonza&#x201d;). Under the terms of the Lonza Development Agreement, Lonza will provide services relating to the development and manufacture of the Company&#x2019;s anti-claudin 6 bispecific monoclonal antibody product (the &#x201c;Product&#x201d;) in accordance with the project plan attached to the Lonza Development Agreement and any other work as may be agreed to between the Company and Lonza. The Lonza Development Agreement will terminate upon the completion of the agreed upon services, unless earlier terminated by the Company or Lonza for uncured material breaches, insolvency of the other party, or if a party determines that it is not possible to complete the services for material scientific or material technical reasons.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In addition, on November 7, 2022, the Company entered into a License Agreement (the &#x201c;Lonza License Agreement&#x201d;) with Lonza Sales. Under the terms of the Lonza License Agreement, to the extent incorporated into the Product, Lonza granted the Company a non-exclusive license to use certain proprietary Lonza intellectual property and systems for the Company to develop, manufacture and commercially exploit the Product.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<!SZ'.G;U1P)\HW1)RJ>P-]A/TC=E1;<F%(7O% B;)00,_ABQ[7@YLAYZL/
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M+YJ=CM=0;]!%:=]^R#)A;S8@8]EST+DHH7"K!&0P)UCB4($@3H@_+GA=EE%
M<(QGZCAZ=)9^L5JHBSIO;@PROA>I<"H6G=8!YSY,K!<DX\.ERY0F-/!]?VY!
M#D4#72X:6C70CKSC!#W5?2\&W8>1&V.>6OHQC2CPFX$\E ATN428"%BSI%]-
MP9\>U=UEM,-RIHQ>'UTUV7N^/YBZ$Z6&$F8/KO@B@F%0[=59VS"R:FZ?;J4Q
MLF@>#YP!=&L W_=2FN>&O=#J+S"W_P%02P,$%     @ UX!I57?PH?WW @
M80H  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM5EUOVC 4_2M6-DVM
MU)$/($ 'D5JJ:GN8A(JV/4Q[,,F%6'7LS#;0[=?O.J$9H7R$;CP0?]QS?,[U
M=>+A6JI'G0(8\I1QH4=.:DQ^[;HZ3B&CNB5S$#@SERJC!KMJX>I< 4T*4,;=
MP/-"-Z-,.-&P&)NH:"B7AC,!$T7T,LNH^G4+7*Y'CN\\#SRP16KL@!L-<[J
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M,VGP@E$T4[P#@K(!.#^7TCQW["VCNE5&?P!02P,$%     @ UX!I5>&0H\
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M\.W7E4?5[?;_/]4'<AAJ?A#V;J)-S)LS^!B(]FM0+46U#-5R5"M.V_4E.JA
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M:@+5)*6IV6RK,:ZY&J-.4WA]8')>TX,)I\T)<_6QR??NC[8S*,UGTWJQWLT
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MJDE*4X+EMU4;WSSISAG3&)O%H6%"M1C5$E\SXXZ^C*U94E_&UBRH*V.CKZ-
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M-U]^<]7X3\O5;[LQ/OP_4$L#!!0    ( -> :545,C2*? (  .(%   8
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M%34TB97<$F6CD<U.7&X<&MTP85]Q:12>,L299"Y%AF\"&<&9EIQEU.!B:7#
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MSYOJ/>^WKI44N8OS39.?DF*S$0NU=IIL[EFSY)MM<[%=$ZX4%M3_AM)\*"V
MTA@]['\K0AQ*Z417YW"_:>]^4[W[?5NFCW'-C=M,]/'F0@GJ;T-I/I060&D,
M2@NAM A%&^JN=\JI=YYZ,H4ZX5":#Z4%4!J#TD(H+4+1AEKL/76J]]1OX^?V
M1F]R.38Z$2AYUMP;5<RGLM"\[=+E]B5=[DO/KV=?I6ZA'CN4YD-I 93&J&(W
MN[)&J B<S+7GV,YN]VZ^K7?SO][^JE*&OM6IRH#2?"@M@-(8E!9":1&*-E1:
M7TVP3]OX?O3L:D-K"%":#Z4%4!J#TD(H+4+1AEKL:PBVOH;P?YE=]6,X6;?0
MB@&4%D!IS#Y<,5"$S#SB+B:W%D*-;*BSOF)@ZRL&O[_<"K.K$,@]-T7^QRYO
M[S?TE-9K>8?,HXM0^NY.EA2T.@"E!5 :@])"*"U"T882?76';_O<17X;6ER
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M<Y$-&_C[SA@_3H*#Z16W_A=02P,$%     @ UX!I55,]39&)!P  >A,  !@
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6S-6&UOXS82_BN$NVCO ,-OL7>S
MNTF [+:'+G!%%YM>^^'0#[0TLGB12)6DXN1^?9\92K*<.+D%^N6^V"+%&3[S
MS N'NM@[?QM*HJCNZ\J&RTD98_-N/@]92;4.,]>0Q9O"^5I'#/UN'AI/.A>A
MNIJO%HO7\UH;.[FZD+G/_NK"M;$RECY[%=JZUO[A U5N?SE93OJ)+V971IZ8
M7UTT>D<W%/_5?/88S0<MN:G)!N.L\E1<3JZ7[SZL>;TL^-70/HR>%5NR=>Z6
M!Y_RR\F" 5%%660-&G]W])&JBA4!QA^=SLFP)0N.GWOM_Q#;8<M6!_KHJM],
M'LO+R?E$Y53HMHI?W/Y'ZNS9L+[,54%^U3ZM/<..61NBJSMAC&MCT[^^[W@8
M"9POGA%8=0(KP9TV$I3?ZZBO+KS;*\^KH8T?Q%21!CACV2DWT>.M@5R\^F+"
M;5#:YNJ?YH_6Y"8^7,PC%//K>=8I^9"4K)Y1\E;]Y&PL@_K!YI0?R\\!:$"U
MZE%]6+VH\(::F3I;3-5JL5J]H.]LL/),])V]:.7UV$KU[^MMB!Y1\?LI@Y.^
M]6E]G"GO0J,SNIP@%0+Y.YI<??O-\O7B_0MHUP/:]4O:O]8G+RHY#?&$9O5+
M2>JCJQMM'U2I@S(V:[VG7%4N!$JK+>TT9X_*="A5@4P.JO"N5B@.7G-Z!14@
M2"Q-3<HWR)4ZQS]2+VOKMM(16I$Q)C-1N4*]6B]F&P1U5<GZP'/P?*1Z2WYP
M_^P(H;81X@U4]4B-W2F=PQ0HT56/NL6Z"J4F*U5$$9DJ4RBZ(S]5L=11 4 &
M8#NRC)\ ?F<-@$$]2LT=V98Z"TT,JO$N;S,1R4TN>PM'-E8/0 &;[E#=&M2J
M>(QV2Y7!NR!:A#MF11X(_-_I"B)B]ZNSM[/U_^1":0^L;<$40E)%IXH6&CN0
M_T&I \4CIZ!J*YA;D0Y8#626[J-:KE2=$E9,Y'D30JO9@6P>;X[) '\[9+0-
M4(JGX"JQ/E>%L5AL0'>(F&##PTS]Z/:)XM BM=A36#!R32<%?^UA)\@!&D+!
M4-L'P="S-K9J9 M3AU>9JVORO#G([YA/_":7R+JBC2VH>NHX\8]G>Y5UX#FT
M7LR6J)!P>8I2WVE3Z6U%:E^2[4&#63E5.-[E921?0_\G*\84QH/R4E<%LPGG
M+:='1GIMF-97F]EB<+MAY9%19]@C(!)3SL!J%@T(%U;&QMZ0-XBK:_8+.(^&
M$2#1"Y+<Q;F1W:J_??O-^6JU>#\LON%IF5R^_[L0M=<>!,04*4PM8(BP&/)S
M%AW'WU/X&?*,)+F-->+HIMU6)@,^0&#V^LT_??ZYWW'*%NY+ Y:1@!QRH@)P
M796KS?3-9C%=+!8JE(CSP(&KGZAMO,F$!69NH1 >:;G@[8-MRK(,EV&R5 IH
M!2S'9G08!A; =-/Z#'605-OP<'6,"8K&+/&*G+AZ4'K)RIL*9;>64-P-)>'1
MY'?AL&FI45G!)-US7 <:V?AZMMH<;!2NM 0:ORVX(C^0]J,\[M.WSV?0@G3)
M#::1+E ,-W?A!#N:BJ16C^E!7O7CCB5VW_+-^_ DOA@.1H0^D</OB)@N+K'6
M6&S(I\!NY_D<$7SKZ?GF;+HY.WN.6-:]/E],U\O-@:E'2M].SY>OGU%P7(@]
M902V\N/\@HAN,+HW=>+GU6I]7(4U) ,:O)Z1/@PEVKZ'TOIT>G0!C<!Y%#Q2
MJ(X#:$>0]*@VL3P=B*?T'.E 5FGV[1V3.PHT<<]7&GX^>]L;/E,_:*1H"KE3
M?D'12W9*E4R0U9[+JM@]F"0)C*5;]";YJ13F\$Z.>I0,0XQOT"&D$)>-OR))
MOJH0/"'K_Z0L#*GVEXO#@;@7:L,X18#$BJ6!Z'9\;&>Z,1'_ICO8TM$:2^_:
M7>IC(O=E^1RE):=M/)R@8:H:[2-ZK%":!B/<5G"0NNY$G\H9*I$2'.@EV3Z#
MY0\*]\?3)0@HK;210\N5;G9 RZ?[I^(D=#[MX^.#W#-VU*]CW]?Z08[XY,,*
M(SX96Q\A^[@E&769W+%P@)DPY-Q,_:I1<%ON5.$6!L0^0@>6!@6 .SA(^@R-
M[$"G F I=?AL9I"GZ_"3?G1+B#]*6<WISL<Y;MFWJ._<'_,9VZ)5":%HJU$+
M9?XKEJ1(0'7F)MV!_J2G YST]*V.S>CY\^$QKBE:3[M#86,)4Z<@S5R0@MKY
ML <X1L5SJ0,]86L7:P4<TOH>3"W5ADMO1";U" <[I/2%CFLN>CXUD!WMIZPY
M-+G<!9OA4M,EP"$,CO,(7@5&GVY:(;C,2 \GY3V53>[%]J4[&!>DKS]QD<"2
MI A7G:K-J6OA._^>;*U3A\P'.TFT\MU/HW0)])%^5,:LQ.5$8O:%=<IM^5J!
M>(8S<7FC+LQCBNJ*/Z^TB6 0@DK@^3L(UB(+/$I#[UU/2"#+HW +'\ $+ \.
MR5Q-NST;XLL&AY=5MX1,E--5ZF>M+;S:X4:9W:6Z >I/W;?GH^\A"*F=?/7A
M<Q?YFCZ-#+/#AZ7K]#WEL#Q]E?I)^YU!IE=40'0Q>[.9) O[072-?%W9NAA=
M+8\EZ9P\+\#[PKG8#WB#X7/;U9]02P,$%     @ UX!I55<Y&[28$P  43D
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M\)NRI][/F$V8U=GF$((9]LAQ:*#$:+/D8J**2K=1Z9*5IKEK@;=\@)-J@KJ
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M@A'$FK=4YC(&QS[ Q,B3LYTW:^.6M.M_<^T&I40$YQLIC'/^Q7X#^A<&+&5
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ML.2O&[3>@/=7AI/737R _GMI\3=02P,$%     @ UX!I5;K$AB"_ @  , 8
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MH\=QN.BFP!]X-TMON=Z*QH#$DJCL\FH0@.[F4[>QJO4S8:,L31B_K&BDHW8
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M'Q@OTL[ Y<@B%0(<)?6R-W[9Z,2RY^RC*FQFV%V10MJ=/T(7&C^BO1\WT8N
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M[)A\_U[U M%QV.E/1TSGLWVPC>M0>%WAKD<18931!HSQ+1>KGRJ3 D/'/ES
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M3NT>,^!X.B8#_+Y1>'2J7VB!YF>1Y=]02P,$%     @ UX!I5>!D*+@V!P
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MQ:-0A;@O&J&+VM6 TV5NO^[%!A986LI*&I\XCY(]\2@9(9RO=,ZZ-0S[W"O
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MJZ>8DR[K>N=L%7;J7)=QX&FMS&SM/(.WI!$/6$!*EJ1N<X^']F$/N?N&V],
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M ST=XK"DMQHZ%J#]I;6AG["!X?4W_P]02P,$%     @ UX!I5<^9%RRO#P
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MX9YC#KGQXL3%BSP */2:)DPNK8-2V:-MR^@ *9$// .F5W9<I$3I2[&W92:
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MJ3U< XM!Y@7,_:4P+\GE25Y!M?5U\A]02P,$%     @ UX!I51#\)\&E#P
MP^,  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULM=U?4Z-8 L;AKT*Y
M6UNS53UM(!!CKVU5MW#X.S/6N+-SL;47F!R5FB1D@.ATU7SX!40)$4_"^',O
M=MJ8\QQB\@HYOH&SAS3[+;^3LM#^6"Y6^>>CNZ)8?SH^SF=W<AGG'].U7)7?
MN4FS95R47V:WQ_DZD_&\'K1<'!NCT>1X&2>KH_.S^K;+[/PLW12+9"4O,RW?
M+)=Q]NVK7*0/GX_THZ<;?DYN[XKJAN/SLW5\*Z]D\<OZ,BN_.GY6YLE2KO(D
M76F9O/E\]$7_%$V,:D!]C_\D\B'?^K=6/93K-/VM^L*??SX:55LD%W)65$1<
M_N=>7LC%HI+*[?B]08^>YZP&;O_[21?U@R\?S'6<RXMT\6LR+^X^'TV/M+F\
MB3>+XN?TP9/- [(J;Y8N\OK_M8?FOJ,C;;;)BW39#"ZW8)FL'O\;_]'\(+8&
MZ.8K XQF@+$[X.25 >-FP/C0&<QF@'GH *L98.T.L%X9,&D&3 Z=X:09<'+H
M@&DS8'KH)ITV TX/G4$?/3USHT.?"?WYR=Y]MHU79WEZNO7Z^3Y^?&'5KTH[
M+N+SLRQ]T++J_J57_:-^:=?CRQ=CLJI2>%5DY7>3<EQQ?I&N[F56)-<+J5V6
M 9!9)N?:59'.?ON@_2SGL@Q]];V+=+DL0U-_0XM7\^X-WVL_QED65X'2OK-E
M$2>+_)_EK;]<V=IW?__GV7%1;FHUX?&LV:R+Q\TR7MDL7?LA715WN>:LYG+>
M,UZHQX_WC??5XT_WC0_W;+^A ([+Y^CYB3*>GJBOAE*\DNN/VGCT03-&AM[W
M U4/M^6L'*Z_.MQ6#_]I5BB'.^KA0EY_U(SIJ\.%>GBP62D?NZL>_F6=*8=[
MZN$_Q)GRL?N'/W%&S_#@;<][^+;G/3K\L1N*5_'X^=?-N/;&K_VZ6<1YKJ4W
MVJ_5[XM5H:695N_YM?]&Y5TUOY#+_'\]V_GUT37[W>I8Y5.^CF?R\U%Y,)++
M[%X>G?_C;_ID]*^^K)"836(.B0D2<TG,(S&?Q (2"TDL@K!.;LWGW)HJ_;R)
M:ZZMLZ2,;)%JL_K H3X8_RY9:?E=7,[:MZ?_JI2')I?$[$?,JK'J[<K]N3D=
MF;IU=GR_G4ER3D%B+HEY).:__-%:T\FH_%_W9QN0DX8D%D%8)V[6<]PL9=R:
MH_+R2#Q>IIM5T1<KI3 T5B1FDYA#8H+$7!+S2,Q_Q"9;X=N-W<M[E/&<&*<[
M]PO)S8H@K).HR7.B)H?MP#(YJXY!DYND3%>R*O=D\7R>5"M"\4);Q\G\^V3U
M_2Q>)T6\Z(N=<IJAL2,QF\2<R8L7B#YZ^>M;D'.Z).:1F$]B 8F%)!9!6">@
M)\\!/3E@EU<?3Y9O#V=;RU*KM)!Y=<BY?EZ?RNM5ISW'G<KYAB:5Q.R3GN-.
M:VR-QSL'GN2D@L1<$O-(S">Q@,1"$HL@K!/5Z7-4I\JH7F;I3,IYKMUDZ;+<
MAY9[SVK?N;E>)+,RO&5&D]5M7R*5[-!$DI@]?;&[,TRS9X?GD+,*$G-)S",Q
MG\0"$@M)+(*P3B1/GR-YJHRDB)-,NX\7&UGM/1^>#G9OTDRKIDIFLEJZ2>^3
M_K]F?%7J0Y-)8C:).20F2,PE,8_$_-.];R9/7QS.C$_TZ>G.,EI(;E4$89VP
MZ:/VCZ:C/0>KU1\_'\'Z+Z!]F5(;0T.%:C:J.:@F4,U%-0_5?%0+4"U$M8C2
MNGG=*CGH[_1GQP:F0DQJ-JHYJ"90S44U#]5\5 M0+42UB-*Z(3;:$!L#5HBV
M%H/J):"ZE)2UA:798S_I\9N]R38.6X6Y4&_6X-"2FH-J M5<5/-0S4>U -5"
M5(LHK1O:MN^C*VL)Y_[E3[WA0^L\J&:CFH-J M5<5/-0S4>U -5"5(LHK9O0
MMMFCF^]U;(PV>U#-1C4'U02JN:CFH9J/:@&JA:@645HWQ&U?2%<7AG[<+*]E
M5J6X.1I.\GQ3%QRTH@QU'M>?>>D-,=HC0C6[T3HMLA.KYZ\RZ+0"U5Q4\U#-
M1[4 U4)4BRBMF\^V?:2KZT=7\:+^RTS^^,&:=9;,I+8N$UO'M6XRS-/%(L[R
M]M;>4H-ZGL%Q10M(^LO2T&Z5%IU0H)J+:AZJ^:@6H%J(:A&E=8/:MI!T=0WI
M,DONXT)JEXMRCJ7LK]ZJC<$A1+M%J.:@FD U%]4\5/-1+4"U$-4B2NOFM:TB
MZ=/W>O>*MI%0S48U!]4$JKFHYJ&:CVH!JH6H%E%:-\1M>4E7MY?>\.X5+2[I
M+YLL];O-W?>;-CJM@VH"U5Q4\U#-1[4 U4)4BRBM>^:!MNYDJ.M.V+M7]3Q#
MX]IHTZVX3CX:.V\Y;71.!]4$JKFHYJ&:CVH!JH4'O8XB:LYN!ML*DZ%L5YP_
MGFBEVC'&JYG\4'U")D_FLCKI2GT^I)E,[ON[O6IX<.CT%XL\QO2T;R>)SNN@
MFD U%]4\5/-1+4"U$-4B2NL&M*TG&>IZDO]\S%I&<]6<9.PA*>[J4Z]HKQ0A
MU.C@<*)5)51S4$V@FHMJ'JKYJ!:@6HAJ$:5U ]Q6E8SW.C>1@;:94,U&-0?5
M!*JYJ.:AFH]J :J%J!916C?$;9O)4!8MWG2B(C4].,9HGZG1MI>FC+XF!#JK
M0#6W[S&8^MCL/@0/G=0_\ <7H+.&J!916C=3;;G(4)>+GO:'\@^9S9)<-@M
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M42VBM&X2VU*2I2XE73U=$>/R^1QEKYXY5$T-3B2IV:CFH)I -1?5/%3S42U
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MG19%NJS_>2?CN<RJ.Y3?OTG+]]S-%]4$#VGV6_TPS_\/4$L#!!0    ( ->
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M.0</^'QH5GIAU@":E:%HN@0:;]@^-Z?5/->1_$ZZ3%<Q9^NL ZB?#*51*"V
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M%&A]"Y8(\XMVY5C/08N-D"PMA94%:9P5__2Q=,2> /%?$""E &D*!"\(^*6
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MH%T OE\K9?<;EZ"]R]-?4$L#!!0    ( -> :56,9]EF/@<  #0]   9
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M:@1WR@C #A"P@[A@I\P(X\)$[C08U_0]C/.FKEF8P,=8!A_'Q;QD0I,'5C5
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M>AOJ;>_4.\1KZ<.CY[[&V\AW4AW[=_WC\[?E?1-Q'MUP=G!9O_H%4$L#!!0
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M'/Q9]U=@]@502P$"% ,4    " #7@&E5!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -> :55^^SDO
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( -> :5697)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ UX!I54EK:EL0!@  KB
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( -> :57F4& B/@4  ,P4   8              " @5,.  !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #7@&E5=_"A_?<"
M  !A"@  &               @(''$P  >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L! A0#%     @ UX!I5>&0H\  !0  .!,  !@              ("!
M]!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -> :544
M18&G?!8  #Y, 0 8              " @2H<  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    " #7@&E5%3(TBGP"  #B!0  &
M    @('<,@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MUX!I550O90::#   %W8  !@              ("!CC4  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -> :55F5O4-)P0  -$)   8
M          " @5Y"  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " #7@&E54SU-D8D'  !Z$P  &               @(&[1@  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ UX!I55<Y&[28$P  43D
M !D              ("!>DX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " #7@&E5]I<#^N(#   ["0  &0              @(%)8@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -> :56ZQ(8@
MOP(  # &   9              " @6)F  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ UX!I5>0_D)5%!   3 H  !D
M ("!6&D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #7
M@&E58@C*B1 &   B$0  &0              @('4;0  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -> :57@9"BX-@<  "@2   9
M          " @1MT  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#
M%     @ UX!I586XSR\""P  L!T  !D              ("!B'L  'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #7@&E5SZ5PIRH$   )
M"@  &0              @('!A@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+ 0(4 Q0    ( -> :57/F1<LKP\  %8O   9              " @2*+
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ UX!I50$X
M0O(O P  WP8  !D              ("!")L  'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6Q02P$"% ,4    " #7@&E5%X8]L_("  #C!@  &0
M    @(%NG@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M -> :548TZ$AT (  /L%   9              " @9>A  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ UX!I54>O6/+J @  2@8  !D
M             ("!GJ0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " #7@&E50JXAO*H$   Q"P  &0              @(&_IP  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -> :56!&PH_*@(
M ,X$   9              " @:"L  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ UX!I57VB=@G""   \5L  !D              ("!
M :\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #7@&E5
M?Z3?LSD"   F!0  &0              @('ZMP  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( -> :55-K4H'%00  ((6   9
M      " @6JZ  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ UX!I57DV]S(" P  K0P  !D              ("!MKX  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #7@&E55\%QK-0"  "\!P
M&0              @('OP0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( -> :56C:6-SDP4   8K   9              " @?K$  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ UX!I51#\)\&E
M#P  P^,  !D              ("!Q,H  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " #7@&E5$C*&^%8$  #,'0  &0
M@(&@V@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ->
M:57A!YM-=@@  (M6   9              " @2W?  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ UX!I58#1U!.7 P  TQ   !D
M         ("!VN<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " #7@&E5F(*^D0L#  !C"   &0              @(&HZP  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -> :57)%_@@@ 0  +@5
M   9              " @>KN  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ UX!I5;$:+)0V P  KPL  !D              ("!H?,
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #7@&E50!_R
M7< "  #7!P  &0              @($.]P  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( -> :56,9]EF/@<  #0]   9
M  " @07Z  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MUX!I5? 1N+4N P  [A(   T              ( !>@$! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #7@&E5EXJ[',     3 @  "P              @ '3
M! $ 7W)E;',O+G)E;'-02P$"% ,4    " #7@&E5"V#N 8(#  "P&@  #P
M            @ &\!0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ UX!I
M54"[PRV' 0  O!<  !H              ( !:PD! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ UX!I5?]Y:I*? 0  '1@  !,
M         ( !*@L! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "\ +P#
)#   ^@P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>219</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Convertible Promissory Notes and Other Debt</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt</Role>
      <ShortName>Convertible Promissory Notes and Other Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Risks and Liquidity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails</Role>
      <ShortName>Risks and Liquidity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Convertible Promissory Notes and Other Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails</Role>
      <ShortName>Convertible Promissory Notes and Other Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Commitment and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitment and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails</Role>
      <ShortName>Commitment and Contingencies - Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cntx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails</Role>
      <ShortName>Commitment and Contingencies - Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  cntx-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="cntx-20220930.htm">cntx-20220930.htm</File>
    <File>cntx-20220930.xsd</File>
    <File>cntx-20220930_cal.xml</File>
    <File>cntx-20220930_def.xml</File>
    <File>cntx-20220930_lab.xml</File>
    <File>cntx-20220930_pre.xml</File>
    <File>cntx-20220930x10qexhibit311.htm</File>
    <File>cntx-20220930x10qexhibit312.htm</File>
    <File>cntx-20220930x10qexhibit321.htm</File>
    <File>context-lonzalicenseagreem.htm</File>
    <File>lonzacontextdmsa.htm</File>
    <File>tyligand-cntxamendno3proce.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="453">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cntx-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 173,
   "dts": {
    "calculationLink": {
     "local": [
      "cntx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cntx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cntx-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cntx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cntx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cntx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 349,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 29,
   "keyStandard": 190,
   "memberCustom": 18,
   "memberStandard": 22,
   "nsprefix": "cntx",
   "nsuri": "http://www.contexttherapeutics.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.contexttherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Convertible Promissory Notes and Other Debt",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt",
     "shortName": "Convertible Promissory Notes and Other Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Share-Based Compensation",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitment and Contingencies",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Subsequent Events",
     "role": "http://www.contexttherapeutics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ie6e9a07f9c2946a8b52c28630a825031_I20210430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ie6e9a07f9c2946a8b52c28630a825031_I20210430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "if1081ba53b574bb2adf21cf126fc5f4a_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Risks and Liquidity - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
     "shortName": "Risks and Liquidity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i5bffcb105fba4c288989c8360b034b50_D20211001-20211031",
      "decimals": "0",
      "lang": "en-US",
      "name": "cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "if18940842a4d4141bb83557faaaa3f5d_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails",
     "shortName": "Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "if18940842a4d4141bb83557faaaa3f5d_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i27893806b30342149eb85b8143f8df92_I20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Convertible Promissory Notes and Other Debt (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails",
     "shortName": "Convertible Promissory Notes and Other Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i27893806b30342149eb85b8143f8df92_I20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ifdb18b5ff7dd4565b0689e48dd33cb0f_I20211031",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "iab205c27896840a48993517f0d658e53_D20210201-20210228",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i9221ebd2e24a4ed8a7ebac7631396cde_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "role": "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "id527e215cc174d55a56cc5895cb43547_D20220101-20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
     "shortName": "Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "id527e215cc174d55a56cc5895cb43547_D20220101-20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "if1081ba53b574bb2adf21cf126fc5f4a_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i061af97dccdb4fda98333d1bb3013560_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Commitment and Contingencies - Operating Lease (Details)",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails",
     "shortName": "Commitment and Contingencies - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails",
     "shortName": "Commitment and Contingencies - Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i1476e493307e4b08b37ea40f6a957180_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
     "shortName": "Commitment and Contingencies - Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i8773e0c5834143cbb0d43e34a17e2a92_I20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i91d778453bdd415ca0474d3b80c97e81_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ibcd65be15ec347ac9fa3116e9151dec9_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ibed9ebe777744942b2d52251d599962a_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cntx:TemporaryEquityOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ibed9ebe777744942b2d52251d599962a_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cntx:TemporaryEquityOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "i6a3b92f32156461a9d9b0e41efd56e2c_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Description of Business",
     "role": "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Risks and Liquidity",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20220930.htm",
      "contextRef": "ia51b886fb0d24ad8960934c44e30b573_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "cntx_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Warrants Issued For Services",
        "label": "Adjustments to Additional Paid in Capital, Warrants Issued For Services",
        "terseLabel": "Fair value of warrants issued as placement agent fees"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedForServices",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "terseLabel": "Maximum development and regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "terseLabel": "Quarterly sales payment due upon completion, percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Maximum sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Payment Period",
        "terseLabel": "Quarterly sales payment due upon completion, period of payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty payment, percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Maximum obligation amount"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_ContextTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Context Therapeutics LLC",
        "label": "Context Therapeutics LLC [Member]",
        "terseLabel": "Context Therapeutics LLC"
       }
      }
     },
     "localname": "ContextTherapeuticsLLCMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_DebtConversionConvertedInstrumentPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Converted Instrument, Price Per Share",
        "label": "Debt Conversion, Converted Instrument, Price Per Share",
        "terseLabel": "Debt conversion, price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentPricePerShare",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cntx_December2021PrivatePlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2021 Private Placement Agent Warrants",
        "label": "December 2021 Private Placement Agent Warrants [Member]",
        "terseLabel": "Issued in connection with 2021 private placement"
       }
      }
     },
     "localname": "December2021PrivatePlacementAgentWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_December2021PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2021 Private Placement Warrants",
        "label": "December 2021 Private Placement Warrants [Member]",
        "terseLabel": "December 2021 Private Placement Warrants"
       }
      }
     },
     "localname": "December2021PrivatePlacementWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_DeferredOfferingCostIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Cost Incurred but Not yet Paid",
        "label": "Deferred Offering Cost Incurred but Not yet Paid",
        "terseLabel": "Deferred offering costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostIncurredButNotYetPaid",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_FairValueAdjustmentOnConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustment On Convertible Debt",
        "label": "Fair Value Adjustment On Convertible Debt",
        "negatedTerseLabel": "Change in fair value of convertible promissory notes",
        "terseLabel": "Change in fair value of convertible promissory notes"
       }
      }
     },
     "localname": "FairValueAdjustmentOnConvertibleDebt",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "label": "Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "terseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_IntegralMolecularIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integral Molecular, Inc.",
        "label": "Integral Molecular, Inc. [Member]",
        "terseLabel": "Integral"
       }
      }
     },
     "localname": "IntegralMolecularIncMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForProfessionalConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Professional Consulting Services",
        "label": "Issued for Professional Consulting Services [Member]",
        "terseLabel": "Issued in 2022 for consulting services"
       }
      }
     },
     "localname": "IssuedForProfessionalConsultingServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Services",
        "label": "Issued for Services [Member]",
        "terseLabel": "Issued for services"
       }
      }
     },
     "localname": "IssuedForServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedInConnectionWithIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued in Connection with IPO",
        "label": "Issued in Connection with IPO [Member]",
        "terseLabel": "Issued in Connection with IPO"
       }
      }
     },
     "localname": "IssuedInConnectionWithIPOMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedToPlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued to Placement Agents",
        "label": "Issued to Placement Agents [Member]",
        "terseLabel": "Issued in connection with 2021 IPO"
       }
      }
     },
     "localname": "IssuedToPlacementAgentsMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedToSeriesAStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued to Series A Stockholders",
        "label": "Issued to Series A Stockholders [Member]",
        "terseLabel": "Issued to Series A Stockholders"
       }
      }
     },
     "localname": "IssuedToSeriesAStockholdersMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_PatentCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs, Policy",
        "label": "Patent Costs, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_PaymentProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Protection Program Loan",
        "label": "Payment Protection Program Loan [Member]",
        "terseLabel": "Payment Protection Program Loan"
       }
      }
     },
     "localname": "PaymentProtectionProgramLoanMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_PlacementAgentsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agents Warrants",
        "label": "Placement Agents Warrants [Member]",
        "terseLabel": "Placement Agent Warrants"
       }
      }
     },
     "localname": "PlacementAgentsWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_RedeemableCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Common Stock",
        "label": "Redeemable Common Stock [Member]",
        "terseLabel": "Redeemable Common Stock"
       }
      }
     },
     "localname": "RedeemableCommonStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Abstract]"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cntx_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 100 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 100 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 100 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp100KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 300 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 300 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 300 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp300KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_SeniorConvertibleNotesApril2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes, April 2020",
        "label": "Senior Convertible Notes, April 2020 [Member]",
        "terseLabel": "Senior Convertible Notes, April 2020"
       }
      }
     },
     "localname": "SeniorConvertibleNotesApril2020Member",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_SeriesSeedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Preferred Stock",
        "label": "Series Seed Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "terseLabel": "Annual rate at which authorized shares of common stock increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "label": "Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "terseLabel": "Conversion of preferred shares and redeemable common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Shares issued upon conversion of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityDecreaseDueToConversionToWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Due To Conversion To Warrants",
        "label": "Temporary Equity, Decrease Due To Conversion To Warrants",
        "negatedTerseLabel": "Fair value of warrants issued in conjunction with the Series A preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseDueToConversionToWarrants",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees",
        "label": "Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees",
        "negatedTerseLabel": "Fair value of warrants issued for services"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "label": "Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "terseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Offering Costs",
        "label": "Temporary Equity, Offering Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "TemporaryEquityOfferingCosts",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "label": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "terseLabel": "Temporary equity, price per share (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodPricePerShare",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of debt to equity (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Issued For Services",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Issued For Services",
        "terseLabel": "Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Temporary equity new shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of debt to equity"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Issued For Services",
        "label": "Temporary Equity, Stock Issued During Period, Value, Issued For Services",
        "terseLabel": "Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TyligandBioscienceShanghaiLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tyligand Bioscience (Shanghai) Limited",
        "label": "Tyligand Bioscience (Shanghai) Limited [Member]",
        "terseLabel": "Tyligand"
       }
      }
     },
     "localname": "TyligandBioscienceShanghaiLimitedMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_WarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued",
        "label": "Warrants Issued",
        "terseLabel": "Issuance of warrants in conjunction with Series A preferred stock",
        "verboseLabel": "Issuance of warrants for services provided"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued in Conjunction With Series A Preferred Stock",
        "label": "Warrants Issued in Conjunction With Series A Preferred Stock [Member]",
        "terseLabel": "Warrants issued in conjunction with series A preferred stock"
       }
      }
     },
     "localname": "WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20220930",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r217",
      "r324",
      "r325",
      "r326",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r30",
      "r32",
      "r66",
      "r67",
      "r152",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r151",
      "r188",
      "r219",
      "r220",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r379",
      "r380",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r151",
      "r188",
      "r219",
      "r220",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r379",
      "r380",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r133",
      "r151",
      "r188",
      "r209",
      "r219",
      "r220",
      "r254",
      "r255",
      "r256",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r379",
      "r380",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r133",
      "r151",
      "r188",
      "r209",
      "r219",
      "r220",
      "r254",
      "r255",
      "r256",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r379",
      "r380",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r31",
      "r32",
      "r66",
      "r67",
      "r152",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r265",
      "r266",
      "r267",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r185",
      "r201",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "negatedTerseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r222",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r147",
      "r201",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Fair value of warrants issued for services",
        "verboseLabel": "Warrants reclassified into additional paid-in-capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r7",
      "r65",
      "r112",
      "r114",
      "r118",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r281",
      "r285",
      "r300",
      "r327",
      "r329",
      "r359",
      "r372"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r19",
      "r65",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r281",
      "r285",
      "r300",
      "r327",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r5",
      "r54"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r54",
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r301"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r62",
      "r65",
      "r85",
      "r86",
      "r87",
      "r89",
      "r91",
      "r97",
      "r98",
      "r99",
      "r121",
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r186",
      "r187",
      "r191",
      "r195",
      "r201",
      "r300",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r207",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants prior to conversion (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r207",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r363",
      "r376"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r134",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at September\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r103",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r8",
      "r360",
      "r371",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Converted amount",
        "verboseLabel": "Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued as a result of converted debt (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r172",
      "r173",
      "r175",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes and Other Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r64",
      "r68",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r312",
      "r360",
      "r361",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r10",
      "r176",
      "r361",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Outstanding principal balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Convertible debt beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r148",
      "r177",
      "r178",
      "r310",
      "r312",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r25",
      "r64",
      "r68",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r64",
      "r68",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r202",
      "r203",
      "r204",
      "r205",
      "r309",
      "r310",
      "r312",
      "r313",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Loan term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r52",
      "r111"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r260",
      "r261",
      "r263",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r40",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r83",
      "r85",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r289",
      "r290",
      "r365",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r40",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r85",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r289",
      "r290",
      "r365",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r35",
      "r36",
      "r37",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r96",
      "r122",
      "r201",
      "r206",
      "r265",
      "r266",
      "r267",
      "r277",
      "r278",
      "r288",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r323",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r52",
      "r184"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrants for services provided"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r163",
      "r177",
      "r178",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r292",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r163",
      "r210",
      "r211",
      "r216",
      "r218",
      "r292",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r163",
      "r177",
      "r178",
      "r210",
      "r211",
      "r216",
      "r218",
      "r292",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r163",
      "r177",
      "r178",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r292",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r163",
      "r177",
      "r178",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r52",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r124",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r51",
      "r318"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r38",
      "r110",
      "r308",
      "r311",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expense payable to related party"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum payments due"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r65",
      "r115",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r282",
      "r285",
      "r286",
      "r300",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r65",
      "r121",
      "r300",
      "r329",
      "r362",
      "r374"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r65",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r282",
      "r285",
      "r286",
      "r300",
      "r327",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Issue date fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r25",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r29",
      "r42",
      "r280",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r100",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r33",
      "r34",
      "r37",
      "r39",
      "r53",
      "r65",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r81",
      "r82",
      "r88",
      "r112",
      "r113",
      "r116",
      "r117",
      "r119",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r290",
      "r300",
      "r364",
      "r377"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r112",
      "r113",
      "r116",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r317",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Reduction in the carrying amount of operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments for offering costs related to the private placement sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from the sale of Series A preferred stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r123",
      "r329",
      "r368",
      "r375"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r217",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r217",
      "r324",
      "r326",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and development costs incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development charge"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r59",
      "r387"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r206",
      "r329",
      "r373",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r122",
      "r265",
      "r266",
      "r267",
      "r277",
      "r278",
      "r288",
      "r381",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issuance, consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r258",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r221",
      "r223",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r230",
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r207",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r11",
      "r12",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of common stock available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of grants during period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at period end (in shares)",
        "periodStartLabel": "Outstanding at beginning of period ( in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at period end (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r229",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based award contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at September\u00a030, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at beginning of period",
        "verboseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at September\u00a030, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r62",
      "r65",
      "r85",
      "r86",
      "r87",
      "r89",
      "r91",
      "r97",
      "r98",
      "r99",
      "r121",
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r186",
      "r187",
      "r191",
      "r195",
      "r201",
      "r300",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesandOtherDebtDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r28",
      "r35",
      "r36",
      "r37",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r96",
      "r122",
      "r201",
      "r206",
      "r265",
      "r266",
      "r267",
      "r277",
      "r278",
      "r288",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r323",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r96",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Series A preferred stock issued for acquired in-process research and development"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r166",
      "r201",
      "r202",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes to preferred stock (in shares)",
        "verboseLabel": "Conversion of preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r28",
      "r201",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation expense, including vesting of restricted stock and issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r65",
      "r120",
      "r121",
      "r300",
      "r329"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r206",
      "r208",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Temporary equity new shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual Risk or Uncertainty [Line Items]",
        "terseLabel": "Unusual Risk or Uncertainty [Line Items]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the unusual risk or uncertainty and its financial impact or potential financial impact.",
        "label": "Unusual Risk or Uncertainty [Table]",
        "terseLabel": "Unusual Risk or Uncertainty [Table]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, term from date of issuance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r84",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r83",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r394": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r395": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r397": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r398": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r399": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r400": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r401": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001842952-22-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001842952-22-000096-xbrl.zip
M4$L#!!0    ( -> :55BQN@_O7X! 'RR#P 1    8VYT>"TR,#(R,#DS,"YH
M=&WLO6E7&\FR+OS]_ J]G//>T[T6A7,>W+U]%VVP-^<886/1WO#%*T<HK(&M
M@<&__D9FE9BQL2V0!/+JMJ%4RLK*B'CRB<C(R#__[VFGW3@._4'9Z_YC":^@
MI<;_??7G_U<4__IK^UUCK>=&G= =-E[W@QD&WS@IAP>-3SX,OC1BO]=I?.KU
MOY3'IBCR=U[WCL[ZY?[!L$$0(=<^[+\,CD7'(RT8<O"7"ZJP1.#"2LZH%\X@
MHY;W7PH*OPIMBR"\@ML$+U0,LF!&"2^ME=2(9?]28*)")!(+[AD2PFC.C>+:
M,HM"(#(]]F (;P=OV!V\;)?=+_]8.A@.CUZ^>'%R<K)R:OOME5Y__P5!B+Y(
M'ULS"$OU[:<W[C^A^6ZLM7Z1/SV_%1KRY?F]E]L5+ZH/Q[>.!L6^,4?G]T8S
ML/G>^H,7:=S&-Y>G=_47TQ=E%[H0DI#&M_MPK0^#X%;V>\<OX(,K[9X.RMM>
M#+J+7_QK\]U'=Q ZIBB[@Z'INO,!&?2'-[L-%Z\T[;K#JYUVO>XPG Z'!Z%O
MCL)H6+H!7.OD+R%-4?W%NP<Z2?!B0(8%O-25F\<O>3$>+X9]TQW$7K]CAJ#4
M:;AX@51!\7D[@QXC6'Y#&^H[+DNX_-;MU\8*.GK[W=_J)4$%(@6NQO)EVW3W
M_[$4NL7.QR70XV#\JS\[86@:J=DB_'M4'O]CZ74:W>ZP:)T=P;-=]=L_EM*(
MO\@#]^+5?_S'?_PY+(?M\"K)IAB/^Y\OJHM_OJB:MCU_]NI/7QXW!L.S=OC'
MDB\'1VUS]K+;ZP;H0'GZ,MT8^M6/I?>AFW^$SYL $?W2-6I9;X?XCZ72<&R5
M$M$B3YCQ2@MX+'.,!8HLE_3S6NX*1KBXT(6NZ:1'A_+E*J".3\CSIFWVEQK5
M.$&SI\.7L3P-OHBFG8RU]'#1T[_/[%KO^!W9/MZEFR-_N'Z\]U8?;AWNGFX>
M'K3W#C?H9FL7[ZU].&D>[AULM7;P;FL?;WW:0+N'?[7W6AOT'6VV=[_VR&9K
M@^U]VCUK?ETGS4\?T.;:+MEM?<'-3^NLV6J7S;<;)WN?=LZ:6*%W9.]L]Y,3
MNZTW';B&-C]]X-!^V5S[ZP#NA\_@>2WW=6MMAV^M?<&[9/W8OWU3VK<[8J^S
M@9NM[8/=UBX\[TV[^?8#W20;J-GZZ\LFV?S:;'TXVUQ;)YMKKO[.W] >[^ZU
MCCJ[ASNX^?;-01/>;1>>N[?FONX>?L";;S]\W?VZB9MK&R?POB?0QZ_O6NO#
MS8_H]%T+^O9U_>RSB8HBHG"!-24%(X"S%M-8"!R#I=0BCN+2JS>K[SZN__GB
MBH ?4M[CB>9-.7"FO1M,_PU<&2P$_#T!HYL"UA'&'>96JD@$ 3-<:.9M@4.$
MJ5-J$ 98=!+"U.3['MKO^86$[R5A?$/"0C-'P'P+PPS0HFA<83T'._9>>!<"
MQP$MO?I 'U&^ZUV83\Y>@X3[IKW1]>'T?\/90K;?DRVY(=L8D<#>^P)S#!PY
M!EV8H&.AG%+1!9-$L/0* 5=3@-W\,6WX]:C?OP+1ZUV_!E[!U>G9PY6B X\]
M*+Q9J,!W58#>4 'N$+@Q#+!;>UZP8&AAM0;*@QFH@,!4.[[T"A-@M#\B?6&C
MI9X1 O, ,P3T1Q'"0(]@YK?6ZBQ]C%@E??CA0OJU=_+RXX'IA[_ 2_*O>YVC
MT!UD[KK:!RJ['Q*\_W5V<<M[<Y8NK9Z8OL]__1T&P[*[7X$_GJYFD,V/NN,Z
M;[I;'1CUMWN=S=:;@TWR ;3@P^DNV3O8>[O=V6I]8%NM?9#8!@+)D7=TNQW^
MN7VV]\D?6<+$WMH7M->!?GY:_PH_L^;:F\.]SILO>V]W>7-M']IJ'FX>?CC9
M6]N+6ZTO_+.V+F@=;2$4 O%:%@K-G00+-S)8B82.8-SO\>X/634S#"-H #0#
MY@*IJ (_V#D)UP@/:"'7AY3KYN'.:?/#9QUQ<)S*(G+!"H;A)[#@4'#.$MPB
M^#S>+MD75_VI?H@!4-:%P2UN8(HZO!QD_QQDW\A1B)=#</[^L30H.T?MY(#F
M:P?]I!I7/+Z5TX&')EY<;:-Z_L5#ZSX,>J-^_BU[OB]K?:LD^S.SR+BAD&G"
M^+?2I]]C&?J-W*%PJV?_>N-_KTYXU[_\:GSI:NM'61_'OX&#WA^FV2HSWP(Z
MA_#X>Q>?G7?37[I5%\E?OOK)^/?Q0UY<&:A;QPU&*MFFBT@;4 JMO"<\1H<)
MY0PY_'DC/0Z#@<[ <%41C6$U A@&BYTW5']ROQ$8=<OJ]0<)/P;G;]8)9C#J
MAU>U /*'XR;&GXU_3VW<.J+ E$S4TCOG+8O>:$4I]=A:BC#E E4C.B,*>&5$
MK^C43X[H*-OSU2&KXU8O=SZN_?!H1HP4MH93,&)F+3$^$NPB)B(%;9G)HXE!
M6_%LC28N:BKTJZ,)$UB>Y<Y?SY?'T*W+MV;4-L->_R<'_L;WT\6UT.UURNYM
MS=[7/*XT\>)J[[\G=V&HU212@F'J HO27EL4& [1<Q&(J_%<SC:>RT?'<] \
M@IQ6)KC$JJT55&@NI:#&.B)5S;ODF'?-X+CA^X\;GMBX264 H06SG#O&J;-4
M4FJE .\F6*3'XX9G>]SNRQ\F-VX:>RD5C)CUGF'N#&*2>6H5**$,JN(/Z#'P
MN7[KL)_\@.I7#P\[/6J7KAQNAHZ%1_@2/JU6%<_=C"&\>OK.Z[89#+;BQV'/
M?5D]+8$6G-\"XQ$&J^\S(^T'GV^I6OSSQ:T/.A^[\_[\V/2!?F7ZN*K8QF+M
MP#U/9!@&SSCM(IB_0\0:Y^E<"RCY$K5T/@9P N=10" '%L E%@3X8@ O1E(>
MD3/<4*0B%O,OH.W@ SAVMAW D>_TNO,DG6B\-<%K;85G429\$T(IY'70D5 ]
M1])9__<H1<-[G:->%WX=7,6X^1.-0HQA3:R,AC+$HP(?5CMNA9;)>R5/1C2K
MWI<I]&7:[TWI-[JOS5$Y-.TY$9-VT@O@[AQ98%9<&6$C-5X9CS4*@CT9,6V'
MH2F[P:^;?K?L[@_F1#XP[7C#(_:68!:M4E()0@6BV/) F'L\^4QK!)R5UD<M
M$2@G,]:#WQE,U,[)(!"7[CKWIS,Q%+_ _>FE<?L%[F^=%]P&S(.C3 *Q!"#&
M6 2-.?;!Z2F,V_P[ =,7JY32$R*MMI8P;:,-*F@M !T4=B::>13KC$RPTQ>N
M\DIZSAU@'F4A6IB=@T])C5%P@9&<(^'6IOK)I!7!X59_.^7X7G([Z@\&&X/!
M*"2I]KJ'HZY+@OY4#@]^QIX7BO?S@4F/(O?(:68(,U1:&PB0#*""FF'&%HKW
M!$5.N"<F!!*"9AQ+XXG5"IQIA +Q89Y$/@M.] P(U,>HK 5V3 )31&GA@"\3
MIHST'LSZZ0GTX7VZZ4L51I8*A<%"K60H(B-(,!91X1#3T<5JB74NA#EU]GYE
M!?B*@'[%0Z=!(B&ID,@RSH0&=Q4N41YE,%[(N1;0]$+XDQ,06(MFP;*('6-:
M:FV$088!7!IX&TSF7T"/'\*?G'1XX#8(%93%GFF-%0^*6+B(J&&*SQ.^S48(
M?W*BP5IQ(W'T)"@P%V00"(5[Q6$^ G=4/QG13".$/SDQ(4Z!L/.4SN89=];H
MJ+27B L$?(&()R.F1PWA3TX^U%'*K#"44I)"^,;JP#13-+A /7Y$^4QK!"QX
ME<$&"7]@!F;$@KH2PK'G.H4NS?5T<S&3Z3OL_MQ?3"9]!S,I0%4H13(PBY2E
M0"G!"4C[UB56-]+T'V'<YM\)F+Y8P4>P*0?>@^08P40I8L#+\QPQ, L_#7/X
M6;$NHKSSI'@><#=XXBQFE%%.=)3(&R^Y84%$Y1>*]^1$3G 04OJ8:IV T+7Q
M@0/(8&<P3+[G0<%Y$/G"GF\(%TF*1"3 \C&+5!K+7502[-OQ !)_>L)]U!#^
MXPLT>L$8MHIZJEG R I$3$3((6EPT',IT.G&K*8O4Q<% Y>/NJ@%XYH;H5W:
M4$ULQ-8Z.H\RG;:?/GVIJL"2 RM3KC'#$AOK)+!X%FC$GB%;._7S(,RI>V17
M8P[BI[<Y7LV3(EIKJ5B$_UB42DL!U <CYX(FFJJY%M!4EV4F)*!8;>@*V%O)
M& V*Z& LQ4H&B:V)\R^@J2S+3,I\D+4D:F*LC"PX;!TV1F"MG&,(Y#1'TIF9
M99D)B<9&CY!BE 1#F?=,<Q\HIIP[RAVW\X1L,^+)/8B8TLX^D!(2)EC&+5(P
M_R"KHM0X&D[XDQ'38R_+3&K^89RJ5!\)<\,<8=IKX@T8EM&&\. ?3S[3&@&&
MC2.1@8>) Q.1**1(6IMBP7ME/9[";O2?5=7OA0.K,.";7A](TW'IPO>4=&ZA
M; ;VZFL;%0\,BT@90@1@,-+(#4Q-WIKS5.+GJ%5S*4_G1<1"!2&09=H9^"_&
M$(D(7 @5IU&S8IXIX?0%2C40$J&(]!:!E7*E"+-&,,\X84K:IR?09X2^U!KJ
M/+7,60[HJVQDTGM/C.;:!"R>GG ?/]KX^%)E"B41:F^X8,IY\,*)<=(ZBX(6
M'-=<=1Z$.6/1QI\OJG8U')QJ]$5JK$V97=@8@K@S"A$:*(K6S;6 IAIMG)"
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M$B,3&N8,(K&L2W;*.2C9N=%UO4XX!\)W/9<K,MZHQAK2ENA5&+*TY;EWE(.
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M+J[3.FN7^Z;K_RI[ U>&K@L?#^#1!Z9\5W9*4*T'U28TL8TP,CH2E;<Q6LS
M][!61% CR:D)+MA0)PBKA38]76V"F5Q-J$J:$R%R<%BEL^"G4BN-HSI@H=/>
MCOI$T)G&IM?FJ!R:=ODU^->]P1"XV4[WJ-\[#OY]OW>4]N9?/5%XM=.#:U\S
MD?SKK+[G;"OM'C@,[DJ! 6?:8><((_2_93L7XH+&WVZ^?]LW/N1MK:/N]^2\
M,(HYA%CKC#51@@NE.0-8U3K0"(Y4D%Y)C]#L&\5<:-.C63!]4 M^)D81HL1>
M!$*59,P! 1'1\)18I;$"/Q#7]33IN)[FPCJ>FEI=K_Y)[U_]DTYFX<T0(+@6
M8\,\9LJG:FJ$IM.@M;+"T##[F^.>@NIMP > I>W-7CNX4=OT-[IN7G;Q(8NC
M2[4?0+;(*861<S#)"VF4,I8_K16;!ZW+M=#D^5EU<M+#=!P0U2XPC:1ES"LG
M%-'!:E$?R#O3\=J%MDTULFRCHH)AS@7"C 9I#&'"2T2%15I*,D=Y] M-^MF<
MG ?.[7]1GK[LAT%OU'=A4/UZ$,!/2YWWY?&K/^&O>OD)$Q5BVH;%/4-"F+20
MKKBVS*(0B/R</(^+[PR&9VU0LT[9+0Y"*A[QDJ$5?C3\XZ3TPX.7&*'_?RG?
M^>K/P9'IOOK3]E_ ]ZN?JV9N-F;Z^]">[0V'O<Y+<32$%H:I\N/X!E *Z'KA
MDH(<#<++\0]_^')PU#9G8(WMLAN*_*4_KC:7^I:K2H+[6H!CO-]]F8:H_OBB
MVRNHZOH0AFCHQT^N/U[)'[T8^IN?:;6BT=T?HQ5\_MF+W'9_?$,]?K1Z7]^
MMTK#](\ENG3MQ>M7P4?#QJ#7+GWC/U'^\T?]^;!W])+<^/#(>%]V]U^B!LZ/
MN.C#BSQ0MT@BCTPU2"XD@_DC7RF["2M>ZMQ,ZN/X?NARK_]R_, (VE=$TRG;
M9R__NP4&.&@TPTECN]<QW?]>'H#-%P/0UUC=."B_AI<8I%W]>E*-AH1VLBSK
MT<%4P_CM-#=:ZVN-CZW5UOK'J]HT![W_N/YZ9WNCM;'^L;':7&NL_^OU/U>;
M;]<;K[<V-S<^?MS8:L[0*^%[O=(G,S@ W1KVNLN-M977*__G/[% ?U1_$\29
M_LDW8GSRKW1=2.SZ&Y%DOI^__V>&I'0_Q7NSM;W9^!.PO]OK-D<=:,0UZBEB
M.\04 ^#8*B6B19XPXY46P#;2:>>!(LOEK9N!&EV3B(8/Y<NUGLN%A!,-6*HW
M)M"_S^Q:[_@=V3[>I9LC?[A^O/=6'VX=[IYN'AZT]PXWZ&9K%^^M?3AI'NX=
M;+5V\&YK'V]]VD"[AW^U]UH;]!UMMG>_]LAF:X/M?=H]:WY=)\U/']#FVB[9
M;7W!S4_KK-EJE\VW&R=[GW;.FEB=OB-[9[N?G-C]NDDWR?^46ZW5T[W.!]9<
MVSC=>[O.]UJ;\,QF>[.U?[JY]E=GL[5Z[-_^S?P__Z>]1]K']O#H</.K^[K;
MV>";:V\Z>VO[://PS9?=5KN]^?7O+YMDYW1K;?UD\RV\QQMU!N]P\IGYP+QG
MJI"8QX(I<#&TI^!G"*(,3*%&(K'T"J/B0YZ!+Z3PZEF8QZ25'GVOIYA#3QO5
MG]_2F>V-7C?\?N=8SS7O("N"WH]V_$BK;(7RN[_YLZTJO2*Q_A&.=!<A&G,:
M<G2:6$TC_[N"@/S\<<ERVB'>&/QJW"<.Q-_529)TLIH8SQ6Q'H2)OA]PP/N_
MW"=X1GK.X-=>ZQ&FE@\C\(U"OWVV'8YZ_>%2(_;Z'3.$!YP.7\;R-/ABV!_-
MY^SSIK1O=\36V@=X]OK9UMH7 GW\TGR[0YJM+U\WR3K:.]R%YT%/4_\_;=;?
M^1N>Q;M[K1ZTOUVF?FZU=L^VWGY >_!N6ZW-K[NM[4[S$-Z--.'?]=-=K$[>
MM=:'FQ_1Z;O6!P[O=/:92XDX]JK *L+L%; IM.&BP$QS++##G(FDNH33/^Z<
MOZ:NRC]IIS<(4U;H#SNKVZWU[7>[C>WU]UO;K<;[G>V/.ZO-5J.UU0 :WP*N
MWL"TL;7=P/PW_WMCZTVC]<_UQB6&?\[N5U^WTL<8M/[*:,V8!Z;OQR1[_<;P
M(#3^/3;'1A5Y: 3HF'\,COD^/V^]BG]<A0$/5XH.//,@?:WPYJPX"Z9?A.Y<
MPL*OD-+-SX0+&JTG!?<!K)H&75C/*;!3)B7U3"K%P24-1\,J4$;1<B.-^W4+
M;]R?HB[='>OY%MOZX[:&%OQKP;\6_&MV^%<.U9<I4G\W 8NF/9AG!M;\N@?]
M O;T=A/M?MW_VER#-LG&5W@^V3WT[;W.WX>;G0VV^77_.@.CS<[?'6!A7W:_
M;A]NK6VB)O1_]W 3WG6O;)*_.WN?-L]V#_>_;KVYA8%Y+HDWPA8D"E<P@6QA
M8\2%%L9QC7$@B"V]ZCT3\M7:7FU^W,@4ZY'8UR._);X)10]*Y6Z/CXRIW/#<
MLL=<+O9[G<:E@$YCV&M<#?&LS%#<ZGMOJ]!-X)\3MIU*()>Y^'HCED"'NJ-$
MU5XV'I)GK^?%RS?PN&9^VESB^:]0YQWT&0:+:*\YH+ S!8L2%1IQ7F BC4'2
MQ:!P6DK'!4."LPD%=2_4[#L,^M&UE9![J>N#:^5VV,]%G;K#M';_[#3S _],
MD+<,,5-H[$+!)(^%8<@4)@;!05NQ00%P8ZO96O]7*TV*VZOOUW=:&Z\_-C::
MKU=^P;E[;$2\,6EE%?MM_=2X85:,1B\V^N<*T3"#QN HN)3(XAMEMU$.!PUW
MD*,4=T?^'W^V^BZC5Q-9A'S -U YS>-79]RY7G-A]\_U>*!F?\P]OQEAF1VV
M_^"31JIWT#_*Z63I:$0S##D)K'_VNN>O!A#A%5Q*PAJ&M%,FM3.GD</:G7V[
M=]#\M/-U]ZMCNX=OP#W=X'N?-DCS\.]V<D\WR5Y[\W#_9//077=GT5YG'>^U
MFH?-KP?EYJ==F)C:[=W#7>CO#H;[O^YU=LZVUE93'\&=7;WJSAKI@L#2%BIP
M5C!/7&$<N+,A\E0<C1N#P9U="VUS8OKAU[W:9ZW>+7.Z46=P5H4\YIBV/[;>
M7@O#,*&Y]X@7/,A8,"9P85F,A4/:J^B$I13T5HF"2JJDDM_4W#E Z._/Y)4.
M_Y91,_&MWO @]!N'HWXY\&7.VTU7R\L(V^CUX;]]TZTW$_X^)_9\[\'86-E>
M^;C2J"OX]1M7K:]1F=_O/[#45W.7E+QYUVK(X\8>\*, UZKW_3 8U/^\@P[@
MN02M7XHU?/WL9!I-#2,E%(".\+@PQO'"&LMQ5,)J#Z!#$,*-E,D4AHV/PWX(
MP^6;OMSC2XP\.XGMGGY6"*5I A664UDP@H'>$/#&/6):&R)#P'3IU<=1"9A)
M->;+C51;I_&?F/_ZVNH3!8'79=IKWNJ=S"??_B4(H)^U4 1'(@NKG2^8%*$P
MC+%":$4<!BIMA5EZ]?Z@;!L?VD<'I9F>\6<JD,L"',.T_T3]IU^2Y^EGBW':
M22,++R,O6,2Z,"*(0FD:F7 "&0*0_CYTNX.S]C$P)3,U<;[O@;S:>^51Y0P_
M)UGAS=;Z9Z:LCLS*PGBJ"H8#&"%UM"#.$1+2N<R<+[W"&B-Z?_"^&HQ"*R@Q
MRTLLK[[RX!A_#TJ;4?ZW6AD2ES_J@UF71Z;="*?!C=(6/+@<TV&_RXGHMT>)
MJ3>^ED>@E/X;2=43R0Z:WMC=;W[\[0'M-,V)J_U@GJ%E-K_N?Y:6<,>\+1#V
MP+(,487B7A2.LTB9YPI\<N#%XH87_OM#@F>JEMI^?]#K/M?5T0_TL\*,B*@<
M\%^?5D<Y+6RPJ C4 6H:(SDF(!G"BW0@^@QQWGOCX<4ZX__Y3Z!F\H]!8QC:
MX2C)O5Z$OPR&!JST,= P10?J4$F14G;2"Y%+U_K5ZDMU\5Y+6X^[XJ+EBN;T
M9Q9<J%[1C$U\P870%4+4Q)NE%$1POV9OC1+J^P3&'B^W\KZ1L8_ %_IE*BQ6
MK\N&?O"-HU%_,$H+M,-> ^[(,3),?K._)[:1\H]6W?#E@T9.'VM4;EL J'KG
M@ZNCHR]'8'_]=-?2JU8Y;.>HZKIQ!XU<<>8A8J4S^_I]D]'SXUG']MJ_#1XD
M4#RK+]^L$QBRZ-=/72HS!A>ZC4\')5S9/K>?)V$9CYZU7$/1&28V6]E<TK1J
M-6SW\ M<V_G:/(3OM'9.FVL[?*MU\ 7Z>KK[:0?ZL<KW/OW=WNVL7UL-.X+G
MK)\T6YL$J%V[V5I'S=87OO5VNP,4[V"O!>^\UF[#=\O=O]79C55<##S.H*@*
M:XD&FF=)6L7U!8D:*^-DD#%6*8J@MKD*UG+CR/0;QZ8]"HW_2LD5.&64-@8'
MC[3*^V35N8;*"BD7NGP/7;ZVLHM2'#YEU-NH1<%H3,%[9@MG2#X0$WDE0)>;
MK7\M]'0"L#N>T*HLS>L1X@"?SG%P^+%5>>.J*D?-M3 H!9?37I&( *")#(61
M.@@I!:-. ;D"8MTT V_^74'S>.WPW;O7W\]:N+%2_?B:FI,]-[H^K:J'ACUK
MN(, ;]%)M1Q.#D).0TC.PT4"Z,O&;_CW*NGPP QROKQOF'8;;DG[E9)/\N]1
MF3P2<$1LJ&^ EFNGI/HJIBE_H=I54OLGE]R:<Z(&/DOZ..TJ:7CX%&ALNO6H
M'US(I!:3JKV\&W70^ T:!3-H#$9 [@8'O925.MYM,3PPPVOOTC@Q5_N;L__S
ME^NW^7VY8;J^\1NY],H6+ INLJE><_I2OA^^F?I3-Y9V<@UR3W)WS6#8T*AJ
MP9NSP<K#KSN\'O7[T(EJ$UF:TX9F.!K,)1#\4AB-?38$^4"0*[C%I&"(T13@
MM 6*6CMB-25:+KW:#8/K!EO)J_&#6X>^M]7POD8YK@/P /N6[M^%/ #-WG1'
MHG='H9L[8GI3"F;^$(@V$HX A'3*X1"0)[0!2OJ];N(N[;-& !YSUDAU$ONI
M:.-Q:*R9H6FDO4+7T?6BC0131[W!\%HH:'L$7V*()Q@%;W?4KK*G/A:MQF])
MK/(/0LE*?</PH,S)_$<IF?\NP&U,"&NKKI^C9QC\_@BP>&E0TYC6*/GL8''G
M[+,P,(Q2J,(C#6ZGL+K02.H"<V0IC)UARLX6+-;;.:<)BU7!JRD"8N[ 4P1$
M ![3:)L^D#[C' !BWR0H2\#03QSLUJL-4,OBU@\&'4!2>$I_S'\ 2SHP"F?+
MB7="<T#1TKK*?F._WSL9'HP_7@$:&G+??(AE-V_7S>OU:8&*P&O>T</\,?YC
M?-MW;[B[?^,;$Y[7-]_1U_&=9;=">4QL0<9L^C*%7KEO"L6<;0\B; 5K,OG5
MJA7%Y.0W':$51B:_E^D!QV#*!4PZI??M,*WHS;MDZ!7,7S+FZD*VZ%D(6'VW
MK,GUXK)W56O1DK$?*==RI<3QTQ+\ZG.4]A,UXD<IW]!_#;JRW^N?W1*!S3=E
M!7+U37,=C-WL;.#-7"IQYVSKT^YI\VWS2Y-LL,TU=]KL;'S=:QVTFV0=^G*C
M=.+9[B$X(:U-N&>#[QVNHUWR@>X>[I^D/N\>-MM;;W?H+GQ_-_7Q^AJ9$)I9
MA7BAC<8%,]@7*C #;@MUP@K/G4!+KYJWL<%97&B8I"6+!6Y763$5HZXP^YQ6
M5[_6A/D)B?[!D2T/YU^C 3QY,'B"56 ?#\H^7(4RQ4D 283"46H+$(H!*,.N
M\,P:'83 ,M!+IOWK.U]_P.8?YM9Y0Y+UJ^[V D)^$D+&X_@V#^/K:@ 74/*S
M4')V TJ,#,:@E&CA;,JV4+%0G)*">2J8$<AA'GX 2F9F.3I^(T"7\L%OC2N6
M\;8UEKRR E2PV\NK(:-!%=P#1:\**=]2E*_7S\]JGZ6'GY3P:'ALHPLOUTOQ
MNN-RD*EEUW1=:=HI%IC*G*2;TPEEWO3]H)'VY97^KJQ<^IOY_=MQNGN.^VH?
M>O"+H_WP,'!Z4=.T*BI]TU&RO5[; N'H#6WO="ZAX)=68]AGRJ3S-+("!CKM
MCS.AT%ZH FMG&=$P]H)<<MV_4P?OB2P'# Y"NSTV_,9O8,XY*%_5'4LA[SJ7
MY'+<&\SH]Y7=,/BILI^36J!Y>':>1N8;,^K\5@C^)3OBGQG7RFA!"XP$+ABQ
M(17W]86DQB(18>@Y^D:%WZE8QN6SO*J_QPN,,['&>M_"=[,%-RDQK]I!EI A
MIT;G=3Q7Y5$/<K)>;S3,<W;>7#9L-'O'58U^5I7HSRD+M2V_Z5?G9S9&W;*R
MY*K-I:O6#?8L%54N(FU8M%IY3WB,#A/*&1"RZK!:C!%; C!S)7C9@W\LW9:_
ME?N9<PH_Y@=M7?3UJL7#6Q:^ES= I.; #P'7(N1&GYG];Q*@Q%(2P-7""8<*
M%GTL-&.H<"Y0J@*CSJ03POBR%F(9\?/-YF/QOJI5Y>["RW.]8OJ(AV?>/!_S
MTN&9-T_6_(G#,Z^>AWK4JRCFRWYHYQ-M;YR0>M'/:L_[Q5>,A<Z,AC>_\KU#
M57_T;%>Y-/[.0?\B7K ?"ML/YDMAXC#T7YKVB3D;++VXZP!82>X\_O46F(UQ
M(E7W;D/9;VV\^M/,3%\:!_V$S?]Y+_&TLBG#1/$ZP7IW./CSA;E5](^YH?K[
M-1"S*]?8:*ZM_RL5[\\'4:9S$+^S"WR:!7@OYYC^Z"$V5\HCSP_ZDA5*)G_:
M#%]A<J*Y&C\:V\TQW<8M\<Z\47Z&#J;Y%F"]!QC^D?"Z->[+?K\'+11UYX%C
M!$"XG]U+_JWB+.I;]OE0J/J= 7M4A/]V7^Z/\!B\OX_OUU]OK+YK-+=:ZXWM
M];>KVVL;S;<),S_!C\6[K:W_3;_GPZ\WUYNMC[=, 7=;QD(OYE4OZ!UROIT)
M8_XM*GQ#"6+^<SO-G40;,X96/U(X:J&G/Z"GX+V^7]UN-39R<C#&?S3>;#17
MFQG0-IJ)]ZVV\@'W"\AZ!JH@O@U9/PTMDT:#*]64Q$(#)J0!>NG5QC!T@('?
MC"%?_OO-^6IE+BM:[4[];=0U(U\.@__]LA8]/BM?>O7R%Z#J835WH:B34M2)
M0=4#$Y<K4,46*C A%2 DU;!)89N4/@$_Y?!O3M/]R[0!G4+CXT$(M\;;%LSE
MZ>G"7#*7!1Q,3 7XG7!PB:+T8F/K*%2/^55@6/"$^= *N> )SUH%U/>!(2_/
MY:S)0<H$@YNR$-,JT'MX3NCW\]VY4MYV\"%T\@K1Y1)Z>7MU_NF@UX9>#NH"
MQ(VU$$M7#A<LY%EHFEJPD.>L A3_,-C<AAGK_QZ5P[,%/WD6^J(7_.19JP"[
MI^/RV@P.&F_:O9-%1.-Y: 5&"S+QK'5 I@H$0^C3L)>WHNR,UU<:=P#&;<LR
M"Q;Q+!0%XWFD$8N5VTDE&J-ZY99\9^5VTW3-?D:&_QXTULJ!&PT&:1=*"E^L
M=DW[;%!FMG$!)0EKJ@VMZ9[M,!BU)QQ)71"2^5 P,C&,662'S$Q??B2E<0PR
M]#L@\R'M4"^'>==,1@VXT![_GD"GW1N,TOZY5=L;#<<E[K?+P9<%6WD>:D07
M=.5YZP"MH81]!TK2KJD^Z$&&D??]G@L^(<>"<3P/'9D<3OSBU#"-+,9K6]D6
MF?T+^_DA^SE/[;_([=]J_7-]^W)>_UC'%G#Z'-2!DAF!TP7MFHX.W#?!_UW8
M-^V*;^5C6A9AY&>B'9-#B(5C-C-]^0$=P&2,$*M7("(%9QIOC!OV^@OGZYGH
MP8(M/',=X/=<5-KI]L_//6]\-.VJ,EJ5Q7;Y&,X4P]D9Y&HX-;58\(IGHD<+
M7O',=4#=<^UH+4235YAWCE)N?>B6O?XE#%EPC^>A*PON\;QU@.![+A!M0L/
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MG\K=TO/#T6!8QK/[O?']M/&/.YM_/ 4EB'QS5FGUC0_Y%+=F#]0FS*<!WF8
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M1"R]PLN"H&4LV U;?HB8;37OT1GG ZU>VD4]@:F_'H3[1?,7I. .(%E QL-
M1GEC^B?:(BL ,C#C B!#J4(9$8I(@]-.>!&L 7\%+VNJP5^YB1D_YZ_<>[5K
MFM&6'VGCIY;OYMK4)\09%J;^4*9^G1U8)S4/+D5.L2T8=:8P&(.I(RFQ1DIY
M!4R?XV7"^3(5>,+T8(ZC!5OGQ5>JL\FRW1:]6(RJ#-\P7(0)'I@1G(O@79+
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M/>H*CH+WO"!:V8(%S0J#3 "4#"(8C 6=S93C9Y@@.>%0QJ(VY"]1CX53])!
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MG/NINN\JM=/#ZLG)H8K83E[G/> D)LEC?W&MGHPP2!Q)>/KU3_>6L$$" ];
M%G0JQECCWKWZNM;8:SEKI0[4>^6^K5NOV$7?YR#67;21NR@(+IT"2I)4G("0
ME!AC;6FL$3AR[<#CUG;F4'K9J*29!SHG..R\+^+]L7/EQAL5L8]6-F?WW)YK
M-MAHYW1\,!AF*@XU3M'2C?AY[X\W#K2$$$H8LW38YDH3FY(F(0B,D7*5-^0W
MZ.S27;6\B:]U5VWFKO)@N/2!$0U,$D@V$B=I(M)S0QTMQ4BPM<UH-UMWY<\-
M.&ZRTSKX90/<ENM6N"N?CT:GLSNREK.U83.RO0]OI*$\46U(_I,WHV">.#24
M6% )\R;E/L!M*6Z%BO/%Z7@TQG[QFNJ.:N>.TB&R:*@@DI4=E<5/G(V24)JR
M42>BHSZU:$=5>FKS9K(>=3#H"3<V;R8>.+%1L4Q47)C\1 JV3198I:?6[R@?
M)+=4<A(9S3O*^&Q]Q0A$*1,2&+3:^JWM_N!ZJ^OF=EFOX9C.8-@9?-T@7Z*L
MH?>^GNA<X82Y\S!MXCP5FLN"YDPV,'JI' =#I'29HYE$@I&6YNX<990NXXZU
M<:1$/8W=SGJ>BMT58G<F56JC"RGX0*(RII3T"&(3!1*HD=18*[RXSY-J'TI.
MK]08#/J+)/26E(J97$C-PRP/T[O7F,HG[_8^AX/\^L^[O_YV_"+?\ZN\+B^>
M'ASO[3_CNY__X*^.7Q_LY7MZ\;?Y^&+G#9<FJ4B1""UX=KZ,(TX)2C(=@%1<
M:=H4]]Q93KANH=9OH20-$P(=B2)D;TO%TN+022*2C"!!4*K3YJ3RSFVXFG'9
MD%WX>??M&U"*.6,H09LM&K J[\+@%?&&&F>10Q!W%46J6VHSMY2E7 6%AB1>
MIGVX*(@3TA"OG&>.1A8PEB3>)F;QYO;D93'RNA];LQ_9WLX;B,R'(#QA@5$"
MP4,F.P7$L*BE53HZJ=I"<5=&R>N>:M6>4BXD;S"1O(7*@'GJB;&HB:-),YD"
M,\+>42:O[JD-W5/6@>".6\(3-.F7[%.6B>$:71DZK"'&V)8]5=5>Z[=3C$QI
MXX!PXT7).#ABHA4$$T,'F:,DSVJ/R6ZV^;M4S@^A7SRKUW1>_LH^'1QW7L:3
M<3QV<3@)BPK:[90=V+ST:?3GGV+-4VR!9."#:+FV?(A?DDVHV%X0VS/I0.4T
M Y4D\=$Z CQQ8IPR1 G!# N:B^#.P-FB1FNU7V([LX$5O"L%[^SHOPA:.S3$
M2U[JK;PB*+4F2E(1G;:*:]E"\#ZH(1#YDLMRXU'G!'N!]/H=CR>],1[5@0^K
M'OCP9>E_SRO_O/]DLNZ5DI9'2?/SLC2SV7=4D1C/8ND2SXE-+! 7#2B0U#LK
MFO[+TM@N ]ZB*H5:8=1.FZ+B>!TXGBTU*E6V/!I"?2K-PI(F!A(2B,I'1T.&
M=S8MM.Y*1KN&MFENRT,:][#C_>GQZ5&IJ<@02CW?>VCC'?Z]#L-BE&_SO[?(
M+#/]&<>8+R@\PV$_+]OHG#2>3H1126IY)#4_6XH)E:Q)B0!DBP."]L1:2HF(
ME''F E<1M[:!=J4076G-'$G-M=&JL8M-Q/5W&QH5U^W ]>Q\2^$!,6J2(G,$
MF !BK%-$&>=#\CXSMM[:YK;+)70!YNLV[@37#W#XP^B2UE1U^L.=13S.=PI[
MU@BC\M3R>&I^V)2R*E$G17:2>""0C"&N3)SR*)*5J+/H8&M;F"[5I:7R/$^U
ML1%\'?^P:0&2"OL5PWYV_$-TJ%S)F5*=W8Z,=&)X#-E: 68$>J.5RFZ'Z7+-
MNT+4^0\MM5[.S7]HRCYN8LW<L/_U]+Q97H=.&)RZHS@1U )$U[HU_->=+,V]
MX?[E3\_8Z8>J"5:I">;'?UEE;0"M" U&$3!1$NLISXK!*L^T-R:4 !3O4B.Z
M=/&AR$M$TAU'KRJ/5AYMDPU=>72M/#J;;4Q9;* M">"S(^W!$^,%D,!BD+P<
M1 U^:UNRKJ"RJ^7"CG0+>+2QMW\88_ZZLY+B^;8%S7?SBP3F8][]P]4!L_G$
MQR7#WO/?ABIK3.F#V$'O!\?Y:CZ5VNK^8%SLZ6%^N-_IY6M].VR*GX;CSB!U
MQ@=Q%#.>\33T2M(R8SG$_FCR6[/$32XS]?K8][TFQ)@?:.8M/+I8@'UNM:87
MI,M*G0Q&3;7 XV$\PG'O??SQ0R^,#_(-TO]SL37$64^(KV]!EZ_@='SU6U8O
M!GX=/S:+KF9JT<_]+%?;<)!BW,3$-5,R %4*K91HI'7@:(Q<O^%RZ^Q-!\.S
M.SC!MY&X8<1W!%.^P<=X] $_C;9^N+@]\]X\O^BSZW7EJJ2T&JV15V6"D<S(
M@S*Q.TLSXST.RZOR-6%KKJ5S,"QZZ[^NEX_.X"KT4&!3!HT4#/ST VY?)ONU
M[M'9%="7[M$G$RW=R00QQ)-XFJEPU'G>]X\Z5^*X19<^):4GYTGIY1<J*B*9
MCH;/+VC_#?W[KS/"_<_\Q=X-A<UH[.]1@(WR_,KFC;;.EW^$)Z/X^.R7'T-O
M='*$GQ[W^LU%-&_Z\6);H-+_9T99-]\W>7K*;I8_LH87@IM&R:9?/.6^1PWW
MS5@>D^= /9+ KGR:/KKZN6]]+&./!/^^C_WV<\#- []8_HA1O2D76U96W?1C
M+_'=SP"2[>G8CE=>$XN^-N5DYUYZ22!@0B-WY/;.T?0D+)UM@]@YSJ\[&'5B
MUD'AZS'%CJ#=&PQ]NK=KLY<?66QI[G9/SK]T,]:]1*&7L>\V^/[9 [__*O]5
MD\L=$-:]&(TX]<'Z;SOQXTGQV$8+#4:\^>31NQJ96*^P)5=X#_"^R:=J_?^>
M]LK0R^S#GPP'/HY&G6$<11SZ@Z:4(\3W\6AP4H(UBQQ!NF\9Q,MN\=YD A4*
M9WD2G$D%BJ$-UM$(+*8@5>3^S=.FHD)31FY46O'G=$/M],/3K]OI>?_WR89K
M?9?SO9=GR<"_\FN?R=>'!^]>_/KJT^O#/S[GSX!7I5W/X=O\[]='>__L]7:/
M_Y!?DX&[GU_L/_NT=_B'*']>[?\A7WW^N_?BZ7/VXM=?#O9^_>-COE[8Y:\/
M9Y.!NY]W9;Y.OO?4YS_A8._IT>'>/\]A]_ O>/7/,_KZZ2_O]IZ^_?SZ>"^=
M)0)W7U+Z8M]_+%T;N9"&)4ZH](8 FM(NR 1"19:F JUH.4'<OB;G2ZJ;K?1T
M3^DI^Q&<>FLP^@"<.Z>$LE)K)=!YKDU#3^R,GEBEIW;0T^<9>LJ:)6H9D"0I
M,ST9J@@&T[0Z8,A]H,AII:=*3ZVXMUO0$\K2?ELE1P.'O*-MT;/@ :*@3FHQ
MM9[82JRGMM93;0A'L1F.HLH$FJ0CBJG,48">F""!:.>\#%QKYK()):]H>ETY
MJG)4.SE*&W1.*'!2>I#".Z&%<%HQ,-%1>V9"L9684)6C%N(H,<-1'K,OYYTF
M$+@DX%R99ZP]"<X*PRSW4MNM;=&E1G>-:'^?J'L0$-S@/CA_WC#X=\^;9K0N
M6O9LDI9Y]M$?G9;%/ O<?N'8)X/1AC33V 2>W7LR%TYC"3DP=(3:+$IPEA$C
M!1*33<32((=[#EO;O$M++Z]6M0FM?7(V,@)5(;]NR,^%J&RDW!E!K)>60&2&
M&%5BZ<RQS.00P:>M;2WLI3VQ*N#O#>#7$].I@%\WX&?C/5J+Q)SP></Q2, ;
M4Z!?FO@GCMXX9$U#BJX%U144*N3O+^37$R*ID%\WY.?")Q*%XL )Y\)ER'-*
M4$ J0UNE4Q*H0U',>LE8%T3[M?P]")]L<#W5K[$?RRG=$CW!<-SK]T;C87-Z
MMDXI6%< 92J#3+0[%R0PY=K*IDMCTY=S01+TFB)GGB@I)('$)7&& LG"LTE0
M[K4H4Y"Z5M.N7+R-2_M29A76JPJ25%BO#]:S@1!A#%6H@4! 0[+7*\K 746,
M3XR&"-&H;"09;KJ@%O:**JC;"^IE!T(JJ-<'ZME@A]0H?&":>"H%R<"UQ#D6
M"$<:1+1&8N!;VV62:/9^Y,()C0KK]L)ZV<&."NOUP7HVH$%]BD(R4\K^(P%7
M!IG3Y$A*D3.G@^()B@EN!'05+*NG;@UHW-,.O_\S&(TZ:3@X[@R^].E9I!CD
M7K4HO\ULE<7#'%<,6?ER=O=YWP^.8Q%8)=BE$6QO+L91VHH)SQ,Q:!B!Q#AQ
MX!B)EK.$(#W'5))$%$PINEM\ILI&]*&M'+"6F$CE@#OA@-F B$H #!DE6H K
M<<Y($*TGFDHG&!?>6U:,+*DR!ZCYHMO* 0^6 Q8/H50.N!,.F#L<Q$V4VFK"
MD 8",3+B>#8+HDJ"4:,4FN)HL2Y8TS5J"</5*@G<%Q)8/.!22>!.2& VVI*R
MKL\"<\0Y0 (BI4P"S!,/03#-LJDGU-:V[H(07<OFHRT;P0'W( 1S>9BJU9&7
MYZ6%6QR-.[T&RIU_3UMS_:?;Z<?O.Y#S((+9RZXG.9/#A%&G(>R]6,OREL>K
M\\UKD%F%/@A")4@"F+TL)WA).W-E0E3!!YF-*\N[? -BV#4UU<*82<7U&G ]
M&SBAS'!-M<E =D" 2DE<3)YHJ8) I )<*H$3KN:+PVYN*U5 MU<]+[N$I,)X
M#3">.RCC5%#<9LTLR@^(GF2;"XBB27MG579K^=8V9[:;(5[5\X:AN161C(KK
M->!Z+IQ!8Y#..Q)\ULQ@!!!DV0"/A@*G0FD9V=:V@JZ4B\0R:M'(O>PB_N0
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MH'3&< X-0<>Y,\8C"KZU;0"Z9FF-@%I41/A &6!UN;U;P+])[%7TKQ/]<]T
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M,D 0C"N-A$LK"$ TF04B$NM1.!<#Y91N;?.NXM 5?%F%WI4%-I$%YBV#U5!
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MPV:70;KJSV7B?:8Y0HH^.,8"41@% >FAA,TY$=1'D;BG*M$2+ <&76DJZA\
MZF]3]H<N:VT0-.\>!])1HT*D+MMCEB647%X)^RNJ_2K^5XS_V>I=&;(51@4G
MZ%5IV:\E<8E)8K4P43J',H6,?^AJ9KO:S!?2W/K(?<7^/<%^ BE,8F"81/ <
M;+ \8#8"T"*7,53LMPW[,^6^3%H900LBA8H$:'+$\.@(ESKIH)4R267L\ZZ@
MT#5RWGUN&?8?0"..7RYTA/\P'>?>#(Z.H:"E,YI.=*^M.NJ!DBJE*J4JI2JE
M*J4JI?4U@=BD'.$%^5PNI74OW_G<+GVDY04[N7;2N#=(JE*J4FI_7@<8>IZ
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MMWCS],IPE>'N_*9O4XC,J&'9+Q5.:G".8TB<^<2X2EXFP&J^M8'7Y RO<66
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M6#?!!#)4XZC4'AG./&(J4%N$PG/*-C$C89V.$BHWG(V\O*JYY5U\(Z8_<'Z
M1OW3/^*$#/N=MLOB.SU&+-L(OK+G1W'%WE4=GUZ<?X*EFX&V[<FZ-81E?=CV
M=3GKFS-#M -LD\0AKIA!FA*%''-8"JPH-3I&O.5$M41^%\YR(U7Z2:Z5JP=S
M%Z?+DT6-^^SVW:#&0Z#& B,B.I<DR!S97'K$0PYFCO(YRG&NK=-8&4ECST7)
MBI7M1#8,-7ZM+N'%Y?PH=/IGPRP,^EU@2=_\<)W]O^^ I3^I,_@-1_BDDO]N
MTC/\B9TR/F3L]3M]'F=\>-"O%FC24WAUR^%FVUO;MG>R7->1>&L%$06RV$C$
M=>Z0I,$C91T)O-#<8WYY__ F"ON74/'U%Y9N5/P!57RQPJ.C1B@BD26<(,Y4
MCJ0#99>8,V^"\<R+9\^IV" 5?U+UD=Z-02'B:6,_Q-+28/B-SA,_\: [MV<G
MC_=D8J/8R;MJ1=YU=&\$L/6J7I0&M-8'6LNE&W/*+9,!>(D3L;<GMT@SK1&E
M@>32^L)B!>9X#O;X<NG&YM1Q8W5[DUC)-56[.7:\O58O4)&8 J8TRY%.Q::E
ML#%(.T?6*FW!WM#$KJ^5S88>.[+-<:M=X]AQE4^M.79\!,>.;^N%:PX0[@/;
M=I<8"]7">4$Y"C1@Q&DND1**(H%SV,:HPRJ09\_%G2G+)AXZ-D>+C^AHL4&&
M^T:&I6 K84C #A5"QEI;+B M.4'.V(+D1>&Q8&MTP#0'B^L^6 SMGN[9YF"Q
M.5@L'7:5(1E!,^N' '<!T;#]X2@>,';T"*CSJ)_:M9P.VM_@]^RTHZU/9<^'
M *5E0[ENMQ^'WK=?F]/'2S='G M;>(FIHXH31[0(W%.1B[S 2HO\MOZ]_? Q
MSOS;X7 ,JNU?QL5K=L'U[8++Y9YXX3SWUB$0+K#]::PXZ0Q!RG"LO1? @>2S
MYP33%B[6$)3W2%GP(U3G&V@S%T+G7DI/E>,^4 W<EVHF \T)5<+<UJ5WM38W
M3KS;*_("G35,\2 *AZ@L8AM;S9#*>8&4TM)K^%2'C>Q'_;0.%>-YNW<5@8U4
MI"8>'^&&\)QMX"955=:2A+2RWBT[Q3V)TXBU'S16"_0:UJ?&K?WPP3OON[%&
MS$P3S'?U0B60:W!M+;BV7!2*.:8P!8+"B#2(2^V05)8@30QFA96A<$V7EJ>@
MZFL_>%R/JC<&R1WU?3$NBBDFC;0(3!&%.*PRTMPQL$\H%EAQQD+Q[#EO*4E;
MDHD-TOBGZ&U)G6XO];6T09O;NI.=CDVG;2<7/C''RDW\*CR7!&L27.'@9DZ#
M8::4!>82BZ<%=7]^E8:QW!+!OL[UE=N]V/[B'7&!$HV(8CGB-A"D"@Z_$L&,
M\EPZ3S;1$FO\*NMVDX(!4M@B-UIPRK'@6FE@'%(6'#.AU#TZ5AI6<D>=/I_7
M:4JYP(YAQ+@.B&M1@!4B7"Q2:V5N Q7,/WLN2=Y2Y"X=.S;4L?(XBC+\5H5'
M_1X#MM/A>F;.5QX3WL6A\F0C(GYVK-3K>N&:B(C[ +GE0I>88<ZI5DBSW"#N
M*$:2$8R(4Z8(N<4B9^LX"[J1(CTB_\LOA0P/Z)EI\."!\&#!%>,X!QO%$Q1$
M@1&72B/#"P_SJZTF!0G:)%<,R070GCL7OOTIL+ F)\U&DR'0G^PW5U5Q^QT(
M4?E3#!RWH%>M].^4Q_8-]*-7==T=^.%HT+;1=1,_;\+)-XDB13R,_[R:+MJ'
MR7K%#[9[;OX/,U>^@Q?ON^7R?K8SCHOQZKM-#9D_Z)%_%<"@:9+HU@BKRZ4[
MF=6&,9$C(C1!O(CMF$(!/Y&":F^4"Q%6"6Y1(5L\OTNGDR8J_1$ S ,RK096
M'C&L++ UZ;C.X?](*)HCGNL"&1\\8KF6Q/(H*^'9\T*V"+GSJ5D3T[Y&O]7U
M^%BF1YGQ1^U>+[JR8E&"I'Y-:-!E6!D(EL1HP8!X<6.HCH<R-A":!RL"UU_>
M1H@DE)'[@\@&\>[EH*UNHFUP004.R&/&@4AY@0P3&'@5;'V,>.JX!_M4M7(I
M6D(NI_<UT4&_C+939YP6@3A#"0]@A!4RIRP',3#"4VZ3MN-&VQ^1MB]6*< !
M@)L)5(A80!B@&VG&:0P1"J1PA9%!/'O..&EAMGP$]^C#@GXA&N-C9[G+",P]
MFGX;-VW_=4\O_\N@.LZ)#JIPUCK#@]-*,L8< 1L8$R9RG%#]ZC"H!M4W ]4O
MMI?K,P@O,-8<"2$8XEY3I'@(R% I@O*V\(P!JJL6IP58KNOJKO<H/&(-%#90
M.#5G70X$2&FI;,%ECI5GG@CE2&$HY825YFP#A8\("A=KW4N!J> .8>-4S.#3
M2'M?(!>8-EB#:9,#P>5$M<# ?10X6%'?>A25Z.<)Y!ZV>@*#-W+]L>GXC2WP
M<*TA_EK&Q>JZ'Q_'IZ>=5*9!=S+7'MI.?S@>I*Q)4 !46A5WK !RW;.IA[S'
MO??\3+^W>PYF^@\4+]BDK;),QQK&73+5Z9@D9\5@SVY[..P/SD$>1G[8BA$/
MY1D4R$79U;P-.VFT1%LQ+>6R7-N[> =^-9:UZA5_&2ZU[JSA'6]&4_FL$@=C
MR!KPJ'$$KNTNS.V(-"DW:Z%.RU7^"/;*Q2X) =83<2X,4MYPQ!27!5:6BYS_
MPDG"#5#]HD"U[GB/VP%58^C=$:T6##V=%QZ[ $!EC45<Y13IPF!$@L\ET+\\
M)0B*ELSS%E7+M0<?_5G&XTAQKM/K(M\\TX.!CD<:,8:VWSL9]TK=/6N/CN_.
M)Y>-\<N,OU\1P6_X]K\,N-/@O*8J]]H57$HJ*<V)<981Y8-PY+HLU/9&W__X
MMQ+0*+3>-41S+=#]?HEH2@S+P#Q#A<, W9Q0I)0RB!$""^BHMW9]U6ANIAB/
MY["B ;=?']RT<,:R A-C+-!7'GL]8V6(4C)XHNQUF>N5X-:0TSLBW!(YE<9+
MG"-,@)?R8!W26CDDO,EY3KE1,A[(8M5B=Z>F/P?AGE2)P<O(:-9.RI.J(^L[
M]&!=PPG&KXCS-WS[7PCGU^M*G10V\:YQEZX'XY>+/ALN5(BM4*@/#''-8\H_
M\TA2PS&!I5/2K-M=NB$L]HZ>U ;=GA2ZK=O_>CFZ-33VCA"WF TGB!92> 2K
MX@#B;$ RX (@SA(EB?%:\6?/8PG) OZY<SC-SP&Y)^5^W:GIZT)]R78OGNK'
M8XIA=JK/8ZG6Q%GKHW[__=3WALLUGAH'1>.@N ?BFAP4M:SN5Z(:*_*][=EQ
M_-N+\6BO/_KL1^]TNW',K@?OE\N$DX)YHP-%0CN.>. 62:D(\MX(;F01E%6-
M8[;!O2>/>^NBM'?!O8;LWA'\%LAN+A36>9$C'%CL_<((4IYBQ/-0%#FL=8[#
ML^>DA3%O27'G/.C&:_MS8@VBJQ;N]ZUMX4%U2=/&']MX+'Z4,8FQM+@H1$$9
M9TKI@BNA<:&DHS14O;S6$5308/A=,'RY*IC"0@4K!3)8YH@73"!)A4"*Y][!
MGZB,(:R,BY9@ZPH)VQ "V_AD&X2[0=@4+P@MF"VT9S$ 1P'6J5PQ2;P2A(:U
M118TUOGMP6VQDBP5E$B&D1*1EA)K@: Z@6@AG-+. O+A1W;@]*1\L1_BSZ@?
MT'CH,ST<^E'6-R,-U\48@LQ7I?X28^VD6K-] Z/6<?D:/VSCC_B) 01)5/?#
MIZ'?CG*Z7XGIVUY=C_)U?[!_Z@<@F[VCOZ.L_MW6IMUIC\X;@KN^/6"Y6AMS
MN3-.421)X(C[G "W+0+*C;(:M@=OM7_VG##<XO(>RGPT'MK-@(8&$7]VT,':
M$+$AQ+<'P\5B=@8;IS%&A?$!K'T!A)CA@ J1\Y@6 INA>&3'54_*7_NRY+O
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M+1>F/9R:*\F%=IFLS!8KF&SM9?;@]'+_O9UB$](XHW-^.%-2OBJ6-5O[O3S
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MBB%%@B;>>TJBURN=#M$_EZIGE'7V%U5M;>I5(Q2^OGK]B E<!8J7LHD&,JZ
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M8(Q09D*-OK>*KG6X[ZKC"VB110'XY,HWW,1^K(-0IXC12)6OJ6ZMU4>E%XJ
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MX:M%FP39K!;=P:J[;'CUTBM$R<'E,4<8==A_CZ3"]\"4#$%H!]S3OO2Y3X.
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MB[PT"'%,%,,9#ZGQ@H"C ^'#]R")\WXU(AFW?IED9$*$@FD1$QWPR.=)1.,
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M<BWWR:OOOW3.X>4QM'AYFJG31@7KF;@:7P]>[GFCRG)%'_.N-?*N>XVWC;?
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M4^I)20,/1%H2BA0\4J/ ?)V?'^N;(>9IG:F:8J8+:P'.![D>J6%G-,S ]Z^
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M\=:_V^8..U6@+%#-B@J::2R?0>^?Y:B;K-R%:T"V=YM-'97H:20($6=B?@U
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MWM69UF /0 %@+&&#07WTY8RF,M2"-=\(2(=94S.WBF:ZX*&LB'"1V87UXVT
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M<FAD_!'&&T>J#9?0]TR(B0O(C"#S$J7]A#+1]TQ!;TD>:O%'>KSNXC25(BH
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MR.9 LS3X.\498<WDG+9%KTU$*L^.Y!4(3-Q#[7?&THTX9O)(>;<]T>M(1Y.
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MEC?MT(SG1T-1K*O=[VJ'L4L5D'"9BV 9&"]JR\C$VD:4P)T/.6EM$VNM ]^
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M)UY:'V,]">H%L687=71P\KD2X/@2\]M^B/W!O V[<48*'QQH(ZKG1SY@0!-
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M&-KQN%*M;Q6/?B9R8^5O(N(]ST0NW-<,)PN>P,P+$)RB&)67'%5)M!?FYGO
M,4V^V%5;&\RZV$34'?@!=].</HW#<!)FAQ63GZ_N_F9&?Z9=5B$A.,E) C8)
M('_8 :)U-B1M0FK=1F%]=*?B*72DCPZ2TN[B6;PCZR#JK'?0,IK#N Y=Z>\1
MFNP@_$[Z_MQ#EJ+@GAL!18O:CH8%\"HIR$'41#K,@;7NF[XO.CSA2QR.#9O(
MO"$+)N-I[ZR4_J!? ?TRG/:G5]?5J=8475( 51,ME)0)?$H9:HL969C1?KV:
M,'K$'0;0OVZU__#3#]%Y9S>=C)H*]$'/82_5G'?=G@^T4#RO^^2KT?GY:#C[
M81CF.__ZK8Y^J4-E6A5[[OK\#FM!FXIFJ50T9IZ]Y,)%@XH5$3DYF]Y*XJ%4
M3OA>4R1-0M#%U)]WXP_]SU_NY&ME+7,ND4%PM2.G)Q<\:G+!480B.;T_5K2N
M<7D<T4XGKY_P_&(T#N.KVG-K>C63Y[Q6\?5E[9?TGN*%49[7,/Z&?\Q^->G9
M+&T)H8"6WM892 )\R0A<6_J)2=PQ]=1KL?WC#Q:$M:#$-^>SW4N_]=W\>HC?
MC_L)KZ>W]D+,&'SD0#*IC6MD!H>N !<\41RBM5:B(5N^>?A+X\KVDN_  5\/
M\JP^]I;=Z%U)MD0PL\L.F3U%JTE#M*5H&9UPH756\#8X3X)8>U-4!QD$*\7Q
M[G(ZF9)W0)A[W)D@M,ZU!TT=#%TX.*<3!<Y*11TSDUV=&S^(Z:1(TU0!W5TH
M?8OOES]QG/H3G-G)FU].%K^=\%[BZ! %V<B8?*V3(-D49D%:5)*GZ"1KG6ZP
M%=#3IU)35754"OMHYX]YY0VG71A3U%P!3YYV89TL!&7HC2B:V223S-CZM'I=
M;"?%HDX4TE$%[08M8W(.BARU J;4,_Q:)>1L$/3/R!F)PXG4167U,3?R.22)
MME=.P^+<643P)-1O@X&LO?.24!H1R5QFFR!R$R!SEJ)-3JN\7OK49L\]"79T
M+>\.ZF_/\G]>3J:S[GZ?1F<YSX0>!N]#GQ"_"A?]:1@L1#0G<T_2-EJ$YX F
M5G\MVUHP+"&QK))D6)1I'7EM#/(DV+0?%750Q?LQ#'"1B_#;914;_>...7PS
MO'.SU%/,I"A% (^V=BJ)&IS.9!\#4QA#R<*UKMK9!-]),:DSQ=PGD6](HB6#
MB>B*,05B;0>JL!B(2F30F(I2KA2_?$[8DC"GMVDU%?B*X\'=3I(?/>R^W6;?
ME=O[H-FOSH;YWIW0[!<]PT6.-GC PF@Y@?[P2A:07KAB?? DP/7RPUM#.PDZ
M'8'65I!P]^3#=5=TYXKR8QTG,ILXTBO1.$?1)" W=;JRU."-E! LKS_)9&E;
MUZGMAO@DN'@ Y:W@WLYGV._'HX28)[^2S.HJPC#AFZH.<@(OXZ"?WA5ZB>I9
M:HBYT/_,DC$MF6K#P?$<:/=V*6MMR%JW3EQ:&]Q),:H;E:P@S\[GV]<'HM6T
MSDY$[YR]SQJ'Q>S(LC*BL_(4+.B(X#QFL"*(&*00].O&G'D*TTE1I:D"5C!D
MYQ/JE6N_B0]NS."K,!A@_OEJ^82]AXDE%052H%!*K3,D3S$P#5)S6V]OF&3-
M1[SN!OFD^+5/]:V@W\[GW'?B#MI^)WWZVE"5\0$3]K_6*6UWH]*"@7%4'+(B
M2ZI20@@F*"A2&,:TRC$U+_38!.!)4:L[U:P@TLXM*&]G_MT<F-W>!_9BS)'5
M*%8986J-@R6:ZP),U?,-57CI;N+/*D G191VHE]!C)W/N%<N?%[YPGP(Z!V'
MXB6Y]K7I?JSES4%(*Y460OC6#O/#:/;58W#?F]'FHCZ6CH,/EU9*@=F@9^"C
MYW5TE0 OO(*4N,9DHLZ\M==\=$7GK92]=NWY)D+?3]7Q.HA>;.WY1NIZNOQX
M&UGOAP6,_&4AHB:VNWK?YCWX+"C&)[AUUI5SV/I*XNAKSQLK?Q,1[[GV/'I6
M7)$>K D>%.<:7)W9DYG3FFDIDFU^MGODM><;:6N#VO--1-VZIF&.ZR-B7ET6
M;Y*+FF4H+,IYN474CG8\;D11QC IE_*('VP[]-ASGJUZ6\NPD_:B-\5BU_,G
M!4_9*@4^..*;3 4<L@2NQ)B\<='I]BU%ET \6XVW$6O#FH 9!5=6"BYP!>%L
MR<F#P%"K5*,#7[MH,I-0,(DENO5RWQYYR+-59U/I=9#(OZ(#7@J<>6$E!(I:
M06$F'\0K UQ$XW74/-O6AX7'TQVTH^AL1S'OLTGH.KA>:I/0C72V;G/(;02^
MSR:A0:-+IC@HG&R?XJIF,ID,%(Y82XZDU:F+8;?'W"2T$QYL(N?#- DMRBF-
M'L'E0)ZFT!:\YA)JOK7V3*!<<Z=_;DU"-U+-YDU"-Y%K1X.+[\]!<*H(5F;7
MFK5A6>U9:H,%RZ7)KGB!RQ4-)S4AIB,_8&=1=^ "/C2Y9 U4+W90S"8:6W-0
MS!;BWM^@&&E9RH9(GG4M-U;<@$O,0599B9(9_:KU:=W1#XIISX%-I+SW03%)
M,UVB3Q"U8!2H9H1@)0>38F+!<.%*\Y+_9S$H9B.M;30H9A.1=^ 7O!FFT3G>
M7%:\K?]!%7!E?_8AN<(#&%N'FCC)(&B'((15V6D?O&L_C?Q!."?F);02? >%
M^0] 6[P*ZX#KR&=X%-AA7(=F:ER/'COHH(/-Y'&0V@IG5#8@6<WOYDF!$VB!
M!X82BV7<M3YC/ !!GG K#L./343?2>/8"=(7?CD;YM?X%0>CBXKQES\O2&C7
M^YZ47BG4$J0TY%IQ)B XIX%)=(S9HC63C=FQ!JS].QP-%7FOE6Q;+73@?:S<
M6V?OAO&9LY@T."9\S;T6X.H8;A>="4GK()<[)':3?GB"GD<;H7?0UV4EL,6+
ML ZT;M/)5L$ZC,_12('KT&('Z7>78+828M A%5<';J8:J@N9(*@8 (N2P446
MW7[RE0_H:^R?%YL(O?5UQKQJ]=/H_2"DV=9Y]KDV EEL;$IER1U/D)VM?858
M/7BW'*RV16$JF4+XM:XQ'GW,D90J;*.-42>B;)U:=HULD?HV2ZKX,AK0-U^C
M2\9HGH0$8;6K1W0((=L(,5B3T28NEC-,GU#T@X\Z,66W$6DW;_6;VAUJ.!^V
M^X_^],N;]^\6V+STA6MNZHQ=5EO/"8B%')^2=#$EH=9VO>O))QYT4LIN(\[6
M^6:O,<U D&[X^W'_*T5 -P;HND+J.BVNN)QK 9T)P=5(F4Q0M!XP28Q(6UA.
M?BVMK__,$R% 1T)N>$7Y),S99K2$-=AH0PI(<2LF4(:$$F,QLQ$K3F?KHRL[
M$V+%@U\ *W85=\,#Z3LF[-?1^/UX5' RF;5XJT6W%&OTAY]I&_O:3WB-E,FB
M@M7$6F,E!<8B@W>)?)?,HXK6\I0W\?O6?.R)T*([47=P6O#Q,D[ZN1_&5W>*
ML>>96R(C\90XJJLAX^BK_X*TLRFEL/8;Q=8%S0^".;&SHS9";]C(]0;8G09^
MX9S^>J?^_CH'<PV$'1TA/8WN0!6*;=3Y2#/%AKKHHGCM::2E)(:&23!<:5#D
M%8,W3H*.2=BLE ZV=3_[0['EJ8K&0Y%E$Q5T<<MY$RUI63R&$,"964F($>"8
M4X!1%1:\(KZV+GHZ8$#:6C/+-YA;B;6#2ZAE!_C:O8FYKL&"5I@I-*Z=R95B
MD)U)*NLBT;5N&[\:R<EIOH' N]@+KJ]@YS-\7HW.+T;#>@PZSP1D@AE+OA>O
MQV$*M8-@;*F5VTSJZ))OOPT\!NC4_,IFPN^@$_P2INMDWC5 =>1.K@1TX!X7
MNRMNU)74.S 6J\%)[YD@9PABM8Q*%=K2E+/@,2E,(1'DUH'G'JFP;L.+/3%A
M$V'OI23>BR)0AP+)52_82P8.0X* ,A:?N=6E>;?'P]=0-U#.DU7QFTCV68U'
M_IB^8+X<X.AV.M=M"]0#C4Q>"]/QC%'>7(1+HY55%D%DX9#%H"+C@209N(A>
M(,8H]4ZCE=="U^FX96/0\6 UV.3)\'I=A]U* T$'1&-SS+B7O)BWNXY;?O3;
M[XY-3)%AYC6MEFD*31BMW<>B@?%BHX@QY]A1SZGG,[=R$U9L/+=R$P7L*ZGT
MR6&(AJ(7EY&!T;4?9S81(GH+(:=20H@IJ>]S*_="I::JVE<6XCP$]EYDK\D]
MH;V8W)[");A47=TD@V=%>H*X#Q(=4]/4YOS87-3'TC3UX03-C"8K%P786(7$
M& +Y<KS>M_,2BF9Z/[OTD1XM;:3LM=/=-Q'ZGK.9UX'V/=U](P5ND-:\C?3W
M3)!2HDQ,>4A8!^\R7E\& JNS2)Z7*(1H75SW?-+=N^+%)D+?;[J[IVU41V_
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MT@*UQC?RVD97]4%L9I Y VYD5CB-F?=K+:S34"4#4)S%'/6--7'PD(':AU%
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M9G0IO@BF+M5UQ182<>Z'(=9%(KFR0$4**!0($([#A 4Q)])H>7$OVMR6DYW
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MJ-9UZ,+B8MIMUY2))W/"Y607<G#CW>[FM*->:U]S/8M;#;U*Q8E6$8?P.U]
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MQ;,I] %!' %,6$"$[R?$)\:G=3T#S8U%=Z)ZW3 WBS.H/E0-#NT<834RKYV
M:4B']CZ\+([L'.$VT8F=[6MF=U!G@$7O.5W?_=,=TQEHL7=*9W+] );<+Y.Q
M2(,P8(1RD) ( T1]"6@4$1!"'XL41E$4&@5*'WGVW+A02U5E6.QE9J^T7?FW
MS8I5MLQO6?GMPGJWQU"FG,4RQA@PM=X 1*@$:8(@" A)<<PIY *;)6-?B/,T
M:=9'D>XFORMDUT\9[XFO/@NIP=HS'*:1EYL7-8R&@V"QH P'8Z(UQ!04N[7C
MN-J]R\6+6Z9;(8[+NK<HG+ADF-^B/@VMNCKI^?V@D513_&:M8^D6&$&(*9'
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M5*#] $]?,+!FGE KOKA[%#G1Y60_Z'+:VP3*ZE\Z=7+A^T(P+ 5(2(@!8DP
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M#7G$$.&I5=IT_W!S^U K:76 ;=LQ9YU[E<07!'"< =QLQ78'X\@?^H4(VE>
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MWVZ;$"]B$:>Q#$,=PQ0!%,D8I"&-0"(X$XGO^Y2I+>ZZ)$NSS])\:*OO=BO
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M[:]"YW4+?OLD<G(OWGX7.<L*4=7NTT%6LHDCA $**?<QB+E:[Y&D%!#U-8,
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M\F. L+)12(0YH$$L$@G]B/E&U;!/#S&W3W4GI5>+:?:1]F#8_ZFZ06;D#_8
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M00 IU6$Y/B X92!$/,1Q#&,8A%;&K>' <R/SCMQ5>LNQ;LJ65J[I%!A:N2,
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M/5H8$E95=@^'F!M]W^7W9)7]<Q?)\T84+,\JN#49O-H4BKM[G%>FT)H1[&6
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M&Z\1U/O4"]J DJ-GX7!69/3T2!.7%3VK\F$AT?.W3-YP_D.V$N]+\5 L@B!
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M!9D@ B">84!53 "+&2^*5!54.EGN3KN8V@3]O*++R.0!Z97NPV!GMSONA\C
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M[88)3@V)>,C(U"!RC1^6&A+.LS&I03OP/=W="J&G2=G\\7F^E.F,\U@J3 J
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MY[]4"4=MRTIV@)G'14)YD@$HS*Y-Q 709[0,B#SG"O)$$DEG=7:S7S=Z9,>
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M2OWZX^U2M/,+[IGN79--X=M*TY=:K9\^KM9WFT<]@;]551IA1G/*"04JACE
M#"< )R(##!*J]%DL4=PJ##*\:%,CI*UFYBRUU:W*(WJ0.K2=:W2K8.4W7:M8
M^1752D:_5VHZDEC H;=CO;<9T*$/3F./I;M??'#80_G3AQ-L7#_\X(">^.^'
M[\%S>:!&B&I?^N7%.-[IOU3;V?IFX=.R2JAF#(GZ3*Q/)R)-B *8) 2@HBB
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M&HUNQ:[+"32B1K22U8U >PZ3'86.!_[ )-HH$K6%C(PJ-]%N2 ZT.7SRMGN
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M O[.53-HA^.MJ4/@=+#B#M*!;Z[@=WIBK.GBTU+(/_Y=OLY$7HA<0 J2@E&
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M@R-T8"H/WWK0/+@?YTNZY.?SK18,DYS)0B^DH@ HA3%@A<P EC'&64YE =,
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M83I[FQK1[)/:+XRTT=J("U8*O.B_4".Q8]&B3JCM6"48@ -SRAZ[2M#FN&G
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M9-\M:%G>J2:!Q=VZOIG=Y[.<%;*(LYCF>F?.N;F%X(# + :2B3Q1F&0<.EU
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M>&ULW+W9=IO)<BYX[Z>HWGW;X<IY\+)]EDJJ<FL=[9):TFZ?TS=8.41*L$E
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M@Y>G8?:!A??"@>@?!Z?(LQ-(?,#%=)Y_G>4W="A/#+?<R&0@&(?UC!1 _TP
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M@)M=^K>;29AJ%E&!D9EB3955E4L!]$D''[PUS6.JNU1TXA2?IM[;7LYILNX
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M0^UA!\&33.B4(7647%\3A,YVW;NSM2/PO!R.^UK9V&OM&!PO?>M,@A'&2<-
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M_:NTFGZOXW%N7?0E)6)T"):S.EF")0A$*7VEA;=2,IE;SQ\]G>IQZP$[@_N
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MU<X)FV+C+1=*9^W1.O!<5RY$(1]?)C#*6EX8ET*W[L1S/R7C!O4#HZ:!\#N
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MYT$9_^35\C$+CYO8^.R(.E7T'3A"5WE)6^%=7VO8H+652=;">?(32S&U(:<
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MT0&ZKD,)+8O'$ (XL\[U-0(<<PHPJL*"5UB:3X<^+'(;#BN-M7K[H>PH$7>
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M^<A?.&/_,9[,/LW#!0GSU]_>_SH/&6O])[GY><V7<9P[81W(6%L834[@K!3
MK(G684#]N(O[J=>[[9<.B[,]]#H[@I [ 8_<A"_K);D^GN)#Q0Q%BH'<(D7"
M<Z9D9A#1%+X->#;YTF'34&W!TUS( X)G,5^24WU9U_R2*)=7OX<+7)W!S EI
M3$R@0TV*24['KW4&4M0Y)BOJ2]LFMQI]P;T;C?YV=YL]]]T#]]D-ZV8U4<C
M@#K'+Y<DM[# VTS%8Y9>SVH1R<B2. P&1:"H$1IZ X[G )K.&2<5+SQN5+WZ
M Y1M3- P=UP;G<\.K8"A[[B/5Y/QIS#-K\:S!47\TX0?/I,I?@[CM^.+\1)O
MCMX03$K"(7"4=+ZK$B!H0V87>8E69B6=V.A^V_ +AP/-@?0\.[#0AP92W6I/
MM_?D-_HWT^4DS-],TYH-S[7GQ1(;-B"HZ#+$D!@=WCISJ3Q#3!MAY_GO&.9Z
M.Q)<&HFV@R#_ ^GD6D23L" _[\-REOYG=2J7DEWPF*!$++#R)'T=18U>&[M:
M(R>;3SMXCIB!FY_[2$FU454'F+M/_]H2D[%%>B' Y-I1K4TBN:0$AF?N=8Q&
ME.:9TR=4#)SX;*/>QWG,_63= 5H^X'R,B[/W-U^_8F5]V.J4HT<;B/9(DI'&
M@G/$BA JA6(3Y[SYZ(?GR1DX1;FGIA^?-HW$W@&"/M+GWI5[I_3*J@3GD8?@
M(64M0:7BP"6&X)3'6!@+Z%JW%'Z3D(&G O1QM^VOH@YP=G^R.4GQ]UK#<ON3
MC_1?"Y)>K2M<FY&3R5H7%3 ;*)CPN4!@2-ZH\0DQZAA*ZPJ[+4D<]D1K (K9
M\334 0#OE<]\Q;-O<O:/\?+S^QH&?9P]]^DU[Q2H!%[H\L!:WZJRX.!$3B!E
M-*Y8(ZQ*K5VRAO0/"]V# NVQBS>4UCM _!Z7UMOQ%-^0Q[T8::L5B9B!#260
M?^TU. P.C."8?6T>M:V7N;:@>]@^NDX<AZ,#8.BLWG/VNQK=4,^:=[&F,E>'
MRQ]?2&_3Y;J);&09MP4S'3*:*PH'G(*(.D!D,O.L0\CF42/Q,UF_W6D8]E0^
M/EAFQ]=<!Z?R.A3]Q^K.6[Z;KSB\WNI* 2JFR_FX%LS\%"83S*^NUI];K#^X
M&.58-",&(0M,]54Y0118QZM'Z[@0UOOFK6;[D3SL8^Y@N!Y"X;WB^\%>@-M?
MWO+(1SF'R)V28-!9<JV<@)B]A2"8R0IC8.Y .<[M"!TVV=XGEILJ]Y1<B-_&
M$UPL9].;3O11<"H'$BN4;,E 94((60K@7MNDM5;6;E96M0\5P^;,3L>-V$M[
MIP33_[RDZ!;GDZL/@3B^F9IPT_J8I FHG 99>*F7"KE/D>(-SI-F3%DA1'O'
M][LD#1N[G0Z V^GUE-!\G]GKM9<C:W)4*"QD:1DHHR6$NG;(,!>DR(KG;)M#
M^"D=PPY;.1W<[JG!H<'Z$2^^$*/SJY__]W*\O%J]_;U9+"XQOR97?OKIFJ75
M4.;%]<])T!]P_I6\H\5(E>*-DD@6:6HR,SJ(=96(%E$QYE6VUF^$U;W(&'9Y
MT[!0/9[^3@.I?X;))3YEU%GF=.!U95NIZS4L,:J+A*)\DMQPAS$V!.JWJ=@(
MI^[OC-,&VAL:IMO<'??U,,WG^.ER4O_IJ\?._&(]N&9$HE:<<P\Y&:PS5TG\
MS#DH0B3GK&>2E^:^P;94;@1S_S)AWHWV3\D,5B[4\UP+*5W"#+&47&OB:C*\
M]B$Q%U..F#)CA_&']P+X75W4WQ?A[11[2G#^.$:B[GQV%2;+JYL 5JNDN- )
M4@BQ[NA4X'PA*Y:9VURBEH]G9#1 \;<HV0R\_WJ8VU^-'3Q?["'M5?/[FVFZ
MK&3_.I\M%J-HB_ I6["K%YND#$2C-(6Y25BF&%+4T$_UQ%,&-H/^RWV[&PX-
MAY_/M?Y%_:,NC_KW?_M_4$L#!!0    ( -> :54TVQP3;P<  !XC   ?
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M>)!PZ?H%%5+O]6Z#B>\.F.)V=.3\<$4&GD( ?8;Z<M";+GDFO#+;=W%9;$Q
M2CU3R(NJTA@ S#*5QO,5I*CPX[@Z><5TZVRI*<,%T%DGQA5\FC63ND8)UH,N
M1F52^/VFJ<9&"LFU= ;(D+X]?Q=NI,JXE.H7D/'YU[,;-K10"#M-WZE$T2B3
M*N..E&&65V*5FM$C)/KU^@178W*"X$WT)_$"GMQU:(]W!]HU3UY/>5;Y\+LX
M49HB7<HI%2CL-M/>DD:W@'.X?3P3>EBC(Z!H0KX=J\H^K<$V"XXOI<D5$^F7
M2T(V7I0I?HE2\ 3T\0!T$WR?($QV!X1+?@T!W@2*VZO4^=*W/(I&Z8Y>BE#7
M.7 P%^ZU<B^,%;@(G*F2I-(.#FL$]<BHN3(6S]W!#L8R"0;Z+6R*V?X375+@
M&ON2!]*UXJ@GR6^SW ZLJ)9Z'02M)MPLV1SDR?TZ(.$SB?<'-ZI (3+'9NJ.
MLGK/]4"^^6(7O1#[NUZH]G<'^R\J5/V)C5BLFN:*RARSKB-WQ6H.>UO#H+E9
M.RQ5XZ@?K-*!@IV,?X A\UQ:2_1,WA@KKCTY"PG]_"#[P#=HVK@T@+^NBEDL
M2OJMDE#?+\"J2/S6[.#_A>_7).8+[*9=02H!/K?]<!N91!+04J?X90$Z(W[G
M<C:9!>&%4M8?(RUVUO\5!NM:,>S)'F$_+M#1T)+\GL3K6&;2^BX G=)8+KYP
M,*@:3)4#,O"2-Z9..H^>06Q-C&-EK<H#_/[4<-R]8O4"U4"J03=-8(,\0P)=
M_FBPAF$S)%-93%4V)9=1"WY;GW#JFE0I+S,U)[3.)BHP*;\'<H#R#RDWVEM"
MY;4/L3MEH(7 &# EW8*S,UX:&BPN3L'Y9<;G UEXE_E.I_>'<R_EIBYQH BI
MH>4A%9I7[^O:47AG9S7^B\7,=7/;-W6LV&P[/&Z?1$\W1^WXR;8_:-B.5SFH
M#<^8DA=O&KW&HD.-G4&W_,SBTC+_MQT]>&/GD+7A)U5^_<46]V'8%0#L4QM[
M#SCE8R#JI.G?\2Y!5'OERP9OOI?<'3M?[1UB#?G?1]\#WK-VRSA'SNC&LQZJ
MUY,G8B#"'WJPA;7/N.]ID#Q>=-3OQ+_^B^''O?VLAY]Y'?]-E;Z<2$K9NR6?
M?@B5[[9YM[U+ =C_B"UF(DN8L6'0P8//(Y:([WA67[/TR4\JUKSPX*N,4H7/
M4@;A,'!*&]]IK):&]UNTZL+'6!^5W>SRA4\[ZM_PH8G_Y.7\/U!+ P04
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MAG6GR?.$*IN@C"DDI&%&;[F8YY1,(<V]_O"3H5Q@0J"5.CE- 53]>\%=/6*
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M?Z!_:P5]UP_M2.3?'<$3:(JEWC[RD:UU_5GMT.TV__ O4$L#!!0    ( ->
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M;SQ)T@DN)USW^C(87!94SR0E=?3G7W;V?H7+C-24WBKMFL*.@>L,8G WDLF
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MN-5]:S+[L'L#.\\8<<%PF@,L6*^M0J%R?/+!2A#=>D:'4MU*==E*<1;=\>)
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M!L1Q#R".5571<]+5:E7B\3M-/+Y^^>;%XQ\_"F^6JK44H/'RPO!TD&CG\YK
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M%N[=(?*U<AVK?Q6D](TA5;/I#4EZ)8)D@1."F00"@K-:(JC;#.[%6WO\_+X
M"TZ='/<5HN<HX_[XN0#$',<.M6A)7U:J2$M_.F+I9J_ :AI7DM0T+2<M=]L[
M(9;%_%R372$KSOZ=Y#PEL1[9&FNY6[V$9&4=R.K.KK((0*\TY<P<4V3.8F$6
M;9 -Y^CY*&8.2=S8T864FYI4 %+JP'# UC)(3>&_U,QP[F;PD692TO<R$?DW
M5)KSZM#?EF?*I.8FD93._P<+M=G.S.<3[CM;$5MPL:^Q%#0M25=C8MXD),6^
M*\TB:"9:^=31V"5LI6/LM/AEE7V55XU+_3<Z\L*\A.?9P3 XP(>7:3O-[67K
M[MNB)5)B72VLC,-A1-O'-\ONLLAQBBNKV-V^'L']LH3/VWUWV'QN/!S[\XAQ
M DIHFR-"/%<@<71"Z&)UI8+0D$+206%2E5)U>R&)J$SLJV^XW ;!.,#S)!ZF
M,$6X*VW8J&O;!NP3DNIE\O+LS^/E@2E"Y1>9!5IDMDEG$=@#)2Q1KV"3U3BE
M@AI1G &Q?K!.+"+)YB]%<^!XQ6KM5XJ5]5/][PF,#\Y8[D?4+*$I3ZV7M%B@
M48SB$(HK,B9NI:]HC!"Y:]D^,$V\FXSN73*ZNTU&M\GHWD-&]P4+T%JK4_BD
M'!N0+'\D:M+DB1@[7E^9F%A:H/)W6&11_NHK'<;C/&27R]\*9F,P9 VUIA7,
M>8A9XN+PCPTB5EU$WBJ+W)?I7=1BF8_+':$(HISHBYC2P!0N=:*UL'XZN\;U
M-7Y]8$*VML2O4.!)O%I" .?ZJ//R!"82.!M,4B[](,)I!],JDG*J3B28'76-
MX[X.^#=9X0',JTK ^;\(4HN.IR&.G/+L$DE[<5S:8+YEHUE@,9MUU# FR21W
M+&^.M);2V/QFJ1GM618/?G@]0_1D^YHHL35D*L6W)EIW!MT6@M>5(0B*W_'!
MF"DQ&%=$<)C ;:1\[1:2%J)$=D7SG[7$NZ'LS@A)V$N1PB)B&":??!][I3Q%
M0V46:!N/>#F+!AG%S ?30@39W4K$;4?K2(6J&'B&RU!3J+97WNS,99>/\88T
M*#^@]<JDNUHAG^0F@5YBFZ?]>B"N$U)V$D%XNIV<CT%TX"'#E00GV2_ /+3-
MC!CD>MG4ML42>:*.3/?\(''*(4BHT10== 3ZFQWJGH_EU:,>Q]'&.WKN52A(
MM6E9L ;TU)0D6!B-3#GVDYA@I)_T.DHXWWH^%<]C<T5S%KW4P$*DI?R@())+
M/Y0:;\R#"5DF"69S@'ET1(IKHR_P>"*ML6$BR"6LY*H;>V7S":D0^WT2#42M
MA($>6@I*<V=ZTT>MYJ.VH10>P9FF=;>;(TM6#$=T4(LCJBZ8[Z& '9 R?&8,
MV@<W\1H)Q-_)]'*1D",1.7B$D2?44DG.D"H50&B@H7Y_$ ;RI^'%P#373S2<
M+4RV<[6%@;Z8-\5VDP2E5T_P,Y_!QP\(JHA>3AJ+R<09?KHDM7[$0@^DZ^%$
MIXHRA3X+94=0]+3P9[[F;JPN&BQ@@%#^\] $@4EBY9NB)6S.B/!!Z,/]7!*3
M!Y8C1$GC0E,_7 8U.4Z TUFEC](.,W/(:\.$*<2!/ K27/11T7%BBH )>S&]
M#1]-$R>]X8#41K:1--L]&@Y[*67](WT-\TZD\<5*Q?K38DN+D3<;]Q\C4F))
MUD<> 6P&U&F/-ZS<7+I9\2VMIP%.6F8:#-D+I<8A<MJVSM"7PFD<(LUY*FZL
MV_8//)X8OT!P.F= E$XSO$M%]*)SAC%WB= $'M9M^)]?&-/SP2VZODJ67++I
M5EAAG,EA 3>D2P9[!%XB"04F>P+[#5'B$PX#Y)T2!G@/+9XU[BLB5'/Z:M5R
M:1D#<X9_J^URT\^J;^E$9F&,::;'_ VW.E8P6KYKF5)%/AO<_!W>[$&Y2P)A
MN!RSH%^BM2?(CB(@V-2FIQ:<.XX)P%F(!'A5F$ [>15P8D%OV?:LA"&QD#-A
M;,C9D6MGQN7ETCDS*#<BQ_=&Z.#3A'&GST+/ 45GVC@?HQD4K!T57]BQL[#(
MFGL>"/L"OMD'H31D3%H0P78D%N?<MA!X4I;$W"U=YS;M#?M+5&EA86;R3%(E
M?:Z3)* @5E#H+IP3"M@R5^8BA]4<@GR%/;M&S&4V:(6-WB;(_#"AJ-QE$D\N
M+DW\5#0TJ?NK@/DPE,1]B1*\6 %N(U]Y.3WVN<(%,=QO!I<8E\A9V*PRW%].
M<R7Z8=Y(+5]]F5@W+B>U_(/U,B$W'3_>6\XO*>'*XZEO( 83RT$PC$XQA9E5
M&"[O_[T'>)ILWYQLWYLFV]=D^^Z6[5NQ&$EGLS9(<JZI+Z:/TIXZD,!Q?H%A
M9)BA6I_^O*HND8QS*A=D9=DS+5N]]RIS"T!03P?1A,IJR$-AO4 Q%?H-!?\P
MNDCM6Q-K(5['2>C;=IZR.J 9M$K PTWJ:)SKT5:=3;1<S(OE--U[&EOA9A\"
M#62[)A7L&Q>,:YS5]09'++WH'7_#^'\O,5\,<UY?&<#@X^IL;^T:$)::#D5_
M6CW9>>K%MO:59JETK(<&KUPT><EV;-"I"ZWH''BJB\%&44J@>]M<NK[.FDUX
M#.TEG%!A9'N"O,I<:J D(V^N,5!C@W[G!-&Z@U+.2Q8D/>//M](M:IG;MN7/
M0'<TVZS4VS=/'DGVF8$.J8S'0/)>:']*VBCU0%AWHP1('&C":1A(Q$GT=9\9
MY,E!0#^>2C)&XTF8"@#C"GR3B"K6P@#FW^?L^EJI*UX)TB$]V-$QI7[K"$K*
M6]"ID0HO5(X>(L?1;6?.92^C,9>F82$17DK:#5+8<?XE<3_Y 9&M&?0"9_Y,
M)M!V<:=.<9-(^B,BET Z&4F#B2*4(7.[;[&K7]7H<-UT$\:K2G<[1CU<87-A
M/*=:FQ 9A?;!JP\,B=JEL,%10Q6*E2@?1#0'56/J'AH'W'D /Z>X@C2 5(Q@
M(5F0IIJ7E2-=Q"B.LY%R'$<@-9PBH*)*K.Y \*W(;MH7!(\9:(7,=:4Z0=PD
M*DFH,-BVC&\LHKHCNN/-XZ:<:;-#$VVJ0U5F:[:3B6T.65'5F=<'Y7TA3-K<
MM,^8J_2#$:F$#+EW<R/,  =%/!>;C#,1YM(7?D'QO(2%KU?BA4)H='-TRM7
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M\^&4*HV33F$5V$\=3Z-[U@):[_1J"';&+\)6..$T56<Z:L2EBE75P(Y3NXX
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MJK$2I/4K\JMA76<WY;.;E=1C]2VB)5U0G<;HOIKBC=[;MOP@ C* _OY5=X$
M5J3O/)10Y/9C*/(JH<B[S(1?K<CBDIPVZX?#BWI P&R(^O$60WY>%(;90[MP
MP'O$RR_WV0"6/4C+D4JK&%@!GH-F^&_0YBIQ2]EZ>#\/W7^1G[*>E@8*5FK^
M@:U]RG5JF<6F!&5 UT]8S2>:*H*@G\_3NE;*I*(,EFOI":?>:MT9@RHS=2(I
MDO35-_L+9/'[#4%RA;Y01-_H?=S+7I1PFSZRK:*TK>,Q4,5NNU 7/HN.XX!X
MJ)A\MHZ'5>#^\U.U=(8>!9U KA/%$O7L!E(F^;&;QMUY>B]4GO='0*(Q^F!O
M0]_YDS(Y_<O28,7#^Z/6)8'[H $B*A,9Q$PRK1N!-6#7PAB.3-_&V5S"'4D7
M;A="LMJQCB0/3M/3PG:OJ&HP/+B4S-XQ)_A-N=C 9J),M88#<CYVT]C(->Y,
MS-RB7)T4=:IM)9O@"0-LZ(48SEB[2Q?"XHD++OEMW(OK#EBUCO]6#G_X^#M;
M;H-<%!U",1()$NLP4KL-:F&-?)HW(,(:K@^PC0NXSL%X*%II529$!M-]QB:[
M'\M<*NPIL\5!3L)</92&H7KF#DKSB'KR@<2;4N>WU"EL@[E@=,W4MND9!YVM
MZ$L0)ZM .OF!-%Y$)95%.+@WKAV)NI##8VGP@>3;/B3^#KP"NN],7:H_+$W(
M!03?<DQ1^/^[P&@C ZO4<;HPW\:080TG32GO%E\0;%)5GDK-GRF8,168B%C$
M?8;\";I XB(WN+SSO_=#MYD:\792!!=-":;;5<!0[_"57($)IK>L8OI)@E9R
M%EY)^ _!2L'.S1$#JN<(1?W<T@G:;"=V0"2MD#543,(W8ZDICE[QI+42OML@
M]/T*,"NSH'I77&;%]?9N]X@>H,L()L  ZDX@FE&@<=YGQG5)2![&<^DJQEH7
MWDR>/IQKV$ZTLB?L@\&UX<.Y<B=E)+*N8("'03]#S$3=9L!:-M&2[ HTRUIL
M>PZKF063J$JK,5 )NZ_,#PFZ>Z(P#:SGC5H(5<;N-!R]YR6553<I\R_*\Y3P
MN\NE+=1QDA[&;8-:LLY<4$?<NE)-T1;L4B)A2&J-M&?'_+;6O+/(\'JW]CSX
MO+X[(E;UL#1].7[IHXF8@CZ='MB=B_2GQ)3)A'J*]23F4>2(=\B(3_]*'SE>
M@!6)BCA9F+Y_F@FR*2VE#$/3T@BFD#(T'95W$ID0S]%. :H-[!-!&RE'AJ%W
M5N02^PG$P!5JHBCO!,F,2Q2W"M&.E2G9;%F!W0DYAM=#]6OPGS[V4Z;5-_R<
M1D= N&B.%.3ZH!QI(7+/Q[5U)6-W'KH3QPXJF(YVE%(82K!I80(G)<[ I@<+
MBF-18V> DY.28>IL7KQ!FD7JZ\&O(+TXBU*06UMG,R7P#:97'_KG2OA?]X7H
MWP5VA6S+=#-(&O0]L=!#FIOGE'BL$V/AH-*X=J=56N5[)"_,Y9[0MN$/6Y 7
M ]8 7GOU/59.MS*S#\B?Y@B?'2B$GL3S\J^SW;S/Q (7B&CNRNE^/J2QP_JT
M_(V\R</0"P<IT0SK6.@B-*;4 ->%$SY)3_%@5\C)+D/%P8AD+B8:V^F"C/Q!
M[4=49O(+^T^8-3I"WN$E<5>15-PS;B;I8WQHYS$^=)7XT!V^^\-%_E^Q?;A[
M.;KUN<@HVP_T<85># !D/$$T*2C))^&Z&68W&) (N7VY#COCY:;(T[SR:FHZ
M.1@RA-;0N N1T=(Z,R0_,&L:UC%#ND>Q!(DZ%N0!^Q;LMD4U2CRH2MK.AD&]
MDCL,S5BYI9E<Q]ZV*K<6E@%;W228-B7M2L^L?%X<>AO7\?,0>!+MC>(#8]<*
M!9!Z:EAL=+"#=&0!C8R:MX+-#B=>]6=9_?;W2?G;FI)Z#X:23^IB\4NWHF//
MUOV9[D9[/[#(KX.WL+L+EW78Z-8&VX<H!WH@VMG(I+;=\?9]""6X]O.MI!,%
M^U4@CB[#:7K\+=H[X-G[OCM@?X&=:M+OP?XX.(C:O11T+0GW,(L$H'+A<JNC
M5I=Z"4.'7BB.OW,+@T(W#3 I09E87;V(1<Y!%<]4TF2:Y2-PHSL5'W(*72(T
M."<C.*A$/1AW%<$4F5B[YHP&)=&!_3MD&T6=:IF%IL\T2ZF2QD8OK NTZVY9
M@8<1K@3+H+CH"8C3,C=BRP<<)8>ES8D4O%&JUDDD.Z#C =*N3L_[VD[:E+#(
MOAW;:9(\LI!3OA.)_5*T9EJ23*5=.#0./E%' )A9ZP4DC">XJ31_ZT?$HS4E
MJ.T?7<R?):!"W4X6'0]7.[QCH N!=LYPC+^XWZ$U;("M.O:[*\>!M6 BJ;;9
M"=.9?HOX1])%!6:J%H(>ZKR!)L5CX?;$T2**I8:>R3RMB%0DRV9@E)X E(E=
MRXH\,MEB3>""C:,XGZ6N([R[@:2<<,,9S7M&]B#- H?\@CI%V.TL:]"XB[Q-
M_WJI$B^DM"$P,[.^]:65V^Z^ L'(-J*S39N9W[\[WKE/4M<J0;<B>O]L]5Q2
M;:D9\D?</XDX=K18%"E>!4./<UH#,)19P8_TI.,BFZ^4TCE[+;CA#:7$P9YF
M=XH2J=\-BA(\C-LAPV[<8X&F9"W\$>MP0M01\\+EAVB9M>-;"O0HL/84 VKF
MB)F'*H_HEQHR>Q52M6VN'#%& Z5T.$A[_07>IDT1A^)1=A038N8(V5 J1,XF
M_[&4;\CDR.MO0LTK>QS94F7=L]PI5D9-(#GE1H):2&^1%#)9I)0202J+ S;,
M94PSE258XI'SWG)G1L+N500"2EW=!K:V-R2-8I(QX^&/":H&DR6IEBG>QY31
MT=H=TOPHEFZACLV)L3T/!3<Q3AY)=3;L.YR*SJG!=$\<U/F<2Z[H8:)Q\KXB
M^'GMZ,]#!(.SK]K57FQ & ] 3^Q-#U>U2<ZA\L[#6]7(?SU^@-HN44>+="V
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M1+6Q[4ZH@MGB]DXQD8#R&+@34(!8^E2PQNCG]%Z*8GHP,EO(0_V4]DG;4^Y
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M-;&U5PBMJV&+.W;V!E+H^A9!EXIPAUJQ+^N-P9A=I!5V+ /P&V.S+3<RAM=
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M=G\);L_1E_%,X.K<( &_8E13JD.$,ZP;:A_B3[0N3A@(F;@#H\1A+)VP/27
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MN=X6&AV^KRZRBC)EXF!3;#@V8:<9'<4<C)DB&>EJ$PIA&+P'A);EONJ4RD"
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M5[9+330I3A5!B7)= G- ^27%&ZQ1J0'LG7+?3CW&J+4?>I*\1+2))KI=!^:
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MJ:,E?!OB!@8GQD,> 7YPZ5@1TF&2SUT-%6:L=.X(=%?-P:_ZR427@UDNO&U
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M/!-U.D1P)'M/7/E.GQ(I&CSX4?T>^(1_#4;=,^>1<R .U#.5H=>8=<AY,XA
M2KB'C=O"X2O8PA98NXL^R^<>Z_;_Y/N?3T[<;7\%VY_/V)3W)\0?J35&<! ?
MNB%'\0"/\';KD*?\#1[^?G5YUN.C0@?2.P18?_2\7KK'B3LJD>LM#D2]Z][%
M'N]"W]@NFE,0S;G*C^;\_"58;/E?7Y_7JS]^ %!+ P04    " #7@&E5UXC0
MAD8/   [=   '@   '1Y;&EG86YD+6-N='AA;65N9&YO,W!R;V-E+FAT;>U=
M;7/BMA;^?G^%FIV[S<X8@WE) DEWADW8+6U",@G;;?OECK %J#$6(\MAZ:^_
MYT@V&# DV28Q;+,SFX"MUZ/S\IRC(^7DA[/+T^X?5RTR5".?7'W^<-X^)7N%
M8O%+Y;18/.N>D9^[%^>D:I<<TI4T"+GB(J!^L=CJ[)&]H5+C1K$XF4SL2<46
M<E#L7A>QJ6K1%R)DMJ>\O?<G^ 1^,NJ]_\_)#X4".1-N-&*!(JYD5#&/1"$/
M!N2+Q\);4BC$I4[%>"KY8*A(N50NDR]"WO([:MXKKGSV/FGGI&B^GQ1U)R<]
MX4W?GWC\CG#OISU>IY6>=^1Y]5Z]7*T?'?9<CWF.>U2N'WCTR'/^Y\ @BU#<
MU G5U&<_[8UX4!@R[+]Q<&#7#\;J>,(]-6PXI=)_]W31]R>*]GR6U.@)Z3%9
M<(7OTW'(&LF'8X^'8Y].&SSP>< *NM+QB,H!=-$32HE1HP;-WS&IN$O] O7Y
M(&@H]E7%K^.>:V6[5CW"SI6$_U[2<3PN6X^KJ+S5=_4CNUY:_[ID.[-W1=VV
M3 K$)'!@@'NZ(LPJ'-/@I[W*7E)F3#T/%K!1(HXNE::BF:428^CD$"89ERWX
MK ^MZN)]$2A8-.BV:#Z:M9B/IJ@I-GN^LE+S/H!3:\N=');L@W+JH>:IV5--
M94-P%UB)R7A 2>,P72$;;TKZWS&^*?3IB/O3QH]=/F(AZ; )N18C&OQHA2 A
MA9!)WC<%0_XW:S@P2?-UPN*>2\>:#Q+2ZH5I7K0Z9_"_2SJ7-JF0[B6YNKX\
M;=W<D+/6;ZWSRRO]LOGINM72G]Z^J1P=D\5J#E8#&6YU;EI6NIY%+IJ=SQ^;
MI]W/U^W.I[CR1?/ZUU87O\^:75R"=0M9V[1NJ4HIXOX5A8KWI\].W6HF=;M#
M'I)DF#NQO"\SV&QJ[:LA Q8Y*I=+Q\\\#MUB@RM@$O<!9#QC=\P78VT\FO#3
M,^H_/U)I*CG'[W)E+AIXSZ8(\B JV5X&/.=@)4*V5<QG$60 1!O,51P$9$HF
M7 T)$C%38"QX!?IP*PF\381]1X!*K-\W9"4T)*)O2'?X+*,[M!%FW3N^X[$P
M0+PAF4]Q:,=HE@L5^R@#1O9HR+"%O?=JF*M0>W2*].N(.S;J,6E0_?9*^HP1
M26O& 6?@K6P#7QJ)1^9$Q H.% ^4(+VI?MQC:L)80+I36']\\(&+T.4L<!G9
MOQG28#"D_!TYYR,.OI=%AO0.O2^N0B+9@(>F1='O@ZHC5)&/X,M)L"C[7UBH
MR+GHQ?TTHZ_<YU1.869B!&.JZL<UBW3%!-;7@=7M"-N!-_"+5 [+1Q;YA0>W
M#"I0Z#@9"[GBOH!^)&/H97J,_"D"AKQR=7U*]K>2.Q+B;@,W:+*?0G% VZ0[
M9)*.600J("3GYZ? *F $?#JADA'?K#G\ICU8.S4%JS$"9VYZ+Q.42R6'7%!Y
MRQ2Y4;!28$1N(FB,5.H.+/GG@*LW^.%JR'U80G\\Y!2^-8E3=TJ5+5W%F&C;
ML(CV7%[3RXFK%HH14[I/R?I,XL* M,,Z,QZ Y(._Q;V(^F#VP4+1[=2F5U2J
MZ1;0>14J <VVU@8AU3@+\Z2;'1/N(8&!H^SH2RTS^E+;GNB+&8;'7"&IQE51
MX#%I0--UZ[3=;9[?/"PP4GU@8&0A9'6P0C2GM$*QFGVT2*\XH&(>@18 \C4J
M-;L^C\V\(!&=&K#*EY];UZWF34[<JH=@96O1!9BDAF#/7 #)%-3GE10N"\-%
M/VD ]LWX2:O@GY&#Y\'^#YH?>'5YDC>&\( #W"'B]Y*E30XB9: NX,(Y:$;(
MYV32K^SDYCS!)+[5>0KS0@F:\(GSU!Q+[B/E'>,";*)^.9/Z%>DEC?T2 <K&
MMLC^O!UK*ZVA)D*FC.:Y*G-W;#+D(!$B4EC(  JMMD.]2J*'.@F93B]#IHK2
M$1O)PC&L&-%:B@%.";P(OD*=1%_!2.\ DH=8I,?(F,F^D".S_$F[;]_4ZNOM
M]3,8FLVV;K<MFP9!L66S<HW*>Q%+&.,F<M%J]2,?^&<T]AGREI9BC_6A(EJZ
MU?#?"XG,6JG.GM9+A<ZS>T^)(TJS<W@<DG&,";P4\4"5"JE":[MHEROI@+]>
MJ;'LJA'JAV(#WHSW#ZRT9%H J(*H3UT520S"Q'LR.MB"WV>"2X21ZG)E%\//
M,M=@V0Q!10,P+S'LV4:HL[C-E#/,68HZ@PY<59=I-6FB*Z,1DRZ'J?ZM04\"
M/=%4"7"MLPS5RH3?)6^Z3$JNA)P^K-HK^/DNP0\N=J)B0:N"JX)82.O91,NN
MV>S$<I*Y8A! =\9I0F8Q:AEK@;F_XZ$&Y\!5-^@QX>>*#0KB@OLL5 (P/7!_
MQ2Z3_6LQI;Z:ZJ\'4("IH?#T7@6=8G>A"<=7[$.R#]B^#_)N>+EYW6V?GK=(
MN]VVR.EEYZ9]UKIN=MN7G40^,L$:"8?4]TD8 >Z_8XE$C):%(1XV<4HP[$WM
MO0K(OUA 5K(7L,P^?V><?\VXX((JJMB<H>Q:.<V^#CEK?6QWVLBX-PFGK:AA
M"UK=V&S5+J-\?9(4!O&!NK<+,E(E[8NKZ\O?3"K4^DZP9>@(>GJ\A#]J"-AH
M4J^.M5 &%\K72;=U?4&:G3/]H=U9$.V5L6>(-?LZYG+!8&;4BGI_)0$"&$$8
M&]S XT9I*=P5$OUL&7\*<3S8=F'L7'XA713(CY?7K7Q%$KA#9P3C:M$[P5$2
M<,<UZ$?(C,_M2VXD4ZZ$01@Y$,)HACOJ1SJ+&@@3<B"7%@$3A@2I9GQL8&48
MX68TIC%H'&\B;K@]BBR/*0GN;2 F/O,&21 S48=80 DK5HOH49G@F<\&>M>T
MAZ#4(A,>#E=T)@]3RG*N6L#X]H7OBTD(HG;TH,VQDEW;N;39MV^<@]+QZD_'
M7O<F/Y[>M(EW%@,EU-KY[J:2)FA]EXZU)_@W[N1K-1Z%\#'>T3>684ACLS!B
M-$">I:$K>4_O_:\C/J,8A-:V8T12^#!NF"*7\SX)A%IZ93V@4Z);7]=UTNNF
MN"-HPTPC#E9L/ :<C%K ?KQ0;)TL/9X[-R0U;\.$'J<<'C'R1=QP\ *@(7LJ
MY1W39POX/>7Z'6YT_?)5?*DTROENY+HD2^OAL\(TR 0"Q%NA*8?#>["I_D;]
MLICL4LZ$Q[D)J(YL:@KFM_:;^/A&NS_4SY<S;^YQJI*D[Y3-0F[$LCR('3:Y
MXKZE*\3F%0TOU7RN&PCCV2?]*1Y$:'3A$?<P.1.?LP#0LLN2?$UH.N7-QH8=
MN@9V#XV93EQ*O?$\1CC-8@' ML,(C'AZJ#(]#\3(KA]IC)P.A.G8EXEXQ<$M
MXWLW,=0/T/VW-DQ(BF@PG#WZO7UOYM@W2ER\>M4#NX2AH=7=B.5CFO/SF?JH
M96E>A?9"X4=JM<I+G^PLV\YAZ64.=MYWB+,\_HK'.--J#'7;RKZ.'OZ&PYX'
MRTEME:<W[_4'2;BSR$J;SY6:GT,Y)\N %7J2T=L"[8.H-*@_H=-P[_6L\$Z>
M%=X!=V#M$;,==HD>YT%4O@LXCH'S=8'<W83BFV:4,PQ/Z8[RLN9 5)XO!,\S
MTAL/899T^&L@)H6?Q60)G>5!G4ROI$?=VX'$D&PA'D=?_SM^J5%A[ OS>/P9
MJ<Q.DL:7>!K'U\=&@)0>ER :\"7>7ILE.""JQ@"T%#I_T\2J>Z [<)B8\2GQ
M!,I"TB;6P=-7S7X?3]4I%EJXV^,;.8-J\!Y]!$E=)63X[>!Z6Y3\[HZ\^CV8
M)[/[^5W9I\U3>HT3W6.D#/FV,U TWZ3?N5#13,''S#? J83S YX8OG']* 1^
MMD@_\OUI84RY1Z*Q1:1)-BKT<<\Q-@5DWY@3$U(R1@7/ 8R9BN)8$I>2W0F]
MGP+-Q$FC&^-3L<%B%.C-Y&)H:Z4P3"(9_3B28407-4L=^<C2O\H6MHR?*O@A
M;>[6U:SB:8KD]@IS_1>4T$1+V4,PCKBI'DQ)>X3Q,#;;GUW!.2CAD:\3:?M2
MC'2[%-4'UYO#FLD4O67!9FN,3Q;LL8$#WK+MMY9?Q"! 4R(]Z64^F0P99F^0
M,50.3*P :@0B*,R?F S,.>MXRX,T&^6I4<;Y/2.8H&6V]T;4@X\1YB #91@>
MY;*2'$YK(7D32H3,]RT\!FZR&,Q7#C.5IGM@*ORX#'YP8?A\8>*\%&A 1 KW
M^!<3.V=Y/(\8Y^8Q6#/HM6DP7.<;8)',86E:9_=O5BRD/EN7\9K58(+9"'D*
M*['C/G[M>P!1=;NZI1#J<0@*WZ;V"# #!F\+24P, :Y$A&2$#%/ZH,44#31@
MVL#5WRUDFIF+?B2U\DXE(87S=*'0.)#W)>]E@(?9)HP!9UBAGF#<C VF^=[/
M]#';4\^U4[,#P=9/+& 28--"9M .S_]Q2OA@QY1P*U!<;HV.)2W,B-(WFRP*
M?IQXG,X=1+PZ,  O^VZVF22CC-^7)67I9$G%5:3BT\;,4(;.$7U_(0<RZWAQ
MHH]&5&'&HTD=_AX2L!XG!(<[)@0?P4<D'S$I0/.*L>5Y2\)7EV&>;ICD(OCS
M*(OQ>RT=48VY4FA!6&\$_YEL&%LHV0@/7$:!B]>,Q=$>>( N-NG/R&?N2, 7
MU 5J>Q2!3R*B'%P#\$'!C/IFM/\^Z3C:,>EH1FH(:Y;O95.+MB$._$B&DJ$]
M4&2\"94F$J2M!08G,0*)S#G6U^=I])A,9F->^GJF_+;T\\5M=[N<OI[(G *)
M'[[\[4WK>+?N'-_ ,*B*P ABRL8\EENO/ C7+DS@-0'I-0'I"1.0RJ\)2*\)
M2/](Y2R,K/)01;YXRUSF)7/;<W"OW2%?VMT.WHBO#]1>?LS3@B^=(,. M#[_
MXE)]5(<2+T*(:^PSGN.967=M K2]_LI<4.TKA\CNC<>MVO-'+'9B8\Q5C M\
MLY&!U]G_FGT82].+:H^Z8Q\XWV20JF6[5#U\D/9X3+,U)$0E!SL':[>W 9Z5
M<KGN$2=[>MGIMG[O9N^6?]-9XYPTS[JKD_^)&,::^HDN02B4[3QRV,H59/@/
M4Q/?ST<=XQ@V^7MOWU0/CT/]$Z],4GC'$AO*?)W6;$*2#ATQ0\O42+=(/%9-
M(=YRV,6_K66&?3KDK$]:VK"AM;K4]X/+#"CT JJO5K&K^5QVB]JO^\=Y^U.S
M<_9$ZB^WR2S<9K_Y3P7DI ]CTBR'(&HZ!I&S3MP!I=@5P93\B6NYY3I1#_0/
MVXQUNZ3F"15CAH]XCR2]AJ1>0U)/'I*J/#XD531_5E/_@<_W_P=02P$"% ,4
M    " #7@&E58L;H/[U^ 0!\L@\ $0              @ $     8VYT>"TR
M,#(R,#DS,"YH=&U02P$"% ,4    " #7@&E5C^3(UA8-   \B   $0
M        @ 'L?@$ 8VYT>"TR,#(R,#DS,"YX<V102P$"% ,4    " #7@&E5
MTWB]S\\.   2@0  %0              @ $QC $ 8VYT>"TR,#(R,#DS,%]C
M86PN>&UL4$L! A0#%     @ UX!I5?'J%O3?1   Q_P" !4
M ( !,YL! &-N='@M,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( -> :54;
MA+S7Q:   $/)!@ 5              "  47@ 0!C;G1X+3(P,C(P.3,P7VQA
M8BYX;6Q02P$"% ,4    " #7@&E5:%Z."4EH  #OK@0 %0
M@ $]@0( 8VYT>"TR,#(R,#DS,%]P<F4N>&UL4$L! A0#%     @ UX!I533;
M'!-O!P  'B,  !\              ( !N>D" &-N='@M,C R,C Y,S!X,3!Q
M97AH:6)I=#,Q,2YH=&U02P$"% ,4    " #7@&E5P%A&]7@'  !-(P  'P
M            @ %E\0( 8VYT>"TR,#(R,#DS,'@Q,'%E>&AI8FET,S$R+FAT
M;5!+ 0(4 Q0    ( -> :560+!ZFN04  "@8   ?              "  1KY
M @!C;G1X+3(P,C(P.3,P>#$P<65X:&EB:70S,C$N:'1M4$L! A0#%     @
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#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
